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Preface
“Experimentation and clinical tests have shown that for the graft to take root, not 
only should it be as viable as possible, but from the very beginning it should have a 
strong relationship with the host” Vittorio Putti 1912 [1].
Bone has an efficient ability to regenerate. But the critically large defects in bone, either 
postsurgical or after trauma, progress to nonunion and instability in 10% of patients 
and therefore require implantation of a bone graft [2]. In the USA alone about half 
a million bone grafting surgeries are done annually [3]. Furthermore, the rate of bone 
grafting procedures is expected to rise due to the constantly advancing techniques of 
bone grafting.
Autologous bone grafting is the gold standard for the reconstruction of critical 
bone defects. However, autologous grafts have several significant disadvantages, such 
as donor site morbidity and limited availability. The alternative use of allografts or 
xenografts is limited due to the risks of rejection, infection, and high nonunion rates. 
Progress in bone tissue engineering is essential to provide an unlimited source for 
autologous-like bone grafting source. There is an indication that the method to generate 
autologous bone-like material, as live autologous bone tissue, originating from patient-
specific osteoblast-like cells, grown from bone marrow on β-tricalcium phosphate 
supporting three-dimensional matrix under optimal biomechanical conditions, is 
possible (Figure 1) [4, 5].
But meanwhile other methods for effective bone grafting are under ongoing develop-
ment aiming to achieve optimal osteoconductivity and osteoinductivity similar to the 
autologous bone graft material. Thus, the potential of the newly developed tissue engi-
neering methods for bone grafting is discussed in this book. According to the ongoing 
research, progress of the methods to create readily available autologous-like bone graft-
ing material that doesn’t cause additional surgical morbidity, is anticipated to evolve. 
Naturally, these methods are expected to fulfill the regulatory requirements, including 
clinical studies, that will allow the start of widespread clinical use. For this purpose, a 
thorough understanding of bone regeneration control in vivo by systemic humoral and 
local factors is essential. In this book, several such factors are presented and discussed.
The classic method of local bone regeneration by means of distraction osteogenesis, 
which is based on mechanical stimulation at the bone deficient site is presented by 
Domingos et al. This widespread effective clinical method requires a good understand-
ing of the optimal mechanical and humoral factors – those are presented in the chapter.
Figure 1. 
 A- micrograph (HE staining) of a critical bone gap in rat calvarium, 6 weeks after the creation of the gap. 
No evidence of bone bridging. B- micrograph (HE staining) of bridging of the critical bone gap by young 
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Berdyugina OV and Berdyugin KA present the immunological aspects related to bone 
regeneration. Those are not always apparent to the clinicians who are involved in the 
treatment of bone deficiencies.
The microRNAs control the proliferation and differentiation of osteoblasts and 
osteoclasts, which influences bone formation, and this is described in the chapter by 
Kaur T et al. This rarely addressed subject might become an important therapeutic 
tool in the treatment of bone related disabilities.
The additional important issue of systemic effect of bone damage due to osteomyelitis 
is reviewed by Tsiskarashvili A et al. The systemic metabolic changes that occur in 
that situation are crucial for understanding the treatment of bone deficiencies due to 
osteomyelitis.
The maintenance of bone remodeling is governed by the thyroid hormone. The relation-
ship between thyroid impairment, and bone mass, especially in the aged population, is 
discussed in the chapter by Ayotunde Oladunni Ale.
The biological effect of vitamin K and bone maintenance is not widely apparent but 
in the dedicated chapter by Sawsan Jaghsi, this subject is discussed aiming to open an 
additional niche for possible pharmacological intervention in bone metabolism.
These chapters address the less discussed aspects of bone regeneration and mainte-
nance, therefore the reader may find new areas of interest when approaching the deep 
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Chapter 1
Marginal Bone Changes around 
Dental Implants after LIPUS 
Application: CBCT Study
Elaf Akram Abdulhameed, Marzuki Omar and A.R. Samsudin
Abstract
To assess the effect of LIPUS on marginal bone regeneration during insertion 
and following loading using CBCT scan imaging, a trial of RCT of 22 subjects need-
ing dental implant was conducted. The participants were randomly allocated into 2 
groups; both groups underwent similar two-stage implant surgery of one maxillary 
dental implant. The control group (n = 11) of the implant site was allowed to heal in 
a conventional way, while the intervention group (n = 11) was subjected to LIPUS 
therapy at the implant site (twice a week, 20-minute duration, from week 2 after 
stage I implant surgery and continued for 10 weeks). Similar ultrasound protocol 
was repeated 2 weeks after crown installation and again continued for another 10 
weeks. The assessment of marginal bone loss around dental implants was carried 
out at three different views (coronal, sagittal, and axial) of the implant site imme-
diately after surgery, 3 and 6 months later. Statistical analysis of ANOVA within and 
between two-group analysis that was applied followed by pairwise comparison with 
confidence interval adjustment showed that there is a significant difference among 
the groups (p < 0.05). The CBCT imaging (coronal view) values suggested that 
bucccal bone regeneration around the dental implant has significantly increased 
during the early osseointegration period in the LIPUS-treated subjects than in the 
control group. LIPUS enhances bone formation in particular buccal bone plate 
around the dental implant as confirmed by the coronal view.
Keywords: LIPUS, coronal, sagittal, axial, osseointegration
1. Introduction
The introduction of osseointegration, in 1969, by Professor Per-Ingvar 
Brånemark, at the Institute of Applied Biotechnology, University of Goteborg, [1] 
opened new avenues in the dental implant treatment for the partially or fully eden-
tulous patients [2]. Titanium endosseous implants are widely used successfully in 
association with this treatment modality. Various investigations proved this method 
to be superior for long-term prognosis for dental implant treatment [3, 4].
Osseointegration is a process of connecting structurally and functionally an 
ordered living bone with load-carrying implant [5]. When histologic features of 
the osseointegration were observed, functional ankylosis was found without any 
intrusion of connective or fibrous tissues between the implant surface and bone [6]. 
However, in some situations, osseointegration does not take place adequately and 
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at times leads to implant failure. Continuous investigations looking into implant’s 
chemical and physical characteristics, structures, and the biological responses from 
the surrounding bone are being conducted to identify its cause.
Implant success depends upon successful osseointegration. Evaluation of the 
bone surrounding the implant is a common method for observing the implant 
prognosis [7–9]. Care of the bone that supports the implant is vital for the beneficial 
results of the implant treatment [10].
Various studies have shown that there were changes in the marginal bone level 
and loss of different amount of bone that occur mostly during the first year of 
dental implant placement [11–13]. Assessment of changes in marginal bone height is 
considered an important parameter in evaluating implant success [14, 15]. Excessive 
marginal bone loss after implant or following prosthesis may be seen in the first 
year. However, in the early phase of osseointegration, the process of bone healing is 
not well understood [16].
One of the etiological factors of marginal bone loss is the disruption of the 
periosteum and blood supply during flap elevation and placement of implant 
[17]. Some studies showed that less marginal bone loss was noticed when flapless 
technique is used as compared with full-thickness flap technique that showed more 
marginal bone loss during healing period [18–21].
Other studies showed that periosteum disruption not only affects marginal bone 
level but also has other effects on bone formation around the implant during the heal-
ing period that compromise the stability of the implant and delay healing [21, 22].
Previous studies [19, 23] reported that the decreased blood supply to the bone 
after periosteum elevation has the same effect of flapless technique on the level of 
marginal bone and bone formation rhythm.
Continuous bone resorption affects function and esthetic. There are several 
ways to restore and regenerate bone such as advocating bone grafting procedures, 
usage of growth factors, laser therapy in low levels, and therapeutic ultrasound.
Low-intensity pulsed ultrasound (LIPUS) stimulation is a classical therapeutic 
modality for bone regeneration. Its efficiency has been widely reported over the 
years. LIPUS stimulation can be used as a tool to enhance tooth and periodontal 
regeneration [24].
Della Rocca [25] in her study on the effect of LIPUS on bone regeneration on 
Wistar rats confirmed that LIPUS can consolidate fractures and reduce bone healing 
time. It is also shown that LIPUS enhances bone regeneration based on its angio-
genic and osteogenic values both before and after dental implant placement [26, 27].
1.1 Ultrasound
1.1.1 History and development of ultrasound
Ultrasound has been discovered 50 years ago for therapeutic and diagnostic uses 
in the medical field. Ultrasound refers to the sound with frequency greater than 
that audible by the human ear. It is a mechanical compression-rarefaction wave that 
travels through the tissue, producing both thermal and nonthermal effects [28].
The thermal effects of ultrasound can increase the temperature of deep tissue 
with high collagen content to increase the extensibility of the tissue or to control 
pain. The nonthermal effects of ultrasound can alter cell membrane permeability, 
thus facilitating tissue healing and transdermal drug penetration. Therapeutic 
ultrasound may also facilitate calcium resorption. To achieve these treatment 
outcomes, appropriate frequency, intensity, duty cycle, and duration of ultrasound 
must be selected and applied.
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In evaluating an ultrasound device for the clinical application, one should con-
sider the appropriateness of the available heads and BNRs for the types of problems 
expected to be treated with the device [28].
1.1.2 Diagnostic uses of ultrasound
Transthoracic ultrasound (US) examination can be used for (1) chest wall 
lesions; (2) pleural lesions such as pleural effusion, pleural thickening, or pleural 
tumors; (3) peridiaphragmatic lesions; (4) peripheral pulmonary lesions which 
abut the pleura; (5) pulmonary lesions with an accessible US window; and (6) 
mediastinal tumors in contact with the chest wall [29–31].
On US, pleural effusion is characterized by an echo-free or hypo echoic space 
between the visceral and parietal pleurae that can change shape with respiration. 
On US, peripheral lung tumors appear as well-defined, homogeneous, hypo echoic, 
or echogenic nodules with posterior acoustic enhancement.
Diagnostic US is efficiently used for the visceral examinations, e.g., the liver, pan-
creas, kidneys, etc., at 3 MHz frequency. The neck, breast, and children are exam-
ined using a frequency of 5–7 MHz. The increase in the frequency in the ultrasound 
examination increases the visibility and discrimination of details of the image.
Diagnosis of benign or malignant growth in the uterus, fallopian tubes, and 
ovary is routinely made in the obstetrics using ultrasound. It is also used for the 
progressive assessment of pregnancy.
1.1.3 Therapeutic uses of ultrasound
1.1.3.1 Osteoradionecrosis
Harris [32] claimed that therapeutic ultrasound increases the blood supply and 
the deposition of new healthy callus replacing the necrotic bone. Therefore, thera-
peutic ultrasound can be used as conservative method of management of osteora-
dionecrosis of the mandible.
1.1.3.2 In vitro and in vivo bone regeneration
Ultrasound and some other physical factors stimulate the bone healing process 
by increasing the intracellular calcium levels. Deposition of intracellular calcium 
enhances the formation of bone [33]. In vivo and in vitro studies have shown that 
ultrasound treatment increases the activity of alkaline phosphatase in spontane-
ous and experimental fractures in rats and rabbits as compared with untreated 
animals [34–36].
Animal and clinical studies conducted in two phases by John et al. [37] reported 
that ultrasound-treated groups have increased formation of callus. Increased activ-
ity of the osteoblasts was observed cytologically in the ultrasound-treated group.
1.1.4 Ultrasound treatment setting parameters
General guidelines of parameters for ultrasound therapy are given for different 
clinical applications as follow [28]:
• Duty cycle: The proportion of the total treatment time that the ultrasound is 
on. This can be expressed as a percentage or a ratio: 20 or 1:5 duty cycle, that is, 
20% of the time on and 80% of the time off.
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at times leads to implant failure. Continuous investigations looking into implant’s 
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• Effective radiating area (ERA): The area of the transducer that radiates ultra-
sound energy is known as ERA. ERA is smaller in comparison with the area of 
the treatment head.
• Frequency: Frequency is the measure of compression-refraction cycles per unit 
of time. It can be expressed in Hertz (Hz) or cycle per second. Frequency used 
for therapeutic purposes ranges from 1 to 3 MHz. Increment in the frequency 
decreases the concentration and depth of penetration of the ultrasound energy 
in the tissues.
• Intensity: Intensity demonstrates power per unit area of the sound head. It 
is expressed in watts per centimeter squared (W/cm2). The recommended 
limit of the intensity for therapeutic purposes is 3 W/cm2 by the World Health 
Organization.
• Power: It is the amount of aural energy per unit time. It is expressed in watts (W).
• Pulsed ultrasound: During the treatment, periodic or sporadic supply of 
ultrasound is known as pulsed ultrasound.
• Spatial average intensity: The average intensity of the ultrasound output over 
the area of the transducer.
• Spatial average temporal average (SATA) intensity: The spatial average inten-
sity of the ultrasound averaged over the on time and the off time of the pulse.
• Spatial average temporal peak (SATP) intensity: The spatial average intensity 
of the ultrasound during the on time of the pulse. This is a measure of the 
amount of energy delivered to the tissue.
1.1.5 Mechanism of action of ultrasound therapy
Although the exact mechanism of LIPUS interaction with the viable tissues and 
stimulation of bone healing is still unclear, there are several studies that showed 
that LIPUS stimulates regeneration of the bone and decreases the osseointegration 
time and promotion of the quality of osseointegration [38].
The mechanism behind the effect of LIPUS on bone regeneration might start 
from the mechanotransduction pathways of LIPUS on bone wound healing which 
is considered a complex process as numerous cell types respond to this stimulus 
involving several pathways. Mechanotransduction refers to the processes through 
which cells sense and respond to mechanical stimuli by converting them to bio-
chemical signals that elicit specific cellular responses [39]. Typically the mechanical 
stimulus gets filtered in the conveying medium before reaching the site of mecha-
notransduction. Cellular responses to mechanotransduction are variable and give 
rise to a variety of changes and sensations. From definition of mechanotransduc-
tion, LIPUS promotes activation of osteoblast and other necessary cells’ function 
which are considered decisive elements in bone healing by increasing proliferation, 
migration, and differentiation of these cells and changing it from inactive phase to 
active cells. The cellular responses underlying this mechanism are termed mechano-
transduction [40].
Ingber [41] demonstrated in his work that the integrins are the most important 
key in the transduction of the ultrasound signals with evolutionary conserved 
mechanoreceptors, are expressed by various cell types, and convert mechanical sig-
nal into biochemical response. This form of sensory transduction is responsible for a 
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number of senses and physiological processes in the body, including proprioception, 
touch, balance, and hearing. Mechanotransduction involves various signal transduc-
tion pathways, including the activation of ion channels and other mechanoreceptors 
in the membrane of the bone cell, resulting in gene regulation in the nucleus [42]. 
Identification and functional characterization of the mechanotransduction compo-
nents may improve bone tissue engineering. In this process, a mechanically gated 
ion channel makes it possible for sound, pressure, or movement to cause a change in 
the excitability of specialized sensory cells and sensory neurons [43]. The stimula-
tion of a mechanoreceptor causes mechanically sensitive ion channels to open and 
produce a transduction current that changes the membrane potential of the cell.
Padilla et al. [44] and Sato et al. [45] updated the information in this area of 
interest that the mechanotransduction pathways involved in cell responses include 
integrin/mitogen-activated protein kinase (MAPK) and other kinase signaling 
pathways, gap-junctional intercellular communication, upregulation and clustering 
of integrins, involvement of the COX-2/PGE2 and iNOS/NO pathways, and activa-
tion of mechanoreceptor. Along with the direct effect of ultrasound, sensitizing 
mechanosensitive receptors, channels of the cell and the indirect effect of acoustic 
streaming-governed-shear stress on the cell surface (Figure 1). Acoustic streaming, 
giving rise to a unidirectional bulk fluid movement, can improve the circulation of 
molecules within the extracellular matrix in the culture wall, or trigger fluid flow 
in vivo, and thereby increase the delivery of cytokines secreted by other cell partici-
pants or other essential nutrients, and remove cellular waste products [46]. Tang 
et al. [47] stressed with his co-worker that the transmembrane mechanoreceptors 
increased surface expression in rat primary osteoblasts (in vitro study) of a2, a5, b1, 
and b3 integrins and clustering of b1 and b3 integrins have been shown to be upregu-
lated within 24 hours after 20-minute treatment with LIPUS. In the same cell type, 
but using continuous ultrasound exposure, enhanced expression of a2, a5, and b1 
integrins has also been reported and also showed upregulated expression [36]. After 
ultrasound exposure in mouse, osteoblasts isolated from long bones, gene expression 
was also significantly upregulated of a2, a5, and b1 integrins, whereas Watabe et al. 
[48] revealed in his vitro study that only expression of a5 was enhanced in mouse 
mandibular and calvaria-derived osteoblasts stimulated with LIPUS. Zhou et al. [49] 
explained in his amazing work that inhibiting b1 integrin by blocking antibody or 
RGD peptide in human primary skin fibroblasts led to restoring basal levels of DNA 
synthesis, which had been upregulated in response to ultrasound before.
Ren et al. [50] has reported that p38 MAPK kinase is crucial for LIPUS to induce 
and enhance differentiation of human periodontal ligament cells (HPDLC) which 
are similar to mesenchymal stem cells and can undergo osteogenic differentiation. 
Treatment of cells with the p38 inhibitor significantly reduced ALP activity, osteocal-
cin concentration, and matrix mineralization in response to LIPUS, compared to the 
control group, where no inhibitor was added [44]. Whitney et al. [51] also explained 
in his study that the LIPUS in continuous mode caused more intense phosphoryla-
tion of FAK, Src, p130Cas, CrkII, and Erk1/Erk2 in primary human chondrocyte 
culture, suggesting that this pathway is involved in US-induced mechanotransduc-
tion mechanism. However, several studies in mechanotransduction suggested that 
voltage-sensitive calcium channels (VSCCs) have been reported to be the key regula-
tors of intracellular calcium signaling in osteoblasts for bone formation [40].
Most recently, Kang et al. [52] studied the effects of 20 minutes a day stimula-
tion by a low-intensity ultrasound (1 MHz, 30 mW/cm2 continuous sine wave) in 
combination with cyclic vibratory strain (1 Hz, 10% strain) on MC3T3-E1 cells in 
a 3D scaffold. The stimulation did not change the cell proliferation over a period 
of 10 days, but significantly upregulated several gene expressions—COL-I, OC, 
RUNX2, and OSX—indicating accelerated differentiation.
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synthesis, which had been upregulated in response to ultrasound before.
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and enhance differentiation of human periodontal ligament cells (HPDLC) which 
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Treatment of cells with the p38 inhibitor significantly reduced ALP activity, osteocal-
cin concentration, and matrix mineralization in response to LIPUS, compared to the 
control group, where no inhibitor was added [44]. Whitney et al. [51] also explained 
in his study that the LIPUS in continuous mode caused more intense phosphoryla-
tion of FAK, Src, p130Cas, CrkII, and Erk1/Erk2 in primary human chondrocyte 
culture, suggesting that this pathway is involved in US-induced mechanotransduc-
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a 3D scaffold. The stimulation did not change the cell proliferation over a period 
of 10 days, but significantly upregulated several gene expressions—COL-I, OC, 
RUNX2, and OSX—indicating accelerated differentiation.
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The accessibility of the crucial factors to the compromised cells supports their 
viability and maintains the indispensable microenvironment in the healing fracture 
through the regulation of pH and oxygenation, which may be enhanced by the 
ultrasound treatment. A mechanism of improved oxygen and nutrient transport in 
response to ultrasound has been suggested by Pitt and Ross [53].
These studies suggest that LIPUS are able to enhance osteogenesis and angiogen-
esis in vivo and in vitro as was well documented by literature review that angio-
genesis precedes osteogenesis process [54]. Angiogenesis is closely associated with 
osteogenesis where reciprocal interactions between endothelial and osteoblast cells 
play an important role in bone regeneration [55].
Angiogenesis has a key role in bone repair by not only facilitating the supply 
of oxygen and nutrients required for bone repair and the removal of waste prod-
ucts but also by providing conduits for the invasion of osteoblast and osteoclast 
Figure 1. 
Summary of hypothetical LIPUS effects on bone cellular events in vitro data. The columns represent the four 
phases during in vivo endochondral bone fracture healing: phase 1, early events soon after the bone injury: 
hematoma formation, inflammation, and migration of osteogenic precursors; phase 2, angiogenesis, proliferation 
of mesenchymal stem cells (MSCs), and osteoblasts and osteogenic differentiation; phase 3, chondrogenesis and 
maturation of osteoblast; and phase 4, maturation of chondrocytes, woven bone formation, and remodeling [44].
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progenitors into the healing site [56]. Vascular endothelial growth factor (VEGF) is 
a potent and vital angiogenic cytokine. It is a specific mitogen for vascular endo-
thelial cells (ECs) [57]. Shiraishi et al. [58] demonstrated in his vitro study that 
the application of LIPUS led to the upregulation of interleukin-8, basic fibroblast 
growth factor, vascular endothelial growth factor, and non-collagenous bone 
proteins, and the downregulation of osteoclasts resulted in bone regeneration. 
El-Bialy et al.’s [59] study in vivo has demonstrated that therapeutic LIPUS can pro-
mote bone repair and regeneration, accelerate bone fracture healing, and enhance 
osteogenesis at the distraction site on rabbits ultimately offering long-term benefits 
to patients.
1.1.6 Ultrasound in dentistry
Low-intensity pulsed ultrasound technique is used for the evaluation of bone 
growth in the permeable implant surface [60]. Pulsed ultrasound produces a 
pressure wave which serves as a noninvasive mechanical stimulus and promotes 
the growth at the site of injury. Amplitude of the pulse is kept as low as 0.3 mm 
showing no ill effects on the process of recovery. However, mechanism of cellular 
response produced by ultrasound is not well defined [61, 62]. Low-intensity pulsed 
ultrasound, which is used for only few minutes in routine, has shown beneficial role 
in the healing evidenced by experimental and clinical trials [62, 63].
The intensity of ultrasound used for soft tissue application ranges from 500 
to 3000 mW/cm2. Much of the clinical benefits from the ultrasound in physical 
therapy have been attributed to the controlled heating of the tissue. Because heating 
bone may also have significant deleterious effects, intensity used for bone applica-
tion is much lower, in the range 30 mW/cm2, which does not induce applicable 
heating of treated hard and soft tissues [64].
1.1.6.1 Applications of ultrasound in dentistry
1. Ultrasound is widely used for fracture detection in dentistry. Fractures of the 
nasal bone, orbital rim, maxilla, and mandible zygomatic arch are commonly 
detected by ultrasound. The position of the mandibular condyles is also located 
by ultrasound. To observe the healing fractures after surgery can be easily 
performed by ultrasound [66].
2. Focal disease or parotid lesions can be observed easily using an ultrasound.
2. Materials and methods
2.1 Study design
This study was a randomized controlled clinical trial (RCT) in which patients 
who visited the University Dental Hospital Sharjah (UDHS) for dental treatment 
and requested for oral rehabilitation of their missing teeth were selected for dental 
implant therapy. Those patients were examined in the oral surgery implant clinic 
and provided with new registration serial number. All the odd number patients were 
in the trial (ultrasound) group, and the even numbers were in the control group.
The aims and objectives of this study were to evaluate the effect of ultrasound 
therapy on osseointegration using clinical assessments, measurements of RFA values, 
and radiological assessments using linear measurement of marginal bone loss around 
the dental implant-supported prostheses using CBCT. The selected age groups were 
between 20 and 40 years old. All patients were recruited following specific criteria 
Clinical Implementation of Bone Regeneration and Maintenance
8
The accessibility of the crucial factors to the compromised cells supports their 
viability and maintains the indispensable microenvironment in the healing fracture 
through the regulation of pH and oxygenation, which may be enhanced by the 
ultrasound treatment. A mechanism of improved oxygen and nutrient transport in 
response to ultrasound has been suggested by Pitt and Ross [53].
These studies suggest that LIPUS are able to enhance osteogenesis and angiogen-
esis in vivo and in vitro as was well documented by literature review that angio-
genesis precedes osteogenesis process [54]. Angiogenesis is closely associated with 
osteogenesis where reciprocal interactions between endothelial and osteoblast cells 
play an important role in bone regeneration [55].
Angiogenesis has a key role in bone repair by not only facilitating the supply 
of oxygen and nutrients required for bone repair and the removal of waste prod-
ucts but also by providing conduits for the invasion of osteoblast and osteoclast 
Figure 1. 
Summary of hypothetical LIPUS effects on bone cellular events in vitro data. The columns represent the four 
phases during in vivo endochondral bone fracture healing: phase 1, early events soon after the bone injury: 
hematoma formation, inflammation, and migration of osteogenic precursors; phase 2, angiogenesis, proliferation 
of mesenchymal stem cells (MSCs), and osteoblasts and osteogenic differentiation; phase 3, chondrogenesis and 
maturation of osteoblast; and phase 4, maturation of chondrocytes, woven bone formation, and remodeling [44].
9
Marginal Bone Changes around Dental Implants after LIPUS Application: CBCT Study
DOI: http://dx.doi.org/10.5772/intechopen.87220
progenitors into the healing site [56]. Vascular endothelial growth factor (VEGF) is 
a potent and vital angiogenic cytokine. It is a specific mitogen for vascular endo-
thelial cells (ECs) [57]. Shiraishi et al. [58] demonstrated in his vitro study that 
the application of LIPUS led to the upregulation of interleukin-8, basic fibroblast 
growth factor, vascular endothelial growth factor, and non-collagenous bone 
proteins, and the downregulation of osteoclasts resulted in bone regeneration. 
El-Bialy et al.’s [59] study in vivo has demonstrated that therapeutic LIPUS can pro-
mote bone repair and regeneration, accelerate bone fracture healing, and enhance 
osteogenesis at the distraction site on rabbits ultimately offering long-term benefits 
to patients.
1.1.6 Ultrasound in dentistry
Low-intensity pulsed ultrasound technique is used for the evaluation of bone 
growth in the permeable implant surface [60]. Pulsed ultrasound produces a 
pressure wave which serves as a noninvasive mechanical stimulus and promotes 
the growth at the site of injury. Amplitude of the pulse is kept as low as 0.3 mm 
showing no ill effects on the process of recovery. However, mechanism of cellular 
response produced by ultrasound is not well defined [61, 62]. Low-intensity pulsed 
ultrasound, which is used for only few minutes in routine, has shown beneficial role 
in the healing evidenced by experimental and clinical trials [62, 63].
The intensity of ultrasound used for soft tissue application ranges from 500 
to 3000 mW/cm2. Much of the clinical benefits from the ultrasound in physical 
therapy have been attributed to the controlled heating of the tissue. Because heating 
bone may also have significant deleterious effects, intensity used for bone applica-
tion is much lower, in the range 30 mW/cm2, which does not induce applicable 
heating of treated hard and soft tissues [64].
1.1.6.1 Applications of ultrasound in dentistry
1. Ultrasound is widely used for fracture detection in dentistry. Fractures of the 
nasal bone, orbital rim, maxilla, and mandible zygomatic arch are commonly 
detected by ultrasound. The position of the mandibular condyles is also located 
by ultrasound. To observe the healing fractures after surgery can be easily 
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the dental implant-supported prostheses using CBCT. The selected age groups were 
between 20 and 40 years old. All patients were recruited following specific criteria 
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of inclusion and exclusion. Patients of this study were divided into two groups, 
namely, ultrasound and control; each patient received one dental implant to replace 
single missing maxillary first or second premolar teeth. In the first trial group 
(ultrasound), the ultrasound therapy was applied twice a week for 20 minutes that 
commenced 2 weeks after stage I implant surgery and continued for 10 weeks. At 
2 months, uncovery and placement of gingival former for 10 days were carried on for 
all patients in both groups (ultrasound and control), then the impression taking was 
done for all patients, and installation of screw-retained porcelain to fused crown was 
performed 2 weeks later after the impression was taken. The same ultrasound ther-
apy protocol was repeated 2 weeks after the crown installation for another 10 weeks. 
In the control group, patients were not subjected to application of ultrasound 
therapy. Clinical data collections composed of measurements of resonance frequency 
analysis (RFA) values using Osstell ISQ device and linear measurements of different 
variables using CBCT images taken immediately after the placement of the implant 
and during follow-up clinical examinations at 3 and 6 months postoperatively.
2.2 Flowchart
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Thorough medical and dental histories were taken from all patients presented 
in the study project. General clinical assessment of oral hygiene and gingival and 
periodontal health in terms of gingival color, contour, size, and consistency was 
documented. The height and width of the available bone around the potential site 
of the dental implant were assessed using a bone caliper.
2.3.2 Preoperative radiological screening assessment
An orthopantomogram (OPG) and intraoral periapical radiograph (IOPA) 
were taken preoperatively during patient selection and were kept in the patient’s 
record; they gave an indication about the location and proximity of the vital 
structures and anatomical landmarks, bone quality, quantity and the presence 
of sufficient bone height and width in terms of mesiodistal dimension around 
the dental implant, absence of pathological lesions that may affect the outcome 
of dental implant success (periapical cysts, granulomas, osteomyelitis), and 
the angulation and position of the potential dental implant in relation to the 
adjacent teeth.
2.3.3 Operative techniques
All patients underwent two stages of implant surgeries. Stage I implant sur-
gery was performed in which one SPI dental implant (THOMMEN Medical SPI 
ELEMENT MC INICELL) bone level type with a length of 9.5 mm and a diameter 
of 4 mm was positioned in the maxillary edentulous premolar area in each patient 
of the 22 sample size. A stage II implant surgery was carried on after 2 months of 
implant placement in which the dental implant had to be uncovered and impression 
was taken for crown installation.
2.3.3.1 Group I (ultrasound) group
1. The ultrasound group patients (n = 11) were then subjected to the applica-
tion of low-intensity pulsed ultrasound 2 weeks following stage I implant 
surgery placement. The machine employed was Gymna Pulson® 330 Belgium 
(Figure 2). The intensity of ultrasound therapy used was 30 mW/cm2 with 
a frequency of 1.5 MHz and temporal average power of 20 mW (Table 1). 
The therapy was delivered intraorally on the buccal part of the implant site 
for duration of 20 minutes twice a week starting 2 weeks after dental implant 
placement for the subsequent 10 weeks (Figure 3). At 2 months, uncovery and 
placement of gingival former for 10 days were carried on, then the impression 
taking was done for all patients, and installation of screw-retained porcelain 
to fused crown was performed 2 weeks later after the impression was taken. 
The same ultrasound therapy protocol was repeated 2 weeks after the crown 
installation for another 10 weeks.
2. Clinical data collections composed of resonance frequency analysis (RFA) 
value measurements using Osstell ISQ device (Figure 4) and linear measure-
ments of CBCT images at three different views were taken immediately after 
the placement of the implant and in the follow-up clinical examinations at 3 
and 6 months postoperatively.
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2.3.3.2 Group II (control)
The control group patients (n = 11) were not subjected to the application of 
ultrasound therapy. Those patients went through two stages of implant placement 
surgery. At stage I implant surgery, the dental implant was placed to replace a single 
missing maxillary premolar tooth. Uncovery and impression were taken for the 
dental implant at stage II implant surgery, and supra-structure prosthetic construc-
tion comprising of screw-retained porcelain fused to metal crown was inserted 
at 2 months postoperatively. Clinical data collections composed of resonance 
frequency analysis (RFA) value measurements using Osstell ISQ device and linear 
measurements of CBCT images at three different views were taken immediately 




Temporal average power 20 W
*Kerr et al. [65].
Table 1. 
Intraoral ultrasound device: technical specifications of the ultrasound signal.
Figure 2. 
The therapeutic ultrasound machine Gymna Pulson® 330 with intraoral probe and actual setting parameters 
on display.
Figure 3. 
Ultrasound therapy delivered using probe on the buccal aspect of the implant site.
13
Marginal Bone Changes around Dental Implants after LIPUS Application: CBCT Study
DOI: http://dx.doi.org/10.5772/intechopen.87220
2.4 Data collection
The CBCT scan of each patient was carried out at the Radiographic Department, 
University Dental Hospital Sharjah, Sharjah, United Arab Emirates. All patients 
underwent computed tomography scans using GALILEOS; then, the data are 
converted to DICOM format in which they get exported to USM to be processed 
using Planmeca Promexis 3D software, and then the data returned to UDHS where 
data collection started (Figure 5).
The machine used produces X-rays in cone shape that centers on the X area of 
the detector. Its tube detector system can be rotated at 360° around the patient’s 
head which exposes the patient for a series of images to be taken by GALILEOS/
Sirona Dental Systems Scan specifications summarized in Table 2.
The cone beam volumetric tomography (CBVT) X-ray unit used in this study 
was Planmeca ProMax 3D Max. It records the finest details of the patient’s oral 
anatomy. It offers a maximum field view (Ø23 × 26 cm) which explores new pos-
sibilities in diagnostic radiology. It has an advanced imaging software system that 
increases its benefits.
Figure 4. 
RFA measurement procedure, the probe close to the SmartPeg™. (A) At bucco-palatal and mesio-distal 
directions, a value of 70 reveals as primary stability on the day of implant placement surgery (B).
Figure 5. 
Flowchart of steps for data transformation from UDHS to USM.
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CBVT technology is utilized in Planmeca ProMax 3D Max. It is an advanced, 
multipurpose, and active imaging machine. It can be utilized in various fields of 
dentistry that include maxillofacial surgery, implantology, endodontic, ortho-
dontics, periodontics, and for the analysis of TMJ. The newly designed advanced 
ProMax has evolved into a classical 3D platform with CBVT.
Instead of a continuous beam, each volume is produced by throbbing the X-ray 
tube during the scanning. It reduces the dose as well as the rotational distortions 
during the scanning procedure. The total time required for scanning may be from 
18 to 26 seconds. However, the exact exposure time may be only 3 seconds. Accurate 
and distortion-free image for 3D construction is produced by the ScI semiconductor 
flat panel. Correction for geometric magnification is not required for the images 
produced by Planmeca ProMax 3D Max.
To ensure immobilization of the patient during exposure, standard methods 
have been taken as follow:
1. Frankfort plane of the patient parallel to the floor.
2. Midsagittal plane perpendicular to the floor.
3. The patient was asked to bite on the bite block of the machine using the upper 
and lower incisors to standardize patient’s position according to X-ray tube 
head rotation.
Lead apron was placed on each patient prior to exposure. All metallic objects 
(e.g., hairpins and earrings) and any intraoral removable prosthesis were 
removed.
3. Results
3.1 Radiological results using CBCT images
The orthopantomogram (OPG) was shown to be a useful tool for radiological 
screening of the patient during selection stage. Complex cases such as proxim-
ity to vital structures and inadequate bone height and width were excluded from 
the study. In the CBCT images obtained at day 0, there was adequate availability 
of bone height and width at the platform of dental implant for both groups. At 
3 months, there was an increase of buccal plate thickness of 0.3–0.6 mm in the 
Scanner name GALILEOS ComfortPLUS
Manufacturer Sirona Dental Systems GmbH, Bensheim, Germany
Detector type Image intensifier (I.I.), Thales or Siemens




Number of single exposures 200 200
Table 2. 
Specifications of CBCT machine used in Dental clinic, UDHS.
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ultrasound group compared to the control group. At 6 months, there was marginal 
bone loss around dental implant in the control group and marginal bone increase in 
height and width in the ultrasound group (Figure 6A–E).
3.2  Evaluation of marginal bone changes for both groups at different time 
intervals
CBCT images were obtained at day 0, 3, and 6 months follow-up. The marginal 
bone level was assessed and measured at three different views (coronal, sagittal, 
and axial) at time-point interval.
In the coronal view, there was an overgrowth of the bone width at corono-buccal 
and corono-palatal and less reduction of the bone height at apico-buccal and 
apico-palatal in the ultrasound group, but the bony tissue overgrowth was more 
pronounced at the buccal bone plate at 3 and 6 months rather than at the palatal 
bone plate. In the control group, the marginal bone loss was more in height and 
width than the in the ultrasound group (Table 3).
In the sagittal view, there was an overgrowth of the bone width at sagitto-mesial 
and sagitto-distal aspects of dental implants and less reduction of the bone height 
at apico-mesial and apico-distal in the ultrasound group, but the bony tissue 
overgrowth was more pronounced at the mesial bone plate at 3 and 6 months. In 
the control group, there was a reduction in the bone width and height from day 0 to 
6 months (Table 4).
In the axial view, the bony tissue overgrowth was revealed more at the axio-
buccal than axio-palatal at 3 and 6 months in the ultrasound group, while in 
the control group, there was marginal bone loss in all aspects of dental implant 
(Table 5).
Figure 6. 
Representative CBCT images of marginal bone level in the coronal view. Both groups showed an adequate 
availability of bone height and width at day 0 (A). An overgrowth of buccal bone plate thickness observed 
in the ultrasound group at 3 and 6 months (B, C). Marginal bone loss around dental implant observed in the 
control group at 3 and 6 months (D, E).
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Representative CBCT images of marginal bone level in the coronal view. Both groups showed an adequate 
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Day 0 CB** 1.43 (0.24) 1.43 (0.50)
CP# 1.44 (0.37) 1.42 (0.36)
3 months CB 1.62 (0.36) 0.92 (0.25)
CP 1.55 (0.34) 1.37 (0.26)
AB† 1.20 (0.73) 1.20 (0.39)
AP‡ 0.89 (0.83) 0.87 (0.74)
6 months CB 1.81 (0.41) 0.85 (0.30)
CP 1.62 (0.22) 1.02 (0.34)
AB 1.65 (0.73) 0.88 (0.29)
AP 1.02 (0.62) 0.76 (0.53)






Descriptive statistics of linear measurements (mean, SD) of marginal bone changes between ultrasound and 






Day 0 SM** 1.40 (0.30) 1.39 (0.41)
SD# 1.41 (0.35) 1.38 (0.34)
3 months SM 1.47 (0.39) 0.88 (0.26)
SD 1.46 (0.20) 0.92 (0.25)
AM† 0.89 (0.72) 0.83 (0.74)
AD‡ 0.87 (0.83) 0.84 (0.45)
6 months SM 1.66 (0.57) 0.65 (0.29)
SD 1.62 (0.23) 0.78 (0.30)
AM 1.18 (0.73) 0.75 (0.32)
AD 1.12 (0.60) 0.71 (0.40)






Descriptive statistics of linear measurements (mean, SD) of marginal bone changes between ultrasound and 
control groups in sagittal view (values in millimeters).
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3.3  Comparison of marginal bone changes within each group at three different 
views
In the coronal view, within the ultrasound group, there was statistically signifi-
cant increase in the buccal and palatal bones’ thickness (height and width) from 
day 0 to 3 months, day 0 and 6 months, and from 3 to 6 months as p value was less 
than 0.05, but it was more pronounced at the buccal bone plate, while in the control 
group, there was no statistically significant increase in bone thickness, and there 
was marginal bone loss at all aspects of 9*dental implant.
In the sagittal view, within the ultrasound group, there was statistically signifi-
cant increase in the mesial and distal bones’ thickness (height and width) from day 
0 to month 3, day 0 and month 6, and from month 3 to month 6 as p value was less 
than 0.05, while in the control group, there was no statistically significant increase 
in bone thickness, and there was marginal bone loss at all aspects of dental implant.
In the axial view, within the ultrasound group, there was statistically significant 
increase in the buccal, palatal, mesial, and distal bones’ thickness (height and 
width) from day 0 to 3 months, day 0 and 6 months, and from 3 months to month 
6 as p value was less than 0.05, while in the control group, there was no statistically 
significant increase in bone thickness.
3.4  Comparison of marginal bone changes between two groups at three 
different views
In the coronal view, there was statistically significant increase in buccal and 
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Descriptive statistics of linear measurements (mean, SD) of marginal bone changes between ultrasound and 
control groups in axial view (values in millimeters).
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3.3  Comparison of marginal bone changes within each group at three different 
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was marginal bone loss at all aspects of 9*dental implant.
In the sagittal view, within the ultrasound group, there was statistically signifi-
cant increase in the mesial and distal bones’ thickness (height and width) from day 
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than 0.05, while in the control group, there was no statistically significant increase 
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as p value was less than 0.05. Thus, this increase in bone plate width is contributed 
to ultrasound therapy. There was no statistically significant increase in buccal and 
palatal bone height at 3 months between ultrasound and control groups, but there 
was statistically significant increase in buccal and palatal bone height at 6 months. 
Thus, this increase in bone plate height is contributed by ultrasound therapy.
In the sagittal view, there was statistically significant increase in mesial and 
distal bone plates’ width between two groups (ultrasound and control) at 3 and 
6 months as p value was less than 0.05. Thus, this increase in bone plate thickness is 
contributed by ultrasound therapy. There was no statistically significant increase in 
mesial and distal bone height at 3 months between ultrasound and control groups, 
but there was statistically significant increase in mesial and distal bone height at 
6 months. Thus, this increase in bone plate height is contributed by ultrasound 
therapy.
In the axial view, there was statistically significant increase in buccal, palatal, 
mesial, and distal bone plates’ width between two groups (ultrasound and control) 
at 3 and 6 months as p value was less than 0.05. Thus, this increase in bone plate 
thickness is contributed by ultrasound therapy.
4. Discussion
4.1 Introduction of marginal bone loss around dental implant
Marginal bone loss is considered to be an inevitable risk factor in implant 
therapy. The reduction in height and width of marginal bone level affects the suc-
cess rate of implant treatment in terms of esthetic and function.
The majority of marginal bone loss occurs in the first year after implant place-
ment [67]. Thus, the clinical crown-to-implant ratio rises with time to become more 
unfavorable as years go by. However, the etiology of long-term marginal bone loss 
or late implant failure seems to be of different origin and prone to peri-implantitis 
or occlusal overload [68]. It is important to consider multiple factors together in 
assessing implant failure rates as interactive effects may be observed in the estab-
lishment and maintenance of osseointegration [69, 70]. Thus, in the present study, 
attempts were made to control the relevant confounding variables (patient gender 
and age, implant location, implant diameter and neck design, insertion torque, 
insertion depth, and crown-to-implant ratios).
In this study project, we tried to measure the marginal bone level around the 
implant and its stability both at the time of implant placement and at the time 
of loading. For this reason we chose the 3- and 6-month intervals to examine the 
marginal bone level and implant stability after soft and hard tissue maturation and 
early bone remodeling [71].
Ultrasound is the generation of sound waves with a frequency above the limit 
of human audibility of 20 kHz that transfers mechanical energy into the tissues; it 
is used extensively in sports medicine and physiotherapy. Therapeutic ultrasound 
can induce angiogenic and bone morphogenetic factors and bone formation 
in vitro [72].
Dinno et al. [73] demonstrated that intensities of ultrasound of less than 
100 mW/cm2 spatial average and temporal average were nonthermal. Duarte [63] 
and Pilla et al. [74] reported that low-intensity ultrasound treatment in the range 
of 30–57 mW/cm2 yielded minimal temperature changes when applied to the site of 
a bone fracture. Application of low-intensity pulsed ultrasound (30 mW/cm2) was 
considered to have little thermal effect.
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4.2 Clinical evaluation of application of ultrasound therapy
All patients in the ultrasound group tolerated the ultrasound therapy very well. 
The therapy was conducted over 20 minutes comfortably without any rejection from 
the patients. The results showed that the ultrasound therapy with the intensity set at 
30 mW/cm2 generated minimum heat that did not cause discomfort for the patients. 
Furthermore, the color of the gingival soft tissue remains pink and did not change 
to erythematic state at the end of the procedure which further proves there was no 
inflammation and untoward tissue response following the therapy. Therefore, the 
pain symptoms from patients were minimal as shown by minimal need for analgesia, 
and healing of the soft tissue wound in the ultrasound group was excellent. These 
clinical findings demonstrate wide acceptance of patients toward postoperative ultra-
sound therapy. Kamath et al. [75] in his study on the effect of LIPUS on healing of 
femur fracture revealed that there was more significant callous formation at the early 
stage of femur fracture in the LIPUS group than in the control group. Therefore, even 
in other parts of the body like femur, there are good results when LIPUS is applied.
In view of the increasing use of high-intensity and low-frequency ultrasonic 
technology, in medicine and in surgery, better understanding of the benefits or side 
effects of US application is significant in order to establish appropriate clinical stud-
ies. LIPUS has disadvantages besides the advantages as mentioned. Erdogan and 
Esen [76] showed that the effects of ultrasound therapy on growing bones and brain 
tissues are unclear. Thus, its use in children and in skull bones should be avoided. Its 
use in sites with suspected neoplasia and acute infections is contraindicated because 
of possible accelerated disease progression. Patients should be evaluated for allergic 
reactions to the coupling gel, and patients with cardiac pacemakers should avoid 
ultrasound treatment because of possible interaction with the ultrasound signals 
specially when using US with both high-intensity and high-frequency waves.
Miller et al. [77] mentioned that the induced heat by US is the result of the 
absorption of US energy in biological tissue and the heat can be concentrated by 
focused beams until tissue is coagulated for the purpose of tissue ablation. Unlike 
ultrasound for medical imaging (which transmits ultrasonic waves and processes a 
returning echo to generate an image), therapeutic ultrasound is a one-way energy 
delivery that might cause harmful effect in a cumulative way into the tissue, which 
utilizes a crystal sound head to transmit acoustic waves at 1–3 MHz and at amplitude 
densities between 0.1 and 3 W/cm2 [78]. US heating, which can lead to irreversible 
tissue changes, follows an inverse time-temperature relationship. Depending on the 
temperature gradients, the effects from ultrasound exposure can include mild heat-
ing, coagulative or liquefactive necrosis, tissue vaporization, or all three [77]. Angle 
et al. [79] demonstrated that the therapeutic ultrasound with frequencies varying 
between 0.5 and 1.5 MHz and intensities 30–200 mW/cm2 is known to promote 
healing, bone deposition, and growth. Nevertheless, therapeutic ultrasound is 
proposed to deliver energy to deep tissue sites through ultrasonic waves, to produce 
increases in tissue temperature or nonthermal physiologic changes [78].
Ebadi et al. [80] explained that ultrasonic energy causes soft tissue molecules 
to vibrate from exposure to the acoustic wave. This increased molecular motion 
generates frictional heat, thus increasing tissue temperature. The thermal effects 
of ultrasound are proposed to increase collagen extensibility, increase nerve con-
duction velocity, alter local vascular perfusion, increase enzymatic activity, alter 
contractile activity of skeletal muscle, and increase nociceptive threshold [78].
However, in our study, the intensity of LIPUS used was 30 mW/cm2, and 
the duration of application was only for 20 minutes, and this treatment was 
commenced 2 weeks after the acute inflammatory phase has subsided. We 
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as p value was less than 0.05. Thus, this increase in bone plate width is contributed 
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Ultrasound is the generation of sound waves with a frequency above the limit 
of human audibility of 20 kHz that transfers mechanical energy into the tissues; it 
is used extensively in sports medicine and physiotherapy. Therapeutic ultrasound 
can induce angiogenic and bone morphogenetic factors and bone formation 
in vitro [72].
Dinno et al. [73] demonstrated that intensities of ultrasound of less than 
100 mW/cm2 spatial average and temporal average were nonthermal. Duarte [63] 
and Pilla et al. [74] reported that low-intensity ultrasound treatment in the range 
of 30–57 mW/cm2 yielded minimal temperature changes when applied to the site of 
a bone fracture. Application of low-intensity pulsed ultrasound (30 mW/cm2) was 
considered to have little thermal effect.
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ies. LIPUS has disadvantages besides the advantages as mentioned. Erdogan and 
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tissues are unclear. Thus, its use in children and in skull bones should be avoided. Its 
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of possible accelerated disease progression. Patients should be evaluated for allergic 
reactions to the coupling gel, and patients with cardiac pacemakers should avoid 
ultrasound treatment because of possible interaction with the ultrasound signals 
specially when using US with both high-intensity and high-frequency waves.
Miller et al. [77] mentioned that the induced heat by US is the result of the 
absorption of US energy in biological tissue and the heat can be concentrated by 
focused beams until tissue is coagulated for the purpose of tissue ablation. Unlike 
ultrasound for medical imaging (which transmits ultrasonic waves and processes a 
returning echo to generate an image), therapeutic ultrasound is a one-way energy 
delivery that might cause harmful effect in a cumulative way into the tissue, which 
utilizes a crystal sound head to transmit acoustic waves at 1–3 MHz and at amplitude 
densities between 0.1 and 3 W/cm2 [78]. US heating, which can lead to irreversible 
tissue changes, follows an inverse time-temperature relationship. Depending on the 
temperature gradients, the effects from ultrasound exposure can include mild heat-
ing, coagulative or liquefactive necrosis, tissue vaporization, or all three [77]. Angle 
et al. [79] demonstrated that the therapeutic ultrasound with frequencies varying 
between 0.5 and 1.5 MHz and intensities 30–200 mW/cm2 is known to promote 
healing, bone deposition, and growth. Nevertheless, therapeutic ultrasound is 
proposed to deliver energy to deep tissue sites through ultrasonic waves, to produce 
increases in tissue temperature or nonthermal physiologic changes [78].
Ebadi et al. [80] explained that ultrasonic energy causes soft tissue molecules 
to vibrate from exposure to the acoustic wave. This increased molecular motion 
generates frictional heat, thus increasing tissue temperature. The thermal effects 
of ultrasound are proposed to increase collagen extensibility, increase nerve con-
duction velocity, alter local vascular perfusion, increase enzymatic activity, alter 
contractile activity of skeletal muscle, and increase nociceptive threshold [78].
However, in our study, the intensity of LIPUS used was 30 mW/cm2, and 
the duration of application was only for 20 minutes, and this treatment was 
commenced 2 weeks after the acute inflammatory phase has subsided. We 
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feel that this dosage of US therapy is harmless to the active cells in the healing 
wound which was in the proliferative phase. The dose recommended may be 
harmful to the cells in the healing wound because they are vulnerable to damage 
from heat generation or prolonged treatment duration. Therefore, although the 
mechanotransduction mechanism for cell stimulation following US therapy is an 
acceptable phenomenon, it may only work favorably within certain limitations of 
the delivered energy.
4.3 Evaluation of marginal bone level
CBCT images showed adequate availability of bone height and width at the 
dental implant platform at day 0 for both groups at the time of implant placement. 
In this study, results obtained using CBCT images were reliable for linear measure-
ments of bone thickness in height and width for both ultrasound-treated group 
and control group. CBCT enables us to expose the patient to low radiation doses, 
giving more comfort, and it is an economical procedure [81]. At 3 months, there 
was an increase of the mean difference of buccal bone plate width of 0.19 mm in the 
ultrasound group compared to the control group. At 6 months, there was a mean 
difference marginal bone loss of 0.58 mm in width of the buccal bone plate around 
the dental implant platform in the control group, while there was 0.38 mm increase 
in the mean difference of buccal bone width in the ultrasound group. These find-
ings were consistent with the previous study by Chen who investigated the effect 
of LIPUS on bone regeneration in the rat parietal bone defects [26]. In Chen study, 
the defects were analyzed with micro-CT (μCT) and then histologically, which 
demonstrated new bone formation with the newly formed thick and matured bone 
compared to the one of the control group.
The justification of using LIPUS in this study is to accelerate the bone wound 
healing processes within the region of interest (ROI) which is the region replacing 
single missing maxillary premolar following trauma to the bone as implant place-
ment surgery is considered to be a traumatic procedure even though the surgery is 
minimally invasive to the bone. Our aim in this study is to mimic what happened 
in natural tissue repair by inducing, triggering, and provocation of the cells related 
to bone formation by encouragement of mechanotransduction pathways involved 
in cell responses. These responses include integrin/mitogen-activated protein 
kinase (MAPK) and other kinase signaling pathways, gap-junctional intercellular 
communication, upregulation and clustering of integrins, involvement of the 
COX-2/PGE2 and iNOS/NO pathways, and activation of mechanoreceptor [44]. 
Mechanotransduction involves various signal transduction pathways, including 
the activation of ion channels and other mechanoreceptors in the membrane of the 
bone cell, resulting in gene regulation in the nucleus [42].
Based on time intensity and period of exposure of cells to waves of ultrasound, 
LIPUS can recruit mesenchymal stem cells from neighboring tissues and other 
sites in the body in attractive processes (chemotactic) with other biomedical 
pro- inflammatory mediators (growth factors) that are considered necessary in 
bone wound healing processes and trigger it from inactive form to active phase 
when LIPUS is used. This suggests that LIPUS is able to enhance osteogenesis and 
angiogenesis in vivo and in vitro as was well documented by literature review that 
angiogenesis precede osteogenesis process [54]. Angiogenesis is closely associated 
with osteogenesis where reciprocal interactions between endothelial and osteoblast 
cells play an important role in bone regeneration [55].
In our study, the marginal bone level was assessed and measured at three 
different views (coronal, sagittal, and axial) in which four points were located and 
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measured per implant site (corono-buccal, corono-palatal, apico-buccal, apico-
palatal, sagitto-mesial, sagitto-distal, apico-mesial, apico-distal, axio-buccal, 
axio-palatal, axio-mesial, and axio-distal), respectively, and at three different 
time intervals postoperatively at day 0, 3, and 6 months. The results of this study 
showed an increase in buccal bone width from 1.43 mm at day 0 to 1.81 mm at 
6 months which revealed that the mean difference of buccal bone plate width 
increased by 0.38 mm, while the palatal bone mean difference width was also 
increased by 0.18 mm at 6 months. In the sagittal view, there was an increase of 
mean difference of 0.26 mm at the mesial aspect of the dental implant at 6 months 
in the ultrasound group compared to the control group that had marginal bone 
loss from 1.43 mm at day 0 to 0.85 mm at 6 months at the buccal bone plate in the 
coronal view. The reason why the height and width of bone thickness had increased 
in the ultrasound compared to the control is that LIPUS can promote bone healing 
and repair by inducing osteogenesis and angiogenesis. Earlier work has shown that 
the therapeutic range of US stimulates bone formation, osteoblast proliferation, 
and the synthesis of angiogenic vascular endothelial growth factor (VEGF), basic 
fibroblast growth factor (FGF), and interleukin 8 [72, 82]. Ramli et al. [83] have 
proven that ultrasound should be considered to have angiogenic and osteogenic 
values in their in vivo study looking at ultrasound effects on angiogenesis using 
the chick chorioallantoic membrane. In vitro ultrasound has also been shown to 
upregulate the release of the osteogenic cytokine OPG and downregulate RANKL, 
the ligand of the receptor activator nuclear factor kappa B, which recruits and 
activates osteoclasts [83].
In this study, the transducer was applied on the buccal aspect of the dental 
implant very close to the buccal bone plate and showed clinically that at 1.5 MHz 
frequency, a penetration of up to 2 cm is possible, thus influencing the palatal 
plate. Ramli et al. [83] demonstrated that the traditional 1- to 3-MHz frequency of 
ultrasound therapy has a penetration of up to 2 cm. Doan et al. [72] reported that 
the best effect of therapeutic ultrasound on angiogenesis occurs with intensities 
between 15 and 30 mW/cm2 and a frequency of 45 kHz, as the long wave machine 
has a theoretical advantage of penetrating tissues up to 10 cm.
Results of the control group showed increased loss of bone height from 1.20 mm 
at 3 months to 0.88 mm at 6 months at the apico-buccal aspect of the dental 
implant and increased marginal bone loss (MBL) in width from 1.43 mm at day 0 to 
0.85 mm at 6 months as compared with LIPUS-treated group. It reveals that LIPUS 
has a positive effect on the healing of bone, and the loss of marginal bone in the 
control group was contributed by not using US therapy. This finding is consistent 
with those of [26, 84–86].
Angle et al. [79] explained in his vitro study, using rat bone marrow stromal 
cells that the LIPUS intensities below 30 mW/cm2 are able to provoke phenotypic 
responses in bone cells. They cultured bone cells under defined conditions with 
intensities of 2, 15, and 30 mW/cm2, compared them with the control group 
(0 mW/cm2), and then studied them at early (cell activation), middle (dif-
ferentiation into osteogenic cells), and late (biological mineralization) stages of 
osteogenic differentiation. They concluded that LIPUS with intensities of 2, 15, 
and 30 mW/cm2 showed a positive effect on osteogenic differentiation of rat bone 
marrow stromal cells in early stage compared with the control group. Monden 
et al. [87] also suggested that the injured bone may be treated with LIPUS, as 
LIPUS has the capability to induce the cellular as well as molecular pathways of 
bone healing. LIPUS treatment matures the newly formed bone in the cortical 
bone area producing bone differentiation markers, osteocalcin (OCN) and osteo-
pontin (OPN), and reduces the depression by enhancing the periosteal cellular 
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differentiation. In vitro studies have shown that LIPUS leads to the increased 
expression of genes related to the bone formation. These genes include osteocal-
cin, aggrecan, bone sialoprotein, insulin-like growth factor-I, collagen types I 
and X, transforming growth factor beta, alkaline phosphatase, and runt-related 
gene-2 [88, 89].
Additionally, LIPUS treatment also promotes the synthesis of protein and 
uptake of calcium by osteoblasts. LIPUS treatment also plays an important role 
in the remodeling of the bone by stimulating the cyclooxygenase pathway. LIPUS 
increases the expression of COX-2 gene that promotes the synthesis of prostaglan-
din E2 (PGE2) in the osteoblasts [88, 89].
Huang et al. [90] concluded in his recent study in vitro that the LIPUS stimu-
lates the expression of BMP-2 which means positive effects of LIPUS on osteogen-
esis. In vitro study by Sun et al. [91] showed that LIPUS upregulated osteoblasts 
and downregulated osteoclasts in the rat alveolar mononuclear cells. Lu et al. [92] 
explained that the mechanical signals from LIPUS could stimulate osteoblasts by 
means of gene expression and stimulated proteins that were translated by these 
genes causing activation of apoptotic genes and osteogenesis in acceleration 
of the tissue remodeling and expedite clinical outcomes as we have seen in our 
current study.
Iwanabe et al. [93] demonstrated in his recent study in vitro that the number 
of cells at 5 days after LIPUS exposure was significantly higher than that of the 
control, while that at 7 days was about 35% higher than that of the control. This 
means that LIPUS has the potential to be an effective agent in inducing migration, 
proliferation, and cell differentiation.
In vitro as well as in vivo studies, using animal models showed that LIPUS 
has stimulatory effect on cellular activity, release of cytokines, and bone heal-
ing [94]. Cell physiology is directly affected by LIPUS. It increases the uptake of 
calcium by the developing cartilage and bone cells in the culture. It also stimulates 
a large number of genes that help in the process of healing [62]. Barzelai et al. [95] 
reported that LIPUS not only modulates the expression of genes, but it also 
enhances the process of angiogenesis and increases the flow of blood at the site of 
fracture.
4.4 Clinical significance
• LIPUS may be utilized as treatment modality to save dental implant with 
questionable primary stability during stage I implant placement, with the aim 
of achieving adequate osseointegration and improving implant success.
• LIPUS can be recruited to promote and accelerate healing time particularly in 
patients with medical conditions such as diabetes mellitus and other diseases.
• The clinical results shown in this study confirmed that low-intensity pulsed 
ultrasound (LIPUS) presents low toxicity, noninvasiveness, and repeated 
applicability. The risk of thermal injury is unfounded.
• Application of LIPUS on dental implant wound at 2 weeks postoperative seems 
to be a favorable time when the acute inflammatory phase has subsided and the 
cellular proliferative phase has actively began.
• RFA gives clear image about the stability of the implant and the condition of 
the bone around implant.
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5. Conclusion
5.1 Summary and conclusion
Animal experiments using LIPUS for healing of wounds have shown effective 
and favorable results with histological evidence. The effects of the ultrasound 
waves on the cell and molecular biology phenomena of wound healing have further 
confirmed the fundamental mechanisms underlying this interesting wound healing 
treatment modality. However, we still lack clinical studies in this field, and our 
study is one of the few clinical trials of the effect of ultrasound therapy on osseo-
integration and marginal bone loss around implant-supported prosthesis, which 
showed favorable results. We have compared and contrasted two groups of patients 
receiving implant therapy where the first group was given LIPUS during the early 
healing period and post loading as an additional treatment modality and the second 
group was allowed to heal in the conventional way. Comparative bone thickness 
measurements using CBCT images and implant stability measurements using RFA 
values showed consistently higher stability with an increase in bone thickness 
(height and width), and the ultrasound therapy group demonstrated much higher 
implant stability values than the control group.
The overall clinical results contribute to the following findings:
• LIPUS enhances bone formation around dental implants as confirmed by 
radiological investigations, RFA values, and pre and post prosthetic loading 
behaviors.
• LIPUS technique employed in this study promoted increased in buccal bone 
plate height and width much more than that occurred in the palatal side. This 
may be attributed to the design of the US delivery probe.
• With an increase in bone height and width, we expect a simultaneous increase 
in bone-implant contact that leads to higher osseointegration as evidenced by 
RFA values.
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a large number of genes that help in the process of healing [62]. Barzelai et al. [95] 
reported that LIPUS not only modulates the expression of genes, but it also 
enhances the process of angiogenesis and increases the flow of blood at the site of 
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Abstract
Demineralized bone matrices (DBMs) have been used in a wide variety of clinical 
applications involving bone repair. Ideally, DBMs should provide osteoinductive and 
osteoconductive properties, while offering versatile handling capabilities. With this, 
a novel fiber technology, LifeNet Health-Moldable Demineralized Fibers (L-MDF), 
was recently developed. Human cortical bone was milled and demineralized to 
produce L-MDF. Subsequently, the fibers were lyophilized and terminally steril-
ized using low-dose and low-temperature gamma irradiation. Using L929 mouse 
fibroblasts, L-MDF underwent cytotoxicity testing to confirm lack of a cytotoxic 
response. An alamarBlue assay and scanning electron microscopy demonstrated 
L-MDF supported the cellular function and attachment of bone-marrow mesen-
chymal stem cells (BM-MSCs). Using an enzyme-linked immunosorbent assay, 
L-MDF demonstrated BMP-2 and 7 levels similar to those reported in the literature. 
In vivo data from an athymic mouse model implanted with L-MDF demonstrated the 
formation of new bone elements and blood vessels. This study showed that L-MDF 
have the necessary characteristics of a bone void filler to treat osseous defects.
Keywords: demineralized bone matrix, osteoinductive, osteoconductive, allograft, 
growth factors, bone formation
1. Introduction
Bone voids may occur due to trauma, surgery, tumor resections, or other fac-
tors. For decades, surgeons have used bone grafting to treat a wide variety of bone 
defects. Bone grafts may contain up to three of the vital properties necessary for 
bone formation: osteoconductivity, osteoinductivity, and osteogenicity [1]. The 
property of osteoconductivity describes the way the graft acts as a scaffold on which 
host cells can attach and proliferate, leading to osseointegration. Osteoinductivity, 
on the other hand, describes the cellular signaling potential of a graft. Whether 
endogenous or recombinant, specific growth factors, such as bone morphogenetic 
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1. Introduction
Bone voids may occur due to trauma, surgery, tumor resections, or other fac-
tors. For decades, surgeons have used bone grafting to treat a wide variety of bone 
defects. Bone grafts may contain up to three of the vital properties necessary for 
bone formation: osteoconductivity, osteoinductivity, and osteogenicity [1]. The 
property of osteoconductivity describes the way the graft acts as a scaffold on which 
host cells can attach and proliferate, leading to osseointegration. Osteoinductivity, 
on the other hand, describes the cellular signaling potential of a graft. Whether 
endogenous or recombinant, specific growth factors, such as bone morphogenetic 
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protein 2 (BMP-2), attract host cells to a graft and encourage mesenchymal stem cells 
to differentiate into lineage-committed bone cells. Finally, osteogenicity describes 
the ability of a bone graft to form bone matrix directly, which can only happen when 
live cells capable of producing bone matrix are contained within the graft. Bone graft 
options may contain varying amounts of these properties and are chosen based on the 
characteristics that the patient needs in order to achieve bone fusion. There are several 
graft options available, including autograft, synthetic bone substitutes, and allografts.
Autologous bone is harvested from the site of surgery in the patient or a second 
site, such as the iliac crest. It is still considered the gold standard by many surgeons 
because it can theoretically provide all three vital properties for bone formation, 
does not provoke an immune response, and has a long history of use. However, the 
use of autograft bone is associated with several disadvantages such as donor site 
morbidity, insufficient supply, and variable quality [2, 3]. Up to 30% of patients 
experience significant donor site morbidity as well as infection risk, increased 
operative time, blood loss, and the potential for arterial and nerve injury [4]. 
Additionally, autograft is limited, and the quality may be poor depending on the 
patient’s health. For example, diabetes, low bone mass, and smoking can all increase 
the risk of fusion failure as well as intraoperative complications [5].
Synthetic bone substitutes are designed with the goal of mimicking the natural 
properties of human bone. They can be comprised of a variety of materials including 
but not limited to, ceramics, cements, and bioactive glass. These grafts are generally 
biocompatible, osteoconductive, and may be mechanically similar to bone [6, 7]. This 
category of graft has typically been manufactured to contain porosity similar to bone, 
but may lack other desirable surface properties, such as hydrophilicity or a rough 
surface on which cells can attach. Synthetic bone substitutes have gained popular-
ity due to reduced cost and ready availability; however, they may have mismatched 
resorption rates compared to bone and generally lack osteogenic and osteoinductive 
properties [8]. Some synthetics, such as recombinant human BMP-2, depend almost 
solely upon osteoinductivity and often result in rapid bone formation. However, 
several studies indicate substantial side effects, including osteolysis, heterotopic bone 
formation, and swelling/edema [9–11]. While synthetics have improved over the 
last few decades, mimicking natural bone has proven difficult, and allografts, being 
natural bone, have continued to be a reliable source of grafting material.
Allograft bone is obtained from deceased human donors and has a long his-
tory of use. It is readily available in a variety of forms, shapes, and sizes provid-
ing surgeons with several graft options suitable for various procedures [12–14]. 
Allografts can provide up to all three properties necessary for bone formation. For 
example, mineralized bone allografts have similar osteoconductive properties to 
autograft while avoiding complications such as donor site morbidity [15]. Some 
mineralized grafts have been processed to increase desirable characteristics such as 
increased surface area on which cells can attach as well as increased coefficient of 
friction to prevent the graft from shifting once implanted. Other allografts, such as 
demineralized bone matrix (DBM) are both osteoconductive and osteoinductive. 
To produce DBMs, acid demineralization is used to remove a portion of the mineral 
component of bone, thus exposing the active signaling proteins necessary to induce 
new bone formation. The ability of DBMs to facilitate bone healing was demon-
strated in clinical applications as early as 1889 when Dr. Nicholas Senn reported 
using demineralized bone as a vehicle for antiseptics to treat patients with osteo-
myelitis [16]. However, it was not until 1965, when Dr. Marshall Urist characterized 
specific proteins trapped within the bone matrix, that it was understood that bone 
morphogenetic proteins (BMPs) contributed to the osteoinductive property of 
DBMs [17]. Since the discovery of BMPs, other proteins, such as those associated 
with angiogenesis, have also been found to contribute to the process of bone healing 
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and regeneration [18]. In addition to containing active signaling proteins, optimal 
surface characteristics of DBMs are essential for supporting cellular attachment and 
proliferation. For example, it is crucial to provide enough space for blood vessel for-
mation and for the patient’s own cells to migrate into and proliferate on the scaffold 
[19, 20]. Therefore, some allograft processors work to maintain ideal porosity for 
cell migration and angiogenesis. Other processes are designed to create a hospitable 
topography for cell attachment and proliferation as well as to enhance handling 
characteristics to facilitate implantation and mitigate migration.
DBMs are available in varying forms, including powders, putty, strips, and 
moldable paste. These grafts often contain carriers such as glycerol, starch, or hyal-
uronic acid to improve handling. Without a carrier, bone grafts may be difficult to 
implant in the desired area, or may drift away from the area during surgical irriga-
tion or exposure to blood. However, despite improved handling characteristics, it 
has been reported that some carriers may inhibit osteoinductive potential [21]. In 
addition, a carrier dilutes the bone concentration and may easily elute from the sur-
gical site, effectively reducing the implant volume. With these limitations in mind, 
a novel DBM with unique fiber technology was recently developed as described in 
Section 2. These fibers (Figure 1) are composed solely of demineralized cortical 
bone and are designed to provide surface features conducive for cellular attachment 
and easily moldable handling characteristics, all without the addition of a carrier. 
The purpose of this chapter is to present original research, detailing the composi-
tion, osteoinductive nature, cell attachment properties and endogenous bone 
growth factor content of these bone fibers through in vivo and in vitro test methods.
2. Methodology
2.1 Fiber generation
The fibers described here are referred to as L-MDF (LifeNet Health-Moldable 
Demineralized Fibers, LifeNet Health, Virginia Beach, VA and clinically available as 
part of PliaFX® and OraGRAFT® Prime brands). The particular fibers studied below 
were prepared from human cortical long bones that were aseptically recovered from 
donors, debrided, and disassociated from marrow and trabecular bone. The result-
ing tissue was processed by a proprietary computer numerical controlled-milling 
method (CNC-milled) into long fibers and disinfected using a proprietary process. 
The fibers were then demineralized using proprietary procedures. Following 
demineralization, fiber samples were taken to quantify residual calcium levels 
(average 1.7%) using a calcium reagent kit (Eagle Diagnostics, Cedar Hill, TX). 
Figure 1. 
Rehydrated moldable demineralized fibers.
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tion or exposure to blood. However, despite improved handling characteristics, it 
has been reported that some carriers may inhibit osteoinductive potential [21]. In 
addition, a carrier dilutes the bone concentration and may easily elute from the sur-
gical site, effectively reducing the implant volume. With these limitations in mind, 
a novel DBM with unique fiber technology was recently developed as described in 
Section 2. These fibers (Figure 1) are composed solely of demineralized cortical 
bone and are designed to provide surface features conducive for cellular attachment 
and easily moldable handling characteristics, all without the addition of a carrier. 
The purpose of this chapter is to present original research, detailing the composi-
tion, osteoinductive nature, cell attachment properties and endogenous bone 
growth factor content of these bone fibers through in vivo and in vitro test methods.
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2.1 Fiber generation
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were prepared from human cortical long bones that were aseptically recovered from 
donors, debrided, and disassociated from marrow and trabecular bone. The result-
ing tissue was processed by a proprietary computer numerical controlled-milling 
method (CNC-milled) into long fibers and disinfected using a proprietary process. 
The fibers were then demineralized using proprietary procedures. Following 
demineralization, fiber samples were taken to quantify residual calcium levels 
(average 1.7%) using a calcium reagent kit (Eagle Diagnostics, Cedar Hill, TX). 
Figure 1. 
Rehydrated moldable demineralized fibers.
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The demineralized fibers were then freeze-dried, placed in final packaging, and 
treated via low-dose, low-temperature gamma irradiation, at a level necessary to 
achieve a sterility assurance level (SAL) of 10−6.
2.2 Cytotoxicity testing of L-MDF using L929 mouse fibroblasts
The cytotoxic potential of L-MDF were quantitatively evaluated by the MTT 
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay using L929 
mouse fibroblasts. Three samples of 2.5 cc from each of the six donors (n = 18) 
were rehydrated with 5 mL sterile saline (0.99% w/v sodium chloride in water). 
Sample extracts were prepared by incubating 0.2 g of each sample with 1 mL of 
extraction medium (Minimum Essential Medium supplemented with 10% v/v 
fetal bovine serum, 100 U mL−1 penicillin, 100 μg mL−1 streptomycin, and 2 mM 
l-glutamine) for 24 ± 2 h at 37 ± 1°C. Negative and positive controls were prepared 
similarly. Extraction medium alone was used as an untreated control “extract” for 
quantitative comparison of results. L929 mouse fibroblasts were cultured in 96-well 
microplates to half-confluency and subsequently exposed to 100 μL of sample or 
control extracts for 24–26 h at 37 ± 1°C. Following extract exposure, cell viability of 
each well was measured using a MTT assay. The average results for each group were 
normalized to the untreated control to determine a percent viability. Per ISO 10993-
5:2009, percent viability less than 70% indicates a cytotoxic effect.
2.3 In vitro metabolic activity of seeded bone marrow-mesenchymal stem cells
Human bone marrow-derived mesenchymal stem cells (BM-MSCs) seeded on 
L-MDF were measured for metabolic activity using an alamarBlue® assay (Bio-Rad, 
Raleigh, NC) over the course of 7 days. L-MDF from six donors were placed in tripli-
cate in low-attachment 24-well cell culture plates at a density of 13.1 mg of fiber per 
cm2 and seeded with BM-MSCs at 62,500 cells per well on day 0. BM-MSCs without 
fibers served as the control. After 2–4 h in culture, 1 mL of complete media was 
added to each well, followed by incubation at 37°C. Samples remained in the incuba-
tor until specific time points designated for analysis, at which point media was 
replaced. The metabolic activity of cells adhered to the fibers was measured after 1, 
4 and 7 days in culture. At each time point media was aspirated and replaced with 
1 mL of 10% alamarBlue reagent and incubated for an average of 2 h at 37°C. The 
solution was collected from each sample, centrifuged to pellet any debris, and mea-
sured in a 96-well plate at 544 nm excitation/592 nm emission. Fluorescence was 
recorded using relative fluorescence units (RFUs), and values were normalized to 
its time-matched control. A one-way ANOVA in conjunction with a Tukey post-hoc 
was used to determine differences in metabolic activity over time.
2.4 In vitro cellular attachment of seeded bone marrow-mesenchymal cells
Scanning electron microscopy (SEM) was used to qualitatively evaluate the attach-
ment and morphology of cells seeded on four L-MDF samples (25 ± 1 mg) at 0.5–1 h, 
1 and 7 days in culture. The fibers were placed in separate glass scintillation vials 
with 1 mL of complete media and incubated at 37°C. Following incubation, excess 
media was aspirated and BM-MSCs were seeded at 100,000 per cells per vial. At each 
time point, corresponding vials were removed from the incubator, excess media was 
removed, and 3 mL of 2.5% glutaraldehyde in cacodylate buffer was added to fix the 
samples. Cell-seeded samples were rinsed in 0.1 M cacodylate buffer, incubated in 
1% osmium tetroxide for 60 min, and then dehydrated in a series of ethanol solutions 
increasing in concentration up to 100%. Samples were then dried via evaporation of a 
chemical drying agent, hexamethyldisilazane (HMDS). Prior to imaging, all samples 
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were sputter coated in gold palladium for 200 s at 60 mA, then secured to a holder that 
was placed inside a vacuum-sealed imaging chamber. Samples were then imaged at a 
magnification 3000× using a Zeiss Gemini HD Scanning Electron Microscope.
2.5 In vitro growth factor analysis
L-MDF were analyzed for the presence of BMP-2 and BMP-7 using an enzyme-
linked immunosorbent assay (ELISA) (R&D Systems, Minneapolis MN). L-MDF 
from six donors were weighed (30 ± 10 mg per donor) and placed in microcentri-
fuge tubes. Samples were then rehydrated with 5 μL of Dulbecco’s Modified Eagle 
Medium (DMEM) per milligram of fiber, followed by the addition of purified col-
lagenase (14.47 Units/mg of fiber). The samples were digested at 37°C with constant 
mixing for 16–18 h. Digestion solutions were centrifuged to remove remaining 
undigested components and the supernatants were collected for testing. The result-
ing solutions were analyzed for BMP content in triplicate using an ELISA assay. The 
measured BMP content was averaged across all six donors and results were reported 
in ng protein/g of demineralized fibers.
2.6 In vivo osteoinductive potential (OI)
The osteoinductive potential of L-MDF was evaluated using an in vivo athymic 
mouse model at NAMSA (Northwood, Ohio) following American Society for 
Testing and Materials (ASTM) F-2529 guidelines. Four 20–25 mg replicates of 
L-MDF were rehydrated with 100–150 μL of sterile 0.9% w/v sodium chloride and 
loaded into 0.3 cc sterile syringes. Samples were then compressed to remove excess 
solution, and implanted bi-laterally between the biceps femoris and superficial glu-
teal muscle of athymic mice. All mice were euthanized 5 weeks post-implantation 
by carbon dioxide inhalation. Explants were fixed with 10% formalin and bisected 
along the long axis. Bisects of each explant were paraffin embedded, and three 
slides were generated each with 4–6 μm-thick tissue sections. Once stained with 
hematoxylin and eosin (H&E), slides were evaluated by a blinded pathologist. The 
presence of cartilage, chondroblasts, chondrocytes, osteoblasts, osteocytes, osteoid, 
newly formed lamellar bone, and bone marrow were evaluated as new bone ele-
ments as they are indicators of endochondral bone formation process.
3. Results
3.1 Cytotoxicity
Cytotoxicity assay results showed that negative and positive controls behaved as 
expected (i.e., percent viability ≥70% for the negative control groups and <70% for 
the positive control groups). The average percent viability for negative and positive 
controls were 94 and 4%, respectively. The average percent viability of L-MDF 
(91%) was above the 70% threshold, and thus, based on the criteria of the protocol 
and ISO 10993-5 guidelines, L-MDF are considered to be non-cytotoxic.
3.2  L-MDF supports attachment and sustained metabolic activity of bone 
marrow-mesenchymal stem cells
Overall, the cellular activity of the BM-MSCs was shown to significantly increase 
over the course of the 7 day investigation. The results indicated that cells seeded 
on L-MDF showed a significant increase in proliferation between days 4 (51.3 ± 1.2 
RFU) and 7 (59.5 ± 1.5 RFU) compared to day 1 (21.3 ± 0.8 RFU) (Figure 2).
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its time-matched control. A one-way ANOVA in conjunction with a Tukey post-hoc 
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media was aspirated and BM-MSCs were seeded at 100,000 per cells per vial. At each 
time point, corresponding vials were removed from the incubator, excess media was 
removed, and 3 mL of 2.5% glutaraldehyde in cacodylate buffer was added to fix the 
samples. Cell-seeded samples were rinsed in 0.1 M cacodylate buffer, incubated in 
1% osmium tetroxide for 60 min, and then dehydrated in a series of ethanol solutions 
increasing in concentration up to 100%. Samples were then dried via evaporation of a 
chemical drying agent, hexamethyldisilazane (HMDS). Prior to imaging, all samples 
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were sputter coated in gold palladium for 200 s at 60 mA, then secured to a holder that 
was placed inside a vacuum-sealed imaging chamber. Samples were then imaged at a 
magnification 3000× using a Zeiss Gemini HD Scanning Electron Microscope.
2.5 In vitro growth factor analysis
L-MDF were analyzed for the presence of BMP-2 and BMP-7 using an enzyme-
linked immunosorbent assay (ELISA) (R&D Systems, Minneapolis MN). L-MDF 
from six donors were weighed (30 ± 10 mg per donor) and placed in microcentri-
fuge tubes. Samples were then rehydrated with 5 μL of Dulbecco’s Modified Eagle 
Medium (DMEM) per milligram of fiber, followed by the addition of purified col-
lagenase (14.47 Units/mg of fiber). The samples were digested at 37°C with constant 
mixing for 16–18 h. Digestion solutions were centrifuged to remove remaining 
undigested components and the supernatants were collected for testing. The result-
ing solutions were analyzed for BMP content in triplicate using an ELISA assay. The 
measured BMP content was averaged across all six donors and results were reported 
in ng protein/g of demineralized fibers.
2.6 In vivo osteoinductive potential (OI)
The osteoinductive potential of L-MDF was evaluated using an in vivo athymic 
mouse model at NAMSA (Northwood, Ohio) following American Society for 
Testing and Materials (ASTM) F-2529 guidelines. Four 20–25 mg replicates of 
L-MDF were rehydrated with 100–150 μL of sterile 0.9% w/v sodium chloride and 
loaded into 0.3 cc sterile syringes. Samples were then compressed to remove excess 
solution, and implanted bi-laterally between the biceps femoris and superficial glu-
teal muscle of athymic mice. All mice were euthanized 5 weeks post-implantation 
by carbon dioxide inhalation. Explants were fixed with 10% formalin and bisected 
along the long axis. Bisects of each explant were paraffin embedded, and three 
slides were generated each with 4–6 μm-thick tissue sections. Once stained with 
hematoxylin and eosin (H&E), slides were evaluated by a blinded pathologist. The 
presence of cartilage, chondroblasts, chondrocytes, osteoblasts, osteocytes, osteoid, 
newly formed lamellar bone, and bone marrow were evaluated as new bone ele-
ments as they are indicators of endochondral bone formation process.
3. Results
3.1 Cytotoxicity
Cytotoxicity assay results showed that negative and positive controls behaved as 
expected (i.e., percent viability ≥70% for the negative control groups and <70% for 
the positive control groups). The average percent viability for negative and positive 
controls were 94 and 4%, respectively. The average percent viability of L-MDF 
(91%) was above the 70% threshold, and thus, based on the criteria of the protocol 
and ISO 10993-5 guidelines, L-MDF are considered to be non-cytotoxic.
3.2  L-MDF supports attachment and sustained metabolic activity of bone 
marrow-mesenchymal stem cells
Overall, the cellular activity of the BM-MSCs was shown to significantly increase 
over the course of the 7 day investigation. The results indicated that cells seeded 
on L-MDF showed a significant increase in proliferation between days 4 (51.3 ± 1.2 
RFU) and 7 (59.5 ± 1.5 RFU) compared to day 1 (21.3 ± 0.8 RFU) (Figure 2).
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SEM images confirmed BM-MSC attachment to L-MDF within 30 min of seeding. 
Cells appeared rounded with numerous folds and ridges and minimal surface contact 
(Figure 3A). After 1 h in culture, BM-MSCs became elongated and began spreading 
and increasing surface contact with the fibers (Figure 3B). After 1 day, imaging 
showed flattened cells with multiple adhesion points and cellular extensions as well 
as extracellular matrix (ECM) secretion (Figure 3C). By day 7 in culture, BM-MSCs 
infiltrated between fibers and demonstrated cell-to-cell interactions (Figure 3D).
Figure 3. 
Representative SEM images illustrating the morphology of cells attached to L-MDF. Following culture for 
30 min (A), 1 h (B), 1 day (C) or 7 days (D), respectively, the samples were fixed in 2.5% glutaraldehyde 
and processed for scanning electron microscopy. Images are representative of all samples evaluated and were 
taken at 3000× magnification. Scale bar represents 10 μm. Images were pseudo-colored in Adobe Photoshop to 
distinguish the cells (in yellow) from the fibers.
Figure 2. 
Proliferation of BM-MSCs attached to L-MDF over 7 days. The average relative fluorescence unit (RFU) 
values for each set of triplicate test samples were normalized to the average RFU of the corresponding control 
group (fibers of the respective donor cultured without cells) for all six donors. Asterisks represent statistically 
significant differences from day 1 proliferation activity.
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3.3  L-MDF contains important growth factors and demonstrates new bone 
formation in vivo
The ELISA results indicated the presence of growth factors in L-MDF. The 
average BMP-2 and 7 concentrations in the samples fibers were 11.24 ± 1.49 and 
85.78 ± 6.84 ng/g, respectively (Figure 4).
Additionally, in the athymic mouse muscle pouch model, histological analysis 
revealed new bone elements around and within the implanted scaffold at time of 
sacrifice (5 weeks; Figure 5). Panel A shows a set of merged images that illustrate 
Figure 4. 
BMP-2 and BMP-7 content in L-MDF. L-MDF produced from six different donors were digested in collagenase 
for 16–18 h. Using ELISAs, the resulting digestion solutions were tested for BMP-2 and BMP-7 content in 
triplicate (mean ∓ SE).
Figure 5. 
H&E staining of explants from an athymic nude mouse implanted with L-MDF (*). Merged set of H&E 
images showing new bone elements present in the entire explant at 35 days post-implantation (4× objective). 
Expanded areas show the presence of new bone elements such as cartilage (^), chondroblasts/cytes (#), bone 
marrow ($), new blood vessels (&), and new bone (+) around L-MDF implant (*) at 35 days.
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new bone elements present in the explant (4× objective). Panels B and C highlight 
the presence of new bone elements such as cartilage, chondroblasts/cytes, bone 
marrow, new blood vessels, and new bone.
4. Discussion
Demineralized bone matrices (DBMs) are widely used in spinal, orthopedic, 
craniomaxillofacial, and dental procedures to treat bone voids. An ideal DBM 
provides both osteoinductive and osteoconductive properties to promote new 
bone formation and provide a scaffold upon which cells can attach and proliferate. 
Furthermore, DBMs should be malleable and resist graft migration once impacted 
into a bone defect. To achieve these characteristics important for bone healing, 
manufacturers use a variety of techniques to process and sterilize DBMs. Despite 
demineralization being a well-known technique, the proportion of the osteoinduc-
tive element—the demineralized bone—of clinically available DBM-based graft 
materials varies widely by manufacturer. Differences in carrier material and steril-
ization may also contribute to variability among these grafts. The moldable demin-
eralized fibers described here represent a recently developed allograft configuration 
that can function as an independent bone void filler without the need of a synthetic 
carrier. This study was conducted to ensure L-MDF possess the necessary qualities 
to function in this capacity.
An osteoinductive bone graft has the ability to induce bone growth. Factors such 
as residual calcium level and growth factor content play important roles in a DBM’s 
ability to grow bone. In particular, residual calcium level can serve as an indicator 
for the availability of growth factors necessary for bone formation. The literature 
suggests that DBMs with different degrees of residual calcium show significant 
differences in osteoinductivity. Zhang et al. evaluated the effects of varying degrees 
of demineralization, particle size, donor age, and gender on the osteoinductivity 
of DBM in vivo (athymic mouse model) and in vitro (alkaline phosphatase assay) 
[22]. The authors suggested that demineralized bone with a residual calcium level 
of approximately 2% is “optimally osteoinductive”. Similarly, Turonis et al. found 
that a 2% residual calcium level in human demineralized freeze-dried bone allograft 
appears to enhance osseous wound healing [23]. The L-MDF samples discussed in 
this chapter were demineralized using a proprietary and patented process targeted 
at achieving an optimized level of residual calcium of 1–4%. Furthermore, the 
presence of specific proteins in DBM is frequently associated with its osteoinduc-
tive potential as growth factors can provide signals that direct cellular behavior 
[18, 22, 24]. In particular, BMP-2 and 7 are important for bone growth as they are 
known for their “ability to stimulate differentiation of MSCs to osteochondroblastic 
lineage” [18]. Previous studies have reported a wide span of BMP-2 and BMP-7 
levels in demineralized bone, with ranges from 6.5 to 110 and 44 to 125 ng/g 
demineralized bone, respectively. In this study, ELISA results indicated the pres-
ence of BMP-2 and 7 in L-MDF (11.24 ± 1.49 and 85.78 ± 6.84 ng/g) consistent with 
values reported in the literature. This milieu of growth factors illustrate that L-MDF 
contain the appropriate trophic factor profile necessary for bone formation and are 
consistent with expected physiological levels.
The osteoinductive and osteoconductive potential of DBMs are commonly 
evaluated using an in vivo athymic mouse intramuscular pouch model to histologi-
cally assess new bone formation [25].
In the study described here, histological analysis revealed the presence of new 
bone elements demonstrating the osteoinductive potential of L-MDF. In addition, 
newly formed blood vessels were observed, which can also be indicative of the 
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osteoconductive nature of the bone graft in providing a conducive environment for 
new bone formation. The surface characteristics of DBMs play an important role in 
their ability to provide a scaffold for new bone formation [19, 20]. Bone cells need a 
hospitable environment in which to attach and thrive. In particular, increased sur-
face area, a rough topography, and interconnected networks are known to promote 
cellular attachment and cell spreading [26]. As demonstrated by the SEM imaging 
presented here, the long, interconnected L-MDF create a hospitable environment 
for BM-MSCs to infiltrate and make cell-to-cell connections. The ability of cells 
not only to quickly attach to the matrix but also maintain a healthy morphology 
throughout the duration of culture provides evidence of the osteoconductive quali-
ties of L-MDF.
The need for versatile handling has led to the addition of various inert carriers 
in commercial DBMs. However, studies have shown that carriers may negatively 
affect the inherent properties of a DBM. In particular, Lee et al. concluded that 
Poloxamer 407-based hydrogel may inhibit MSC osteoblastic differentiation by 
filling up spaces between DBM powders, negatively affecting the release of growth 
factors [21]. In a rat calvarial defect model, investigators found that the two types 
of DBM had significant differences in bone regeneration, which was attributed 
to the type of carrier [27]. Furthermore, varying the ratio of carrier to DBM can 
alter handling characteristics such as malleability and resistance to graft migration. 
Through in vivo and in vitro analyses, studies have found that increased bone con-
tent in DBMs produces larger amounts of new bone formation [25, 28, 29]. With 
this is mind, L-MDF were produced by proprietary CNC-milling cortical bone to 
create specially designed rough surfaces allowing fibers to interlock, allowing this 
bone void filler to be carrier-free. The roughness also provides numerous attach-
ment points for the cells and their lamellipodia, encouraging a flattened morphol-
ogy. These interlocking fibers thereby encourage malleability, graft placement in 
the implant site, and resistance to irrigation, all of which represent ideal handling 
characteristics.
Finally, terminal sterilization is a processing measure used to ensure the safety 
of DBMs by reducing the risk of disease transmission. This is in contrast to aseptic 
processing alone, which introduces no additional bioburden from the environment 
but alone does not guarantee sterile tissue [30, 31]. Unlike aseptic-only processed 
tissue, terminal sterilization can result in a graft with a defined sterility assurance 
level (SAL). For example, an SAL of 10−6 indicates a 1 out of 1,000,000 chance that 
a viable organism exists within any single graft [31]. Although gamma irradiation is 
currently the most common method for terminally sterilizing allografts, some reports 
suggests that gamma irradiation can negatively impact the inherent properties of 
DBMs. There are several factors to consider when evaluating the effects of gamma 
irradiation on DBMs such as dose and temperature. Irradiation performed in a high 
dose range or at uncontrolled temperatures can result in denaturing of the osteoin-
ductive signaling proteins, rendering them inactive, and/or structural damage to the 
collagen matrix due to generation of reactive oxygen species. Weintroub and Reddi 
evaluated DBM samples which were irradiated on ice at varying doses [32]. Histologic 
analysis showed DBM irradiated at 0.5–2.5 Mrad were similar to the non-irradiated 
control, indicating no effect on the induction properties of the implant. In another 
study, investigators found that DBM irradiated on dry ice (−72°C) demonstrated new 
bone formation comparable to non-irradiated samples [33]. These results demon-
strate DBMs irradiated at low dose and low temperatures are expected to retain 
properties important to clinical performance. Thus, L-MDF are terminally sterilized 
to an SAL of 10−6 using low-dose, ultra-low temperature gamma irradiation to avoid 
negative impacts to the osteoinductive and osteoconductive potential, as verified by 
the results presented here.
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5. Conclusion
L-MDF were engineered with the ideal characteristics of a DBM in mind. The 
cortical bone fibers are demineralized to target optimal levels of residual calcium 
to yield tissue with osteoinductive potential, and also terminally sterilized to 
minimize the risk of disease transmission. The results presented here demonstrate 
that L-MDF exhibit the osteoinductive potential and osteoconductive properties 
desirable to promote bone formation while also being easy to handle for surgical 
procedures. These characteristics suggest that L-MDF are a suitable option to treat 
bone defects in a number of orthopedic, spinal, trauma, craniomaxillofacial, and 
dental applications.
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5. Conclusion
L-MDF were engineered with the ideal characteristics of a DBM in mind. The 
cortical bone fibers are demineralized to target optimal levels of residual calcium 
to yield tissue with osteoinductive potential, and also terminally sterilized to 
minimize the risk of disease transmission. The results presented here demonstrate 
that L-MDF exhibit the osteoinductive potential and osteoconductive properties 
desirable to promote bone formation while also being easy to handle for surgical 
procedures. These characteristics suggest that L-MDF are a suitable option to treat 
bone defects in a number of orthopedic, spinal, trauma, craniomaxillofacial, and 
dental applications.
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Class III Spine Grafts
Jeffrey G. Marx and Morgan P. Lorio
Abstract
This chapter is focused on the USFDA regulation and the related efficacy 
evidence of bone graft materials, especially Class III drug-device combination 
products for use in the spine. Nonstructural allograft and cellular allograft products 
that do not rely on the metabolic activity of living cells are HCT/P products, which 
require no premarket review for safety and efficacy. Synthetic bone grafts and 
demineralized bone matrices (DBMs) fall under Class II and require a 510(k) for 
market clearance, generally on the basis of an animal study. Drug-device combina-
tion bone grafts are Class III and require an investigational device exemption (IDE) 
clinical trial followed by a premarket approval (PMA) application with the FDA 
to review safety and effectiveness. Currently, there are only two PMA-supported 
Class III drug-device bone graft substitutes with Level I data that demonstrate 
equivalence to autograft for safety and effectiveness in spine: Infuse® (rhBMP-2) 
and i-FACTOR (P-15 peptide). Both of these products have been shown to be effec-
tive autograft replacement options, vs. the other technologies, which are autograft 
extenders. The OP-1 Implant (rhBMP-7) was marketed for a period of time, but it 
has been removed from the market. This chapter will discuss these products along 
with their supporting clinical data.
Keywords: spine, bone graft, regulatory approval, clinical evidence, BMP, P-15, infuse
1. Introduction
The ideal bone graft substitute for spinal fusion would have the safety and effec-
tiveness of autograft when used by itself, be supported by quality published clinical 
evidence, and be available at a reasonable cost. Most of the options available today 
fall short of these goals. The number and variety of bone grafting products avail-
able to choose from is extensive, totaling more than 400 at the current time. The 
claims about the function and value of these products are confusing, even to those 
with the time and expertise to evaluate them in-depth. The preclinical and clinical 
evidence available for making a clinical use decision is also enormously varied and 
subject to misinterpretation. A large reason for these challenges is that the regula-
tory pathways and required evidence leading to FDA approval for spinal bone graft 
substitutes vary widely.
Nonstructural allograft and cellular allograft products, which do not rely on the 
metabolic activity of living cells, are considered to be HCT/P products under the 
United States Code of Federal Regulations Title 21—part 1271 (HUMAN CELLS, 
TISSUES, AND CELLULAR AND TISSUE-BASED PRODUCTS). Section 361 
describes products that are minimally manipulated, are for homologous use only, 
do not have a systemic effect, and are not dependent on the metabolic activity of 
living cells for their primary function, in addition to other qualifications. Once a 
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with the time and expertise to evaluate them in-depth. The preclinical and clinical 
evidence available for making a clinical use decision is also enormously varied and 
subject to misinterpretation. A large reason for these challenges is that the regula-
tory pathways and required evidence leading to FDA approval for spinal bone graft 
substitutes vary widely.
Nonstructural allograft and cellular allograft products, which do not rely on the 
metabolic activity of living cells, are considered to be HCT/P products under the 
United States Code of Federal Regulations Title 21—part 1271 (HUMAN CELLS, 
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describes products that are minimally manipulated, are for homologous use only, 
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living cells for their primary function, in addition to other qualifications. Once a 
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manufacturer determines a product meets all of these requirements and follows the 
appropriate regulations, the manufacturer can place the product on the market by 
simply notifying the FDA of the intent to do so. There is no premarket review by 
FDA for safety or effectiveness of such products. Therefore, there are no require-
ments for preclinical or clinical data. Since most HCT/P products have little to 
no peer-reviewed human clinical data, the surgeons must extrapolate the likely 
benefits in their clinical use.
Synthetic bone grafts and demineralized bone matrices (DBMs) fall under 
Class II under Section 510(k) of the Federal Food, Drug and Cosmetic Act. Section 
510(k) describes a regulatory process for the clearance of products that have been 
demonstrated to the FDA’s satisfaction to be “substantially equivalent” in safety and 
effectiveness to another lawfully marketed device when used for the same purpose. 
Market clearance requires the filing and review of a 510(k) application and a 
subsequent FDA review. This review is generally based on a single animal study and 
bench-top testing comparing the subject device with a predicate. Once again, since 
most 510(k) cleared products have little to no peer-reviewed human clinical data, 
surgeons must extrapolate the likely benefits in their clinical use.
Drug-device combination bone grafts are Class III and require an investigational 
device exemption (IDE) clinical trial followed by a premarket approval (PMA) 
application. The IDE study requirements include strict oversight from the FDA 
from statistical and protocol design through clinical follow-up, data integrity 
and analysis. These IDE studies must be prospective, controlled, blinded and 
statistically-powered prior to the onset. Moreover, the FDA-required outcomes for 
approval must be stipulated in the clinical design protocol. The review of both the 
IDE and PMA filings for drug-device combination products involve both the device 
(CDRH) and drug (CDER) branches of the FDA. The result of this rigorous process 
is the highest quality Level I human clinical data available. Surgeons may rely upon 
this data to make clinical use decisions.
2. Infuse bone graft: bone morphogenetic protein (BMP)
2.1 Bone morphogenetic protein: BMP
In 1965, Dr. Marshall R. Urist showed that demineralized bone matrix (DBM) 
could induce bone formation when implanted under the skin or intramuscular [1]. 
Urist pioneered the theory that a substance naturally present in bone was respon-
sible for the osteoinductive bone healing activity of DBM (now Class II). He named 
this substance, the bone inductive principle, bone morphogenetic protein (BMP) 
and initiated an extensive and difficult search for these active protein molecules [2]. 
More than two decades later, advances in molecular biology by Dr. John Wozney’s 
research team at the Genetic Institute described the first isolated extraction and 
recombinant form of BMP-2 in 1988 [3, 4]. BMP-2 and BMP-7 have been shown to 
have the most bone forming potential out of the 15 BMPs identified and studied 
to date [5]. The recombinant protein available commercially today is a synthetic, 
genetically engineered version of the natural protein.
BMPs are potent bone forming agents in bone regeneration and bone repair 
activity and are members of the TGF-Beta superfamily of cytokines. BMPs drive 
mesenchymal stem cells (MSCs) into osteoblastic lineage. These active protein 
dimeric molecules are osteoinductive and generally require a collagen sponge or 
ceramic carrier to enhance their handling characteristics. BMPs initiate endochon-
dral bone formation, presumably by stimulating local MSCs and augmenting bone 
collagen synthesis. The BMP-2 ligand acts as a rigid clamp connecting type I and 
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type II BMP receptor chains (BMPRs) together for transactivation. This activation 
causes intracellular signaling by phosphorylation of downstream signaling mol-
ecules (Smads). Smads ultimately mediate and regulate the transcription of target 
genes by binding to specific DNA sequences (BMP-responsive elements) [6].
2.1.1 rhBMP-2 pre-clinical
The next direction of rhBMP-2 research was to attempt to define proper dosing 
of the potent protein and to determine if this dosage would be specific to site or 
to carrier/scaffold. Formative work in this inquiry was performed in two different 
models by Sandhu et al. [7, 8].
The investigators first attempted to characterize the dose-response relation-
ship of rhBMP-2 in a canine intertransverse spine fusion model. They compared 
increasing logarithmic rhBMP-2 doses (58, 115, 230, 460, and 920 mg) on a porous 
polylactic acid polymer carrier. Successful fusions postoperatively at 3 months 
were shown throughout this dosing range. A prior study done by this same 
research team demonstrated superiority of a 2300 mg rhBMP-2 dose to autologous 
iliac crest bone graft (ICBG) using this same technique. Quality differences above 
a threshold dose were not reflected in the mechanical, radiographic, or histologic 
features in the canine intertransverse spine fusion model from a 40-fold variation 
in rhBMP-2 dose [7].
Learning from the canine work, the investigators continued their work in an 
ovine lumbar interbody fusion model in conjunction with a cylindrical fenestrated 
titanium interbody fusion cage (INTER FIX, Medtronic Sofomor Danek, Inc., 
Memphis, TN). The cage was filled with rhBMP-2-collagen or ICBG (control). The 
sheep all appeared radiographically fused at 6 months. However, the histologic 
evaluation revealed that 33% (2/6) of the control group were fused as compared 
with 100% (6/6) of the rhBMP-2 group (P < 0.001). The scar involving the control 
group was 16-fold more than that seen with the rhBMP-2 group (P < 0.01) [8].
A rhesus monkey nonhuman primate model with rhBMP-2 on a collagen car-
rier within a titanium cage (Sofomor Danek, Memphis, TN) was the subsequent 
evolutionary step from the ovine model [9]. As optimal dosing for rhesus monkeys 
had not been previously established, three concentrations of rhBMP-2 [0.00 mg/
mL sham (buffer only), 0.75 mg/mL low dose, or 1.50 mg/mL high dose) were 
tested. The results demonstrated that both the investigational rhBMP-2 groups 
achieved arthrodesis at 6 months histologically as compared to the sham group. As 
before with the ovine model, the blinded nonhuman primate model radiographic 
assessment was suboptimal but the sagittal CT assessment was consistent with the 
histology. The higher dose rhBMP-2 (1.5 mg/mL) caused faster and denser bone 
formation; this study established the dose used in the upcoming US IDE trial.
Fusion environments differ. A cage environment places the contained collagen 
carrier under protected direct compression forces between large vascularized 
opposing bony vertebral endplate surfaces. Posterolateral fusion presents a dif-
ficult environment with limited surface area and an intertransverse process fusion 
gap under distraction forces. Moreover, the surrounding muscle envelope applies 
mechanical compression on the graft material and may contribute to a pseudarthro-
sis or an hourglass configured fusion.
A standard compression resistant carrier with concomitant dosing concentration 
for rhBMP-2 was deemed necessary. Boden et al. studied a ceramic carrier [60% 
hydroxyapatite and 40% tricalcium phosphate (TCP)] in a nonhuman primate 
laminectomy model. Concentrations of rhBMP-2 (0, 6, 9, or 12 mg) were compared 
to ICBG. Fusion occurred with each rhBMP-2 carrier including the 0 mg/rhBMP-2 
ceramic carrier alone group [10]. No significant overgrowth occurred involving the 
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and analysis. These IDE studies must be prospective, controlled, blinded and 
statistically-powered prior to the onset. Moreover, the FDA-required outcomes for 
approval must be stipulated in the clinical design protocol. The review of both the 
IDE and PMA filings for drug-device combination products involve both the device 
(CDRH) and drug (CDER) branches of the FDA. The result of this rigorous process 
is the highest quality Level I human clinical data available. Surgeons may rely upon 
this data to make clinical use decisions.
2. Infuse bone graft: bone morphogenetic protein (BMP)
2.1 Bone morphogenetic protein: BMP
In 1965, Dr. Marshall R. Urist showed that demineralized bone matrix (DBM) 
could induce bone formation when implanted under the skin or intramuscular [1]. 
Urist pioneered the theory that a substance naturally present in bone was respon-
sible for the osteoinductive bone healing activity of DBM (now Class II). He named 
this substance, the bone inductive principle, bone morphogenetic protein (BMP) 
and initiated an extensive and difficult search for these active protein molecules [2]. 
More than two decades later, advances in molecular biology by Dr. John Wozney’s 
research team at the Genetic Institute described the first isolated extraction and 
recombinant form of BMP-2 in 1988 [3, 4]. BMP-2 and BMP-7 have been shown to 
have the most bone forming potential out of the 15 BMPs identified and studied 
to date [5]. The recombinant protein available commercially today is a synthetic, 
genetically engineered version of the natural protein.
BMPs are potent bone forming agents in bone regeneration and bone repair 
activity and are members of the TGF-Beta superfamily of cytokines. BMPs drive 
mesenchymal stem cells (MSCs) into osteoblastic lineage. These active protein 
dimeric molecules are osteoinductive and generally require a collagen sponge or 
ceramic carrier to enhance their handling characteristics. BMPs initiate endochon-
dral bone formation, presumably by stimulating local MSCs and augmenting bone 
collagen synthesis. The BMP-2 ligand acts as a rigid clamp connecting type I and 
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type II BMP receptor chains (BMPRs) together for transactivation. This activation 
causes intracellular signaling by phosphorylation of downstream signaling mol-
ecules (Smads). Smads ultimately mediate and regulate the transcription of target 
genes by binding to specific DNA sequences (BMP-responsive elements) [6].
2.1.1 rhBMP-2 pre-clinical
The next direction of rhBMP-2 research was to attempt to define proper dosing 
of the potent protein and to determine if this dosage would be specific to site or 
to carrier/scaffold. Formative work in this inquiry was performed in two different 
models by Sandhu et al. [7, 8].
The investigators first attempted to characterize the dose-response relation-
ship of rhBMP-2 in a canine intertransverse spine fusion model. They compared 
increasing logarithmic rhBMP-2 doses (58, 115, 230, 460, and 920 mg) on a porous 
polylactic acid polymer carrier. Successful fusions postoperatively at 3 months 
were shown throughout this dosing range. A prior study done by this same 
research team demonstrated superiority of a 2300 mg rhBMP-2 dose to autologous 
iliac crest bone graft (ICBG) using this same technique. Quality differences above 
a threshold dose were not reflected in the mechanical, radiographic, or histologic 
features in the canine intertransverse spine fusion model from a 40-fold variation 
in rhBMP-2 dose [7].
Learning from the canine work, the investigators continued their work in an 
ovine lumbar interbody fusion model in conjunction with a cylindrical fenestrated 
titanium interbody fusion cage (INTER FIX, Medtronic Sofomor Danek, Inc., 
Memphis, TN). The cage was filled with rhBMP-2-collagen or ICBG (control). The 
sheep all appeared radiographically fused at 6 months. However, the histologic 
evaluation revealed that 33% (2/6) of the control group were fused as compared 
with 100% (6/6) of the rhBMP-2 group (P < 0.001). The scar involving the control 
group was 16-fold more than that seen with the rhBMP-2 group (P < 0.01) [8].
A rhesus monkey nonhuman primate model with rhBMP-2 on a collagen car-
rier within a titanium cage (Sofomor Danek, Memphis, TN) was the subsequent 
evolutionary step from the ovine model [9]. As optimal dosing for rhesus monkeys 
had not been previously established, three concentrations of rhBMP-2 [0.00 mg/
mL sham (buffer only), 0.75 mg/mL low dose, or 1.50 mg/mL high dose) were 
tested. The results demonstrated that both the investigational rhBMP-2 groups 
achieved arthrodesis at 6 months histologically as compared to the sham group. As 
before with the ovine model, the blinded nonhuman primate model radiographic 
assessment was suboptimal but the sagittal CT assessment was consistent with the 
histology. The higher dose rhBMP-2 (1.5 mg/mL) caused faster and denser bone 
formation; this study established the dose used in the upcoming US IDE trial.
Fusion environments differ. A cage environment places the contained collagen 
carrier under protected direct compression forces between large vascularized 
opposing bony vertebral endplate surfaces. Posterolateral fusion presents a dif-
ficult environment with limited surface area and an intertransverse process fusion 
gap under distraction forces. Moreover, the surrounding muscle envelope applies 
mechanical compression on the graft material and may contribute to a pseudarthro-
sis or an hourglass configured fusion.
A standard compression resistant carrier with concomitant dosing concentration 
for rhBMP-2 was deemed necessary. Boden et al. studied a ceramic carrier [60% 
hydroxyapatite and 40% tricalcium phosphate (TCP)] in a nonhuman primate 
laminectomy model. Concentrations of rhBMP-2 (0, 6, 9, or 12 mg) were compared 
to ICBG. Fusion occurred with each rhBMP-2 carrier including the 0 mg/rhBMP-2 
ceramic carrier alone group [10]. No significant overgrowth occurred involving the 
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thecal sac, as bone growth induction was confined to ceramic carrier. The ceramic 
carrier was judged to be satisfactory for posterolateral application.
2.1.2 rhBMP-2 clinical trials
The “elimination” of the gold standard, autologous iliac crest bone graft (ICBG) 
harvest, in lumbar fusion was scientifically proposed by Burkus et al. in 2002 [11]. 
Anterior lumbar interbody fusion (ALIF) utilizing a combination of rhBMP-2 
(1.50 mg/mL concentration) on an absorbable collagen sponge (ACS) carrier-filled 
tapered titanium fusion cage was shown to have an equivalent (~90%) radiographic 
(X-ray and CT) fusion rate to that of ICBG. This 2 year, multicenter, prospective, 
randomized, nonblinded human trial design compared an investigational Class III 
drug/device combination product (Infuse®, Medtronic Sofamor Danek, Memphis, 
Tennessee) on a Type-1 ACS (143 patients) to a control ICBG (136 patients); all 
273 patients received the same tapered titanium fusion cage (LT-cage, Medtronic 
Sofomor Danek, Memphis, Tennessee). Osseous fusion rate was confirmed in 94.5% 
of the investigational group versus 88.7% of the control group at the two-year 
follow up. Outcomes of particular surgical interest including operative time (1.6 h), 
estimated blood loss (109.8 mL), adverse events from iliac crest harvest (0%), 
reported bone graft site discomfort (0%), and bone graft site appearance complaint 
(0%) were all less in the investigational group as compared to the control group at 
2.0 h, 153.1 mL, 5.9, 32, and 16%, respectively. FDA approval was granted on July 
2, 2002 for the rhBMP-2/ACS combination product in conjunction with the tapered 
titanium fusion cage (Infuse®/LT-Cage or Medtronic Sofamor Danek, Memphis, 
Tennessee) in the treatment of lumbar degenerative disc disease.
A traditional posterolateral spine fusion application (PLF) was the next step in 
the evaluation of rhBMP-2 on a ceramic granule carrier (60% hydroxyapatite and 
40% TCP) in humans as a forged extrapolation of the seminal nonhuman primate 
work by Boden et al. [12]. Randomization of 25 patients (whose spondylolisthesis 
was ≤ Grade 1) into one of three groups was performed; five patients (control 
group) received autograft PLF with pedicle screw instrumentation, 11 patients 
received rhBMP-2 PLF with pedicle screw instrumentation, and 9 patients received 
rhBMP-2 PLF in situ only. A 20 mg rhBMP-2 dose was evenly divided in a bilateral, 
posterolateral application in those patients receiving rhBMP-2 on a ceramic granule 
carrier. Load bearing through the hardware until osseous fusion ensued was revela-
tory in the Oswestry scores. Oswestry scores demonstrated significant improvement 
in the rhBMP-2 PLF in situ only group at 6 weeks, rhBMP-2 PLF with pedicle screw 
instrumentation group at 3 months, and control, autograft PLF with pedicle screw 
instrumentation group, at 6 months. The fusion rate with the combined rhBMP-2 
PLF groups (in situ only or with pedicle screw instrumentation) was 100% (20/20) 
and with the control, autograft PLF with pedicle screw instrumentation, however, 
was 40% (2/5). The radiographic fusion rate for the combined rhBMP-2 PLF groups 
was statistically significantly higher than for the control (P = 0.004).
A trauma application was then explored in a prospective, controlled, random-
ized multicenter clinical trial evaluation of patients with open tibial fractures. All 
450 patients received intermedullary nail stabilization. Patients were randomized 
equally (n = 150), dividing them among one of three treatments: a standard of care 
(control group) or alternatively two different concentrations of rh-BMP [(0.75 mg/mL, 
total dose 6 mg) or (1.5 mg/mL, total dose 12 mg) respectively)] on ACS carrier. 
The control group standard of care was defined, for purposes of this study, as 
routine soft tissue management. The specific key measure outcome in the study 
was defined by the proportion of patients for whom secondary intervention was 
required due to delayed union or nonunion within the index postoperative year. 
53
Class III Spine Grafts
DOI: http://dx.doi.org/10.5772/intechopen.87706
The 1.50 mg/mL group demonstrated a 44% reduction in the risk of failure requir-
ing secondary intervention because of delayed union. The 1.50 mg/mL rhBMP-2 
group had both significantly accelerated fracture healing and wound healing, 
higher osseous union rates, significantly fewer secondary interventions, less hard-
ware failure, and less infections (Gustilo-Anderson type III associated injuries). 
Govender et al. further concluded that the 1.50 mg/mL rhBMP-2 concentration 
treatment was significantly superior care to the control, standard of care [13]. FDA 
approval for Infuse® (rhBMP-2 and ACS) in conjunction with an intermedullary 
nail for acute, open tibial fracture treatment was issued on April 30, 2004.
Between 2005 and 2009, three journal articles were published on the results of 
the FDA approval studies on 2-stage maxillary sinus floor augmentation [14–16]. 
Boyne et al. evaluated two concentrations of rhBMP-2/ACS at 0.75 and 1.50 mg/mL 
versus bone graft control; this pilot study was the first randomized controlled trial 
(RCT) demonstrating safe de novo bone induction by a recombinant human pro-
tein, rhBMP-2. Core biopsies retrieved after subsequent dental implant restoration 
confirmed normal bone formation in all groups; the proportion of dental implants 
that remained functionally loaded at 36 months was 62, 67, and 76% in the control 
group, 0.75 mg/mL rhBMP-2/ACS group, and 1.5 mg/mL rhBMP-2/ACS group, 
respectively. Triplett et al. performed a pivotal, multicenter, prospective, random-
ized, parallel evaluation of two treatments for a 2-stage maxillary sinus floor aug-
mentation comparing a 1.50 mg/mL rhBMP-2/ACS group with an autograft control 
group; this study demonstrated no rhBMP-2 related adverse events at 6 months 
after dental restoration and similarly effective functional loading performance in 
both groups. Fiorellini et al. performed a randomized, masked, placebo-controlled, 
multicenter clinical trial evaluating de novo bone formation for dental implant 
restoration following tooth extraction using 0.75 mg/mL rhBMP-2/ACS, 1.5 mg/mL 
rhBMP-2/ACS, placebo control (ACS alone), or no treatment control. The 1.50 mg/
mL rhBMP-2/ACS group demonstrated significantly greater (twice as great) bone 
augmentation compared to both controls (P ≤ 0.05). Furthermore, bone density 
and histology disclosed no difference between newly induced and native bone.
A compression resistant matrix consisting of bovine collagen and Beta-
tricalcium phosphate-hydroxyapatite in conjunction with rhBMP-2 was next com-
pared to ICBG (control). A prospective, randomized, multi-center trial comparing 
the clinical and radiographic outcomes of an investigational optimized rhBMP-2 
formulation to ICBG in one level instrumented traditional PLF in 463 patients with 
symptomatic degenerative disc disease (DDD) with spondylolisthesis ≤ Grade 1 
[17]. Osseous fusion rate was radiographically (X-ray and CT) confirmed in 96% 
of the investigational group versus 89% of the control group at a 2 year follow 
up (p = 0.014). Outcomes of particular surgical interest including operative time 
(2.5 h), estimated blood loss (343.1 mL), reported donor site morbidity (0%), fail-
ures because of nonunion (six patients), and number requiring secondary surgeries 
(20 patients) were all significantly less in the investigational group as compared to 
the control group at 2.9 h, 448.6 mL, 60%, 18 patients (p = 0.011), and 36 patients 
(p = 0.015), respectively. The investigators concluded that clinical outcomes were 
similar between groups; they further concluded that morbidity was eliminated 
with the use of the optimized 2 mg/mL rhBMP-2 concentration in the compression 
resistant matrix. Eight patients (3.3%) with cancer (basal cell carcinoma, lung, 
lymphoma, ovarian, pancreatic, prostate, squamous cell carcinoma, and vocal 
cord) were reported in the optimized rhBMP-2 matrix group as compared to two 
patients (0.9%) with cancer (colon and lymphoma) in the control group. The four-
fold increase in cancer in the optimized rhBMP-2 matrix group was not reported 
as possible device-related adverse events, as the cancer types were heterogeneous 
and statistically nonsignificant (p = 0.107). A nonapproval letter was received by 
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thecal sac, as bone growth induction was confined to ceramic carrier. The ceramic 
carrier was judged to be satisfactory for posterolateral application.
2.1.2 rhBMP-2 clinical trials
The “elimination” of the gold standard, autologous iliac crest bone graft (ICBG) 
harvest, in lumbar fusion was scientifically proposed by Burkus et al. in 2002 [11]. 
Anterior lumbar interbody fusion (ALIF) utilizing a combination of rhBMP-2 
(1.50 mg/mL concentration) on an absorbable collagen sponge (ACS) carrier-filled 
tapered titanium fusion cage was shown to have an equivalent (~90%) radiographic 
(X-ray and CT) fusion rate to that of ICBG. This 2 year, multicenter, prospective, 
randomized, nonblinded human trial design compared an investigational Class III 
drug/device combination product (Infuse®, Medtronic Sofamor Danek, Memphis, 
Tennessee) on a Type-1 ACS (143 patients) to a control ICBG (136 patients); all 
273 patients received the same tapered titanium fusion cage (LT-cage, Medtronic 
Sofomor Danek, Memphis, Tennessee). Osseous fusion rate was confirmed in 94.5% 
of the investigational group versus 88.7% of the control group at the two-year 
follow up. Outcomes of particular surgical interest including operative time (1.6 h), 
estimated blood loss (109.8 mL), adverse events from iliac crest harvest (0%), 
reported bone graft site discomfort (0%), and bone graft site appearance complaint 
(0%) were all less in the investigational group as compared to the control group at 
2.0 h, 153.1 mL, 5.9, 32, and 16%, respectively. FDA approval was granted on July 
2, 2002 for the rhBMP-2/ACS combination product in conjunction with the tapered 
titanium fusion cage (Infuse®/LT-Cage or Medtronic Sofamor Danek, Memphis, 
Tennessee) in the treatment of lumbar degenerative disc disease.
A traditional posterolateral spine fusion application (PLF) was the next step in 
the evaluation of rhBMP-2 on a ceramic granule carrier (60% hydroxyapatite and 
40% TCP) in humans as a forged extrapolation of the seminal nonhuman primate 
work by Boden et al. [12]. Randomization of 25 patients (whose spondylolisthesis 
was ≤ Grade 1) into one of three groups was performed; five patients (control 
group) received autograft PLF with pedicle screw instrumentation, 11 patients 
received rhBMP-2 PLF with pedicle screw instrumentation, and 9 patients received 
rhBMP-2 PLF in situ only. A 20 mg rhBMP-2 dose was evenly divided in a bilateral, 
posterolateral application in those patients receiving rhBMP-2 on a ceramic granule 
carrier. Load bearing through the hardware until osseous fusion ensued was revela-
tory in the Oswestry scores. Oswestry scores demonstrated significant improvement 
in the rhBMP-2 PLF in situ only group at 6 weeks, rhBMP-2 PLF with pedicle screw 
instrumentation group at 3 months, and control, autograft PLF with pedicle screw 
instrumentation group, at 6 months. The fusion rate with the combined rhBMP-2 
PLF groups (in situ only or with pedicle screw instrumentation) was 100% (20/20) 
and with the control, autograft PLF with pedicle screw instrumentation, however, 
was 40% (2/5). The radiographic fusion rate for the combined rhBMP-2 PLF groups 
was statistically significantly higher than for the control (P = 0.004).
A trauma application was then explored in a prospective, controlled, random-
ized multicenter clinical trial evaluation of patients with open tibial fractures. All 
450 patients received intermedullary nail stabilization. Patients were randomized 
equally (n = 150), dividing them among one of three treatments: a standard of care 
(control group) or alternatively two different concentrations of rh-BMP [(0.75 mg/mL, 
total dose 6 mg) or (1.5 mg/mL, total dose 12 mg) respectively)] on ACS carrier. 
The control group standard of care was defined, for purposes of this study, as 
routine soft tissue management. The specific key measure outcome in the study 
was defined by the proportion of patients for whom secondary intervention was 
required due to delayed union or nonunion within the index postoperative year. 
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The 1.50 mg/mL group demonstrated a 44% reduction in the risk of failure requir-
ing secondary intervention because of delayed union. The 1.50 mg/mL rhBMP-2 
group had both significantly accelerated fracture healing and wound healing, 
higher osseous union rates, significantly fewer secondary interventions, less hard-
ware failure, and less infections (Gustilo-Anderson type III associated injuries). 
Govender et al. further concluded that the 1.50 mg/mL rhBMP-2 concentration 
treatment was significantly superior care to the control, standard of care [13]. FDA 
approval for Infuse® (rhBMP-2 and ACS) in conjunction with an intermedullary 
nail for acute, open tibial fracture treatment was issued on April 30, 2004.
Between 2005 and 2009, three journal articles were published on the results of 
the FDA approval studies on 2-stage maxillary sinus floor augmentation [14–16]. 
Boyne et al. evaluated two concentrations of rhBMP-2/ACS at 0.75 and 1.50 mg/mL 
versus bone graft control; this pilot study was the first randomized controlled trial 
(RCT) demonstrating safe de novo bone induction by a recombinant human pro-
tein, rhBMP-2. Core biopsies retrieved after subsequent dental implant restoration 
confirmed normal bone formation in all groups; the proportion of dental implants 
that remained functionally loaded at 36 months was 62, 67, and 76% in the control 
group, 0.75 mg/mL rhBMP-2/ACS group, and 1.5 mg/mL rhBMP-2/ACS group, 
respectively. Triplett et al. performed a pivotal, multicenter, prospective, random-
ized, parallel evaluation of two treatments for a 2-stage maxillary sinus floor aug-
mentation comparing a 1.50 mg/mL rhBMP-2/ACS group with an autograft control 
group; this study demonstrated no rhBMP-2 related adverse events at 6 months 
after dental restoration and similarly effective functional loading performance in 
both groups. Fiorellini et al. performed a randomized, masked, placebo-controlled, 
multicenter clinical trial evaluating de novo bone formation for dental implant 
restoration following tooth extraction using 0.75 mg/mL rhBMP-2/ACS, 1.5 mg/mL 
rhBMP-2/ACS, placebo control (ACS alone), or no treatment control. The 1.50 mg/
mL rhBMP-2/ACS group demonstrated significantly greater (twice as great) bone 
augmentation compared to both controls (P ≤ 0.05). Furthermore, bone density 
and histology disclosed no difference between newly induced and native bone.
A compression resistant matrix consisting of bovine collagen and Beta-
tricalcium phosphate-hydroxyapatite in conjunction with rhBMP-2 was next com-
pared to ICBG (control). A prospective, randomized, multi-center trial comparing 
the clinical and radiographic outcomes of an investigational optimized rhBMP-2 
formulation to ICBG in one level instrumented traditional PLF in 463 patients with 
symptomatic degenerative disc disease (DDD) with spondylolisthesis ≤ Grade 1 
[17]. Osseous fusion rate was radiographically (X-ray and CT) confirmed in 96% 
of the investigational group versus 89% of the control group at a 2 year follow 
up (p = 0.014). Outcomes of particular surgical interest including operative time 
(2.5 h), estimated blood loss (343.1 mL), reported donor site morbidity (0%), fail-
ures because of nonunion (six patients), and number requiring secondary surgeries 
(20 patients) were all significantly less in the investigational group as compared to 
the control group at 2.9 h, 448.6 mL, 60%, 18 patients (p = 0.011), and 36 patients 
(p = 0.015), respectively. The investigators concluded that clinical outcomes were 
similar between groups; they further concluded that morbidity was eliminated 
with the use of the optimized 2 mg/mL rhBMP-2 concentration in the compression 
resistant matrix. Eight patients (3.3%) with cancer (basal cell carcinoma, lung, 
lymphoma, ovarian, pancreatic, prostate, squamous cell carcinoma, and vocal 
cord) were reported in the optimized rhBMP-2 matrix group as compared to two 
patients (0.9%) with cancer (colon and lymphoma) in the control group. The four-
fold increase in cancer in the optimized rhBMP-2 matrix group was not reported 
as possible device-related adverse events, as the cancer types were heterogeneous 
and statistically nonsignificant (p = 0.107). A nonapproval letter was received by 
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Medtronic on March 9, 2011 regarding the optimized AMPLIFY rhBMP-2 Matrix. 
The FDA nonapproval stemmed from the fourfold increased cancer risks in the 
investigational group and was linked to the high dose rhBMP-2 form of AMPLIFY 
versus the prior approved low dose forms.
Amidst the high-profile controversy, Yale University Open Data Access (YODA) 
retrieved Medtronic’s safety and efficacy data on file in toto. Contract funding sup-
port of both the research and preparation of the work was provided by Medtronic 
to Yale. The Centre for Reviews and Dissemination (CRD) was then commissioned 
by the YODA initiative in an unprecedented effort by industry to facilitate unbiased 
review of the relevant benefits and harms of rhBMP-2 as used specifically in spinal 
fusion surgery; CRD has no direct financial conflict with Medtronic. Two succes-
sive publications in the Annals of Internal Medicine were issued in 2013 regarding 
the findings of the YODA initiative; the dissimilitude between the two publications 
were the extraction methods and the different studies included [18, 19]. Simmons 
et al. found rhBMP-2 had increased fusion rates versus ICBG, 12% higher (CI, 
2–23%); Fu et al. found similar overall lumbar fusion rates between rhBMP-2 and 
ICBG Simmons et al. found nonsignificant increased cancer risk after rhBMP-2 
(relative risk, 1.98 [CI 0.86–4.54]); Fu et al. found rhBMP-2 at 24 months had 
increased cancer risk (risk ratio, 3.45 [95% CI, 1.98–6.00]). Fu et al. also found 
rhBMP-2 to have associated increased risk for wound complications and dysphagia 
in off-label use in anterior cervical spine surgery, and nonsignificant increased risk 
for retrograde ejaculation and urogenital problems after on-label ALIF.
The data synthesis from the YODA initiative and more recent publications report 
mixed findings with regards to rhBMP-2 usage complications and cancer incidences 
after rhBMP-2 [20–23]. This same data synthesis suggests that an informed public 
might have benefited from earlier disclosure and blinded outcome assessment in 
retrospect.
3. i-FACTOR™: P-15 peptide
In the interest of developing products with greater biological specificity and 
a potentially better safety profile, a number of peptides (rather than proteins 
like BMPs) have been evaluated for their role and value in bone formation [24]. 
Peptides differ from proteins in size and structure, typically being much smaller 
molecules of between 2 and 50 amino acids compared to proteins (e.g., BMPs), 
which are much larger (>50 amino acids). Many of these peptide sequences are 
known for having numerous biochemical cellular signaling roles, especially 
during de novo tissue formation and in remodeling and injury response. Among 
the more promising peptides are those found in the cell interaction domain of 
the master control region of Type I collagen [25]. Type I collagen is comprised 
of two α1 and one β2 polypeptide chains that wrap around each other to form a 
right-handed triple helix, a collagen monomer. Numerous monomers polymer-
ize to form the massive, rope-like collagen fibrils found in tissues. Type I col-
lagen not only provides a supportive physical scaffold for cells and confers form 
and strength to tissues including skin, tendons and, in combination with rigid 
crystalline hydroxyapatite, bones, it also assumes dynamic, biological func-
tions by regulating tissue assembly, cell differentiation, growth, regeneration, 
and biomineralization. Numerous functional domains and bioactive peptide 
sequences on a single collagen molecule are present at regular intervals across the 
width, and along the length of the polymeric collagen fibril. The high density of 
bioactive sites on collagen makes it the ideal polyvalent substrate for cells and 
bioactive factors.
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The importance of these peptides and their functions is highlighted by the fact 
that they have been conserved over 65 M years of evolution as the cell interaction 
domain remains the same as that found in dinosaur Type I collagen [26]. This 
segment of the collagen molecule tends to become exposed and more bioavail-
able during chemical or traumatic cleavage of the collagen molecule. Among the 
peptides from the cell interaction domain, one referred to as P-15 was found to 
be 4500 times more potent for cell binding than the others. This peptide is a 15 
amino acid sequence that represents a unique “kinked” tertiary protein structure 
on Type I collagen that facilitates its presentation to mesenchymal stem cells 
(MSC’s) and their daughter cells along the osteoblastic lineage [27]. P-15 has 
been found to attract MSC to the implant by providing a favorable environment 
that facilitates cell attachment. The attraction is followed by a specific receptor-
mediated attachment that activates down-stream molecular events via receptor-
activated cascade pathways. These events activate and accelerate new bone 
formation as they attract, attach, and activate bone forming cells. These processes 
are circular and self-reinforcing once initiated. In addition, P-15 has been shown 
to benefit biochemical mechanisms such as proliferation, differentiation, migra-
tion, cell survival, among others.
In 1996, Qian and Bhatnagar published their first investigations on the P-15 pep-
tide for application in bone tissues. In this paper, they showed that attaching this 15 
amino acid peptide (P-15) to a calcium phosphate anorganic bone mineral (ABM) 
led to dramatic increases in cellular response in culture. Their work suggested that 
this combination might be a useful addition to the bone grafting armamentarium 
[28]. The in-vitro model demonstrated the ABM-bound P-15 stimulated human-
derived pre-osteoblast resulting in significantly increased number of bound cells 
and the initiation of down-stream molecular events associated with differentiation 
and osteoinductive activities. Additionally, it was observed that mechanical forces 
on the cellular cytoskeleton may be generated by P-15 surface integrin interactions. 
These forces are believed to contribute to mechanotransduction with profound 
consequences on cellular differentiation.
Over the subsequent decades, numerous in vitro studies demonstrated that the 
P-15 peptide would elicit specific biological responses from bone forming lineage 
cells (pre-osteoblasts as well as MSC.) The stimulation/differentiation of MSC was 
demonstrated at both the molecular level as seen by upregulation of mRNA produc-
tion, and the protein level as evidence by the cellular release of bone-regeneration 
associated proteins and growth factors, including alkaline phosphatase, BMP-2 and 
Collagen Type I [29]. The mechanism of action that elicits these effects is related to 
the P-15 peptide “plugging in” to surface receptors on these cells, which turns on the 
genetically programmed downstream cellular responses.
Qian and Bhatnagar showed that P-15 bound to ABM increases the number of 
bound human fibroblasts and stimulates cellular activation and spreading [28].
Liu et al. demonstrated that P-15 bound to surface increases the number of 
bound pre-osteoblastic cells and stimulates cellular activation [30]. The authors 
also noted a significant increase in specific cell surface integrin activation and 
focal adhesion kinase activation on surface treated with P-15 compared to control 
substrates, an indication of the direct biological influence of the P-15 peptide on 
cells.
Yang et al. demonstrated that P-15 bound to ABM stimulates upregulation of 
cellular BMP-2 and alkaline phosphatase production and the onset of calcifica-
tion. Alkaline phosphatase production is an indicator of cellular differentiation to 
osteoblasts as well as their activity toward bone formation [31].
Yuan et al. found that P-15 bound to ABM stimulates early formation of mineral-
ization nodes [32].
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Medtronic on March 9, 2011 regarding the optimized AMPLIFY rhBMP-2 Matrix. 
The FDA nonapproval stemmed from the fourfold increased cancer risks in the 
investigational group and was linked to the high dose rhBMP-2 form of AMPLIFY 
versus the prior approved low dose forms.
Amidst the high-profile controversy, Yale University Open Data Access (YODA) 
retrieved Medtronic’s safety and efficacy data on file in toto. Contract funding sup-
port of both the research and preparation of the work was provided by Medtronic 
to Yale. The Centre for Reviews and Dissemination (CRD) was then commissioned 
by the YODA initiative in an unprecedented effort by industry to facilitate unbiased 
review of the relevant benefits and harms of rhBMP-2 as used specifically in spinal 
fusion surgery; CRD has no direct financial conflict with Medtronic. Two succes-
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after rhBMP-2 [20–23]. This same data synthesis suggests that an informed public 
might have benefited from earlier disclosure and blinded outcome assessment in 
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3. i-FACTOR™: P-15 peptide
In the interest of developing products with greater biological specificity and 
a potentially better safety profile, a number of peptides (rather than proteins 
like BMPs) have been evaluated for their role and value in bone formation [24]. 
Peptides differ from proteins in size and structure, typically being much smaller 
molecules of between 2 and 50 amino acids compared to proteins (e.g., BMPs), 
which are much larger (>50 amino acids). Many of these peptide sequences are 
known for having numerous biochemical cellular signaling roles, especially 
during de novo tissue formation and in remodeling and injury response. Among 
the more promising peptides are those found in the cell interaction domain of 
the master control region of Type I collagen [25]. Type I collagen is comprised 
of two α1 and one β2 polypeptide chains that wrap around each other to form a 
right-handed triple helix, a collagen monomer. Numerous monomers polymer-
ize to form the massive, rope-like collagen fibrils found in tissues. Type I col-
lagen not only provides a supportive physical scaffold for cells and confers form 
and strength to tissues including skin, tendons and, in combination with rigid 
crystalline hydroxyapatite, bones, it also assumes dynamic, biological func-
tions by regulating tissue assembly, cell differentiation, growth, regeneration, 
and biomineralization. Numerous functional domains and bioactive peptide 
sequences on a single collagen molecule are present at regular intervals across the 
width, and along the length of the polymeric collagen fibril. The high density of 
bioactive sites on collagen makes it the ideal polyvalent substrate for cells and 
bioactive factors.
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The importance of these peptides and their functions is highlighted by the fact 
that they have been conserved over 65 M years of evolution as the cell interaction 
domain remains the same as that found in dinosaur Type I collagen [26]. This 
segment of the collagen molecule tends to become exposed and more bioavail-
able during chemical or traumatic cleavage of the collagen molecule. Among the 
peptides from the cell interaction domain, one referred to as P-15 was found to 
be 4500 times more potent for cell binding than the others. This peptide is a 15 
amino acid sequence that represents a unique “kinked” tertiary protein structure 
on Type I collagen that facilitates its presentation to mesenchymal stem cells 
(MSC’s) and their daughter cells along the osteoblastic lineage [27]. P-15 has 
been found to attract MSC to the implant by providing a favorable environment 
that facilitates cell attachment. The attraction is followed by a specific receptor-
mediated attachment that activates down-stream molecular events via receptor-
activated cascade pathways. These events activate and accelerate new bone 
formation as they attract, attach, and activate bone forming cells. These processes 
are circular and self-reinforcing once initiated. In addition, P-15 has been shown 
to benefit biochemical mechanisms such as proliferation, differentiation, migra-
tion, cell survival, among others.
In 1996, Qian and Bhatnagar published their first investigations on the P-15 pep-
tide for application in bone tissues. In this paper, they showed that attaching this 15 
amino acid peptide (P-15) to a calcium phosphate anorganic bone mineral (ABM) 
led to dramatic increases in cellular response in culture. Their work suggested that 
this combination might be a useful addition to the bone grafting armamentarium 
[28]. The in-vitro model demonstrated the ABM-bound P-15 stimulated human-
derived pre-osteoblast resulting in significantly increased number of bound cells 
and the initiation of down-stream molecular events associated with differentiation 
and osteoinductive activities. Additionally, it was observed that mechanical forces 
on the cellular cytoskeleton may be generated by P-15 surface integrin interactions. 
These forces are believed to contribute to mechanotransduction with profound 
consequences on cellular differentiation.
Over the subsequent decades, numerous in vitro studies demonstrated that the 
P-15 peptide would elicit specific biological responses from bone forming lineage 
cells (pre-osteoblasts as well as MSC.) The stimulation/differentiation of MSC was 
demonstrated at both the molecular level as seen by upregulation of mRNA produc-
tion, and the protein level as evidence by the cellular release of bone-regeneration 
associated proteins and growth factors, including alkaline phosphatase, BMP-2 and 
Collagen Type I [29]. The mechanism of action that elicits these effects is related to 
the P-15 peptide “plugging in” to surface receptors on these cells, which turns on the 
genetically programmed downstream cellular responses.
Qian and Bhatnagar showed that P-15 bound to ABM increases the number of 
bound human fibroblasts and stimulates cellular activation and spreading [28].
Liu et al. demonstrated that P-15 bound to surface increases the number of 
bound pre-osteoblastic cells and stimulates cellular activation [30]. The authors 
also noted a significant increase in specific cell surface integrin activation and 
focal adhesion kinase activation on surface treated with P-15 compared to control 
substrates, an indication of the direct biological influence of the P-15 peptide on 
cells.
Yang et al. demonstrated that P-15 bound to ABM stimulates upregulation of 
cellular BMP-2 and alkaline phosphatase production and the onset of calcifica-
tion. Alkaline phosphatase production is an indicator of cellular differentiation to 
osteoblasts as well as their activity toward bone formation [31].
Yuan et al. found that P-15 bound to ABM stimulates early formation of mineral-
ization nodes [32].
Clinical Implementation of Bone Regeneration and Maintenance
56
In vivo studies using a rabbit drill hole model demonstrated that ABM-bound 
P-15 significantly enhances the generation of new bone formation yielding histo-
logical evidence of mature bone tissue [33]. The P-15/ABM material yielded statisti-
cally more new bone formation at two, four and 8 weeks with over seven-times 
higher percentage of new bone as compared to ABM alone [33]. A sheep interbody 
lumbar fusion animal study demonstrated that ABM-bound P-15 yielded fusion 
rates equivalent to the “gold-standard” of iliac crest bone graft and displayed good 
trabecular bridging bone structure at 6 months [34]. Finally, rabbit intramuscular 
implant studies of ABM-bound P-15 established that the P-15 peptide does not sup-
port bone formation outside of a bony tissue environment. This can be interpreted 
as a safety factor, since ectopic bone formation in clinical use is unlikely. These 
effects translated from tissue culture into animal implantation, showing promise 
for bone grafting applications with strong bone formation in the absence of ectopic 
bone formation.
In 1999, the FDA granted the first of two PMA approvals for the use of the P-15 
peptide for dental bone grafting to Ceramed on the basis of a prospective, random-
ized, Level-I IDE study demonstrating safety and effectiveness. This product, 
Pepgen P-15, has been used in ~500,000 patients to date in the United States.
In 2000, Cerapedics began developing the P-15 peptide technology platform, 
called i-FACTOR™ bone graft (P-15 Putty), for use in orthopedics and spine 
surgery indications. i-FACTOR bone graft is a composite bone graft consisting of 
the synthetic P-15 peptide (biomimetic of the Type I collagen peptide) absorbed 
onto ABM (naturally-derived calcium phosphate particles) and then suspended in 
an inert hydrogel carrier. Cerapedics received the first CE mark for i-FACTOR bone 
graft in 2008 for all orthopedic applications, including spine. Under the CE mark, 
the product has been used in >50,000 patients to date.
Cerapedics initiated an IDE trial for single level ACDF in an allograft ring in 
2006, which culminated in PMA approval in 2015. This FDA-approved trial was 
prospective, randomized, blinded, controlled and statistically-powered, thus 
represents Level I study data [35]. In this 319-patient trial, i-FACTOR bone graft 
successfully met the predefined noninferiority criteria for radiologic fusion (88.9 
vs. 85.8% for control), neck disability index (28.8 change vs. 27.4% for control), 
neurological success (93.7 vs. 93% for control), and safety (97.5 vs. 95.4% for 
control). More importantly, an FDA-mandated, prospectively designed statistical 
analysis of the Overall Clinical Success, defined as individual patients who were 
successful for all four of the primary outcomes, demonstrated statistical superior-
ity to local autograft in overall clinical success (68.8 vs. 56.9%) at 12 months. This 
statistical superiority was maintained at the 24-month evaluation.
Following the introduction of the i-FACTOR bone graft in the EU, based on a 
CE-mark, numerous clinical evaluations were performed with i-FACTOR bone 
graft in the lumbar clinical indication. Mobbs et al. published a prospective ALIF 
study in which i-FACTOR was used as a stand-alone bone graft inside a PEEK 
interbody device [36]. In this study, an independent radiological evaluation found a 
94% fusion rate by thin cut CT at 24 months, along with a statistical improvement 
in all clinical evaluations. The authors concluded that, based on their experience, 
“the study demonstrates a high fusion rate and clinical improvement comparable to 
the published results for ALIF using autograft or BMP, while avoiding the complica-
tions specific to those materials.” This study represents an approved use in the EU 
and Australia, which would be considered off-label in the United States.
Lauweryns et al. published the results from a prospective intra-patient random-
ized study comparing i-FACTOR bone graft to local autograft in PLIF fusions [37]. 
In this study, contralateral cages were randomized to be filled with either i-FACTOR 
bone graft or local autograft, and fusions were assessed by thin cut CT. This study 
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demonstrated faster fusion with i-FACTOR bone graft compared to local autograft. 
i-FACTOR bone graft was statistically superior with regards to percentage of 
patients with complete bridging fusion at both 6 months (97.7% for i-FACTOR vs. 
59.1% for autograft) and 12 months (97.8% for i-FACTOR vs. 82.2% for autograft). 
At 24 months, the fusion rates were no longer statistically different. The authors 
concluded that “i-FACTOR is associated with faster formation of bridging bone 
when compared to autologous bone in patients undergoing PLIF.” This study repre-
sents an approved use in the EU and Australia, and would be considered off-label in 
the United States.
In March 2018, the FDA approved an IDE for Cerapedics to initiate another IDE 
study. This second prospective IDE study is in single level TLIF procedures. In this 
study, an advanced formulation of P-15 (P-15 L bone graft) is being randomized 
against local autograft as the control. This study is expected to enroll 364 patients 
and has a 2-year endpoint for the PMA filing of Level I data.
Both the well-established mechanism of action regarding the stimulatory effects 
of P-15 peptide along with the extensive clinical data resulting from an IDE, Level 
I clinical study, strongly support the safety and effectiveness of P-15 peptide in the 
form of i-FACTOR bone graft.
4. The OP-1 implant: BMP-7
There is a third drug-device combination spinal bone graft product, which 
deserves some discussion: the OP-1 implant formerly commercialized by Stryker 
Biotech under FDA humanitarian device exemptions (HDE) OP-1 was bone mor-
phogenetic protein (BMP)-7 on a collagen delivery carrier. The BMP-7 was bound 
to the collagen prior to packaging and terminal sterilization. Following study in 
long bone nonunions, the OP-1 implant was studied as an autograft replacement for 
primary posterolateral spinal fusion (PLF) under an IDE (IDE G990028).
After failing to meet the primary outcomes of the study to qualify for a PMA 
approval [rejection at the FDA advisory panel meeting in November, 2007], 
Stryker Biotech filed an HDE for revision PLF, which was granted in 2004. The 
Humanitarian Device Exemption (HDE) pathway is a method of gaining very 
limited FDA approval for a medical device. The device has to be intended to benefit 
patients in the treatment or diagnosis of a disease or condition that affects or is mani-
fested in not more than 8000 individuals in the United States per year. Although 
the application is similar to a premarket approval (PMA) application, the product 
is exempt from effectiveness requirements and, therefore, does not require a well-
controlled Level I clinical trial. The application is required to only provide sufficient 
technical information to demonstrate that the device will not expose patients to an 
unreasonable or significant risk of illness or injury and the probable benefit to health 
from the use of the device outweighs the risk of injury or illness from its uses.
The OP-1 device was commercialized by Stryker in the United States until 2010 
and then, subsequently sold to Olympus. OP-1 was later removed from the market 
worldwide.
5. Conclusions
Nonstructural allograft and cellular allograft products marketed as HCT/Ps do 
not require any FDA review for safety or efficacy. Synthetic bone grafts and DBM’s 
require a 510(k) for clearance on the basis of animal studies, and most of these 
technologies have little to no meaningful clinical data. Currently, there are only two 
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form of i-FACTOR bone graft.
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phogenetic protein (BMP)-7 on a collagen delivery carrier. The BMP-7 was bound 
to the collagen prior to packaging and terminal sterilization. Following study in 
long bone nonunions, the OP-1 implant was studied as an autograft replacement for 
primary posterolateral spinal fusion (PLF) under an IDE (IDE G990028).
After failing to meet the primary outcomes of the study to qualify for a PMA 
approval [rejection at the FDA advisory panel meeting in November, 2007], 
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from the use of the device outweighs the risk of injury or illness from its uses.
The OP-1 device was commercialized by Stryker in the United States until 2010 
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not require any FDA review for safety or efficacy. Synthetic bone grafts and DBM’s 
require a 510(k) for clearance on the basis of animal studies, and most of these 
technologies have little to no meaningful clinical data. Currently, there are only two 
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PMA-supported Class III drug-device bone graft substitutes available with Level 
I data that demonstrate equivalence in safety and effectiveness to autograft in the 
spine: Infuse® (rhBMP-2) and i-FACTOR bone graft (P-15 peptide). Both of these 
technologies have multiple peer-reviewed clinical studies that can be used to evalu-
ate their effectiveness and make a clinical use decision.
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Allograft Structural Interbody 
Spacers Compared to PEEK Cages 
in Cervical Fusion: Benchtop and 
Clinical Evidence
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Abstract
Cervical degenerative disc disease (CDDD) can lead to radiculopathy and 
myelopathy, resulting in pain, lack of function, and immobility. Anterior cervi-
cal discectomy and fusion (ACDF) is a common surgical treatment modality 
for advanced CDDD. ACDF involves removal of the affected disc(s) followed 
by replacement with a bone or synthetic graft. Historically, autograft has been 
considered the gold standard for interbody fusion. However, it is often associated 
with limitations, including donor site morbidity and limited quality and supply, 
prompting surgeons to seek alternatives. Two of the most common alternatives 
are structural bone allografts and polyetheretherketone (PEEK) synthetic cages. 
Both, advantageously, have similar mechanical properties to autologous bone, with 
comparable elastic modulus values. However, a lack of osseointegration of PEEK 
cages has been reported both pre-clinically and clinically. Reported fusion rates 
assessed radiographically are higher with the use of structural bone allografts com-
pared to PEEK cages, while having a lower incidence of pseudarthrosis. This book 
chapter will discuss in detail the pre-clinical and clinical performance of structural 
allografts in comparison to conventional PEEK cages.
Keywords: polyetheretherketone (PEEK), structural bone allograft, anterior cervical 
discectomy and fusion (ACDF), cervical degenerative disc disease, synthetic cage, 
allograft, irradiation
1. Introduction
Cervical degenerative disc disease is one of the most common diagnoses for 
patients suffering from neck and back pain. These symptoms may present with various 
conditions, such as radiculopathy or myelopathy, involving compression of the nerve 
root and spinal cord, respectively [1]. Patients may suffer from pain, lack of func-
tion, immobility and sensory loss. Initial treatments often include anti-inflammatory 
medicine, immobilization, and physical therapy [1]. However, when conservative 
treatment options fail, a surgical approach such as anterior cervical discectomy and 
fusion (ADCF) may be warranted. This anterior approach involves excising the 
affected disc(s), removing osteophytes, and decompressing the nerve root or spinal 
cord. Following disc removal, the residual vertebral space is typically implanted with 
a bone or synthetic graft, with or without the additional support of plates and screws. 
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Robinson and Smith described this technique in 1955 [2]. Their approach involved 
implantation of a horseshoe-shaped bone graft harvested from iliac crest, followed by 
immobilization. Patients treated with this technique demonstrated promising clinical 
outcomes [2]. In 1958, Cloward described a similar technique, however, it included 
decompression of the neural structures and implantation of a bone dowel in the 
interbody space [3]. Regardless of the approach, a graft was used as a spacer to restore 
disc height, provide stability, and help promote bone fusion. Autograft, generally 
taken from the iliac crest, is often considered to be the gold standard for interbody 
fusion [4]. The use of autograft has led to high fusion rates and clinical success, 
although there are several disadvantages, such as extended operating time, donor site 
pain, limited supply, and variable quality depending upon the patient’s health [5–8]. In 
an effort to avoid the complications seen with autografts, there has been a decades-old 
shift towards the use of alternative interbody spacers for treatment of degenerative 
disc disease [9, 10]. Two of the most common choices have been structural allograft 
bone or synthetic cages manufactured using polyetheretherketone (PEEK) [10]. 
Here, a comparison of the material properties and clinical performance of structural 
allografts and conventional PEEK cages is provided.
2. Bone graft substitutes as intervertebral spacers in ACDF
Structural bone allografts have been used successfully in a broad range of clinical 
applications including ACDF procedures [11–13]. Although lacking direct osteogenic 
potential, structural allografts have similar osteoconductive properties to autograft 
while avoiding complications such as donor site morbidity [14]. Furthermore, studies 
have shown similar clinical outcomes when comparing the use of allograft to autograft 
in ACDF procedures [15, 16]. Other commonly used implants include interbody cages 
made of various materials, including metals, ceramics, and polymers. Metal implants 
have been widely used as spinal cages for ACDF procedures. In particular, titanium 
implants offer mechanical strength, maintenance of vertebral disc height, and  
are available in various forms including mesh and box implants [4]. However, 
there are concerns regarding the use of titanium implants due to their mismatched 
mechanical properties compared to native bone. The difference in elastic modulus 
between bone and titanium can cause stress shielding, weakening the surrounding 
bone and increasing risk of peri-prosthetic fractures [17]. Bioactive ceramics serve as 
an attractive alternative due to their demonstrated biocompatibility, osteoconductive 
potential, and availability [9]. Despite these advantages, varying porosity of ceramics 
can lead to brittleness, thus making them less ideal implants for load-bearing applica-
tions [18]. Finally, various polymers are used in biomedical applications due to their 
biocompatibility, chemical and mechanical stability, and wide ranging compositions. 
However, some polymers are not ideal for orthopedic implants due to their malleable 
nature and weak mechanical properties [19]. One polymer with desirable mechani-
cal properties is polyetheretherketone (PEEK). Compared to autograft, PEEK cages 
offer shorter operating time and reduced donor site morbidity [4]. This chapter will 
focus on the properties of structural allograft bone compared to conventional PEEK 
implants due to their similar mechanical properties and common use. Pre-clinical 
studies examining mechanical properties, osteoconduction and osseointegration, and 
clinical fusion rates in the cervical spine will be presented.
2.1 Structural allograft
Allograft bone, sourced from deceased human donors, is readily available and 
commonly used [20]. Allogenic bone grafts come in various forms, shapes, and 
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sizes, based on clinical need, and can be either structural or non-structural. The 
bone is typically processed by physical and chemical means to ensure safety, bio-
compatibility and clinical suitability. Processing steps can include physical shaping 
and resizing of the graft for a specific clinical purpose (e.g., an intervertebral body 
spacer), disinfection and sterilization, and preservation to increase shelf life and 
simplify storage.
Allograft use in bone grafting procedures dates back many decades, as evidenced 
by a nineteenth century publication from the Scottish surgeon William Macewen 
[21, 22]. He successfully reconstructed an infected humerus of a 4 year-old child 
using allograft tibial segments obtained while treating effects of rickets. Early in 
the twentieth century, Fred Albee published a book on bone graft applications, 
laying the foundation for a surge in bone transplantation procedures that is ongoing 
[23]. Allograft bone is now widely used for spinal, orthopedic, dental, and trauma 
applications. Notably, allograft usage in the treatment of degenerative cervical disc 
disease has increased from 14% in 1999 to 59% in 2008 [24]. Of particular inter-
est here, the use of structural allografts in ACDF procedures dates back as early as 
1958. Cloward described the use of frozen allograft bone in 46 patients undergoing 
ACDF [3]. A cylindrical iliac dowel, commonly known as the Cloward dowel, was 
implanted into the empty interbody space. Forty-four patients demonstrated com-
plete interbody fusion at 3–4 months post-operative. Numerous studies have since 
been published discussing the use of various structural allografts in ACDF proce-
dures [18]. Structural allografts continue to be used as interbody spacers due to their 
ability to support mechanical loads and resist failure. Such structural allografts 
are comprised of either cortical, cancellous or a combination of both cortical and 
cancellous bone. Cortical bone is more rigid and provides greater structural sup-
port, while cancellous bone confers less mechanical strength, but is more porous, 
providing an osteoconductive scaffold for neovascularization and osseointegration.
Infection due to allograft transplantation remains a risk, albeit rare. A report 
released by the Centers for Disease Control and Prevention (CDC) in 2005 estimated 
an overall allograft-associated infection rate of 0.0004%, emphasizing the unlikely 
event of allograft-associated disease transmission [25]. This number was developed 
before additional advanced tissue processing methods, including terminal sterilization, 
were implemented by many tissue providers. Organizations, such as the American 
Association of Tissue Banks (AATB) and the Food and Drug Administration (FDA), 
maintain standards for tissue banking, including donor acceptance criteria, tissue 
procurement and processing methods, and allograft storage [26, 27]. Additionally, 
FDA published the Current Good Tissue Practice (CGTP) Final Rule, effective in 2005, 
setting requirements aimed at “preventing the introduction, transmission and spread of 
communicable diseases” [28]. AATB and FDA guidelines ensure that human allograft 
tissues are both clinically suitable and safe. Through the combination of rigorous donor 
screening and tissue processing, risk of disease transmission is virtually eliminated.
2.2 Synthetics: polyetheretherketone (PEEK) cages
Polyetheretherketone (PEEK) is a non-absorbable, semicrystalline polymer 
processed through a variety of techniques including extrusion, or injection and 
compression molding [29, 30]. Chemically, PEEK is made up of an aromatic back-
bone, interconnected by ketone and ether functional groups [30]. The chemical 
structure of PEEK gives it distinct qualities such as: stability at high temperatures, 
resistance to chemical and radiation damage, strength and stiffness. PEEK is 
available in several configurations including neat (unfilled) and carbon-reinforced 
PEEK (CRPEEK). The addition of composite fillers, such as carbon fiber, provides 
those forms of PEEK with increased mechanical strength [30].
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2.2 Synthetics: polyetheretherketone (PEEK) cages
Polyetheretherketone (PEEK) is a non-absorbable, semicrystalline polymer 
processed through a variety of techniques including extrusion, or injection and 
compression molding [29, 30]. Chemically, PEEK is made up of an aromatic back-
bone, interconnected by ketone and ether functional groups [30]. The chemical 
structure of PEEK gives it distinct qualities such as: stability at high temperatures, 
resistance to chemical and radiation damage, strength and stiffness. PEEK is 
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PEEK (CRPEEK). The addition of composite fillers, such as carbon fiber, provides 
those forms of PEEK with increased mechanical strength [30].
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Developed in 1978, PEEK was initially commercialized for industrial applica-
tions such as aircraft and turbine blades due to its high chemical and mechanical 
resistance [29, 31]. However, in the late 1980s, it emerged as a potential biomaterial 
for surgical implantation and rapidly gained acceptance as a medical device. In the 
late 1990s, PEEK was introduced as a spinal cage implant and has also been used for 
other orthopedic and dental applications [19]. PEEK cages have become a popular 
choice due to inherent biocompatibility and favorable mechanical properties com-
pared to traditional metal-based cages. PEEK has undergone numerous biocompat-
ibility and cytotoxicity tests in accordance with both FDA and ISO 10993 standards. 
Morrison et al. evaluated the response from mouse fibroblasts and rat osteoblasts 
in vitro and found PEEK to display excellent biocompatibility [32]. Rivard et al. 
demonstrated that PEEK particles implanted in New Zealand white rabbits elicited 
no apparent necrosis or swelling, leading the authors to suggest that it is “harmless” 
to the spinal cord [33].
Compared to other synthetic implants such as titanium cages, PEEK has an 
elastic modulus similar to that of native bone, thus reducing the potential impact of 
stress shielding on the bone healing process [19, 34]. Another advantage of PEEK is 
radiolucency which allows for radiographic assessment of fusion [35]. Furthermore, 
due to its ability to resist radiation damage, PEEK is able to be sterilized by electron 
beam or gamma irradiation. Despite noted advantages, several concerns have been 
raised due to how PEEK’s inert nature and low-surface energy might affect the 
body’s biological response. Adsorption of water at the implant surface plays an 
important role in protein-surface interactions, and thus cell-surface interactions, 
which can determine the success of an implant [36]. The hydrophobic nature of 
PEEK can potentially limit cellular adhesion. This undesirable property has been 
recently reported in studies finding that conventional smooth PEEK implants have 
limited osteoconductive properties and limited bone fixation at the implant inter-
face [29, 37]. For example, Phan et al. described a case in which a patient underwent 
anterior lumbar interbody fusion (ALIF) with a PEEK implant [38]. The authors 
found evidence of poor integration between the implant and surrounding bone 
causing the “halo-effect” on CT scans.
These issues have led to several modifications in an attempt to increase PEEK’s 
bioactivity, including surface coating with synthetic osteoconductive material such 
as titanium, increasing surface roughness and porosity through chemical modifica-
tions, and incorporating bioactive particles [34, 39]. Despite these promising modifi-
cations, conventional PEEK is still commonly used and is the focus in this chapter.
3. Engineering studies of PEEK and allograft
Interbody spacers require appropriate mechanical properties to be clinically 
effective. One important property is elastic modulus, the measure of resistance 
to deformation in response to applied stress. Mismatches in the elastic modulus 
between the surrounding vertebral bodies and an implant may lead to issues such 
as subsidence and stress shielding [40]. Clinically, these issues can cause complica-
tions such as pseudarthrosis and non-unions. Thus, it is ideal for an implant to 
have a similar elastic modulus as native bone. Heary et al. measured the elastic 
modulus and stiffness of various spinal interbody implants including neat and 
carbon-reinforced PEEK and cancellous and cortical bone [40]. The authors found 
that the elastic modulus of neat PEEK was similar to cancellous allograft bone, 3.84 
and 3.78 GPa, respectively (Figure 1). Similarly, carbon-reinforced PEEK demon-
strated a comparable elastic modulus to cortical allograft bone, 17.94 and 14.64 GPa, 
respectively. The study demonstrates the similar elastic modulus of allograft and 
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PEEK implants and contrasts with the stiffer stainless steel, titanium, and cobalt-
chrome materials.
The success of a spinal fusion procedure depends, in part, on the mechanical 
strength of the interbody spacer. Failure of the spacer can lead to graft subsidence 
and non-union. Native vertebral bodies have been reported to withstand average 
compressive strengths up 2400 N for cervical and 8600 N for lumbar joints [41, 42]. 
It is desirable for interbody spacers to withstand a compressive strength comparable 
to that of the relevant autologous bone in that surgical procedure (e.g., cervical vs. 
lumbar). Since structural allografts are typically processed to disinfect or sterilize, 
and to preserve for storage before use, these methods have the potential to alter 
clinically relevant properties. The biomechanical strength of several configura-
tions of structural bone allografts was assessed following disinfection using one 
such method, the proprietary Allowash® process (United States Patents 5,556,379; 
5,820,581; 5,977,034; 6,024,735). In addition, samples were tested with or with-
out a sterilizing dose of gamma irradiation performed at ultra-low temperatures 
(Figure 2). The results indicate that bone grafts can be disinfected and retain a 
strength greater than that of pertinent vertebral bodies, but can also be sterilized 
under controlled conditions without negative impact on the clinically relevant 
Figure 1. 
Elastic modulus of all materials (*p < 0.05; **p < 0.01). Reprinted with permission from Heary et al. [40].
Figure 2. 
Compressive strength of disinfected and irradiated vs. disinfected only structural bone allografts used in spinal 
fusion procedures. Compressive strength was defined as the maximum load that the graft could withstand 
before graft failure. Disinfected structural allografts were divided into either non-irradiated or irradiated 
groups, with a targeted absorbed dose of 15 kGy. Irradiation did not significantly alter the compressive strength 
of any of the structural allografts.
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Figure 1. 
Elastic modulus of all materials (*p < 0.05; **p < 0.01). Reprinted with permission from Heary et al. [40].
Figure 2. 
Compressive strength of disinfected and irradiated vs. disinfected only structural bone allografts used in spinal 
fusion procedures. Compressive strength was defined as the maximum load that the graft could withstand 
before graft failure. Disinfected structural allografts were divided into either non-irradiated or irradiated 
groups, with a targeted absorbed dose of 15 kGy. Irradiation did not significantly alter the compressive strength 
of any of the structural allografts.
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characteristics of the bone. Additionally, it has been separately demonstrated that 
moderate doses of irradiation (up to 28.5 kGy) performed at ultra-low temperatures 
do not alter the compressive strength or elastic modulus of structural allografts 
compared to non-irradiated controls [43].
Likewise, storage conditions can potentially alter properties of structural bone 
allografts before use. Traditionally, bone grafts have been provided frozen, with 
storage at −20°C, or freeze-dried, which allows for storage at room temperature. 
Frozen grafts require special shipping and storage, and must be thawed prior 
to use. Freeze-dried allografts can be stored at room temperature, but require 
rehydration, which may not restore the native biomechanical properties of the 
graft. More recently, a glycerol-based preservation solution was developed to 
allow storage of grafts at room temperature [44]. The flexural strain (i.e., elastic-
ity) and compressive strength of various structural bone allografts preserved by 
either freezing, freeze-drying, or glycerol-based preservation were evaluated. The 
results demonstrate that the frozen and glycerol-preserved groups were not sig-
nificantly different, but did display significantly greater flexural strain compared 
to freeze-dried tissue, even after the freeze-dried bone was rehydrated up to 60 
minutes (Figure 3A). The compressive strengths of different structural allografts 
that were either freeze-dried or glycerol-preserved (Figure 3B) were found to be 
unaltered by the preservation method for each type of graft. These results dem-
onstrate that the processing of allograft bone, including disinfection, sterilization 
by irradiation and varying preservation methods, does not significantly impair 
clinically relevant characteristics, notwithstanding the increased brittle nature of 
freeze-dried bone.
4. Pre-clinical literature review: in vivo models
In addition to testing mechanical properties, it is also important to evaluate 
the biocompatibility of bone graft substitutes. Animal models are a common and 
useful tool to evaluate the in vivo response to implantable materials prior to clinical 
application. Animal studies have demonstrated fibrous tissue growth and lack of 
osseointegration related to the use of PEEK implants.
Figure 3. 
Biomechanical properties of structural allografts preserved by different methods. Different types of disinfected 
structural bone allografts were preserved by either freezing, freeze-drying or glycerol preservation, followed 
by irradiation with a targeted absorbed dose of 15 kGy. Panel (A) shows the average flexural strain of cortical 
bone allografts preserved by the different approaches. The glycerol-preservation and frozen groups were not 
significantly different, but both demonstrated significantly greater average maximum flexural strain compared 
to the freeze-dried group. Modified and reprinted with permission from Samsell et al. [44] according to the 
Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/
legalcode). (B) Average compressive strength of structural allografts that were either freeze-dried or preserved 
using a glycerol-based solution. The compressive strength was not different between the freeze-dried and 
glycerol-preserved groups for all three graft types.
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In a technical note, Phan et al. described PEEK’s poor integration with the 
surrounding bone, producing a “PEEK-Halo” effect [38]. This phenomenon is 
represented by a halo appearance between the implant and bone graft on a CT scan. 
The authors placed conventional PEEK (c-PEEK) and Ti-sprayed PEEK implants in 
cortical bone and cancellous bone of adult sheep tibia. Histological analysis of the 
c-PEEK implant showed a fibrous tissue layer and a gap on the PEEK-bone interface 
(Figure 4). The authors suggest this may be due to inflammatory factors and/or the 
interaction between PEEK and osteoblastic differentiation. In a cervical interbody 
fusion model in adult sheep, authors compared the bone-implant interface of conven-
tional PEEK (c-PEEK) and Hydroxyapatite coated PEEK (HA-PEEK) [37]. Micro-CT 
analysis demonstrated less new bone formation in the c-PEEK group at 6 weeks post-
implantation. Furthermore, histological analysis showed a fibrous tissue interface 
between bone and c-PEEK implants at 6 and 12 weeks post-implantation. Walsh et al. 
likewise compared the mechanical and histologic properties of conventional PEEK 
and Ti-PEEK at the bone-implant interface in a sheep model [45]. Sites implanted 
with c-PEEK appeared static with no bone response. While, encouragingly, Ti-PEEK 
exhibited in-growth of bone, that is not the focus of this chapter. PEEK-bone implant 
interface contained a fibrous tissue layer and a gap at 4 and 12 weeks. Direct bone 
contact for the c-PEEK implants in cancellous bone was minimal at 4 weeks (4.8%) 
and improved at 12 weeks, but only reached 11.5%. This in vivo study is yet another 
example of fibrous tissue seen at the PEEK interface.
The use of structural allografts in ACDF procedures is well documented, with 
reported fusion rates similar to that of autologous bone [15, 16]. In vivo osseointe-
gration of bone was assessed using a calvarial defect model in athymic rats [44]. A 
portion of the rat’s skull was removed to create a critical size defect, which cannot 
close on its own. Following creation of the defect site, the investigators implanted 
human cortical and cancellous bone discs that were preserved by either freezing, 
freeze-drying, or glycerol-based preservation. At 1 week post-implantation, there 
Figure 4. 
Histology of PEEK/bone interface at 4 weeks post-implantation into a sheep tibia model. (A) Presence of 
fibrous tissue (white arrow) between the PEEK implant and adjacent bone—the rim of fibrous tissue results 
in the halo effect seen on CT imaging. (B) Titanium (Ti)-PEEK/bone interface demonstrating on-growth and 
ingrowth of bone at the Ti-PEEK/bone interface, with no radiolucent rim evident on CT imaging. Reprinted 
with permission from Phan et al. [38].
Clinical Implementation of Bone Regeneration and Maintenance
68
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moderate doses of irradiation (up to 28.5 kGy) performed at ultra-low temperatures 
do not alter the compressive strength or elastic modulus of structural allografts 
compared to non-irradiated controls [43].
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rehydration, which may not restore the native biomechanical properties of the 
graft. More recently, a glycerol-based preservation solution was developed to 
allow storage of grafts at room temperature [44]. The flexural strain (i.e., elastic-
ity) and compressive strength of various structural bone allografts preserved by 
either freezing, freeze-drying, or glycerol-based preservation were evaluated. The 
results demonstrate that the frozen and glycerol-preserved groups were not sig-
nificantly different, but did display significantly greater flexural strain compared 
to freeze-dried tissue, even after the freeze-dried bone was rehydrated up to 60 
minutes (Figure 3A). The compressive strengths of different structural allografts 
that were either freeze-dried or glycerol-preserved (Figure 3B) were found to be 
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the biocompatibility of bone graft substitutes. Animal models are a common and 
useful tool to evaluate the in vivo response to implantable materials prior to clinical 
application. Animal studies have demonstrated fibrous tissue growth and lack of 
osseointegration related to the use of PEEK implants.
Figure 3. 
Biomechanical properties of structural allografts preserved by different methods. Different types of disinfected 
structural bone allografts were preserved by either freezing, freeze-drying or glycerol preservation, followed 
by irradiation with a targeted absorbed dose of 15 kGy. Panel (A) shows the average flexural strain of cortical 
bone allografts preserved by the different approaches. The glycerol-preservation and frozen groups were not 
significantly different, but both demonstrated significantly greater average maximum flexural strain compared 
to the freeze-dried group. Modified and reprinted with permission from Samsell et al. [44] according to the 
Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/
legalcode). (B) Average compressive strength of structural allografts that were either freeze-dried or preserved 
using a glycerol-based solution. The compressive strength was not different between the freeze-dried and 
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reported fusion rates similar to that of autologous bone [15, 16]. In vivo osseointe-
gration of bone was assessed using a calvarial defect model in athymic rats [44]. A 
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was apparent soft tissue infiltration in all experimental groups, consistent with an 
early post-operative response. These findings support the biocompatibility of the 
bone grafts. Additionally, at 6 weeks post-implantation, the authors observed areas 
of osseointegration similar to autograft (Figure 5).
5. Clinical data: fusion, nonunion, and pseudarthrosis rates
Both PEEK and allograft spinal implants have a long history of use in ACDF 
procedures. While mechanical and pre-clinical results can help predict clinical 
performance, this is ultimately determined through clinical outcomes. Many studies 
rely upon radiographic fusion to determine clinical success. According to Zdeblick 
and Phillips, “most published reports use the ‘fusion’ criteria required by the FDA, 
including motion of less than 5° on flexion-extension radiographs and an absence 
of lucencies around the cages or cage migration” [46]. Some studies also include 
pseudarthrosis rates. In the following section, we will compare clinical outcomes for 
allograft and PEEK implants.
Historically, autograft has been considered the gold standard for spinal fusion 
procedures, and therefore, it is used as the control to which structural allografts or 
PEEK implants have been compared. In a retrospective review, investigators evalu-
ated radiographic fusion in 66 patients who underwent one-level ACDF with auto-
graft (n = 31) or frozen tricortical iliac crest allograft spacers (n = 35), both with 
anterior plate fixation [16]. Radiographic outcomes were assessed at an average of 
12 months follow-up. One hundred percent of patients in the allograft group dem-
onstrated fusion compared to the 90% of patients in the autograft group, although 
the difference was not statistically significant. Three patients in the autograft group 
showed evidence of non-union. The authors suggested that the use of allograft can 
achieve high fusion rates, while avoiding complications associated with autograft, 
such as donor site pain. In a similar study, radiographic fusion was assessed in 80 
patients who underwent multi-level ACDF procedures using autologous (n = 45) 
or allogeneic (n = 35) tricortical iliac crest grafts [15]. Radiographic outcomes 
were assessed in all patients at an average follow-up of 16 months. Successful bone 
fusion occurred in 100 and 94% of patients in the autograft and allograft group, 
respectively. Pseudarthrosis occurred in two patients in the allograft group, but was 
not statistically significant. The authors concluded that allograft can produce solid 
bone fusion similar to autograft without the associated donor site pain. Finally, in 
a prospective study, Cho et al. compared the radiographic outcomes of PEEK cages 
Figure 5. 
(a) Glycerol-preserved cancellous bone in a tight-fit rat calvarial defect. The scale is 500 μm. (b) Freeze-dried 
cortical bone in a tight-fit rat calvarial defect at 6 weeks. The scale is 500 μm. Black arrows mark complete 
bone bridge formation. Blue arrows indicate soft tissue infiltrate. Green arrows mark osseointegration. H, host 
bone; I, implant bone. Reprinted with permission from Samsell et al. [44] according to the Creative Commons 
Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/legalcode).
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filled with autologous iliac bone marrow vs. autologous iliac crest graft only in 80 
patients who underwent ACDF, with the number of levels ranging from 1 to 3 [47]. 
The study revealed 93% fusion in the autograft only group and 100% fusion rate in 
autograft filled PEEK cage group at an average follow-up of 10 months. It should be 
noted that the high fusion rate demonstrated by the PEEK group could potentially 
be associated with inherent bone healing properties of autograft within the cage.
Structural allografts have been used for decades to treat degenerative cervical 
disc disease. Numerous studies have evaluated radiographic fusion rates following 
use of structural bone allografts in ACDF procedures. Abla et al. prospectively 
evaluated 74 patients who were diagnosed with clinically significant cervical spinal 
stenosis or spondylosis and required ACDF surgery [48]. The investigators used a 
corticocancellous composite interbody spacer allograft (Figure 6) combined with 
cervical plate fixation. One-level fusion was performed in 34 patients, two levels in 
23 patients, three levels in six patients, and four levels in one patient. Early fusion 
(at 1–3 months post-operative) was seen in 53% of the patients and by 12 months, 
100% of the patients had fusion (Figure 6). The authors reported no graft failures, 
and an overall patient satisfaction of 90% at 12 months follow-up.
Another study, conducted by Graham et al. prospectively compared fusion rates 
using either freeze-dried or glycerol-preserved Cloward dowel allografts in ACDF 
procedures [49]. The study evaluated 86 patients with random assignment to either 
freeze-dried (n = 39) or glycerol-preserved (n = 47) groups (82 and 100 levels, 
respectively). Radiographic assessment at 6 months follow-up confirmed an overall 
fusion rate of >95% at all levels. Similarly, Rodway and Gander compared the use of 
glycerol-preserved vs. frozen interbody corticocancellous composite allografts in 67 
patients undergoing ACDF procedures, with the number of levels ranging from 1 to 
4 and a 1-year minimum follow-up [50]. Radiographic results demonstrated fusion 
in 38% of glycerol-preserved and 42% of frozen allografts at 3 months follow-up, 
and 100% fusion in both groups at 12 months (Table 1). Of note, the structural 
allografts used in each of these studies were sterilized by a low dose of gamma irra-
diation at ultra-low temperatures. Therefore, the combined results demonstrate the 
clinical effectiveness of structural allografts in ACDF surgery, regardless of method 
of preservation or treatment with a sterilizing dose of irradiation.
Figure 6. 
(A) Structural interbody spacer with cancellous bone sandwiched between two plates of cortical bone. (B) Lateral 
X-ray 6 months after ACDF was performed in a 47-year old woman from C4-C5 using the structural interbody 
spacer shown. Complete fusion and good alignment were achieved. Modified and reprinted with permission from 
Abla et al. [48].
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was apparent soft tissue infiltration in all experimental groups, consistent with an 
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Figure 5. 
(a) Glycerol-preserved cancellous bone in a tight-fit rat calvarial defect. The scale is 500 μm. (b) Freeze-dried 
cortical bone in a tight-fit rat calvarial defect at 6 weeks. The scale is 500 μm. Black arrows mark complete 
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bone; I, implant bone. Reprinted with permission from Samsell et al. [44] according to the Creative Commons 
Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/legalcode).
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filled with autologous iliac bone marrow vs. autologous iliac crest graft only in 80 
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and 100% fusion in both groups at 12 months (Table 1). Of note, the structural 
allografts used in each of these studies were sterilized by a low dose of gamma irra-
diation at ultra-low temperatures. Therefore, the combined results demonstrate the 
clinical effectiveness of structural allografts in ACDF surgery, regardless of method 
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X-ray 6 months after ACDF was performed in a 47-year old woman from C4-C5 using the structural interbody 
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In a separate retrospective study, Muzevic et al. evaluated 154 patients who 
underwent a first-time ACDF surgery for treatment of cervical degenerative disc 
disease over a 3-year period [51]. One-level fusion was performed in 48 patients, 
two-level in 56 patients, three-level in 47 patients, and four-level in three patients 
using either cortical or corticocancellous structural allografts, along with demin-
eralized bone matrix and cervical plating. Solid fusion was achieved in 98% 
of patients at a mean follow-up of 6 months, with improved overall treatment 
outcomes in 82% of patients. Finally, Yue et al. reviewed clinical and radiological 
outcomes in 71 patients who had ACDF surgery performed using structural freeze-
dried fibular allografts an average of 7.2 years prior to the review [52]. The authors 
found that symptoms remained resolved in more than 82% of patients. They 
observed fusion in 93% of disc spaces, which was comparable to reported fusion 
rates for autograft [15, 16, 47, 53, 54]. While approximately 17% of the patients 
required revision surgery, the authors state that this rate is comparable to that fol-
lowing ACDF performed with autograft. Therefore, they attribute this revision rate 
to be a reflection of “normal” degeneration with age and not to use of allograft.
Several studies have assessed the clinical outcomes of ACDF procedures with 
the use of PEEK cages. In a prospective study, investigators assessed bone fusion in 
52 patients who underwent anterior cervical discectomy with empty PEEK cages. 
One-level surgery was performed in 44 patients and 2-level surgery in eight patients 
[55]. Based on radiographic analyses, the authors confirmed bone fusion at 43 
treated levels (72%) at an average of 16 months. The authors note the low fusion 
rates of empty PEEK cages, but stated that the lack of fusion did not affect clinical 
outcomes. Similarly, Suess et al. evaluated the clinical and radiographic outcomes 
of 292 patients who received empty PEEK cages for single-level ACDF procedures 
[56]. PEEK demonstrated radiographic fusion in 126 patients (43%) at 6 months, 
214 patients (73%) at 12 months, and 241 patients (83%) at 18 months. The authors 
noted that slow and incomplete radiographic fusion could be attributed to the use of 
empty PEEK cages, and therefore did not recommend their use. Furthermore, they 
suggest this incomplete fusion may lead to reduced improvement in pain and pos-
sible disability. Finally, Kim et al. retrospectively evaluated 68 patients who under-
went two and three-level ACDF with PEEK packed with demineralized bone matrix 
[57]. At an average follow-up of 28 months, PEEK demonstrated 81% overall fusion 
rate, which is less than reported levels for both autograft and structural allograft.
In a retrospective review, Krause et al. looked at 127 patients who underwent 
one-level ACDF with structural allograft (composite (61/71), cortical (8/71), or 
cancellous (2/71)) or PEEK cages to examine the incidence of pseudarthrosis as 
determined by radiography [58]. Fifty six patients (44%) received PEEK implants 
while 71 (56%) received structural allografts. All PEEK cages were filled with 
allogeneic demineralized bone matrix (DBM) or local autograft. The PEEK cohort 
demonstrated a higher rate of radiographic pseudarthrosis at one or more years 
Table 1. 
Fusion rates by number of patients*. Source: “Reprinted with permission from Rodway and Gander [50], 
according to the Creative Commons Attribution 4.0 International License (https://creativecommons.org/
licenses/by/4.0/legalcode)”.
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after follow-up compared to the allograft cohort, 52 vs. 10% (p < 0.001), respec-
tively (Figure 7). The investigators concluded that there was a five-fold higher 
incidence of pseudarthrosis in patients with PEEK cages, and almost double the rate of 
subsequent revision. Furthermore, the investigators suggested PEEK’s inability to 
integrate with organic bone is due to its bio-inertness.
In a similar study, Teton et al. compared pseudarthrosis rates of 62 consecutive 
patients who underwent multi-level ACDF with structural allograft or PEEK cages, 
with at least 1 year follow-up [59]. Of 62 patients, 31 received PEEK implants, and 
31 received structural allograft. Within the PEEK group, 20 (65%) patients dem-
onstrated radiographic evidence of pseudarthrosis, compared to six (19%) patients 
implanted with structural allograft (p < 0.001), demonstrating over three-fold higher 
incidence of pseudarthrosis rates with PEEK. Furthermore, four patients implanted 
with PEEK required re-operation due to pseudarthrosis (13%), compared to 
zero patients with allograft (p = 0.014). Additionally, in a retrospective database 
review, authors analyzed 6130 patients who underwent ACDF with allograft (4063 
patients) or intervertebral cages (2067 patients) to compare nonunion rates after 
Figure 7. 
Sagittal X-ray films obtained in a patient with a PEEK interbody graft and pseudarthrosis (left) and a patient 
with a structural allograft implant (right) healed 1 year after surgery. Reprinted with permission from Krause 
et al. [58].
*PEEK, titanium, mesh, or porous (unstratified due to nature of data base).
Table 2. 
Nonunion Rates Between Structural Allograft and Cages*. Source: Reprinted with permission from Pirkle et al. [60].
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1 year post-operative [60]. Cages were unable to be stratified by type and may have 
been “PEEK, titanium, mesh, or porous.” Patients were stratified by the number 
of levels treated, tobacco use, and diabetic conditions. Overall nonunion rates 
were significantly higher in the cage group (5.32%) than in allograft group (1.97%) 
(p < 0.0001). Notably, patients receiving intervertebral cages showed higher rates 
of nonunion regardless of other factors such as, levels treated, tobacco use, and 
diabetes (Table 2).
6. Summary
While autograft use is common for bone grafting procedures, it is associated 
with limitations, including donor site morbidity, limited quantities, and unsatis-
factory biological activity. For ACDF, autograft use has steadily declined in favor 
of alternatives, primarily structural bone allografts and PEEK cages [18, 30]. 
Favorably, each has mechanical properties similar to autograft, with comparable 
elastic modulus and sufficient strength for intended applications. However, in vivo 
models demonstrate lack of osseointegration for PEEK, as well as fibrous tissue 
growth. Poor integration can lead to graft subsidence and pseudarthrosis, and 
ultimately pain, immobility and sensory loss. In contrast, structural allografts act as 
an osteoconductive scaffold demonstrating osseointegration in a rat model and have 
a long history of successful clinical use. These differences are reflected in clinical 
outcomes, as detailed in this chapter and summarized in Table 3. As shown, fusion 
rates when using PEEK cages were generally lower than when structural allografts 
were used. Moreover, the use of PEEK cages, and cages in general, in ACDF surgery 
presented a significantly higher rate of pseudarthrosis vs. structural allografts, lead-
ing to a greater rate for the need for subsequent revision surgery.
Due to lack of osseointegration of PEEK reported both pre-clinically and clini-
cally, researchers have modified its surface or sought other materials in attempt to 
improve clinical outcomes. There are promising advances in porous and titanium 
coatings and clinical efficacy is being assessed.
In conclusion, although conventional PEEK cages have similar elastic modulus 
as structural allografts and autografts, they display poorer osseointegration charac-
teristics compared to human bone implants. Comparative clinical analyses indicate 
that structural allografts yield higher fusion rates and lower incidence of pseudar-
throsis than conventional PEEK cages in ACDF procedures.
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Abstract
The scaphoid fractures are the most common of the carpal bones, corresponding to 
60; 10% of these progress to nonconsolidation, moreover, 3% can present necrosis of 
the proximal pole. There are various methods of treatment using vascularized (VBG) 
and nonvascularised bone grafts (NVBG). To evaluate and compare the rate of scaphoid 
consolidation with necrosis of the proximal pole using different surgical techniques. The 
authors conducted a systematic review of the literature using the following databases: 
PubMed and Bireme/Lilacs, where 13 case series were selected (10 with use of VBG and 
3 of NVBG), according to inclusion and exclusion criteria. In most cases the vascular-
ized bone grafts were used, especially those based on intercompartmental supraretinac-
ular artery 1 and 2 due to greater reproducibility in performing the surgical technique.
Keywords: scaphoid, bone graft, scaphoid fractures, carpal bones, vascularized bone 
grafts, nonvascularised bone grafts
1. Introduction
The scaphoid fractures are the most common of the carpal bones, corresponding 
to 60% of these fractures. In spite of the existing consolidation without surgical treat-
ment, some series of cases indicate rates of nonconsolidation of up to 10% [1]. Recent 
data suggest that the major risk factor for the nonconsolidation is the displacement of 
the fragments, which is associated with nonconsolidation rates of up to 55% [2].
Avascular necrosis has an estimate of occurrence of 3% in all cases of scaphoid 
fractures and occurs predominantly in the proximal pole, which has been attributed 
to the peculiarity of vascularization of this bone; studies on this subject describe 
that the arterial supply of the scaphoid occurs through three vessels (volar side, 
dorsal and distal) named according to spatial relationship with the scaphoid [3–5]. 
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More recently some studies showed that there are two arteries: one fully dorsal and 
another limited to the tubercle [6].
For the diagnosis of avascular necrosis the use of magnetic resonance imaging 
(MRI) has been recommended, which has an accuracy of up to 68%, increasing to 83% 
when associated with the use of gadolinium contrast. However, the gold standard is the 
intraoperative assessment of the absence of bleeding in the proximal fragment [7].
Several treatment techniques have been described using bone grafts, both vascu-
larized (VBG) and nonvascularized bone grafts (NVBG). The use of nonvascularized 
bone grafts began with Adams and Leonard in 1928, who used cortical graft of the 
tibia embedded in the proximal and distal fragment through the back access via [8].
In 1934, Murray [9] described the embedded tibial graft usage through the 
tuberosity of the scaphoid; Bernard and Stubins in 1928 described the withdrawal 
of this bone pin from styloid process of the radius [10].
Matti in 1936 developed the technique in which an excavation in the proximal 
and distal scaphoid fragments was performed through the dorsal via, and that was 
later filled with cancellous bone graft [11]. Russi in 1960 modified Matti’s technique 
using the volar via to preserve the vascularization of the scaphoid, performing 
niche filling with cancellous bone graft in a single block [12].
In 1970, Fisk observed the intense reabsorption of the volar portion of the 
fragments and the instability that follows, where distal fragment tends to flexion 
and the proximal fragment tends to stretch together with the semilunate, and later 
proposing the use of cortical cancellous graft correcting this deformity [13]. Later, 
Segmüller in 1973 [14] followed the precepts described by Fisk, but described the 
association of the use of osteosynthesis material (traction screw). Consequently, 
Fernandez, in 1984, described this technique in detail [15].
In 1965, Roy-Camille [16] published the technique of the VBG taken from the 
tuberosity of the scaphoid. Later, in 1986, Kuhlmann described the technique in which 
VBG removed from the medial portion and the volar portion of the distal radius were 
used for treatment of failures occurring after use of Matti-Russe technique [17].
In [18], work describing the vascularized graft taken from the distal portion of 
the radius with the vascularization based of intercompartmental supraretinacular 
artery 1 and 2 (1,2 ICSRA) was published.
In a recent systematic review [19], it was concluded that the consolidation rate of 
scaphoid fracture that evolved to a nonconsolidation with use in vascularized bone 
graft was of 88 versus 47% with use of nonvascularized graft.
In face of these data, this study aimed to carry out an updated literature review about 
the consolidation rates with use of different types of grafts (vascularized and nonvascu-
larized) used for the treatment of scaphoid nonunion with necrosis of the proximal pole.
2. Methodology
A search was conducted in the current medical literature, by searching in the data-
bases PubMed and Bireme/Lilacs using combinations of keywords below [20] (Table 1):
1. Bone graft scaphoid
2. Nonunion scaphoid
3. Vascularized bone graft nonunion scaphoid
4. Cancellous bone graft scaphoid
5. Pseudoarthrosis scaphoid
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All articles that made no reference to the use of bone graft to the treatment of 
nonunion of the scaphoid were excluded, which made reference to the use of graft 
in skeletally immature individuals, citing the use of bone grafts in other pathologies 
of the carpus and published articles for more than 20 years.
Thus the following selection was obtained.
Within the selected articles any work that made no reference to the occurrence 
of avascular necrosis of the proximal pole were excluded.
Therefore, a total of 13 articles were used for the analysis of the results.
3. Analysis of results
After the literature review, it can be seen that in the last two decades there is a 
tendency to the preference for the use of vascularized bone grafts in cases of non-
consolidation of the scaphoid, especially when there are signs of avascular necrosis 
of the proximal pole, the main indication for the use of these grafts.
A systematic review of the literature highlights the use of various techniques of 
vascularized bone grafts (VBG), including: VBG based on capsular circulation, VBG 
based on metaphyseal circulation of the distal radius, VBG based on the volar circula-
tion of the distal radius, based on the VBG supraretinacular artery between the 1st and 
2nd extensor compartment (1,2 ICSRA), VBG coming from femoral condyle and com-
ing from the iliac crest; the latter achieved using microanastomosis in the radial artery. 
All techniques show high consolidation rates, with an average of 89% (Table 2).
Steinmann et al. [21] in his work, made use of the distal radius graft with 1,2 
ICSRA technique described by Zaindenberg; reached consolidation rates of 100% 
in 44 cases treated with this technique. Of these, eight had necrosis of the proximal 
pole. Tsai et al. [22] also by use of the technique 1,2 ICRSA reached consolidation 
rate of 80% (4 of 5 patients). Liang et al. [23] using the same technique described 
above had consolidation rates of 100%. However, unlike the previous work, [24] 
also used the vascularized bone graft technique based on 1,2 ICRSA, reaching con-
solidation rates of 100% in 10 patients, 5 cases with necrosis of the proximal pole of 
the scaphoid (Tables 2 and 4).
However, the study done by [25] in which vascularized bone graft based on 1,2 
ICSRA was also used, shows consolidation rates well below comparing to the studies 
cited above. This work achieved consolidation rates of only 27% in 22 cases of 
nonconsolidation of the scaphoid and if only the cases with signs of necrosis of the 
proximal pole are considered, this percentage decreases to 12.5% (Tables 2 and 4).
Steinmann et al. [21] describe high rates of consolidation using distal radio bone graft 
based on capsular circulation, reaching 80% of consolidation, 10 cases were evaluated 












Bone graft scaphoid 267 22 167 24
Nonunion scaphoid 273 19 182 18
Vascularized bone graft 
nonunion scaphoid
22 20 34 16
Structural bone graft 
nonunion scaphoid
10 8 6 5
Pseudoarthrosis scaphoid 66 10 273 13
Table 1. 
Search in the current medical literature through the PubMed and Bireme/Lilacs data base.
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More recently some studies showed that there are two arteries: one fully dorsal and 
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used for treatment of failures occurring after use of Matti-Russe technique [17].
In [18], work describing the vascularized graft taken from the distal portion of 
the radius with the vascularization based of intercompartmental supraretinacular 
artery 1 and 2 (1,2 ICSRA) was published.
In a recent systematic review [19], it was concluded that the consolidation rate of 
scaphoid fracture that evolved to a nonconsolidation with use in vascularized bone 
graft was of 88 versus 47% with use of nonvascularized graft.
In face of these data, this study aimed to carry out an updated literature review about 
the consolidation rates with use of different types of grafts (vascularized and nonvascu-
larized) used for the treatment of scaphoid nonunion with necrosis of the proximal pole.
2. Methodology
A search was conducted in the current medical literature, by searching in the data-
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All articles that made no reference to the use of bone graft to the treatment of 
nonunion of the scaphoid were excluded, which made reference to the use of graft 
in skeletally immature individuals, citing the use of bone grafts in other pathologies 
of the carpus and published articles for more than 20 years.
Thus the following selection was obtained.
Within the selected articles any work that made no reference to the occurrence 
of avascular necrosis of the proximal pole were excluded.
Therefore, a total of 13 articles were used for the analysis of the results.
3. Analysis of results
After the literature review, it can be seen that in the last two decades there is a 
tendency to the preference for the use of vascularized bone grafts in cases of non-
consolidation of the scaphoid, especially when there are signs of avascular necrosis 
of the proximal pole, the main indication for the use of these grafts.
A systematic review of the literature highlights the use of various techniques of 
vascularized bone grafts (VBG), including: VBG based on capsular circulation, VBG 
based on metaphyseal circulation of the distal radius, VBG based on the volar circula-
tion of the distal radius, based on the VBG supraretinacular artery between the 1st and 
2nd extensor compartment (1,2 ICSRA), VBG coming from femoral condyle and com-
ing from the iliac crest; the latter achieved using microanastomosis in the radial artery. 
All techniques show high consolidation rates, with an average of 89% (Table 2).
Steinmann et al. [21] in his work, made use of the distal radius graft with 1,2 
ICSRA technique described by Zaindenberg; reached consolidation rates of 100% 
in 44 cases treated with this technique. Of these, eight had necrosis of the proximal 
pole. Tsai et al. [22] also by use of the technique 1,2 ICRSA reached consolidation 
rate of 80% (4 of 5 patients). Liang et al. [23] using the same technique described 
above had consolidation rates of 100%. However, unlike the previous work, [24] 
also used the vascularized bone graft technique based on 1,2 ICRSA, reaching con-
solidation rates of 100% in 10 patients, 5 cases with necrosis of the proximal pole of 
the scaphoid (Tables 2 and 4).
However, the study done by [25] in which vascularized bone graft based on 1,2 
ICSRA was also used, shows consolidation rates well below comparing to the studies 
cited above. This work achieved consolidation rates of only 27% in 22 cases of 
nonconsolidation of the scaphoid and if only the cases with signs of necrosis of the 
proximal pole are considered, this percentage decreases to 12.5% (Tables 2 and 4).
Steinmann et al. [21] describe high rates of consolidation using distal radio bone graft 
based on capsular circulation, reaching 80% of consolidation, 10 cases were evaluated 
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where all had necrosis of the proximal pole. The authors highlight the lack of need for 
dissection of small vessels as a great advantage of this technique (Tables 2 and 4).
Using the bone graft taken from the base of the thumb with the vasculariza-
tion based on the first metacarpal artery, [27] have reached the consolidation rate 
of 87% in the series of 24 patients. In this work, four cases with necrosis of the 
proximal pole were included and all obtained radiographic consolidation. Despite 
the need for dissection of a small vessel, the authors report as an advantage the 
constancy in all cases of the first metacarpal artery (Tables 2 and 4).
In the study of [28] they realized the prospective evaluation of 46 patients who 
were treated with the use of vascularized bone graft based on 1,2 ICSRSA versus 
40 patients treated with the use of nonvascularized bone graft taken from the 
distal radius and they obtained a statistically significant result in favor of the use of 
vascularized bone graft with a rate of 89.1 versus 72.5% with use of nonvascular-
ized graft. Within the group of patients who underwent VBG use, 21 presented 
necrosis of the proximal pole and of these 19 have achieved consolidation (90.5%) 
(Tables 2 and 4).
In the study of [29] using VBG of the volar portion of the distal radius based in 
the anterior transverse carpal artery, 73% of consolidation rates were obtained in 
30 cases. In this series two cases had signs of avascular necrosis of the proximal pole 
and neither obtained consolidation with the proposed treatment (Tables 2 and 4).
In their study, [30] compared consolidation rates into two groups treated with 
VBG: in a group of 22 patients they used graft taken from the distal radius with 
circulation based on 1,2 ICSRA and another group with 12 patients they used bone 
graft free from the femoral condyle. They achieved a statistically superior results 
using graft derived from the femoral condyle which reached the rate of 100 versus 
40% of consolidation with graft originated from the distal radius (Tables 2 and 4).
Regarding the techniques that describe the use of NVBG for the treatment of 
nonunion of the scaphoid with necrosis of the proximal pole, only three series 
of case were found in this study that did not have the defined exclusion criteria. 
Matsuki et al. [31] proposed an investigation to assess the rate of consolidation 
of the proximal pole of the scaphoid fractures using NVBG associated with the 
fastening with Herbert bone screws; where 11 patients were evaluated and obtained 
consolidation in all of them (Tables 3 and 4). Using the same technique, [32] inves-
tigated 17 patients with 1 year follow up and obtained a consolidation rate of 52% 
(Tables 3 and 4). Ribak et al. [28] carried out the research on the consolidation rate 
Author Consolidation rate Kind of vascularized graft
[21] 100% VBG based on 1,2 ICSRA
[22] 80% VBG based on 1,2 ICSRA
[23] 100% VBG based on 1,2 ICSRA
[24] 100% VBG based on 1,2 ICSRA
[25] 27% VBG based on 1,2 ICSRA
[26] 80% VBG based on capsulate circulation
[27] 87% VBG based on the first metacarpal artery
[28] 89% VBG based on 1,2 ICSRA
[29] 73% VBG based on the anterior transverse carpal artery
[30] 100%
40%
VBG from the femural condyle
1,2 ICRA
Vascularized bone graft (VBG), supraretinacular artery between compartments 1 and 2 [1,2 ICSRA].
Table 2. 
Consolidation rates according to the technique used to the use of vascularized bone graft.
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with use of NVBG in 40 patients; of these, 16 presented necrosis of the proximal 
pole and the consolidation was achieved in 11 of them (Tables 3 and 4).
4. Discussion
The evidence supports that the arterial supply of the proximal pole is poor in com-
parison to the two-thirds of the distal scaphoid. The proximal pole for being entirely 
intraarticular is covered with hyaline cartilage with only one ligament insertion (radio-
scaphoid-lunate ligament). So its vascularization is entirely dependent on intraosseous 
circulation. Thus, when there is loss of continuity solution due to deviation fracture, 
this circulation is impaired favoring the occurrence of non-consolidation [33, 34].
Tsai et al. [22] cites two basic reasons for the preference for the use of vascular-
ized bone graft (VBG) regarding the use of vascularized bone graft not (NVBG): 
the shorter consolidation time, which implies a faster functional recovery, and 
ability to carry blood supply to a nonvascularized bone.
Since the publication of [18], who obtained 100% of consolidation in cases of 






[21] 8 100% (8/8) VBG based on 1,2 ICSRA
[22] 5 80% (4/5) VBG based on 1,2 ICSRA
[23] 11 100% (11/11) VBG based on 1,2 ICSRA
[24] 5 100% (5/5) VBG based on 1,2 ICSRA
[25] 16 12,5% (2/16) VBG based on 1,2 ICSRA
[26] 10 80% (8/10) VBG based on capsular circulation
EOV baseado na circulação capsular
[27] 4 100% (4/4) VBG based on the first metacarpal artery
EOV baseado na 1ª artéria metacarpal
[28] 21 19/21 (90.5%) 1,2 ICRA
[29] 2 0/2 (0%) VBG based on the anterior transverse carpal artery






VBG from the femural condyle
[31] 11 11/11 (100%) Corticocancellous bone graft of the iliac crest
Enxerto ósseo cortico esponjoso da crista ilíaca
[32] 17 52% (9/17) Corticocancellous bone graft of the iliac crest
Enxerto ósseo cortico esponjoso da crista ilíaca
[28] 16 68% (11/16) Corticocancellous bone graft of the distal radius
Enxerto ósseo cortico esponjoso do rádio distal
Table 4. 
Consolidation rates, considering only cases with necrosis of the proximal pole of the scaphoid (NPP), 
vascularized bone graft (VBG), supraretinacular artery between compartments 1 and 2 [1,2 ICSRA].
Author Consolidation rate Kind of nonvascularized graft
[31] 100% Corticocancellous bone graft of the iliac crest
[32] 52% Corticocancellous bone graft of the iliac crest
[28] 72% Corticocancellous bone graft of the distal radius.
Table 3. 
Consolidation rate according to the technique used for use of nonvascularized bone graft.
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where all had necrosis of the proximal pole. The authors highlight the lack of need for 
dissection of small vessels as a great advantage of this technique (Tables 2 and 4).
Using the bone graft taken from the base of the thumb with the vasculariza-
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of 87% in the series of 24 patients. In this work, four cases with necrosis of the 
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the need for dissection of a small vessel, the authors report as an advantage the 
constancy in all cases of the first metacarpal artery (Tables 2 and 4).
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vascularized bone graft with a rate of 89.1 versus 72.5% with use of nonvascular-
ized graft. Within the group of patients who underwent VBG use, 21 presented 
necrosis of the proximal pole and of these 19 have achieved consolidation (90.5%) 
(Tables 2 and 4).
In the study of [29] using VBG of the volar portion of the distal radius based in 
the anterior transverse carpal artery, 73% of consolidation rates were obtained in 
30 cases. In this series two cases had signs of avascular necrosis of the proximal pole 
and neither obtained consolidation with the proposed treatment (Tables 2 and 4).
In their study, [30] compared consolidation rates into two groups treated with 
VBG: in a group of 22 patients they used graft taken from the distal radius with 
circulation based on 1,2 ICSRA and another group with 12 patients they used bone 
graft free from the femoral condyle. They achieved a statistically superior results 
using graft derived from the femoral condyle which reached the rate of 100 versus 
40% of consolidation with graft originated from the distal radius (Tables 2 and 4).
Regarding the techniques that describe the use of NVBG for the treatment of 
nonunion of the scaphoid with necrosis of the proximal pole, only three series 
of case were found in this study that did not have the defined exclusion criteria. 
Matsuki et al. [31] proposed an investigation to assess the rate of consolidation 
of the proximal pole of the scaphoid fractures using NVBG associated with the 
fastening with Herbert bone screws; where 11 patients were evaluated and obtained 
consolidation in all of them (Tables 3 and 4). Using the same technique, [32] inves-
tigated 17 patients with 1 year follow up and obtained a consolidation rate of 52% 
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pole and the consolidation was achieved in 11 of them (Tables 3 and 4).
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Consolidation rates, considering only cases with necrosis of the proximal pole of the scaphoid (NPP), 
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of VBG based on the circulation of the dorsal radius, particularly with the use of the 
extensor intercompartmental supraretinacular artery between 1 and 2 [1,2 ICSRA]. 
Supporting this data in a recent publication, [19] published a meta-analysis study 
which showed a consolidation rate of 88 versus 47% using VBG and NVBG, respec-
tively. The 1,2 ICRSA runs superficially on the retinaculum of the extentions and 
heads distally to the radial metaphyseal bone. According to the studies using this 
technique, easy identification and dissection of the artery are the major advantages. 
This came accordingly to the work of [35], which showed a consolidation rate of 
93% using the technique described by Zaidenberg.
In [21, 23, 24], the 1,2 ICRSA technique was also used in their work, all reaching 
a consolidation rate of 100%. The three authors consider this a technically easier 
procedure, compared with other VBG techniques, also for being limited to only one 
incision. In addition, the correction DISI (dorsal intercalated segment instability) 
was obtained, caused by the curvature of the humpback scaphoid, a factor that 
helps increasing the range of motion postoperatively. Opposed to these studies, [7], 
the restoration of carpal geometry is essential for the consolidation, however the 
techniques that use bone graft derived from the distal radius, would provide a too 
small bone graft for humpback correction, i.e., the DISI. Thus, a means of achieving 
VBG that met this condition was the use of bone graft originated from the medial 
femoral condyle. The disadvantage of this technique would be the need of micro-
surgical technique usage for small vessel anastomosis, on the other hand, a graft 
with excellent quality would be obtained, that would offer greater rigidity when 
compared to graft taken from the distal radius. However, it should be noted that 
the technique that uses graft free from the femoral condyle requires microsurgical 
technique mastery, requiring specific training and long learning curve [30].
Jones et al. [30] compared two groups: VBG from the femoral condyle based on 
the VBG versus 1,2 ICSRA with consolidation rates of 100 and 40%, respectively. 
Ribak et al. [28] obtained consolidation of 89% using VBG based on 1,2 ICSRA ver-
sus consolidation of 72% using NVBG obtained from the distal radius. But for [25] 
using the VBG based on the 1,2 ICSRA concluded that this technique was ineffective 
in the series, with consolidation rates of 27% and reducing to 12.5% if we consider 
only cases of necrosis of the proximal pole.
Bertelli et al. [27] observed consolidation rates in 21 of 24 patients using the VBG 
based on the first metacarpal artery. These authors prefer to use of VBG due to the 
greater effectiveness in promoting bone consolidation compared to nonvascularized 
bone grafts, even in difficult situations such as avascular necrosis of the proximal pole.
The use of VBG using the capsular movement of the distal radius was described 
by [26] in which obtained consolidation rates of 80%. For these authors, this is a 
relatively simple technique that eliminates the need for dissection of small vessels 
or microanastomoses, and lead to a lower risk of vascular injury. A limitation of this 
technique, however, lies in failing to correct the humpback scaphoid deformity.
Jessu et al. [29] used VBG based on the anterior transverse carpal artery, i.e., 
vascularized bone grafts proposed by [34], obtained consolidation rate of 73% in 
30 patients with nonunion of the scaphoid, however the two cases of proximal pole 
necrosis were not consolidated. The authors considered the consolidation rate disap-
pointing, but still consider this to be an advantageous technique, mainly for its unique 
volar approach that reduces morbidity, but its realization requires long learning curve.
All the studies that use the 1,2 ICSRA technique highlight the easy viewing and 
dissection of the pedicle, which make this technique extremely useful for the treat-
ment of nonunion of the scaphoid with necrosis of the proximal pole [21–25, 28].
The studies that use NVBG, basically used cortical cancellous bone grafts, 
simple techniques that have as an advantage the easy material removal. But there 
was an important change in consolidation rates, where [31] achieved great overall 
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results, amounting to consolidation of 100% in 11 patients with necrosis of the 
proximal pole of the scaphoid. [28, 32], on the other hand, reached a much lower 
rate of 72 and 55%, respectively.
5. Conclusion
There is preference for the use of vascularized bone graft in relation to non-
vascularized bone grafts, although the surgical technique is more detailed and 
demanding specific training, mainly in cases requiring vascular microsurgery, 
works using the technique for vascularized bone grafts reflect a better reproduc-
tion of positive results compared to conventional bone grafts. Therefore, according 
to this systematic review, there is no consensus in the literature that the use of 
vascularized bone graft can be effective in all cases for scaphoid consolidation with 
necrosis of the proximal pole.
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of VBG based on the circulation of the dorsal radius, particularly with the use of the 
extensor intercompartmental supraretinacular artery between 1 and 2 [1,2 ICSRA]. 
Supporting this data in a recent publication, [19] published a meta-analysis study 
which showed a consolidation rate of 88 versus 47% using VBG and NVBG, respec-
tively. The 1,2 ICRSA runs superficially on the retinaculum of the extentions and 
heads distally to the radial metaphyseal bone. According to the studies using this 
technique, easy identification and dissection of the artery are the major advantages. 
This came accordingly to the work of [35], which showed a consolidation rate of 
93% using the technique described by Zaidenberg.
In [21, 23, 24], the 1,2 ICRSA technique was also used in their work, all reaching 
a consolidation rate of 100%. The three authors consider this a technically easier 
procedure, compared with other VBG techniques, also for being limited to only one 
incision. In addition, the correction DISI (dorsal intercalated segment instability) 
was obtained, caused by the curvature of the humpback scaphoid, a factor that 
helps increasing the range of motion postoperatively. Opposed to these studies, [7], 
the restoration of carpal geometry is essential for the consolidation, however the 
techniques that use bone graft derived from the distal radius, would provide a too 
small bone graft for humpback correction, i.e., the DISI. Thus, a means of achieving 
VBG that met this condition was the use of bone graft originated from the medial 
femoral condyle. The disadvantage of this technique would be the need of micro-
surgical technique usage for small vessel anastomosis, on the other hand, a graft 
with excellent quality would be obtained, that would offer greater rigidity when 
compared to graft taken from the distal radius. However, it should be noted that 
the technique that uses graft free from the femoral condyle requires microsurgical 
technique mastery, requiring specific training and long learning curve [30].
Jones et al. [30] compared two groups: VBG from the femoral condyle based on 
the VBG versus 1,2 ICSRA with consolidation rates of 100 and 40%, respectively. 
Ribak et al. [28] obtained consolidation of 89% using VBG based on 1,2 ICSRA ver-
sus consolidation of 72% using NVBG obtained from the distal radius. But for [25] 
using the VBG based on the 1,2 ICSRA concluded that this technique was ineffective 
in the series, with consolidation rates of 27% and reducing to 12.5% if we consider 
only cases of necrosis of the proximal pole.
Bertelli et al. [27] observed consolidation rates in 21 of 24 patients using the VBG 
based on the first metacarpal artery. These authors prefer to use of VBG due to the 
greater effectiveness in promoting bone consolidation compared to nonvascularized 
bone grafts, even in difficult situations such as avascular necrosis of the proximal pole.
The use of VBG using the capsular movement of the distal radius was described 
by [26] in which obtained consolidation rates of 80%. For these authors, this is a 
relatively simple technique that eliminates the need for dissection of small vessels 
or microanastomoses, and lead to a lower risk of vascular injury. A limitation of this 
technique, however, lies in failing to correct the humpback scaphoid deformity.
Jessu et al. [29] used VBG based on the anterior transverse carpal artery, i.e., 
vascularized bone grafts proposed by [34], obtained consolidation rate of 73% in 
30 patients with nonunion of the scaphoid, however the two cases of proximal pole 
necrosis were not consolidated. The authors considered the consolidation rate disap-
pointing, but still consider this to be an advantageous technique, mainly for its unique 
volar approach that reduces morbidity, but its realization requires long learning curve.
All the studies that use the 1,2 ICSRA technique highlight the easy viewing and 
dissection of the pedicle, which make this technique extremely useful for the treat-
ment of nonunion of the scaphoid with necrosis of the proximal pole [21–25, 28].
The studies that use NVBG, basically used cortical cancellous bone grafts, 
simple techniques that have as an advantage the easy material removal. But there 
was an important change in consolidation rates, where [31] achieved great overall 
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results, amounting to consolidation of 100% in 11 patients with necrosis of the 
proximal pole of the scaphoid. [28, 32], on the other hand, reached a much lower 
rate of 72 and 55%, respectively.
5. Conclusion
There is preference for the use of vascularized bone graft in relation to non-
vascularized bone grafts, although the surgical technique is more detailed and 
demanding specific training, mainly in cases requiring vascular microsurgery, 
works using the technique for vascularized bone grafts reflect a better reproduc-
tion of positive results compared to conventional bone grafts. Therefore, according 
to this systematic review, there is no consensus in the literature that the use of 
vascularized bone graft can be effective in all cases for scaphoid consolidation with 
necrosis of the proximal pole.
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Abstract
Distraction osteogenesis is a surgical technique widely used in orthopedic surgery 
for treatment of various pathological skeletal conditions, namely correction of 
limb-length discrepancies, angular deformity and treatment of distal and severely 
comminuted fractures, or bone defects through bone transport. The basic principle 
consists on the gradual distraction of two bone segments, previously submitted to a 
corticotomy and promptly fixated generally using of circular external skeletal fixa-
tion. New bone tissue is generated in the bone gap between the two segments. This 
review aims to describe the biological fundaments and principles of this technique, 
the surgical steps performed to attempt distraction osteogenesis, and its possible 
complications with main focus on its application in companion animals.
Keywords: distraction osteogenesis, principles, bone regeneration,  
companion animals
1. Introduction
Distraction osteogenesis (DO) can be defined as the mechanical induction of bone 
tissue produced after the section and slowly separation of two bone segments, sta-
bilized and subjected through a slow, gradual, and stable distraction. This is possible 
due to the inherent capacity of bone tissue to regenerate and remodel according to the 
mechanical and tension forces to which it is gradually submitted [1, 2].
The DO is a technique widely used in human and veterinary medicine, both in 
adult and pediatric orthopedics. It is used in the treatment of various diseases such 
as limb length discrepancies, bone deformities secondary to trauma, infections or 
malformations, and even as a compensation after surgical excision of bone tumors 
[3]. The physiological bone growth is a result of the tension exercised over the bone 
physis and the soft tissue resistance. This forces act on the same plane but in oppo-
site directions [4].
The basic of the procedure should respect the principles defined by Ilizarov, 
Bastiani, and other pioneers in orthopedic research: (i) the osteotomy will be of low 
energy preserving the vascularization and the soft tissue envelope; (ii) the fixation 
mechanism applied to both segments must be stable; (iii) after the corticotomy a 
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tissue produced after the section and slowly separation of two bone segments, sta-
bilized and subjected through a slow, gradual, and stable distraction. This is possible 
due to the inherent capacity of bone tissue to regenerate and remodel according to the 
mechanical and tension forces to which it is gradually submitted [1, 2].
The DO is a technique widely used in human and veterinary medicine, both in 
adult and pediatric orthopedics. It is used in the treatment of various diseases such 
as limb length discrepancies, bone deformities secondary to trauma, infections or 
malformations, and even as a compensation after surgical excision of bone tumors 
[3]. The physiological bone growth is a result of the tension exercised over the bone 
physis and the soft tissue resistance. This forces act on the same plane but in oppo-
site directions [4].
The basic of the procedure should respect the principles defined by Ilizarov, 
Bastiani, and other pioneers in orthopedic research: (i) the osteotomy will be of low 
energy preserving the vascularization and the soft tissue envelope; (ii) the fixation 
mechanism applied to both segments must be stable; (iii) after the corticotomy a 
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latency period will be applied, and (iv) the distraction rate (DR) must be appropri-
ate for the level and type of bone in which osteogenesis is being performed [5].
After the separation of both segments, three temporal phases of DO can be 
defined: latency period, distraction period, and consolidation period [3].
2. Osteotomy and corticotomy
The DO procedure begins with the transverse section at a diaphyseal or metaphy-
seal level of the long bone to be elongated. Ilizarov described three methods to create 
fractures, including osteotomy, corticotomy, and osteoclasis. The osteogenic potential 
of the osteotomy or corticotomy depends on three main factors: the localization in 
bone, the type of technique used, and the latency period subsequently applied [6, 7].
Regarding the localization, some researchers in the past referred that the bone 
lengthening should be performed in the middle of the diaphysis of the long bone, 
and when necessary elongation was obtained, a bone graft from the ilium crest 
could be applied on the distraction focus to promote its consolidation. Later, Ilizarov 
recognized the metaphysis as the ideal site for the osteotomy, due to its massive 
trabecular bone area, rich in collateral vascularization, and higher potential for 
fracture recovery. Other researchers compared the regenerated bone quality at the 
diaphysis and metaphysis after DO, while using different latency periods. In the 
metaphysis, latency periods of 0 and 7 days allowed a greater osteogenesis and a 
faster remodeling and consolidation, when compared to the diaphysis elongation. A 
latency period of 14–21 days was associated with a premature consolidation in both 
regions. Bone mineralization of the newly formed tissue was faster at the metaphysis 
than at the diaphysis. Curiously, when there was no latency period, the distraction 
was successful and the consolidation faster. The latency of 7 days did not reveal the 
risk of premature consolidation; however, the consolidation and bone formation were 
slower than where there was no latency period. Post mortem torsion and bending test 
revealed that the bone tissue elongated on the metaphysis was tougher and more resis-
tant. Histologically, the osteogenesis is observed to be based on intra-membranous 
ossification and, when a longer latency period is performed, increased proliferation of 
cartilaginous tissue at the osteotomy focus is detected, resulting in an endochondral 
ossification which may end up resulting in a slower process. The same study revealed 
that the metaphysis has more viable characteristics for the DO than the diaphysis [8].
Kojimoto and collaborators showed, in rabbits, the importance of the periosteum, 
referring that when it is removed, a bone callus is not formed and the bone lengthening 
can fail [9]. Ilizarov considered the preservation of the periosteum, and the medulla 
vascularization as mandatory to obtain better results on a DO [7, 10, 11]. Ilizarov devel-
oped the subperiostal osteotomy technique in which the anterior, medial, and lateral 
portions of the cortex are sectioned, and the posterior side is the manually fractured, 
thus preserving the medullar vasculature. Although Ilizarov defends the importance of 
the medullar vasculature, other authors question its importance [9, 12, 13].
3. Segment stabilization
The distraction is performed using an external fixation system, and this can 
be a circular Ilizarov or and longitudinal monoplane unilateral frame [3]. It is 
imperative to keep an adequate stabilization of the fracture, its alignment, and 
osteodistraction [11, 14].
The external fixator frame rigidity must prevent unnecessary micro-movements 
at the osteotomy site, but, at the same time, it should be compliant to allow bone  
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tissue inducting micro-movements along the axial axis [14–16]. A stable external 
 fixator with less stiffness decreases the time to achieve bone consolidation. 
Moreover, the time of consolidation with low mechanical score (less rigid) is 
smaller when compared to more rigid fixations [2].
Kusec and colleagues compared the bone tissue formed by DO using a unilateral 
distractor and an Ilizarov distractor, in a population of 15 German Shepherd dogs. 
No histological or radiographic differences were found on the newly formed bone 
tissue. The regeneration progressed in centripetally from the cortex and the intra-
membranous ossification was predominant at the medullar portion of the distrac-
tion focus [17]. The Ilizarov fixator, comparing to Wagner, Orthofix, and Oxford 
unilateral frames, is also flexible with a consistent stiffness to bending moments in 
anteroposterior and lateral planes. Moreover, the Ilizarov fixator is more resistant 
to axial compression with increasing load and is more flexible in the axial direction 
compared with the other devices [18].
During bone lengthening, the distraction moment where the screws are tight-
ened or loosened in the external device frame may create instability on the distrac-
tion focus and therefore adversely affect the procedure. The use of new compounds, 
such as highly dense plastics, interconnected with metal alloys, helps to prevent 
instability during the adjustment period [19].
4. Latency period
The latency period begins immediately after the osteotomy and extends to the 
beginning of the distraction. This may be characterized as a “rest” period after 
the corticotomy to allow a tissue response to the iatrogenic trauma. This response 
includes a proliferation of fibroblast and the induction of a state of periosteal 
reactivity, phenomena which occur at the beginning of a fracture regeneration [3]. 
The latency period allows an organization of the hematoma and the fibrous tissue 
matrix, which will serve as a mold to the osteoblast proliferation, that on the first 
24 hours produce osteoid at the bone surfaces. This period also allows a periosteal 
and endosteal revascularization [7, 10, 20].
In rabbits, the importance of the latency period was demonstrated in a tibial 
DO. A 7-day latency period allowed a greater regeneration at the distraction focus 
and increased vasculature, in opposition to a DO without latency period character-
ized by a fibrous tissue formation [21]. Other studies showed that the existence of 
a latency period allows the formation of cartilaginous tissue which leads to regen-
eration based on an endochondral ossification, a mechanism that is slower that its 
intramembranous counterpart [8].
Regarding the duration of this period, there is no consensus and several studies 
report variable periods from 0 to 21 days [1, 7, 8, 10]. There are several factors that 
influence the appropriate latency period, such as: age, the osteotomy localization, 
the soft tissue trauma or the existence of a primary pathology. A longer latency 
period may allow a premature consolidation, being then necessary to produce 
another fracture in order to continue the lengthening. And a shorter latency period 
might predispose to a bone non-union [3]. In Veterinary Orthopedics, the recom-
mended latency period is 2–3 days for immature animal or 5–7 days to mature 
animal [1], inferior to the usual 5–10 days reported in humans [3].
5. Distraction period
During the distraction period, the bone segments undergo a stable and constant 
tension force, becoming metabolically active. The formation of bone tissue occurs 
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latency period will be applied, and (iv) the distraction rate (DR) must be appropri-
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seal level of the long bone to be elongated. Ilizarov described three methods to create 
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tant. Histologically, the osteogenesis is observed to be based on intra-membranous 
ossification and, when a longer latency period is performed, increased proliferation of 
cartilaginous tissue at the osteotomy focus is detected, resulting in an endochondral 
ossification which may end up resulting in a slower process. The same study revealed 
that the metaphysis has more viable characteristics for the DO than the diaphysis [8].
Kojimoto and collaborators showed, in rabbits, the importance of the periosteum, 
referring that when it is removed, a bone callus is not formed and the bone lengthening 
can fail [9]. Ilizarov considered the preservation of the periosteum, and the medulla 
vascularization as mandatory to obtain better results on a DO [7, 10, 11]. Ilizarov devel-
oped the subperiostal osteotomy technique in which the anterior, medial, and lateral 
portions of the cortex are sectioned, and the posterior side is the manually fractured, 
thus preserving the medullar vasculature. Although Ilizarov defends the importance of 
the medullar vasculature, other authors question its importance [9, 12, 13].
3. Segment stabilization
The distraction is performed using an external fixation system, and this can 
be a circular Ilizarov or and longitudinal monoplane unilateral frame [3]. It is 
imperative to keep an adequate stabilization of the fracture, its alignment, and 
osteodistraction [11, 14].
The external fixator frame rigidity must prevent unnecessary micro-movements 
at the osteotomy site, but, at the same time, it should be compliant to allow bone  
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tissue inducting micro-movements along the axial axis [14–16]. A stable external 
 fixator with less stiffness decreases the time to achieve bone consolidation. 
Moreover, the time of consolidation with low mechanical score (less rigid) is 
smaller when compared to more rigid fixations [2].
Kusec and colleagues compared the bone tissue formed by DO using a unilateral 
distractor and an Ilizarov distractor, in a population of 15 German Shepherd dogs. 
No histological or radiographic differences were found on the newly formed bone 
tissue. The regeneration progressed in centripetally from the cortex and the intra-
membranous ossification was predominant at the medullar portion of the distrac-
tion focus [17]. The Ilizarov fixator, comparing to Wagner, Orthofix, and Oxford 
unilateral frames, is also flexible with a consistent stiffness to bending moments in 
anteroposterior and lateral planes. Moreover, the Ilizarov fixator is more resistant 
to axial compression with increasing load and is more flexible in the axial direction 
compared with the other devices [18].
During bone lengthening, the distraction moment where the screws are tight-
ened or loosened in the external device frame may create instability on the distrac-
tion focus and therefore adversely affect the procedure. The use of new compounds, 
such as highly dense plastics, interconnected with metal alloys, helps to prevent 
instability during the adjustment period [19].
4. Latency period
The latency period begins immediately after the osteotomy and extends to the 
beginning of the distraction. This may be characterized as a “rest” period after 
the corticotomy to allow a tissue response to the iatrogenic trauma. This response 
includes a proliferation of fibroblast and the induction of a state of periosteal 
reactivity, phenomena which occur at the beginning of a fracture regeneration [3]. 
The latency period allows an organization of the hematoma and the fibrous tissue 
matrix, which will serve as a mold to the osteoblast proliferation, that on the first 
24 hours produce osteoid at the bone surfaces. This period also allows a periosteal 
and endosteal revascularization [7, 10, 20].
In rabbits, the importance of the latency period was demonstrated in a tibial 
DO. A 7-day latency period allowed a greater regeneration at the distraction focus 
and increased vasculature, in opposition to a DO without latency period character-
ized by a fibrous tissue formation [21]. Other studies showed that the existence of 
a latency period allows the formation of cartilaginous tissue which leads to regen-
eration based on an endochondral ossification, a mechanism that is slower that its 
intramembranous counterpart [8].
Regarding the duration of this period, there is no consensus and several studies 
report variable periods from 0 to 21 days [1, 7, 8, 10]. There are several factors that 
influence the appropriate latency period, such as: age, the osteotomy localization, 
the soft tissue trauma or the existence of a primary pathology. A longer latency 
period may allow a premature consolidation, being then necessary to produce 
another fracture in order to continue the lengthening. And a shorter latency period 
might predispose to a bone non-union [3]. In Veterinary Orthopedics, the recom-
mended latency period is 2–3 days for immature animal or 5–7 days to mature 
animal [1], inferior to the usual 5–10 days reported in humans [3].
5. Distraction period
During the distraction period, the bone segments undergo a stable and constant 
tension force, becoming metabolically active. The formation of bone tissue occurs 
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along the distractive stress line, in the lengthening focus at the extremities of 
both bone segments. During this regenerative process, the bone tissue formation 
can reach 200–400 μm/day, which is 4–8 times superior to the physiological bone 
growth that occurs in the physis of a healthy growing dog [22].
With the distraction onset, tensile forces develop at the fracture focus, while 
at the same time collagen is deposited by proliferating fibroblast and organized 
into linear fibrils. This tissue becomes radiographically visible after 7–14 days of 
distraction, and with the continuous process, a radiolucency zone is formed at 
the center of the fracture focus, the fibrous interzone (FIZ). This zone divides 
the regenerated bone in equal parts, and it is rich in chondrocytes, fibroblast, and 
ovoid cell morphologically intermediate between a fibroblast and osteoblast. The 
FIZ remains avascular during most part of the distraction, after its completion, it is 
rapidly vascularized and mineralized during the consolidation period [3]. When the 
FIZ cells differentiate in osteoblasts, they begin to deposit bone matrix forming the 
micro-column formation zones (MCFZ). These micro-columns are similar to stalac-
tites and stalagmites and are identified as cones of 150–200 μm. This mineralization 
proceeds longitudinally along the collagen fibers, parallel to the distraction forces. 
Between the FIZ and MCFZ, a connective tissue is formed, and this contains highly 
proliferative cells identical to those that arise in a primary ossification center [3].The 
fibroblast and osteoblast are arranged along the longitudinal collagen fibers at the 
distraction site and the later deposit osteoid directly into this fibrils [2] (Figure 1).
Although controversial, most histological studies regarding Ilizarov’s method 
confirm that bone formation during a DO is primarily based in intramembranous 
ossification [8, 23]. In humans and in animal models of osteodistraction on both 
long bones and mandible, performed in dogs, rabbits, and sheep, intramembranous 
ossification prevails over its endochondral counterpart [9, 22, 24, 25], mainly on the 
ending stage [26]; however, three distinct ossification methods have already been 
identified. Endochondral ossification can be identified in all DO periods [9, 24, 27] 
and it is usually identified at the FIZ junctions and at new mineralized membranes 
originated from the corticotomy site [26, 28]. The ossification ratio between an 
intramembranous and endochondral ossification is 5–1, respectively [18, 26].
A third ossification phenomenon was histologically identified and termed 
transchondroid ossification, characterized by a bone formed from cells similar to 
chondrocytes and with a transition from fibrous tissue to chondroid bone tissue, a 
tissue intermediate between bone and cartilage, which undergoes a gradual transi-
tion to bone tissue without a blood capillary invasion [23, 28]. Other authors have 
Figure 1. 
Representative radiographic images of a distraction osteogenesis procedure performed in a 7-month-old female 
Greyhound dog due to a premature distal ulnar physis closure with proximal consequences in elbow joint. (A) 
Lateral view of the lower right thoracic limb. (B) Cranial view of the limb after the application of the distractor 
in the ulna. (C) Lateral view upon 11 days of distraction. (D) Lateral view at the end of the consolidation 
period and after the removal of the distractor. (E) After ulnar bone consolidation and lengthening, a 
realignment of the radius with an osteosynthesis plate was performed to fully rehabilitate the limb.
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shown that cells similar to hypertrophied chondrocyte go through an osteogenic dif-
ferentiation with deposition of type 1 and type 2 collagen fibers [29]. The cartilage 
that forms during a DO is usually located near the periosteum, but not within the 
limits of the cortex on the distraction focus [3] (Figure 2).
During the distraction period occurs an enormous angiogenic response. At the 
lengthening site, a peak of blood circulation nine times superior to that of normal 
bone tissue may occur. This hypervolemia persists for a significant amount of time, 
as it was shown that 17 weeks after the procedure the local volemia remains twice 
the normal value [23, 30].
It is believed that bone regeneration occurs in response to a slow and stable 
mechanical tensile force, applied to the bone callus and under which the living tis-
sues become metabolically active, this phenomenon is called mechano-transduction 
[7, 10]. Ilizarov’s experiments demonstrated that mitochondria of the skeletal 
muscular tissue hypertrophied and become more active, resulting in increased 
cellular volume and functional activity of the cell’s nucleus [10].
During the distraction period, it is advised to do a radiographic assessment of 
the patient every 7–10 days, in order to evaluate the regenerated bone tissue, and if 
necessary, readjust the distraction rate (DR) [1]. Once the idealized bone length is 
achieved, the distraction ends. Marking the beginning of the consolidation period 
where the bone and osteoid are mineralized and remodeled [3].
6. Distraction rate and distraction rhythm
The distraction rate (DR), defined as the tension gradually applied to the bone, 
is measured in millimeters per day, the normal being 1 mm/day. However, this may 
vary according with the bone or the site of the bone we want to lengthen [3].
The total amount of distraction performed daily, the DR, is based on the same 
factors that should be considered for the ideal latency period [7, 10]. The typical 
DR in Veterinary Medicine should range from 0.75 to 2 mm/day, which is similar to 
what happens in Human Orthopedics [31–33]. Variables like age, osteotomy tech-
nique, and localization will influence the choice of a correct DR. We can correlate 
excessive DRs with muscular contractures and articular subluxations [34, 35]. The 
choice of an appropriate DR is essential in the prevention of premature consolida-
tion of the regenerated tissue and soft tissue damage, as well as in the maintenance 
of articular congruity and biomechanical stability [1].
Ilizarov proposed an ideal DR of 1 mm/day for bone regeneration, and he based 
himself on his study in 120 dogs, using DR of 0.5, 1, and 2 mm/day. When using 
0.5 mm/day, he noticed an increase in premature closures. And while using a DR of 2 
mm/day Ilizarov reported increased tissue damage due to exceeding the tissues’ revas-
cularization capacity [14]. Recent studies suggest that DR between 0.5 and 2 mm/day 
Figure 2. 
Representative histologic images of a mandibular bone after distraction osteogenesis. (A) Distraction area 
successfully filled with new regenerated bone. (B) Bone defect occupied by connective tissue, a failure probably 
due to mobility of one of the fragments. Magnification ×40, Levai Laczko staining. Courtesy of Prof. Fernando 
Muñoz, Department of Clinical Veterinarian Sciences, University of Santiago de Compostela.
Clinical Implementation of Bone Regeneration and Maintenance
96
along the distractive stress line, in the lengthening focus at the extremities of 
both bone segments. During this regenerative process, the bone tissue formation 
can reach 200–400 μm/day, which is 4–8 times superior to the physiological bone 
growth that occurs in the physis of a healthy growing dog [22].
With the distraction onset, tensile forces develop at the fracture focus, while 
at the same time collagen is deposited by proliferating fibroblast and organized 
into linear fibrils. This tissue becomes radiographically visible after 7–14 days of 
distraction, and with the continuous process, a radiolucency zone is formed at 
the center of the fracture focus, the fibrous interzone (FIZ). This zone divides 
the regenerated bone in equal parts, and it is rich in chondrocytes, fibroblast, and 
ovoid cell morphologically intermediate between a fibroblast and osteoblast. The 
FIZ remains avascular during most part of the distraction, after its completion, it is 
rapidly vascularized and mineralized during the consolidation period [3]. When the 
FIZ cells differentiate in osteoblasts, they begin to deposit bone matrix forming the 
micro-column formation zones (MCFZ). These micro-columns are similar to stalac-
tites and stalagmites and are identified as cones of 150–200 μm. This mineralization 
proceeds longitudinally along the collagen fibers, parallel to the distraction forces. 
Between the FIZ and MCFZ, a connective tissue is formed, and this contains highly 
proliferative cells identical to those that arise in a primary ossification center [3].The 
fibroblast and osteoblast are arranged along the longitudinal collagen fibers at the 
distraction site and the later deposit osteoid directly into this fibrils [2] (Figure 1).
Although controversial, most histological studies regarding Ilizarov’s method 
confirm that bone formation during a DO is primarily based in intramembranous 
ossification [8, 23]. In humans and in animal models of osteodistraction on both 
long bones and mandible, performed in dogs, rabbits, and sheep, intramembranous 
ossification prevails over its endochondral counterpart [9, 22, 24, 25], mainly on the 
ending stage [26]; however, three distinct ossification methods have already been 
identified. Endochondral ossification can be identified in all DO periods [9, 24, 27] 
and it is usually identified at the FIZ junctions and at new mineralized membranes 
originated from the corticotomy site [26, 28]. The ossification ratio between an 
intramembranous and endochondral ossification is 5–1, respectively [18, 26].
A third ossification phenomenon was histologically identified and termed 
transchondroid ossification, characterized by a bone formed from cells similar to 
chondrocytes and with a transition from fibrous tissue to chondroid bone tissue, a 
tissue intermediate between bone and cartilage, which undergoes a gradual transi-
tion to bone tissue without a blood capillary invasion [23, 28]. Other authors have 
Figure 1. 
Representative radiographic images of a distraction osteogenesis procedure performed in a 7-month-old female 
Greyhound dog due to a premature distal ulnar physis closure with proximal consequences in elbow joint. (A) 
Lateral view of the lower right thoracic limb. (B) Cranial view of the limb after the application of the distractor 
in the ulna. (C) Lateral view upon 11 days of distraction. (D) Lateral view at the end of the consolidation 
period and after the removal of the distractor. (E) After ulnar bone consolidation and lengthening, a 
realignment of the radius with an osteosynthesis plate was performed to fully rehabilitate the limb.
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shown that cells similar to hypertrophied chondrocyte go through an osteogenic dif-
ferentiation with deposition of type 1 and type 2 collagen fibers [29]. The cartilage 
that forms during a DO is usually located near the periosteum, but not within the 
limits of the cortex on the distraction focus [3] (Figure 2).
During the distraction period occurs an enormous angiogenic response. At the 
lengthening site, a peak of blood circulation nine times superior to that of normal 
bone tissue may occur. This hypervolemia persists for a significant amount of time, 
as it was shown that 17 weeks after the procedure the local volemia remains twice 
the normal value [23, 30].
It is believed that bone regeneration occurs in response to a slow and stable 
mechanical tensile force, applied to the bone callus and under which the living tis-
sues become metabolically active, this phenomenon is called mechano-transduction 
[7, 10]. Ilizarov’s experiments demonstrated that mitochondria of the skeletal 
muscular tissue hypertrophied and become more active, resulting in increased 
cellular volume and functional activity of the cell’s nucleus [10].
During the distraction period, it is advised to do a radiographic assessment of 
the patient every 7–10 days, in order to evaluate the regenerated bone tissue, and if 
necessary, readjust the distraction rate (DR) [1]. Once the idealized bone length is 
achieved, the distraction ends. Marking the beginning of the consolidation period 
where the bone and osteoid are mineralized and remodeled [3].
6. Distraction rate and distraction rhythm
The distraction rate (DR), defined as the tension gradually applied to the bone, 
is measured in millimeters per day, the normal being 1 mm/day. However, this may 
vary according with the bone or the site of the bone we want to lengthen [3].
The total amount of distraction performed daily, the DR, is based on the same 
factors that should be considered for the ideal latency period [7, 10]. The typical 
DR in Veterinary Medicine should range from 0.75 to 2 mm/day, which is similar to 
what happens in Human Orthopedics [31–33]. Variables like age, osteotomy tech-
nique, and localization will influence the choice of a correct DR. We can correlate 
excessive DRs with muscular contractures and articular subluxations [34, 35]. The 
choice of an appropriate DR is essential in the prevention of premature consolida-
tion of the regenerated tissue and soft tissue damage, as well as in the maintenance 
of articular congruity and biomechanical stability [1].
Ilizarov proposed an ideal DR of 1 mm/day for bone regeneration, and he based 
himself on his study in 120 dogs, using DR of 0.5, 1, and 2 mm/day. When using 
0.5 mm/day, he noticed an increase in premature closures. And while using a DR of 2 
mm/day Ilizarov reported increased tissue damage due to exceeding the tissues’ revas-
cularization capacity [14]. Recent studies suggest that DR between 0.5 and 2 mm/day 
Figure 2. 
Representative histologic images of a mandibular bone after distraction osteogenesis. (A) Distraction area 
successfully filled with new regenerated bone. (B) Bone defect occupied by connective tissue, a failure probably 
due to mobility of one of the fragments. Magnification ×40, Levai Laczko staining. Courtesy of Prof. Fernando 
Muñoz, Department of Clinical Veterinarian Sciences, University of Santiago de Compostela.
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are appropriate, and that the ideal DR must be based on individual characteristics 
such as age, osteotomy site, and need for angular correction [12, 35].
The distraction rhythm (DRy), the number of lengthening times made per day, 
influences the quality and quantity of the regenerated bone tissue and is important in 
the preservation of the soft tissue integrity during the procedure [7, 10, 34]. Ilizarov 
observed, using a canine model, that by using an automatic distractor capable of per-
forming a DRy of 60 times per day, would produce a significantly better quality of bone 
when compared with DRy of 1–4 times per day. A DR of 1 mm a day with a DRy  
of 4 times a day was determined as ideal [7, 10]. In a goat model of tibia lengthening, 
DRy of 1, 4, and 720 times per day would not affect the strength, rigidity, and histomor-
phometric characteristic of the regenerated bone and would not affect the somatosen-
sory potential of the peripheral nerves [34, 36]. Another study using the same animal 
model concluded that increasing the DRy would result in less muscular degeneration 
[39]. In Veterinary Medicine, it is recommended DRy of 2–4 times per day [9, 18, 31, 33].
7. Consolidation period
When finished the distraction period, the external fixator is maintained in 
order to confer stability to the regenerated tissue and allow its mineralization and 
consolidation [3]. In this period, the FIZ starts to mineralize and the central region 
becomes radiographically sclerotic. During the following weeks, the columns of 
regenerated tissue become homogeneous as the primary bone tissue is replaced 
by Haversian bone. In small animals, it will take around 8–12 weeks to form a new 
cortex and medullary cavity [7, 10, 36, 37].
Over time, the longitudinally oriented trabeculae are transformed into trans-
verse plaques, incorporating the collagen template [7, 8, 10, 36]. The bone micro-
columns are covered with osteoblasts that actively produce osteoid. Each column is 
accompanied by a large vascular channel that preserves the ideal distance in order 
to allow a diffusion gradient between cells. The activity of bone cells during a DO is 
similar to what occurs during a fracture healing [8, 28, 38]. However, what hap-
pens at a tissue level, the continuous recruitment and activation of cells capable of 
producing and reabsorbing bone, significantly exceeds a fracture healing process 
[39]. Simultaneously during the extensive bone production, a remodeling occurs, 
producing porosis of the bone cortex and margins of the regenerated bone. After 
2–3 months in animal and 4–6 months in humans, the Havers channels, through 
which blood vessels and nerves pass, are formed [11, 12, 38]. The bone marrow 
components, in the regenerated bone appear after 4 months. Bone remodeling is 
complete after 5–7 months in small animals and 12–24 months in humans. After this 
remodeling period, the mechanical integrity of the cortex is restored [1].
The consolidation period after a DO was investigated in a 20-year retrospective 
study, based on 115 animals submitted to a corticotomy and application of a circular 
external fixator [2]. The authors concluded that the radius requires less time to con-
solidate than the tibia and presented the hypothesis that this occurs due to during 
the march, the radius bears weight in a parallel axis and the tibia carries the weight 
through an oblique axis [40]. Another hypothesis is based on the fact that dogs bear 
around 60% of their weight on the thoracic limbs, therefore the weight carried by 
a radius is superior to what is supported by a tibia [41–43]. In experimental rab-
bit model, the effects of an angular osteotomy after a DO were studied, revealing 
that a 30° axis deviation at the distraction focus resulted in a 50% reduction of the 
regenerated bone [44]. In humans, the femur is referred to consolidate faster than 
the tibia [45]. Ilizarov’s original technique described that the consolidation period 
before fixator removal should be 1 month/cm of new regenerated bone [46].
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The bone formation can be controlled through tomography, scintigraphy, 
ultrasound, and bone densitometry; however, radiographs continue to be the more 
practical method to determine the consolidation efficiency and when the bone is 
ready to remove the external fixation system [1, 38].
Nowadays, numerous studies are focused on the molecular mechanism behind a 
DO, such as, the genetic expression of the bone morphogenic proteins (BMPs 2 and 4) 
which is induced by tension and mechanic stress [47, 48]. Other molecular signs, such as 
the insulin-like growth factor type 1 (IGF-1), transforming growth factor beta (TGFb) 
and fibroblastic growth factor 1 (FGF-1), associated with osteoblast proliferation 
and its differentiation from mesenchymal cells were identified at the distraction site 
[49, 50]. Another study identified that it is possible to accelerate the ossification process 
during a DO by administrating a recombinant homologous growth hormone [51].
Tissue engineering approaches have already been applied to promote bone regenera-
tion at DO. The use of mesenchymal stem cells (MSCs) from autologous origin, isolated 
from the bone marrow or adipose tissue, or from human xenogeneic origin has been 
described in different animal models of DO like rats, rabbits, pigs, dogs, and sheep 
with promising outcomes; nonetheless many of the mechanism behind the process 
remain to be investigated, for example, the recruitment and activation of MSCs upon 
the initial stimulation by surgical trauma. Growth and differentiation factors, hormonal 
proteins, and pharmacological agents can be added in combination to the distraction 
site. The number of cells transplanted is measured in cell over DR (number of cells in 
millions divided by total distractions in millimeters) ranged from 0.03 to 5.00 M/mm. 
The cells can be injected after the distraction period, loaded into scaffolds and then 
transplanted to the distraction focus during the osteotomy or during the latency period 
[52]. Genetically modified MSCs have also been evaluated using growth and differentia-
tion factors including bone morphogenetic protein-7 (BMP-7) [53, 54], BMP-2 [55, 56], 
basic fibroblast growth factor (bFGF) [57], transforming growth factor-β (TGFβ), and 
insulin-like growth factor-1 [58], as well as genes encoding transcription factors, such as 
osterix (Osx) [59, 60] and runt-related transcription factor 2 (Run×2) [61] with distinct 
effects reported in the improvement of bone regeneration [52].
8. Craniofacial distraction osteogenesis
Djasim and collaborators created guidelines for craniofacial DO. They collected 
data from dog, rat, sheep, goat, rabbit, pig, and rhesus monkey models based on 
data from previous craniofacial DO studies. With the premise that intramembra-
nous bones of the skull have a different vascular supply compared to long bones, 
therefore DO parameters suitable for orthopedic DO might be suboptimal for 
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be 1 mm/day, which should be halved when using rats and determined an ideal 
consolidation period of 6–8 weeks [62]. Another review in mandibular DO showed 
that the latency period ranged from 2 to 7 days. The distraction rate ranged from 0.4 
to 2.4 mm/day. The total distraction gap obtained ranged from 3.2 to 20 mm, and 
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are appropriate, and that the ideal DR must be based on individual characteristics 
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The bone formation can be controlled through tomography, scintigraphy, 
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DO can also provide an option for limb sparing surgery upon resection of pri-
mary bone tumors, such as osteosarcomas. The bone transport osteogenesis (BTO), 
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an adaption of the DO technique, is used to preserve limb function after resection 
of large segmental bone defects. Briefly, after the tumor excision, an osteotomy is 
performed on the proximal bone segment, creating a distraction focus and result-
ing on a small portion of healthy bone which will act as the transport segment. 
Then using an external ring fixator, this segment is slowly distracted in the defect 
direction, creating regenerated tissue resulting in bone union and a bridged effect. 
The distraction should continue until 3 days after the segments touch in order to 
compress the distal healthy bone, turning it metabolically active, this process is 
called docking. Successful docking is achieved when the transport segment heals 
with the adjacent bone. It is possible to predict the timing of docking by measuring 
the distance between the two bones on radiographs and calculating the number of 
days required to achieve contact based upon the DR. The surgeon should consider 
grafting when the transport segment is approximately less than 0.5 cm from contact 
with the docking site. When owners strongly wish to avoid further surgery, autolo-
gous bone marrow graft, obtained from the patient, could be mixed with canine 
demineralized bone matrix (DBM) into the docking site, acting as a vehicle of 
mesenchymal stem cells and osteoinductive signals [63, 64].
BTO surged as an alternative to cadaveric allograft bone transports, which was 
seen as the main limb salvage procedure in alternative to amputation; however, 
complications such as non-union, graft fracture, and infection are referred in the 
literature. One study reported that nearly one half of the patients develop infection 
may be associated with the lack of intrinsic blood supply surrounding the allograft 
and tumor resection area [65]. This high complication rate could lead to soft tissue 
lost, chronic pain, non-weight-bearing lameness, multiple surgeries, and even 
amputation [66–68].
The extent of the needed tissue resection can be planned based on detailed 
radiographs, scintigraphy, or ideally, a preoperative magnetic resonance imaging 
(MRI) which will be essential to help build the fixator frame, and assess the extent 
of the tumor involvement within the bone marrow, as it commonly exceeds the 
extent detected on radiographs. The surgeon should plan to excise at least 2 cm of 
bone proximal to the most proximal extent of tumor identified [63]. The patients 
with better outcome in DO upon oncologic surgery are those whose tumors are 
located in the distal radius or ulna, due to bigger pancarpal arthrodesis success [64]. 
The best candidates for limb salvage are those whose tumors involve less than 50% 
of the bone and have minimal soft tissue involvement. In theory, the extension of 
tumor treatable with this technique is limited to by the ability to achieve appropri-
ate margins. There must be at least enough bone remaining in the proximal radius 
to create a transport segment and to place three wires above the transport segment. 
Dogs with infected allografts after prior limb salvage surgery are suitable candidates 
for bone transport, unless they have had recent radiation therapy. Patients with 
pathologic fracture, multicentric neoplasia, metastasis or severe intercurrent health 
conditions should not be considered as favorable candidates [63].
After the tumor resection, BTO is similar to a conventional DO, a latency period 
of 3 days is sufficient unless the dog is receiving chemotherapy treatment. In 
those cases, a longer latency period of up to 7 days should be applied. Afterwards, 
the distraction should consist on a DR of 1 mm/day and DRy of 2–4 times a day. 
Immediately after a chemotherapy session, distraction should be ceased for 3 days 
before being restarted. This waiting period can be eliminated if the patient shows 
signs of premature consolidation. Radiographic reassessment should be made every 
10–14 days during bone transport and every 3–4 weeks after docking. Some ani-
mals may require higher DR to prevent premature consolidation, while other may 
require occasional “resting” period of 2–5 days. If the regenerated bone begins to 
be progressively thinning, ductile, and with “hourglass” shape in radiographs, it is 
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recommended to slow or stop distraction for a few days. Conversely, if the wires in 
the transport segment begin to bend in the direction of distraction, the DR should 
increase for 2–3 days (1.5–2 mm/day) to help preventing premature consolida-
tion. The radiographs and fixator should also be regularly evaluated to adjust DR 
and DRY, document broken wires, evidence of tumor recurrence, progression of 
mineralization of regenerate bone, and time of docking [63].
Fixators should be removed when peripheral bridging of the central radiolucent 
zone within the regenerate tissue is evident on radiographs, the columns of new 
bone are mineralized, and when the docking site union has been achieved. It can 
be difficult to evaluate the stability of the docking site before removing the fixator 
frame, due to the concentration of metal hardware. If doubt exists regarding effec-
tive union, the fixator removal can be delayed provided the patient is not having 
substantial soft-tissue problems. Osteosarcoma patients should be restaged every 
2–3 months to evaluate for metastasis or local tumor recurrence [63].
Negative effects of systemic chemotherapy and radiotherapy are reported in 
distraction osteogenesis [69–71]. Chemotherapy likely impedes the osteoblasts to 
cope with the increased functional demand and compromises bone callus formation 
during a DO. High dose chemotherapy reduces colony forming unit fibroblast by 
50% in the bone marrow, by 10% on cortical bone, and 20% in trabecular bone [72]. 
However, two studies compared patients who underwent DO with and without 
chemotherapy and it did not demonstrate any difference in the bone healing process 
between patient groups [73, 74]. The hypothesis proposed is that DO’s effect on 
osteoblast may counteract the inhibitory effects of chemotherapy [75].
In humans, some bone sarcomas, most commonly Ewing sarcoma, adjuvant 
radiotherapy is a treatment option, being reported adverse effects of radiation 
therapy on up to 74% of patients [76–78], namely wound healing problems, infec-
tion, muscle and joint contracture, ankylosis, osteitis, non-union, pathological 
fractures, tendon adhesion, and radiation induced sarcoma [76–79]. In a rabbit tibia 
model, it was demonstrated that radiation exposure decreases the quantity and 
quality of regenerate and angiogenesis during a DO [80]. Also, in a rabbit mandible 
model, it was found that osteogenesis is delayed after a 60-Gy dose of radiation, 
even though viable osteoblast and osteocytes may still be present [81]. It is therefore 
likely that distraction osteogenesis is negatively affected by radiation [75].
10. Complications of distraction osteogenesis
The complication associated with a DO include muscular contractures, sublux-
ations, vascular and nerve lesions, premature or delayed consolidation, and even 
bone non-union. The placement of intramedullary pins near a nerve or large caliber 
blood vessel can lead to damage on those structures during the lengthening [1].
Neuromuscular lesions are rarely associated with lengthening phases unless they 
exceed 30% of the limb size [33, 82, 83]. Subluxations are associated with muscular 
contractures and can occur in substantially excessive lengthening. Premature 
consolidations can be prevented with an adequate DR and DRy. Delayed consolida-
tions are multifactorial but are more commonly reported cases where an excessive 
DR was applied. Bone non-union is on its own associated to an infectious process. A 
strict radiographic protocol allows a control, assessment, and readjustment in order 
to avoid these complications [1].
One of the limitations of this technique is the long period necessary for the 
newly formed bone to mature, mineralize, and consolidate. The external fixators 
must be kept until the end of the consolidation period in order to confer the stabil-
ity necessary to obtain better quality bone [3].
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During a femoral lengthening, the muscles inserted therein are responsible 
for the majority of the complication that may occur. The quadriceps, glutes, and 
abductors can influence the lengthening progression, and the tension exercised on 
the soft tissues causes pain, reduces the articular mobility, and deforms the regener-
ated bone column. To achieve a successful lengthening, it is imperative that one 
understands this concept and adjust the surgical technique and patient management 
to minimize its impact [5].
Stogov and collaborators showed, in dogs, that a high frequency (120 DRy) 
of 3 mm/day does not only produce viable bone, but also produce compensatory 
alterations to the muscle tissue that would prevent catabolic alterations on the 
anterior tibial muscle during a tibia elongation. These authors referred that a high 
frequency lengthening amount that does not exceed 15% of the initial tibial length, 
does not result in considerable damage to the anterior tibial muscle. Using a DR 
of 3 mm/day while increasing the DRy (180 automated distractions per day) can 
produce a consistent regenerated bone [84].
As mentioned before, the soft tissues are a limitation factor for the procedure 
[34, 82, 85]. Lengthening exceeding 20% the original bone measure is reported 
to damage peripheral nerves, muscular, and tendon structures. Thus, physical 
rehabilitation during the procedures could decrease the severity of the muscular 
contractures and prevents articular diseases. The double-level or bi-level lengthen-
ing, which consist on creating two fracture focus and therefore two focus of bone 
distraction can reduce by half the distraction period duration, dispersing the 
distraction forces applied at the soft tissues and reducing the degenerative effects 
[1]. The correction of biapical radial deformities in dogs has been described with 
success using bi-level hinged external fixators as posterior distraction [86].
Taking into consideration that the DO can also occur along a transverse axis, 
perpendicular to the longitudinal bone axis, it is also possible to perform a widening 
of bone tissue. Some authors have already successfully preformed bone transports, 
in order to correct a defect on a long bone they perform a DO on the contralateral 
bone and use the regenerated tissue as graft to the affected limb. It has been per-
formed in the same bone tibia-tibia but also in ipsilateral ulnar and radial bone 
transports, tibial-humeral and fibular-tibial, and this procedure is also performed 
in human medicine [87].
It is worth referring a recent study in humans, which applied a multidirectional 
DO device, a new technique with the goal of correcting cranial deformities in 
children [88].
Conflict of interest
The authors declare no conflict of interest with any financial organization 
regarding the material discussed in the chapter.
103
Distraction Osteogenesis: Biological Principles and Its Application in Companion Animals
DOI: http://dx.doi.org/10.5772/intechopen.89157
Author details
Guilherme Domingos1, Henrique Armés1,2, Isabel Dias3, Carlos Viegas3  
and João Requicha1,3*
1 Faculty of Veterinary Medicine, University Lusófona, Lisbon, Portugal
2 Hospital Veterinário de São Bento, Lisbon, Portugal
3 Department of Veterinary Sciences, University of Trás-os-Montes e Alto Douro, 
Vila Real, Portugal
*Address all correspondence to: jfrequicha@gmail.com
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
Clinical Implementation of Bone Regeneration and Maintenance
102
During a femoral lengthening, the muscles inserted therein are responsible 
for the majority of the complication that may occur. The quadriceps, glutes, and 
abductors can influence the lengthening progression, and the tension exercised on 
the soft tissues causes pain, reduces the articular mobility, and deforms the regener-
ated bone column. To achieve a successful lengthening, it is imperative that one 
understands this concept and adjust the surgical technique and patient management 
to minimize its impact [5].
Stogov and collaborators showed, in dogs, that a high frequency (120 DRy) 
of 3 mm/day does not only produce viable bone, but also produce compensatory 
alterations to the muscle tissue that would prevent catabolic alterations on the 
anterior tibial muscle during a tibia elongation. These authors referred that a high 
frequency lengthening amount that does not exceed 15% of the initial tibial length, 
does not result in considerable damage to the anterior tibial muscle. Using a DR 
of 3 mm/day while increasing the DRy (180 automated distractions per day) can 
produce a consistent regenerated bone [84].
As mentioned before, the soft tissues are a limitation factor for the procedure 
[34, 82, 85]. Lengthening exceeding 20% the original bone measure is reported 
to damage peripheral nerves, muscular, and tendon structures. Thus, physical 
rehabilitation during the procedures could decrease the severity of the muscular 
contractures and prevents articular diseases. The double-level or bi-level lengthen-
ing, which consist on creating two fracture focus and therefore two focus of bone 
distraction can reduce by half the distraction period duration, dispersing the 
distraction forces applied at the soft tissues and reducing the degenerative effects 
[1]. The correction of biapical radial deformities in dogs has been described with 
success using bi-level hinged external fixators as posterior distraction [86].
Taking into consideration that the DO can also occur along a transverse axis, 
perpendicular to the longitudinal bone axis, it is also possible to perform a widening 
of bone tissue. Some authors have already successfully preformed bone transports, 
in order to correct a defect on a long bone they perform a DO on the contralateral 
bone and use the regenerated tissue as graft to the affected limb. It has been per-
formed in the same bone tibia-tibia but also in ipsilateral ulnar and radial bone 
transports, tibial-humeral and fibular-tibial, and this procedure is also performed 
in human medicine [87].
It is worth referring a recent study in humans, which applied a multidirectional 
DO device, a new technique with the goal of correcting cranial deformities in 
children [88].
Conflict of interest
The authors declare no conflict of interest with any financial organization 
regarding the material discussed in the chapter.
103
Distraction Osteogenesis: Biological Principles and Its Application in Companion Animals
DOI: http://dx.doi.org/10.5772/intechopen.89157
Author details
Guilherme Domingos1, Henrique Armés1,2, Isabel Dias3, Carlos Viegas3  
and João Requicha1,3*
1 Faculty of Veterinary Medicine, University Lusófona, Lisbon, Portugal
2 Hospital Veterinário de São Bento, Lisbon, Portugal
3 Department of Veterinary Sciences, University of Trás-os-Montes e Alto Douro, 
Vila Real, Portugal
*Address all correspondence to: jfrequicha@gmail.com
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
104
Clinical Implementation of Bone Regeneration and Maintenance
[1] Welch RD, Lewis DD. Distraction 
osteogenesis. The Veterinary Clinics of 
North America. Small Animal Practice. 
1999;29(5):1187-1205
[2] Tuohy JL, Marcellin-Little DJ, 
Griffith EH. Durations of bone 
consolidation and external fixation 
after distraction osteogenesis in dogs. 
Veterinary Surgery. 2014;43:903-911
[3] Sailhan F. Bone lengthening 
(distraction osteogenesis): A literature 
review. Osteoporosis International. 
2011;22(6):2011-2015
[4] Merloz P. Bone regeneration and 
limb lengthening. Osteoporosis 
International. 2011;22(6): 
2033-2036
[5] Nayagam S. Femoral lengthening 
with a rail external fixator: Tips and 
tricks. Strategies in Trauma and Limb 
Reconstruction. 2010;5(3):137-144
[6] Ilizarov GA, Zarubin VI. Method 
of treatment of long bone defects by 
lengthening of one of the fragments 
with Ilizarov technique. In: Transosseous 
Compression, Distraction and 
Compression-Distraction Osteosynthesis 
in Traumatology and Orthopedics. 
Collection of Scientific Works from 
Kurgan Research Scientific Institute. Vol. 
2. Russia: Kurgan Research Scientific 
Institute; 1976
[7] Ilizarov GA. The tension-stress 
effect on the genesis and growth of 
tissues: Part I. The influence of the rate 
and frequency of distraction. Clinical 
Orthopaedics and Related Research. 
1989;239:249-281
[8] Aronson J, Shen X. Experimental 
healing of distraction osteogenesis 
comparing metaphyseal with diaphyseal 
sites. Clinical Orthopaedics and Related 
Research. 1994;301:25-30
[9] Kojimoto H, Yasui N, Goto T, 
Matsuda SY. Bone lengthening in  
rabbits by callus distraction. The role of 
periosteum and endosteum. 
Journal of Bone and Joint Surgery. 
British Volume (London). 
1988;70(4):543-549
[10] Ilizarov GA. The tension-stress 
effect on the genesis and growth of 
tissues: Part II. The influence of the rate 
and frequency of distraction. Clinical 
Orthopaedics and Related Research. 
1989;239:263-285
[11] Ilizarov GA. Transosseous 
Osteosynthesis: Theoretical and Clinical 
Aspects of the Regeneration and Growth 
of Tissue. New York: Springer Verlag; 
1992
[12] Frierson M, Ibrahim K, Boles M, 
et al. Distraction osteogenesis. 
A comparison of corticotomy 
techniques. Clinical Orthopaedics. 
1994;301:19-24
[13] Marcellin-Little DJ, Ferretti A. 
Improving bone healing with the 
circular external fixation method. 
Veterinary Forums. 1997;7:40-47
[14] Ilizarov GA. Clinical application 
of the tension-stress effect for limb 
lengthening. Clinical Orthopaedics. 
1990;250:8-26
[15] Paley D, Fleming B, Catagni M, 
et al. Mechanical evaluation of  
external fixators used in limb 
lengthening. Clinical Orthopaedics and 
Related Research. 1990;250:50-57
[16] Lewis DO, Bronson DG, Welch RD. 
Effect of individual components on 
the axial stiffness of single ring IMEX 
circular external skeletal fixation 
system constructs. Veterinary and 




Distraction Osteogenesis: Biological Principles and Its Application in Companion Animals
DOI: http://dx.doi.org/10.5772/intechopen.89157
[17] Kusec V, Jelic M, Borovecki F, Kos J, 
Vukicevic S, Korzinek K. Distraction 
osteogenesis by Ilizarov and 
unilateral external fixators in a canine 
model. International Orthopaedics. 
2003;27(1):47-52
[18] Younger AS, Morrison J, 
MacKenzie WG.Biomechanics of external 
fixation and limb lengthening. Foot and 
Ankle Clinics. 2004;9(3):433-448
[19] Stallings JT, Lewis DD, Welch RD, 
et al. An introduction to distraction 
osteogenesis and the principles of 
the Ilizarov method. Veterinary 
and Comparative Orthopaedics and 
Traumatology. 1998;11:59-67
[20] White SH, Kenwright J. The 
importance of delay in distraction of 
osteotomies. The Orthopedic Clinics of 
North America. 1991;22:569-579
[21] Fjeld TO, Steen H. Limb lengthening 
by low rate epiphyseal distraction. 
An experimental study in the caprine 
tibia. Journal of Orthopaedic Research. 
1988;6:360-368
[22] Aronson J, Good B, Stewart C, 
Harrison B, Harp J. Preliminary studies 
of mineralization during distraction 
osteogenesis. Clinical Orthopaedics and 
Related Research. 1990;250:43-49
[23] Choi IH, Chung CY, Cho TJ, Yoo WJ. 
Angiogenesis and mineralization 
during distraction osteogenesis. 
Journal of Korean Medical Science. 
2002;17(4):435-447
[24] Delloye C, Delefortrie G, 
Coutelier L, Vincent A. Bone regenerate 
formation in cortical bone 
during distraction lengthening. 
An experimental study. Clinical 
Orthopaedics. 1990;250:34-42
[25] Ali MN, Ejiri S, Kobayashi T, 
Anwar RB, Oda K, Ohshima H, et al. 
Histologic study of the cellular events 
during rat mandibular distraction 
osteogenesis. Oral Surgery, Oral 
Medicine, Oral Pathology, Oral 
Radiology, and Endodontics. 
2009;107(3):325-335
[26] Fink B, Pollnau C, Vogel M, 
Skripitz R, Enderle A. Histomorphometry 
of distraction osteogenesis during 
experimental tibial lengthening. 
Journal of Orthopaedic Trauma. 
2003;17(2):113-118
[27] Jazrawi LM, Majeska RJ, Klein ML, 
Kagel E, Stromberg L, Einhorn TA. Bone 
and cartilage formation in an 
experimental model of distraction 
osteogenesis. Journal of Orthopaedic 
Trauma. 1998;12(2):111-116
[28] Yasui N, Sato M, Ochi T, et al. Three 
modes of ossification during distraction 
osteogenesis in the rat. Journal of Bone 
and Joint Surgery. British Volume 
(London). 1997;79(5):824-830
[29] Li G, Virdi AS, Ashhurst DE, 
Simpson AH, Triffitt JT. Tissues formed 
during distraction osteogenesis in the 
rabbit are determined by the distraction 
rate: Localization of the cells that 
express the mRNAs and the distribution 
of types I and II collagens. Cell Biology 
International. 2000;24(1):25-33
[30] Choi IH, Ahn JH, Chung CY, 
Cho TJ. Vascular proliferation and blood 
supply during distraction osteogenesis: 
A scanning electron microscopic 
observation. Journal of Orthopaedic 
Research. 2000;18(5):698-705
[31] Ferretti A. The application of 
the Ilizarov technique to veterinary 
medicine. In: Bianchi Maiocchi A, 
Aronson J, editors. Operative Principles 
of Ilizarov. Baltimore: Williams & 
Wilkins; 1991
[32] Latte Y. A specific vet Ilizarov 
apparatus for the treatment of fractures, 
delayed union, non-union and mal 
104
Clinical Implementation of Bone Regeneration and Maintenance
[1] Welch RD, Lewis DD. Distraction 
osteogenesis. The Veterinary Clinics of 
North America. Small Animal Practice. 
1999;29(5):1187-1205
[2] Tuohy JL, Marcellin-Little DJ, 
Griffith EH. Durations of bone 
consolidation and external fixation 
after distraction osteogenesis in dogs. 
Veterinary Surgery. 2014;43:903-911
[3] Sailhan F. Bone lengthening 
(distraction osteogenesis): A literature 
review. Osteoporosis International. 
2011;22(6):2011-2015
[4] Merloz P. Bone regeneration and 
limb lengthening. Osteoporosis 
International. 2011;22(6): 
2033-2036
[5] Nayagam S. Femoral lengthening 
with a rail external fixator: Tips and 
tricks. Strategies in Trauma and Limb 
Reconstruction. 2010;5(3):137-144
[6] Ilizarov GA, Zarubin VI. Method 
of treatment of long bone defects by 
lengthening of one of the fragments 
with Ilizarov technique. In: Transosseous 
Compression, Distraction and 
Compression-Distraction Osteosynthesis 
in Traumatology and Orthopedics. 
Collection of Scientific Works from 
Kurgan Research Scientific Institute. Vol. 
2. Russia: Kurgan Research Scientific 
Institute; 1976
[7] Ilizarov GA. The tension-stress 
effect on the genesis and growth of 
tissues: Part I. The influence of the rate 
and frequency of distraction. Clinical 
Orthopaedics and Related Research. 
1989;239:249-281
[8] Aronson J, Shen X. Experimental 
healing of distraction osteogenesis 
comparing metaphyseal with diaphyseal 
sites. Clinical Orthopaedics and Related 
Research. 1994;301:25-30
[9] Kojimoto H, Yasui N, Goto T, 
Matsuda SY. Bone lengthening in  
rabbits by callus distraction. The role of 
periosteum and endosteum. 
Journal of Bone and Joint Surgery. 
British Volume (London). 
1988;70(4):543-549
[10] Ilizarov GA. The tension-stress 
effect on the genesis and growth of 
tissues: Part II. The influence of the rate 
and frequency of distraction. Clinical 
Orthopaedics and Related Research. 
1989;239:263-285
[11] Ilizarov GA. Transosseous 
Osteosynthesis: Theoretical and Clinical 
Aspects of the Regeneration and Growth 
of Tissue. New York: Springer Verlag; 
1992
[12] Frierson M, Ibrahim K, Boles M, 
et al. Distraction osteogenesis. 
A comparison of corticotomy 
techniques. Clinical Orthopaedics. 
1994;301:19-24
[13] Marcellin-Little DJ, Ferretti A. 
Improving bone healing with the 
circular external fixation method. 
Veterinary Forums. 1997;7:40-47
[14] Ilizarov GA. Clinical application 
of the tension-stress effect for limb 
lengthening. Clinical Orthopaedics. 
1990;250:8-26
[15] Paley D, Fleming B, Catagni M, 
et al. Mechanical evaluation of  
external fixators used in limb 
lengthening. Clinical Orthopaedics and 
Related Research. 1990;250:50-57
[16] Lewis DO, Bronson DG, Welch RD. 
Effect of individual components on 
the axial stiffness of single ring IMEX 
circular external skeletal fixation 
system constructs. Veterinary and 




Distraction Osteogenesis: Biological Principles and Its Application in Companion Animals
DOI: http://dx.doi.org/10.5772/intechopen.89157
[17] Kusec V, Jelic M, Borovecki F, Kos J, 
Vukicevic S, Korzinek K. Distraction 
osteogenesis by Ilizarov and 
unilateral external fixators in a canine 
model. International Orthopaedics. 
2003;27(1):47-52
[18] Younger AS, Morrison J, 
MacKenzie WG.Biomechanics of external 
fixation and limb lengthening. Foot and 
Ankle Clinics. 2004;9(3):433-448
[19] Stallings JT, Lewis DD, Welch RD, 
et al. An introduction to distraction 
osteogenesis and the principles of 
the Ilizarov method. Veterinary 
and Comparative Orthopaedics and 
Traumatology. 1998;11:59-67
[20] White SH, Kenwright J. The 
importance of delay in distraction of 
osteotomies. The Orthopedic Clinics of 
North America. 1991;22:569-579
[21] Fjeld TO, Steen H. Limb lengthening 
by low rate epiphyseal distraction. 
An experimental study in the caprine 
tibia. Journal of Orthopaedic Research. 
1988;6:360-368
[22] Aronson J, Good B, Stewart C, 
Harrison B, Harp J. Preliminary studies 
of mineralization during distraction 
osteogenesis. Clinical Orthopaedics and 
Related Research. 1990;250:43-49
[23] Choi IH, Chung CY, Cho TJ, Yoo WJ. 
Angiogenesis and mineralization 
during distraction osteogenesis. 
Journal of Korean Medical Science. 
2002;17(4):435-447
[24] Delloye C, Delefortrie G, 
Coutelier L, Vincent A. Bone regenerate 
formation in cortical bone 
during distraction lengthening. 
An experimental study. Clinical 
Orthopaedics. 1990;250:34-42
[25] Ali MN, Ejiri S, Kobayashi T, 
Anwar RB, Oda K, Ohshima H, et al. 
Histologic study of the cellular events 
during rat mandibular distraction 
osteogenesis. Oral Surgery, Oral 
Medicine, Oral Pathology, Oral 
Radiology, and Endodontics. 
2009;107(3):325-335
[26] Fink B, Pollnau C, Vogel M, 
Skripitz R, Enderle A. Histomorphometry 
of distraction osteogenesis during 
experimental tibial lengthening. 
Journal of Orthopaedic Trauma. 
2003;17(2):113-118
[27] Jazrawi LM, Majeska RJ, Klein ML, 
Kagel E, Stromberg L, Einhorn TA. Bone 
and cartilage formation in an 
experimental model of distraction 
osteogenesis. Journal of Orthopaedic 
Trauma. 1998;12(2):111-116
[28] Yasui N, Sato M, Ochi T, et al. Three 
modes of ossification during distraction 
osteogenesis in the rat. Journal of Bone 
and Joint Surgery. British Volume 
(London). 1997;79(5):824-830
[29] Li G, Virdi AS, Ashhurst DE, 
Simpson AH, Triffitt JT. Tissues formed 
during distraction osteogenesis in the 
rabbit are determined by the distraction 
rate: Localization of the cells that 
express the mRNAs and the distribution 
of types I and II collagens. Cell Biology 
International. 2000;24(1):25-33
[30] Choi IH, Ahn JH, Chung CY, 
Cho TJ. Vascular proliferation and blood 
supply during distraction osteogenesis: 
A scanning electron microscopic 
observation. Journal of Orthopaedic 
Research. 2000;18(5):698-705
[31] Ferretti A. The application of 
the Ilizarov technique to veterinary 
medicine. In: Bianchi Maiocchi A, 
Aronson J, editors. Operative Principles 
of Ilizarov. Baltimore: Williams & 
Wilkins; 1991
[32] Latte Y. A specific vet Ilizarov 
apparatus for the treatment of fractures, 
delayed union, non-union and mal 
Clinical Implementation of Bone Regeneration and Maintenance
106
union. In: Proceedings of the Veterinary 
Orthopedic Society; 1991. p. 51
[33] Marcellin-Little DJ, Ferretti A, 
Roe SC, DeYoung DJ. Hinged Ilizarov 
external fixation for correction of 
antebrachial deformities. Veterinary 
Surgery. 1998;27(3):231-245
[34] Birch JG, Samchukov ML, Welch, 
RD, et al. The effect of rhythm of 
distraction during limb lengthening: 
An experimental investigation. In: 
Proceedings of the Fourth Annual 
ASAMI Scientific Meeting; New 
Orleans; 1994. p. 7
[35] Catagni MA, Malzev V, Kirienko A. 
Correction of angular deformities. In: 
Bianchi-Maiocchi A, editor. Advances 
in Ilizarov Apparatus Assembly. Milan: 
Medicalplastic; 1994
[36] Welch RD, Birch JG, Samchukov ML. 
Histomorphology of distraction 
osteogenesis in a caprine tibial 
lengthening model. Journal of Bone and 
Mineral Research. 1998;13:1-9
[37] Latte Y. Studies of 63 cases treated 
by Ilizarov apparatus: Indications, 
results, complications. In: Proceedings 
of the Veterinary Orthopedic Society; 
Alberta, Canada; 1993. p. 12
[38] Aronson J. Temporal and spatial 
increases in blood flow during 
distraction osteogenesis. Clinical 
Orthopaedics. 1994;301:124-131
[39] Welch RD. Biology of distraction 
osteogenesis. In: Proceedings of the 
Annual Meeting of the American 
College of Veterinary Surgeons; 
Chicago, USA; 1995. p. 305
[40] Agostinho FS, Rahal SC, 
Miqueleto NS, Verdugo MR, Inamassu LR, 
El-Warrak AO. Kinematic analysis of 
Labrador retrievers and Rottweilers 
trotting on a treadmill. Veterinary 
and Comparative Orthopaedics and 
Traumatology. 2011;24:185-191
[41] Levine D, Marcellin-Little DJ, 
Millis DL, et al. Effects of partial 
immersion in water on vertical ground 
reaction forces and weight distribution 
in dogs. American Journal of Veterinary 
Research. 2010;71:1413-1416
[42] Molsa SH, Hielm-Bjorkman AK, 
Laitinen-Vapaavuori OM. Force 
platform analysis in clinically healthy 
Rottweilers: Comparison with Labrador 
retrievers. Veterinary Surgery. 
2010;9:701-707
[43] Brady RB, Sidiropoulos AN, 
Bennett HJ, et al. Evaluation of gait 
related variables in lean and obese dogs 
at a trot. American Journal of Veterinary 
Research. 2013;74:757-762
[44] Richards M, Goulet JA, 
Weiss JA, Waanders NA, Schaffler MB, 
Goldstein SA. Bone regeneration and 
fracture healing. Experience with 
distraction osteogenesis model. Clinical 
Orthopaedics and Related Research. 
1998;355(Suppl):S191-S204
[45] Fischgrund J, Paley D, 
Suter C. Variables affecting time to 
bone healing during limb lengthening. 
Clinical Orthopaedics and Related 
Research. 1994;301:31-37
[46] Ilizarov GA. The principles of the 
Ilizarov method. Bulletin of the Hospital 
for Joint Diseases Orthopaedic Institute. 
1988;48:1-11
[47] Li G, Berven S, Simpson H, 
Triffitt JT. Expression of BMP-4 during 
distraction osteogenesis in rabbits. 
Acta Orthopaedica Scandinavica. 
1998;69:420-425
[48] Sato M, Ochi T, Nakase T, Hirotam S, 
Kitamura Y, Nomura S, et al. Mechanical 
tension-stress induces expression of 
bone morphogenetic protein (BMP)-2 
and BMP-4, but not BMP-6, BMP-7, 
and GDF-5 mRNA, during distraction 
osteogenesis. Journal of Bone and 
Mineral Research. 1999;14:1084-1095
107
Distraction Osteogenesis: Biological Principles and Its Application in Companion Animals
DOI: http://dx.doi.org/10.5772/intechopen.89157
[49] Lammens J, Liu Z, Aerssens J, 
Dequeker J, Fabry G. Distraction bone 
healing versus osteotomy healing: A 
comparative biochemical analysis. 
Journal of Bone and Mineral Research. 
1988;13:279-286
[50] Farhadieh RD, Dickinson R, Yu Y, 
Gianoutsos MP, Walsh WR. The role 
of transforming growth factor-beta, 
insulin- like growth factor 1, and 
basic fibroblast growth factor in dis- 
traction osteogenesis of the mandible. 
The Journal of Craniofacial Surgery. 
1999;10:80-86
[51] Raschke MJ, Bail H, Windhagen HJ, 
Kolbeck SF, Weiler A, Raun K, et al. 
Recombinant growth hormone 
accelerates bone regenerate 
consolidation in distraction 
osteogenesis. Bone. 1999;24:81-88
[52] Tee BC, Sun Z. Mandibular 
distraction osteogenesis assisted by cell-
based tissue engineering: A systematic 
review. Orthodontics and Craniofacial 
Research. 2015;18(Suppl1):39-49
[53] Hu J, Qi MC, Zou SJ, Li JH, 
Luo E. Callus formation enhanced by 
BMP-7 ex vivo gene therapy during 
distraction osteogenesis in rats. 
Journal of Orthopaedic Research. 
2007;25:241-251
[54] Zhang WB, Zheng LW, Chua DT, 
Cheung LK. Treatment of irradiated 
mandibles with mesenchymal 
stem cells transfected with bone 
morphogenetic protein 2/7. Journal 
of Oral and Maxillofacial Surgery. 
2012;70:1711-1716
[55] Long J, Li P, Du HM, Liu L, 
Zheng XH, Lin YF, et al. Effects of 
bone morphogenetic protein 2 gene 
therapy on new bone formation during 
mandibular distraction osteogenesis 
at rapid rate in rabbits. Oral Surgery, 
Oral Medicine, Oral Pathology, 
Oral Radiology, and Endodontics. 
2011;112:50-57
[56] Castro-Govea Y, Cervantes- 
Kardasch VH, Borrego-Soto G, 
Martinez-Rodriguez HG, Espinoza 
Juarez M, Romero-Diaz V, et al. 
Human bone morphogenetic protein 
2-transduced mesenchymal stem 
cells improve bone regeneration in a 
model of mandible distraction surgery. 
The Journal of Craniofacial Surgery. 
2012;23:392-396
[57] Jiang X, Zou S, Ye B, Zhu S, Liu Y, 
Hu J. bFGF-modified BMMSCs enhance 
bone regeneration following distraction 
osteogenesis in rabbits. Bone. 
2010;46:1156-1161
[58] Kroczek A, Park J, Birkholz T, 
Neukam FW, Wiltfang J, Kessler P. Effects 
of osteoinduction on bone regeneration 
in distraction: Results of a pilot study. 
Journal of Cranio-Maxillo-Facial 
Surgery. 2010;38:334-344
[59] Lai QG, Yuan KF, Xu X, Li DR, 
Li GJ, Wei FL, et al. Transcription 
factor osterix modified bone marrow 
mesenchymal stem cells enhance 
callus formation during distraction 
osteogenesis. Oral Surgery, Oral 
Medicine, Oral Pathology, Oral 
Radiology, and Endodontics. 
2011;111:412-419
[60] Lai QG, Sun SL, Zhou XH, 
Zhang CP, Yuan KF, Yang ZJ, et al. 
Adipose-derived stem cells transfected 
with pEGFP-OSX enhance bone 
formation during distraction 
osteogenesis. Journal of Zhejiang 
University. Science. B. 2014;15:482-490
[61] Sun JJ, Zheng XH, Wang LY, 
Liu L, Jing W, Lin YF, et al. New 
bone formation enhanced by ADSCs 
overexpressing hRunx2 during 
mandibular distraction osteogenesis 
in osteoporotic rabbits. Journal of 
Orthopaedic Research. 2014;32:709-720
[62] Djasim UM, Wolvius EB, van 
Neck JW, Weinans H, van der 
Wal KG. Recommendations for optimal 
Clinical Implementation of Bone Regeneration and Maintenance
106
union. In: Proceedings of the Veterinary 
Orthopedic Society; 1991. p. 51
[33] Marcellin-Little DJ, Ferretti A, 
Roe SC, DeYoung DJ. Hinged Ilizarov 
external fixation for correction of 
antebrachial deformities. Veterinary 
Surgery. 1998;27(3):231-245
[34] Birch JG, Samchukov ML, Welch, 
RD, et al. The effect of rhythm of 
distraction during limb lengthening: 
An experimental investigation. In: 
Proceedings of the Fourth Annual 
ASAMI Scientific Meeting; New 
Orleans; 1994. p. 7
[35] Catagni MA, Malzev V, Kirienko A. 
Correction of angular deformities. In: 
Bianchi-Maiocchi A, editor. Advances 
in Ilizarov Apparatus Assembly. Milan: 
Medicalplastic; 1994
[36] Welch RD, Birch JG, Samchukov ML. 
Histomorphology of distraction 
osteogenesis in a caprine tibial 
lengthening model. Journal of Bone and 
Mineral Research. 1998;13:1-9
[37] Latte Y. Studies of 63 cases treated 
by Ilizarov apparatus: Indications, 
results, complications. In: Proceedings 
of the Veterinary Orthopedic Society; 
Alberta, Canada; 1993. p. 12
[38] Aronson J. Temporal and spatial 
increases in blood flow during 
distraction osteogenesis. Clinical 
Orthopaedics. 1994;301:124-131
[39] Welch RD. Biology of distraction 
osteogenesis. In: Proceedings of the 
Annual Meeting of the American 
College of Veterinary Surgeons; 
Chicago, USA; 1995. p. 305
[40] Agostinho FS, Rahal SC, 
Miqueleto NS, Verdugo MR, Inamassu LR, 
El-Warrak AO. Kinematic analysis of 
Labrador retrievers and Rottweilers 
trotting on a treadmill. Veterinary 
and Comparative Orthopaedics and 
Traumatology. 2011;24:185-191
[41] Levine D, Marcellin-Little DJ, 
Millis DL, et al. Effects of partial 
immersion in water on vertical ground 
reaction forces and weight distribution 
in dogs. American Journal of Veterinary 
Research. 2010;71:1413-1416
[42] Molsa SH, Hielm-Bjorkman AK, 
Laitinen-Vapaavuori OM. Force 
platform analysis in clinically healthy 
Rottweilers: Comparison with Labrador 
retrievers. Veterinary Surgery. 
2010;9:701-707
[43] Brady RB, Sidiropoulos AN, 
Bennett HJ, et al. Evaluation of gait 
related variables in lean and obese dogs 
at a trot. American Journal of Veterinary 
Research. 2013;74:757-762
[44] Richards M, Goulet JA, 
Weiss JA, Waanders NA, Schaffler MB, 
Goldstein SA. Bone regeneration and 
fracture healing. Experience with 
distraction osteogenesis model. Clinical 
Orthopaedics and Related Research. 
1998;355(Suppl):S191-S204
[45] Fischgrund J, Paley D, 
Suter C. Variables affecting time to 
bone healing during limb lengthening. 
Clinical Orthopaedics and Related 
Research. 1994;301:31-37
[46] Ilizarov GA. The principles of the 
Ilizarov method. Bulletin of the Hospital 
for Joint Diseases Orthopaedic Institute. 
1988;48:1-11
[47] Li G, Berven S, Simpson H, 
Triffitt JT. Expression of BMP-4 during 
distraction osteogenesis in rabbits. 
Acta Orthopaedica Scandinavica. 
1998;69:420-425
[48] Sato M, Ochi T, Nakase T, Hirotam S, 
Kitamura Y, Nomura S, et al. Mechanical 
tension-stress induces expression of 
bone morphogenetic protein (BMP)-2 
and BMP-4, but not BMP-6, BMP-7, 
and GDF-5 mRNA, during distraction 
osteogenesis. Journal of Bone and 
Mineral Research. 1999;14:1084-1095
107
Distraction Osteogenesis: Biological Principles and Its Application in Companion Animals
DOI: http://dx.doi.org/10.5772/intechopen.89157
[49] Lammens J, Liu Z, Aerssens J, 
Dequeker J, Fabry G. Distraction bone 
healing versus osteotomy healing: A 
comparative biochemical analysis. 
Journal of Bone and Mineral Research. 
1988;13:279-286
[50] Farhadieh RD, Dickinson R, Yu Y, 
Gianoutsos MP, Walsh WR. The role 
of transforming growth factor-beta, 
insulin- like growth factor 1, and 
basic fibroblast growth factor in dis- 
traction osteogenesis of the mandible. 
The Journal of Craniofacial Surgery. 
1999;10:80-86
[51] Raschke MJ, Bail H, Windhagen HJ, 
Kolbeck SF, Weiler A, Raun K, et al. 
Recombinant growth hormone 
accelerates bone regenerate 
consolidation in distraction 
osteogenesis. Bone. 1999;24:81-88
[52] Tee BC, Sun Z. Mandibular 
distraction osteogenesis assisted by cell-
based tissue engineering: A systematic 
review. Orthodontics and Craniofacial 
Research. 2015;18(Suppl1):39-49
[53] Hu J, Qi MC, Zou SJ, Li JH, 
Luo E. Callus formation enhanced by 
BMP-7 ex vivo gene therapy during 
distraction osteogenesis in rats. 
Journal of Orthopaedic Research. 
2007;25:241-251
[54] Zhang WB, Zheng LW, Chua DT, 
Cheung LK. Treatment of irradiated 
mandibles with mesenchymal 
stem cells transfected with bone 
morphogenetic protein 2/7. Journal 
of Oral and Maxillofacial Surgery. 
2012;70:1711-1716
[55] Long J, Li P, Du HM, Liu L, 
Zheng XH, Lin YF, et al. Effects of 
bone morphogenetic protein 2 gene 
therapy on new bone formation during 
mandibular distraction osteogenesis 
at rapid rate in rabbits. Oral Surgery, 
Oral Medicine, Oral Pathology, 
Oral Radiology, and Endodontics. 
2011;112:50-57
[56] Castro-Govea Y, Cervantes- 
Kardasch VH, Borrego-Soto G, 
Martinez-Rodriguez HG, Espinoza 
Juarez M, Romero-Diaz V, et al. 
Human bone morphogenetic protein 
2-transduced mesenchymal stem 
cells improve bone regeneration in a 
model of mandible distraction surgery. 
The Journal of Craniofacial Surgery. 
2012;23:392-396
[57] Jiang X, Zou S, Ye B, Zhu S, Liu Y, 
Hu J. bFGF-modified BMMSCs enhance 
bone regeneration following distraction 
osteogenesis in rabbits. Bone. 
2010;46:1156-1161
[58] Kroczek A, Park J, Birkholz T, 
Neukam FW, Wiltfang J, Kessler P. Effects 
of osteoinduction on bone regeneration 
in distraction: Results of a pilot study. 
Journal of Cranio-Maxillo-Facial 
Surgery. 2010;38:334-344
[59] Lai QG, Yuan KF, Xu X, Li DR, 
Li GJ, Wei FL, et al. Transcription 
factor osterix modified bone marrow 
mesenchymal stem cells enhance 
callus formation during distraction 
osteogenesis. Oral Surgery, Oral 
Medicine, Oral Pathology, Oral 
Radiology, and Endodontics. 
2011;111:412-419
[60] Lai QG, Sun SL, Zhou XH, 
Zhang CP, Yuan KF, Yang ZJ, et al. 
Adipose-derived stem cells transfected 
with pEGFP-OSX enhance bone 
formation during distraction 
osteogenesis. Journal of Zhejiang 
University. Science. B. 2014;15:482-490
[61] Sun JJ, Zheng XH, Wang LY, 
Liu L, Jing W, Lin YF, et al. New 
bone formation enhanced by ADSCs 
overexpressing hRunx2 during 
mandibular distraction osteogenesis 
in osteoporotic rabbits. Journal of 
Orthopaedic Research. 2014;32:709-720
[62] Djasim UM, Wolvius EB, van 
Neck JW, Weinans H, van der 
Wal KG. Recommendations for optimal 
Clinical Implementation of Bone Regeneration and Maintenance
108
distraction protocols for various animal 
models on the basis of a systematic 
review of the literature. International 
Journal of Oral and Maxillofacial 
Surgery. 2007;36(10):877-883
[63] Ehrhart N. Longitudinal bone 
transport for treatment of primary bone 
tumors in dogs: Technique description 
and outcome in 9 dogs. Veterinary 
Surgery. 2005;34:24-34
[64] Bella B, Lara-Garcia A, Lafuente P. 
Canine appendicular osteosarcoma. 
Veterinary Ireland Journal. 
2016;6(4):207-216
[65] Dernell WS. Treatment of severe 
orthopedic infections. The Veterinary 
Clinics of North America. Small Animal 
Practice. 1999;29:1261-1274
[66] Asada N, Tsuchiya H, Kitaoka K, 
et al. Massive autoclaved allografts and 
autografts for limb salvage surgery: 
A 1-8 year follow-up of 23 patients. 
Acta Orthopaedica Scandinavica. 
1997;68:392-395
[67] Dernell WS, Withrow SJ, 
Straw RC. Clinical response to antibiotic 
impregnated methylmethacrylate 
bead implantation of dogs with 
severe infections after limb sparing 
surgery and allograft replacement: 
18 cases (1994-1998). Veterinary 
and Comparative Orthopaedics and 
Traumatology. 1998;11:94-99
[68] Ortiz-Cruz E, Gebhardt MC, 
Jennings LC, et al. The results of 
transplantation of intercalary allografts 
after resection of tumors. A long-term 
follow-up study. The Journal of Bone 
and Joint Surgery. American Volume. 
1997;79:97-106
[69] Cao J, Tan MH, Yang P, Li WL, 
Xia J, Du H, et al. Effects of adjuvant 
chemotherapy on bone marrow 
mesenchymal stem cells of colorectal 
cancer patients. Cancer Letters. 
2008;263(2):197-203
[70] Fan C, Cool JC, Scherer MA, 
Foster BK, Shandala T, Tapp H, et al. 
Damaging effects of chronic low-
dose methotrexate usage on primary 
bone formation in young rats and 
potential protective effects of folinic 
acid supplementary treatment. Bone. 
2009;44(1):61-70
[71] Kemp K, Morse R, Wexler S, Cox C, 
Mallam E, Hows J, et al. Chemotherapy-
induced mesenchymal stem cell 
damage in patients with hematological 
malignancy. Annals of Hematology. 
2010;89(7):701-713
[72] Banfi A, Podesta M, Fazzuoli L, 
Sertoli MR, Venturini M, Santini G, 
et al. High-dose chemotherapy shows 
a dose-dependent toxicity to 
bone marrow osteoprogenitors: A 
mechanism for post-bone marrow 
transplantation osteopenia. Cancer. 
2001;92(9):2419-2428
[73] Kapukaya A, Subasi M, Arslan H, 
Tuzuner T, Selek S. Technique and 
complications of callus distraction in 
the treatment of bone tumors. Archives 
of Orthopaedic and Trauma Surgery. 
2006;126(3):157-163
[74] Watanabe K, Tsuchiya H, 
Sakurakichi K, Yamashiro T, 
Matsubara H, Tomita K. Treatment 
of lower limb deformities and 
limb-length discrepancies with the 
external fixator in Ollier’s disease. 
Journal of Orthopaedic Science. 
2007;12(5):471-475
[75] Lesensky J, Prince D. Distraction 
osteogenesis reconstruction of 
large segmental bone defects after 
primary tumor resection: Pitfalls 
and benefits. European Journal of 
Orthopaedic Surgery and Traumatology. 
2017;27(6):715-727
[76] Rohde RS, Puhaindran ME, 
Morris CD, Alektiar KM, Schupak KD, 
Healey JH, et al. Complications of 
radiation therapy to the hand after soft 
109
Distraction Osteogenesis: Biological Principles and Its Application in Companion Animals
DOI: http://dx.doi.org/10.5772/intechopen.89157
tissue sarcoma surgery. The Journal of 
Hand Surgery. 2010;35(11):1858-1863
[77] Sheplan LJ, Juliano JJ. Use of 
radiation therapy for patients with 
soft-tissue and bone sarcomas. 
Cleveland Clinic Journal of Medicine. 
2010;77(Suppl 1):S27-S29
[78] Mahmoud O, Wolfson A. 
Perioperative irradiation in extremity 
soft tissue sarcoma. Expert 
Review of Anticancer Therapy. 
2011;11(8):1233-1241
[79] Al-Absi E, Farrokhyar F, Sharma R, 
Whelan K, Corbett T, Patel M, et al. 
A systematic review and meta-
analysis of oncologic outcomes of 
pre- versus postoperative radiation 
in localized resectable soft-tissue 
sarcoma. Annals of Surgical Oncology. 
2010;17(5):1367-1374
[80] Tsuchiya H, Uehara K, 
Sakurakichi K, Watanabe K, 
Matsubara H, Tomita K. Distraction 
osteogenesis after irradiation in a rabbit 
model. Journal of Orthopaedic Science. 
2005;10(6):627-633
[81] Ma Y, Shen G. Distraction 
osteogenesis after irradiation in 
rabbit mandibles. The British Journal 
of Oral and Maxillofacial Surgery. 
2012;50:662-667
[82] Paley D. Problems, obstacles, and 
complications of limb lengthening 
by the Ilizarov technique. Clinical 
Orthopaedics and Related Research. 
1990;250:81-104
[83] Makarov MR, Delgado MR, 
Samchukov ML, et al. SSEP evaluation 
of acute nerve injury associated with 
external fixation procedures. Clinical 
Orthopaedics. 1994;306:49-56
[84] Stogov MV, Emanov AA, 
Stepanov MA. Muscle metabolism 
during tibial lengthening with 
regular and high distraction rates. 
Journal of Orthopaedic Science. 
2014;19(6):965-972
[85] Eldridge J, Bell D. Problems with 
substantial limb lengthening. The 
Orthopedic Clinics of North America. 
1991;22:625-631
[86] Kwan TW, Marcellin-Little DJ, 
Harrysson OL. Correction of 
biapical radial deformities by use 
of bi-level hinged circular external 
fixation and distraction osteogenesis 
in 13 dogs. Veterinary Surgery. 
2014;43(3):316-329
[87] Petazzoni M. Contralateral bone 
widening and transfer for limb sparing 
in a cat. Veterinary and Comparative 
Orthopaedics and Traumatology. 
2016;29(2):174-180
[88] Gomi A, Sunaga A, Kamochi H, 
Oguma H, Sugawara Y. Distraction 
osteogenesis update: Introduction 
of multidirectional cranial 
distraction osteogenesis. Journal of 
Korean Neurosurgical Association. 
2016;59(3):233-241
Clinical Implementation of Bone Regeneration and Maintenance
108
distraction protocols for various animal 
models on the basis of a systematic 
review of the literature. International 
Journal of Oral and Maxillofacial 
Surgery. 2007;36(10):877-883
[63] Ehrhart N. Longitudinal bone 
transport for treatment of primary bone 
tumors in dogs: Technique description 
and outcome in 9 dogs. Veterinary 
Surgery. 2005;34:24-34
[64] Bella B, Lara-Garcia A, Lafuente P. 
Canine appendicular osteosarcoma. 
Veterinary Ireland Journal. 
2016;6(4):207-216
[65] Dernell WS. Treatment of severe 
orthopedic infections. The Veterinary 
Clinics of North America. Small Animal 
Practice. 1999;29:1261-1274
[66] Asada N, Tsuchiya H, Kitaoka K, 
et al. Massive autoclaved allografts and 
autografts for limb salvage surgery: 
A 1-8 year follow-up of 23 patients. 
Acta Orthopaedica Scandinavica. 
1997;68:392-395
[67] Dernell WS, Withrow SJ, 
Straw RC. Clinical response to antibiotic 
impregnated methylmethacrylate 
bead implantation of dogs with 
severe infections after limb sparing 
surgery and allograft replacement: 
18 cases (1994-1998). Veterinary 
and Comparative Orthopaedics and 
Traumatology. 1998;11:94-99
[68] Ortiz-Cruz E, Gebhardt MC, 
Jennings LC, et al. The results of 
transplantation of intercalary allografts 
after resection of tumors. A long-term 
follow-up study. The Journal of Bone 
and Joint Surgery. American Volume. 
1997;79:97-106
[69] Cao J, Tan MH, Yang P, Li WL, 
Xia J, Du H, et al. Effects of adjuvant 
chemotherapy on bone marrow 
mesenchymal stem cells of colorectal 
cancer patients. Cancer Letters. 
2008;263(2):197-203
[70] Fan C, Cool JC, Scherer MA, 
Foster BK, Shandala T, Tapp H, et al. 
Damaging effects of chronic low-
dose methotrexate usage on primary 
bone formation in young rats and 
potential protective effects of folinic 
acid supplementary treatment. Bone. 
2009;44(1):61-70
[71] Kemp K, Morse R, Wexler S, Cox C, 
Mallam E, Hows J, et al. Chemotherapy-
induced mesenchymal stem cell 
damage in patients with hematological 
malignancy. Annals of Hematology. 
2010;89(7):701-713
[72] Banfi A, Podesta M, Fazzuoli L, 
Sertoli MR, Venturini M, Santini G, 
et al. High-dose chemotherapy shows 
a dose-dependent toxicity to 
bone marrow osteoprogenitors: A 
mechanism for post-bone marrow 
transplantation osteopenia. Cancer. 
2001;92(9):2419-2428
[73] Kapukaya A, Subasi M, Arslan H, 
Tuzuner T, Selek S. Technique and 
complications of callus distraction in 
the treatment of bone tumors. Archives 
of Orthopaedic and Trauma Surgery. 
2006;126(3):157-163
[74] Watanabe K, Tsuchiya H, 
Sakurakichi K, Yamashiro T, 
Matsubara H, Tomita K. Treatment 
of lower limb deformities and 
limb-length discrepancies with the 
external fixator in Ollier’s disease. 
Journal of Orthopaedic Science. 
2007;12(5):471-475
[75] Lesensky J, Prince D. Distraction 
osteogenesis reconstruction of 
large segmental bone defects after 
primary tumor resection: Pitfalls 
and benefits. European Journal of 
Orthopaedic Surgery and Traumatology. 
2017;27(6):715-727
[76] Rohde RS, Puhaindran ME, 
Morris CD, Alektiar KM, Schupak KD, 
Healey JH, et al. Complications of 
radiation therapy to the hand after soft 
109
Distraction Osteogenesis: Biological Principles and Its Application in Companion Animals
DOI: http://dx.doi.org/10.5772/intechopen.89157
tissue sarcoma surgery. The Journal of 
Hand Surgery. 2010;35(11):1858-1863
[77] Sheplan LJ, Juliano JJ. Use of 
radiation therapy for patients with 
soft-tissue and bone sarcomas. 
Cleveland Clinic Journal of Medicine. 
2010;77(Suppl 1):S27-S29
[78] Mahmoud O, Wolfson A. 
Perioperative irradiation in extremity 
soft tissue sarcoma. Expert 
Review of Anticancer Therapy. 
2011;11(8):1233-1241
[79] Al-Absi E, Farrokhyar F, Sharma R, 
Whelan K, Corbett T, Patel M, et al. 
A systematic review and meta-
analysis of oncologic outcomes of 
pre- versus postoperative radiation 
in localized resectable soft-tissue 
sarcoma. Annals of Surgical Oncology. 
2010;17(5):1367-1374
[80] Tsuchiya H, Uehara K, 
Sakurakichi K, Watanabe K, 
Matsubara H, Tomita K. Distraction 
osteogenesis after irradiation in a rabbit 
model. Journal of Orthopaedic Science. 
2005;10(6):627-633
[81] Ma Y, Shen G. Distraction 
osteogenesis after irradiation in 
rabbit mandibles. The British Journal 
of Oral and Maxillofacial Surgery. 
2012;50:662-667
[82] Paley D. Problems, obstacles, and 
complications of limb lengthening 
by the Ilizarov technique. Clinical 
Orthopaedics and Related Research. 
1990;250:81-104
[83] Makarov MR, Delgado MR, 
Samchukov ML, et al. SSEP evaluation 
of acute nerve injury associated with 
external fixation procedures. Clinical 
Orthopaedics. 1994;306:49-56
[84] Stogov MV, Emanov AA, 
Stepanov MA. Muscle metabolism 
during tibial lengthening with 
regular and high distraction rates. 
Journal of Orthopaedic Science. 
2014;19(6):965-972
[85] Eldridge J, Bell D. Problems with 
substantial limb lengthening. The 
Orthopedic Clinics of North America. 
1991;22:625-631
[86] Kwan TW, Marcellin-Little DJ, 
Harrysson OL. Correction of 
biapical radial deformities by use 
of bi-level hinged circular external 
fixation and distraction osteogenesis 
in 13 dogs. Veterinary Surgery. 
2014;43(3):316-329
[87] Petazzoni M. Contralateral bone 
widening and transfer for limb sparing 
in a cat. Veterinary and Comparative 
Orthopaedics and Traumatology. 
2016;29(2):174-180
[88] Gomi A, Sunaga A, Kamochi H, 
Oguma H, Sugawara Y. Distraction 
osteogenesis update: Introduction 
of multidirectional cranial 
distraction osteogenesis. Journal of 














Adequate amount of thyroid hormone is an essential requirement for normal 
development and maturity of bones in the early life as well as for the maintenance 
of the skeletal system (bone remodeling). Osteoporosis, one of the most common 
metabolic bone disorders, is strongly associated with hyperthyroidism (endogenous 
and exogenous), whereas association of the same disease with hypothyroidism is 
not quite established. Most of the data describing the association between osteo-
porosis and hyperthyroidism are collected among elderly population (especially 
postmenopausal women), and only a few studies in literature researched into osteo-
porosis and hyperthyroidism in <50 years of age; hence further studies are required 
in the younger population (including premenopausal women and younger males).
Keywords: bone remodeling, hyperthyroidism, hypothyroidism,  
postmenopausal women
1. Introduction
The skeletal system maintains a dynamic characteristic throughout its life by 
continuously undergoing bone modeling and bone remodeling processes [1–7]. 
Both bone modeling and remodeling processes include bone resorption  mediated 
by osteoclasts and bone formation mediated by osteoblasts. Bone modeling is 
the predominant event during childhood, whereas in adults bone remodeling 
is the principal event [8]. In the case of bone modeling, both bone resorption 
and bone formation lead to major cur independently of one another at different 
sites of the skeletal system and lead to major change in the skeletal framework, 
whereas in the case of bone remodeling, both the processes of bone resorption and 
formation are closely related both in terms of time and site so that bone volume 
and density both remain more or less unchanged. The continuous process of bone 
remodeling repairs micro fractures, prevents formation of brittle bones, and 
balances calcium and phosphate homeostasis [6–8].
A number of systemic and local factors regulate the process of bone remodeling. 
Whenever the tightly coupled processes of bone resorption and bone formation in 
bone remodeling are disturbed, bone mineral diseases occur, excessive bone resorp-
tion leads to osteoporosis, and excessive bone formation leads to osteopetrosis [9].
Osteoblasts and osteoclasts are the two key players of bone remodeling; other 
cells involved in the process are osteocytes (derived from osteoblasts and acting 
as mechanosensor) and the bone lining cells [9]. The process of bone remodeling 
increases with aging; in both perimenopausal and menopausal women, the remod-
eling is faster than premenopausal women [9].
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There are a number of factors which are responsible for the development, 
maturation, and normal functioning of the skeletal system; these are genetic 
factors, maintenance of hormonal and metabolic harmony, adhering to balanced 
diet, exercise, etc. Any change in the abovementioned factors might lead to skeletal 
abnormality including restricted stature, deformity, osteoporosis, etc. [8, 10].
Osteoporosis leads to poor bone mass along with increased risk of fracture. 
Osteoporosis has emerged as a global healthcare problem with an estimated huge 
economic burden. Around 40% of women and 13–22% of men above 50 years will 
experience at least one episode of fracture (usually of spine, femur, or forearm) 
due to underlying osteoporosis in his or her lifetime [11]. Besides postmenopausal 
women and men above 50 years of age, the risk of secondary osteoporosis has 
increased in younger people as well [11].
Due to the increase in the number of patients with osteoporosis, all the second-
ary risk factors attributed to osteoporosis should be thoroughly investigated.
A number of factors are responsible for maintenance and development of the 
skeletal system; these are genetic factors, adequate hormonal and metabolic func-
tions, intake of balanced diet, and exercise (mechanical load) [11]. Any type of 
imbalance among the abovementioned factors might lead to severe consequences 
like short stature, bony deformities, and fractures. The final outcome depends upon 
age, type, severity, and duration of the underlying imbalance. Although not all of 
the abovementioned factors can be modified (like genetic factors), some of them 
can be modified [11, 12].
A rising number of new osteoporosis cases both in elderly and in young patients 
warrant the need for thorough investigations to identify all other secondary condi-
tions that might affect the disease negatively. Of all the secondary conditions, 
hormonal conditions are the most important ones that can lead to or aggravate 
osteoporosis [12]. Most commonly implicated endocrinological conditions are 
Cushing’s syndrome, hyperthyroidism, hypogonadism, acromegaly, diabetes mel-
litus, etc. Fortunately, majority of the negative effects of these hormonal disorders 
on the skeletal system can be modified [10–12].
1.1 Osteoblasts
Osteoblasts, the bone-forming cells in bone remodeling process, are derived 
from the pluripotent mesenchymal stem cells. Osteoblasts are also responsible for 
the secretion of Type I collagen which in turn is the major bone matrix protein. 
Besides the abovementioned functions, osteoblasts are also responsible for adequate 
mineralization of the new bone (osteoid). Bone mineralization occurs due to the 
locally released phosphates from the osteoblast-derived vesicles located within the 
osteoid. Extracellular calcium also contributes to the process of bone formation by 
the production of hydroxyapatite crystals. Maintenance of correct balance between 
bone matrix and minerals is the key factor for ensuring the right amount of rigidity 
and flexibility of the skeletal structure. Adult human cortical bones consist of 60% 
mineral, 20% organic material, and 20% water [8, 9].
1.2 Osteoclasts
These are micronucleated cells that are derived from the mononuclear mono-
cyte-macrophage cells. Osteoclasts, the only bone-resorbing cells, depend on two 
cytokines, colony-stimulating factor-1 or the macrophage colony-stimulating factor 
(CSF-1) and receptor activator of NF-kB ligand (RANKL), for production, expan-
sion, and survival. Osteoprotegerin (OPG) acts as a decoy receptor for RANKL and 
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inhibits the action of RANKL; hence the ration of RANKL to OPG determines the 
extent of osteoclast maturation and expansion [8, 9].
2. Physiology of thyroid hormones
The level of thyroid hormones in the circulation is controlled by the hypotha-
lamic-pituitary-thyroid axis (HPT axis) [13]. Thyrotropin-releasing hormone 
(TRH) is produced and secreted from the medial neurons of the paraventricular 
nucleus (PVN) of the hypothalamus. TRH in turn regulates both production and 
secretion of thyroid-stimulating hormone (TSH) from the anterior pituitary cells. 
Next, TSH through action on its receptor (TSHR) located on the follicular cells of 
the thyroid gland stimulates synthesis and secretion of the thyroid hormones. There 
are two types of thyroid hormones, 3,5,30,50-L-tetraiodothyronine (T4), the pro-
hormone, and 3,5,30-L-triiodothyronine (T3), the active hormone [14].
Thyroid hormones exert negative feedback effect on TRH and TSH and thus 
inhibit own synthesis and secretion.
Thus the HPT axis maintains a balanced relationship between the circulat-
ing thyroid hormones and their regulators like TSH and TRH. The set point for 
adequate functioning of the HPT axis is partly determined by genetic factors; there 
is an estimated genetic variation of 45–65% [13, 14].
2.1 Intracellular T3 supply
Circulating concentrations of both T4 and T3 along with target tissue uptake of 
the same and local activation or inactivation determine the intracellular supply of 
T3 (the active hormone). The thyroid gland secretes the pro-hormone T4 in larger 
proportions which is converted to the active form T3 in the liver and kidney through 
deiodination of T4 by type 1 iodothyronine deiodinase enzyme (DIO1). A major 
part (around 90%) of the circulating thyroid hormone remains bound to plasma 
proteins, and the concentration of free T3 (fT3) exceeds that of free T4 (fT4) by 
three to four times [13, 14].
There are specific membrane transporters associated with target tissue uptake of 
thyroid hormones; considered as monocarboxylate transporters (MCT8, MCT10), 
and organic acid transporter protein-1c1 (OATP1C1) [15]. Activity of T3 inside the 
cell is regulated by DIO2 and DIO3, as DIO2 converts T4 to T3 and DIO3 blocks the 
activation of T3 by producing reverse T3 [16].
Thyroid hormones mediate their actions through interaction with thyroid 
receptors (TRs). Unbound TRs bind with corepressor proteins and bind with 
thyroid response elements located at the promoter regions of the target genes and 
suppress transcription. Once thyroid hormone binds with its receptor, the receptor 
undergoes a conformational change with the unbinding of the corepressor proteins 
and facilitation of gene transcription following binding with the thyroid response 
elements at the target genes [14–16].
3. Thyroid hormone and the skeletal system
Action of T3 hormone on the skeletal system is rather complex and not completely 
understood. T3 mediates its action on the bones via direct and indirect pathways and 
affects the different phases of bone remodeling. T3 facilitates both osteoblastic (bone 
formation) and osteoclastic actions (bone resorption). T3 facilitates osteoblastic 
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thyroid hormones; considered as monocarboxylate transporters (MCT8, MCT10), 
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cell is regulated by DIO2 and DIO3, as DIO2 converts T4 to T3 and DIO3 blocks the 
activation of T3 by producing reverse T3 [16].
Thyroid hormones mediate their actions through interaction with thyroid 
receptors (TRs). Unbound TRs bind with corepressor proteins and bind with 
thyroid response elements located at the promoter regions of the target genes and 
suppress transcription. Once thyroid hormone binds with its receptor, the receptor 
undergoes a conformational change with the unbinding of the corepressor proteins 
and facilitation of gene transcription following binding with the thyroid response 
elements at the target genes [14–16].
3. Thyroid hormone and the skeletal system
Action of T3 hormone on the skeletal system is rather complex and not completely 
understood. T3 mediates its action on the bones via direct and indirect pathways and 
affects the different phases of bone remodeling. T3 facilitates both osteoblastic (bone 
formation) and osteoclastic actions (bone resorption). T3 facilitates osteoblastic 
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activity by promoting production and differentiation of osteoblasts and also 
increases the expression of osteocalcin, collagen (Type 1), metalloproteins, alkaline 
phosphatase, etc. Similarly, T3 also facilitates differentiation of osteoclasts through 
increased expression of interleukin-6 and prostaglandins. It also exhibits synergistic 
action with hormones facilitating osteoclastic activity (like parathyroid hormone and 
vitamin D). Moreover, T3 promotes the expression of mRNA of RANKL, stimulates 
RANK, and thus facilitates osteoclast production [14–16].
Majority of the TRs expressed in the skeletal system (bone marrow, chondro-
cytes, osteoblasts, and osteoclasts) are TRβ1 and TRα1. Molecular studies have 
shown that the expression of TRα1 is far greater than that of TRβ1 in the skeletal 
system, indicating that T3-mediated action on the skeleton system is mostly carried 
out through TRα1 receptor [17]. There were no changes in the bone mass following 
the treatment of adult female rats with TRβ-selective agonist 3,5-dimethyl-4-(4-
hydroxy-3-isopropylbenzyl)phenoxy acetic acid (GC-1); however, the administra-
tion of supraphysiological dose of T3 led to significant loss of bone mass in the 
adult female rats [18]. These findings suggest that T3-mediated bone resorption 
occurs through TRα1 receptors [18]. Animal models with genetic modifications (for 
TRs) have led to better understanding of the actions of T3 on the skeletal systems. 
All these studies showed that mice with mutation of either both TRα1 and TRβ1 
or only TRα1 had delayed bone growth due to delayed ossification and decreased 
bone mineralization in early life, whereas increased bone mineralization in later 
years of life is similar to the effects of hypothyroidism in humans. However, mice 
with mutation of only TRβ1 receptors had skeletal phenotype similar to thyrotoxic 
patients characterized by increased mineralization and faster ossification during 
early life and decreased bone mineralization and poor bone mass in adult life [18].
3.1 Hyperthyroidism and osteoporosis
Thyroid hormones are known to a play key role in the linear growth of the 
skeletal system, and these hormones are essential to achieve the expected bone 
mass [19]. However, hyperthyroidism or thyrotoxicosis, a rather rare occurrence 
in children, if present, leads to accelerated ossification (both intramembranous 
and endochondral) and rapid linear growth [17]. This accelerated increase in bone 
age often results in early epiphyseal closure and short stature. In younger children 
severe degree of thyrotoxicosis might lead to premature closure of cranial sutures 
and craniosynostosis (impaired growth of brain and skull) with neurological 
complications [17, 20]. Sometimes severe untreated thyrotoxicosis in mother might 
lead to craniosynostosis in the growing fetus [20].
In adults hyperthyroidism shorten the bone turnover and poor bone mineral-
ization [11, 17]. Finally there is loss of bone mineral density by around 10–20% 
especially in the cortical bones [11]. The increased concentration of circulating 
thyroid hormones causes significant shortening of bone remodeling cycle by about 
50%. Normally the average bone remodeling cycle lasts for 200 days; however, with 
hyperthyroidism it is shortened to an average of 113 days [11, 21, 22]. Hence the bal-
ance between bone resorption and bone formation is disturbed; the bone formation 
phase is severely compromised (the duration is decreased by 2/3) and is ultimately 
responsible for poor mineralization (loss of about 10% of mineralization of bone 
per cycle) [11]. All these effects lead to increased risk of osteoporosis and increased 
chance of fracture.
Another contributory factor for increased risk of osteoporosis in patients of 
hyperthyroidism is that there is increased circulatory concentration of IL-6 in these 
patients; IL-6 is known to be an activator for osteoclast production and facilitates 
action of parathyroid hormone in bones [11, 23]. Hyperparathyroidism is also 
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known to cause negative calcium balance due to hypercalcemia and hypercalciuria. 
Negative calcium balance further increases the risk of osteoporosis in these already 
vulnerable patients.
Many researchers since Von Recklinghausen have been conducting researches on 
the effects of thyroid dysfunction on bones. Svare A and his colleagues conducted 
a cross-sectional study to assess the relationship between BMD of forearm and 
TSH level in Norwegian female population (HUNT2 Study) [24]. They found that 
women with lower TSH (<0.5 mU/L) had lower forearm BMD than the reference 
category. Similarly, the prevalence of osteoporosis was found to be higher in women 
with osteoporosis than those without any history of thyroid disorder.
Again, the occurrence of osteoporosis secondary to hyperthyroidism (thyrotoxi-
cosis) is more common in postmenopausal women than premenopausal women. 
Ercolano MA and his colleagues conducted a non-interventional and cross-sectional 
study on euthyroid (who had euthyroid for the past 6 months) pre- and postmeno-
pausal women with past history of hyperthyroidism due to Graves’ disease [25]. It 
was found that BMD was significantly affected only in the postmenopausal group 
of women who remained euthyroid for the past 6 months and have a past history of 
Graves’ disease. Again, Tuchendler and Bolanowski conducted a study on premeno-
pausal women with hyper- and hypothyroidism to assess the effects of thyroid 
dysfunction on osteoporosis [26]. They found that only hyperthyroidism and not 
hypothyroidism can significantly affect BMD (measured at the femoral neck), and 
following the treatment for 12 months, a statistically significant increase in BMD 
in femoral neck was observed in premenopausal women with hyperthyroidism and 
not hypothyroidism.
Similar study was conducted in men by El Hadidy and his colleagues [27]. The 
study included males between 23 and 65 years with hyperthyroidism (Graves’ 
disease or toxic nodular goiter). The researchers found that the men with hyper-
thyroidism had a significant fall in BMD compared to age-matched healthy men 
without any thyroid dysfunction. Besides this, the severity and the duration of 
hyperthyroidism were directly related to the increase in bone turnover markers and 
the degree of bone loss.
Similar study was conducted by Ale and her colleagues [28]. This cross-sectional 
study included females and males between 22 and 50 years. It was found that BMD 
measured in hyperthyroidism was significantly reduced compared to age- and sex-
matched healthy controls. Osteoporosis was documented in hyperthyroidism but 
not in the controls.
Again a systematic review and meta-analysis of cohort studies by Yang and his 
fellow researchers documented that although both subclinical hypo- and hyperthy-
roidism are associated with increased risk of fracture, only subclinical hyperthy-
roidism and not subclinical hypothyroidism showed significant association with 
low BMD (osteoporosis) [29].
3.1.1 Subclinical hyperthyroidism and osteoporosis
Although medical data describing the relation between subclinical hyperthy-
roidism and osteoporosis is not much, still there are studies which have explored the 
relationship between the two. Segna and his colleagues published a study exploring 
the association between subclinical hyperthyroidism and osteoporosis [30]. They 
included all the prospective cohort studies (published between 1946 and 2016) in 
the electronic database (MEDLINE/EMBASE) which provided baseline thyroid 
hormone status and repeated measurements of BMD. The study found that in adult 
patients subclinical hyperthyroidism is significantly associated with bone loss in the 
femoral neck region leading to increased risk of osteoporosis and fracture.
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known to cause negative calcium balance due to hypercalcemia and hypercalciuria. 
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a cross-sectional study to assess the relationship between BMD of forearm and 
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with osteoporosis than those without any history of thyroid disorder.
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Ercolano MA and his colleagues conducted a non-interventional and cross-sectional 
study on euthyroid (who had euthyroid for the past 6 months) pre- and postmeno-
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of women who remained euthyroid for the past 6 months and have a past history of 
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pausal women with hyper- and hypothyroidism to assess the effects of thyroid 
dysfunction on osteoporosis [26]. They found that only hyperthyroidism and not 
hypothyroidism can significantly affect BMD (measured at the femoral neck), and 
following the treatment for 12 months, a statistically significant increase in BMD 
in femoral neck was observed in premenopausal women with hyperthyroidism and 
not hypothyroidism.
Similar study was conducted in men by El Hadidy and his colleagues [27]. The 
study included males between 23 and 65 years with hyperthyroidism (Graves’ 
disease or toxic nodular goiter). The researchers found that the men with hyper-
thyroidism had a significant fall in BMD compared to age-matched healthy men 
without any thyroid dysfunction. Besides this, the severity and the duration of 
hyperthyroidism were directly related to the increase in bone turnover markers and 
the degree of bone loss.
Similar study was conducted by Ale and her colleagues [28]. This cross-sectional 
study included females and males between 22 and 50 years. It was found that BMD 
measured in hyperthyroidism was significantly reduced compared to age- and sex-
matched healthy controls. Osteoporosis was documented in hyperthyroidism but 
not in the controls.
Again a systematic review and meta-analysis of cohort studies by Yang and his 
fellow researchers documented that although both subclinical hypo- and hyperthy-
roidism are associated with increased risk of fracture, only subclinical hyperthy-
roidism and not subclinical hypothyroidism showed significant association with 
low BMD (osteoporosis) [29].
3.1.1 Subclinical hyperthyroidism and osteoporosis
Although medical data describing the relation between subclinical hyperthy-
roidism and osteoporosis is not much, still there are studies which have explored the 
relationship between the two. Segna and his colleagues published a study exploring 
the association between subclinical hyperthyroidism and osteoporosis [30]. They 
included all the prospective cohort studies (published between 1946 and 2016) in 
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hormone status and repeated measurements of BMD. The study found that in adult 
patients subclinical hyperthyroidism is significantly associated with bone loss in the 
femoral neck region leading to increased risk of osteoporosis and fracture.
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However, some earlier studies as the one conducted by Földes and his colleagues 
have described that although in premenopausal women with subclinical hyper-
thyroidism BMD in femoral neck, lumbar spine, and in the midshaft of radius did 
not decrease significantly, the same condition might contribute to osteoporosis in 
postmenopausal women especially in the cortical bones [31]. Another study pub-
lished by Lee and his fellow researchers revealed that both subclinical hypo- and 
hyperthyroidism are associated with increased risk of hip fracture in elderly men; 
however, no such association was found with women [32].
Vadiveloo and his colleagues published a retrospective study exploring the 
long-term consequences of subclinical hyperthyroidism (TEARS study) [33]. The 
researchers identified suitable patients using population record linkage technology 
retrospectively between January 1, 1993 and December 31, 2009. They found that 
patients with endogenous subclinical hyperthyroidism showed an increased risk of 
osteoporosis-related fracture (hazard ratio being 1.25) when compared with refer-
ence population; however, once these patients developed overt hyperthyroidism or 
euthyroidism and are excluded from the study, this association is lost.
Again, Saler and his colleagues described in their study that in contrast to exog-
enous subclinical hyperthyroidism, endogenous subclinical hyperthyroidism does 
not compromise BMD in premenopausal women and therefore do not pose a risk for 
either osteoporosis or osteopenia [34]. However, Tauchmanovà and her colleagues 
found that BMD of the femoral neck was significantly decreased in both pre- and 
postmenopausal women with endogenous subclinical hyperthyroidism (greater in 
in postmenopausal women). Study of lumbar spine BMD revealed bone loss only 
in postmenopausal women. Similar findings were documented by Rosario and his 
colleagues [35].
Thus it can be suggested that the threat of osteoporotic fracture is greater with 
exogenous subclinical hyperthyroidism especially in postmenopausal women.
3.2 Overt hypothyroidism and osteoporosis
Hypothyroidism is a rather common condition in children and is characterized 
by delay in the development of the skeletal system, poor growth, and impaired and 
early endochondral ossification leading to short stature and defective bone matu-
ration. Patients often present with patent skull sutures (delay in closure of skull 
fontanelles) and typical facial characteristics like flattened nasal bridge and broad 
face due to defective ossification.
In severe cases postnatal growth can be completely arrested, impaired with 
skeletal growth characterized by epiphyseal dysgenesis, dislocation of hip joints, 
scoliosis, persistent patency of the fontanelles, and delay in eruption of tooth. 
Thyroid hormone replacement therapy in these children leads to “catch-up” growth 
with achievement of skeletal maturity and improved bone mineralization. Finally 
in most of the children, normal adult height and bone mineral density are achieved. 
However, in severely affected children and those with significant delay in receiv-
ing thyroid hormone replacement therapy, expected adult stature might not be 
achieved.
Several studies were conducted in adults to understand the effect of thyroid hor-
mone disorder on adult skeletal system [11]. But several factors like heterogeneity of 
the study population, the presence of different confounding factors, and different 
end points for different studies have led to the uniform interpretation of the results 
obtained from these studies.
Earlier histomorphometric studies have shown that hypothyroidism in adults led 
to slow bone turnover with both poor bone formation by osteoblasts and decreased 
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bone resorption by osteoclasts. Also increase in the bone remodeling time led to 
prolonged secondary mineralization of the bone without any change in the existing 
bone volume. However, all the abovementioned changes are very slow to occur, and 
there are hardly any clinical data to suggest these findings in adult patients [11].
Although the exact mechanism is not known, hypothyroidism is considered to 
increase the risk of fracture. Vestergaard and his fellow researchers documented in 
their study that following diagnosis of primary idiopathic hypothyroidism, the risk 
of fracture (in forearm) was significantly increased in patients above 50 years [36].
However, González-Rodríguez and his colleagues while assessing the prevalence 
of thyroid dysfunction in adult female population, from the data collected in the 
Latin American Vertebral Osteoporosis Study (LAVOS), documented that although 
there was a high prevalence of hypothyroidism in these females, no association 
between loss of bone mineral density and hypothyroidism was found [37]. They 
also found that there was no association between fractures (vertebral or nonverte-
bral) and hypothyroidism.
3.3  Prolonged treatment with TSH suppressive therapy with supraphysiological 
dose of levothyroxine (synthetic form of T4) and osteoporosis
Supraphysiological doses of levothyroxine are prescribed in patients of thyroid 
cancer following surgery and radioactive iodine therapy. Prolonged exposure to 
levothyroxine therapy might increase the risk of secondary osteoporosis [11].
Heemstra and his colleagues described that, although long-term thyroxine 
therapy increased the risk of poor BMD and thus osteoporosis, it was not seen in 
men and in premenopausal women [38].
In the year 2018, Mazziotti and his colleagues published a cross-sectional study 
conducted mainly on postmenopausal women (178 women were postmenopausal 
out of 179 of the study participants) [39]. These women underwent thyroidectomy 
for differentiated thyroid carcinoma and were receiving levothyroxine therapy. 
Radiological vertebral fractures (VF) are considered as an early indicator of bone 
fragility. The researchers found that the prevalence of VF was significantly greater 
in patients with TSH level <1.0 mU/L, duration of levothyroxine therapy, and 
densiometric diagnosis of osteoporosis.
Thus it can be suggested that the risk of osteoporosis increases with suppression 
of TSH therapy.
4. Conclusion
Osteoporosis is considered to be one of the most common skeletal disorders 
affecting both elderly and young patients. Besides the few primary causes (aging 
and menopause), in most of the cases, osteoporosis occurs due to underly-
ing secondary causes. Common secondary risk factors for osteoporosis include 
hormonal disorders like Cushing’s disease, hyperthyroidism, diabetes mellitus, 
hypogonadism, etc. Several studies have established that hyperthyroidism both 
endogenous (due to Graves’ disease or toxic nodular goiter) and exogenous (due to 
prolonged levothyroxine therapy especially in patients with differentiated thyroid 
cancer) increases the risk of osteoporosis profoundly in postmenopausal women. 
Even subclinical hyperthyroidism especially the exogenous ones might lower BMD 
and increases the risk of osteoporosis, more commonly in postmenopausal women. 
Hypothyroidism, on the other hand, although responsible for an array of bone 
disorders, does not usually contribute to osteoporosis.
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of fracture (in forearm) was significantly increased in patients above 50 years [36].
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of thyroid dysfunction in adult female population, from the data collected in the 
Latin American Vertebral Osteoporosis Study (LAVOS), documented that although 
there was a high prevalence of hypothyroidism in these females, no association 
between loss of bone mineral density and hypothyroidism was found [37]. They 
also found that there was no association between fractures (vertebral or nonverte-
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3.3  Prolonged treatment with TSH suppressive therapy with supraphysiological 
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Supraphysiological doses of levothyroxine are prescribed in patients of thyroid 
cancer following surgery and radioactive iodine therapy. Prolonged exposure to 
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Heemstra and his colleagues described that, although long-term thyroxine 
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Radiological vertebral fractures (VF) are considered as an early indicator of bone 
fragility. The researchers found that the prevalence of VF was significantly greater 
in patients with TSH level <1.0 mU/L, duration of levothyroxine therapy, and 
densiometric diagnosis of osteoporosis.
Thus it can be suggested that the risk of osteoporosis increases with suppression 
of TSH therapy.
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Osteoporosis is considered to be one of the most common skeletal disorders 
affecting both elderly and young patients. Besides the few primary causes (aging 
and menopause), in most of the cases, osteoporosis occurs due to underly-
ing secondary causes. Common secondary risk factors for osteoporosis include 
hormonal disorders like Cushing’s disease, hyperthyroidism, diabetes mellitus, 
hypogonadism, etc. Several studies have established that hyperthyroidism both 
endogenous (due to Graves’ disease or toxic nodular goiter) and exogenous (due to 
prolonged levothyroxine therapy especially in patients with differentiated thyroid 
cancer) increases the risk of osteoporosis profoundly in postmenopausal women. 
Even subclinical hyperthyroidism especially the exogenous ones might lower BMD 
and increases the risk of osteoporosis, more commonly in postmenopausal women. 
Hypothyroidism, on the other hand, although responsible for an array of bone 
disorders, does not usually contribute to osteoporosis.
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Most of the studies, exploring the association between hyperthyroidism (exog-
enous or endogenous) and osteoporosis, are usually conducted among elderly 
population (postmenopausal women and elderly men). Hence further studies are 
to be conducted to explore the association of hyperthyroidism and osteoporosis in 
younger population (premenopausal women and younger males).
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Most of the studies, exploring the association between hyperthyroidism (exog-
enous or endogenous) and osteoporosis, are usually conducted among elderly 
population (postmenopausal women and elderly men). Hence further studies are 
to be conducted to explore the association of hyperthyroidism and osteoporosis in 
younger population (premenopausal women and younger males).
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Vitamin K is an essential fat-soluble vitamin. The role of vitamin K as a  cofactor 
involved in blood coagulation is well demonstrated. In the past two decades, 
vitamin K has been receiving more attention due to its role in bone health and 
metabolism. Vitamin K plays a role in activation of vitamin K-dependent proteins, 
which are involved not only in blood coagulation but in bone metabolism and the 
inhibition of arterial calcification. Numerous studies have exhibited the importance 
of vitamin K in bone health. The bone mineral density (BMD) does not remain 
steady with age, particularly declining after menopause. Osteoporosis is a metabolic 
bone disease of reduced bone density, fragile bone, and elevated susceptibility to 
fracture. A greater understanding of the biological linkages between vitamin K 
and bone may conduce to new treatment for osteoporosis that may improve bone 
density and prevent the adverse outcomes of osteoporosis.
Keywords: vitamin K, phylloquinone, menaquinone, bone mineral density, 
osteoporosis, Gla protein
1. Introduction
Vitamin K is an important fat-soluble vitamin. The discovery of vitamin K was 
in Germany in 1929 by Henrik Dam in his research on sterol metabolism, and he 
suggested the name vitamin K on the basis of its role in coagulation (koagulation in 
German spelling).
The exact function of vitamin K in the human body was discovered in the 1970s 
with the discovery of γ-carboxyglutamic acid (Gla), an amino acid found in all 
vitamin K proteins [1].
Gamma glutamyl carboxylase is an enzyme that located in the endoplasmic reticu-
lum and mediates the posttranslational conversion of glutamyl to γ-carboxyglutamyl 
residues in vitamin K-dependent proteins; this enzyme needs vitamin K as a cofac-
tor for this conversion; thus the important role of vitamin K appears in tissues that 
contain vitamin K-dependent protein to make them a functional protein [2].
During the last two decades, the researches have focused on the role of vitamin K 
in osteoporosis [3], cardiovascular disease [4], diabetes [5], and cancer [6] besides 
its role on coagulation [7].
In the liver there are several vitamin K-dependent proteins which all play a 
role in hemostasis. In addition to the hepatic tissue, bone tissue contains vitamin 
K-dependent proteins such as osteocalcin (bone Gla protein) and matrix Gla 
protein (MGP). Mineral binding capacity of osteocalcin needs vitamin K for adding 
mineral to the bone matrix in normal bone growth and development [8].
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Studies have reported that  vitamin K plays a role in bone metabolism in other 
mechanisms. There is an evidence that vitamin K positively affects calcium balance 
and increase of calcium retention [9]. Vitamins K and D work synergistically on 
bone metabolism, the form of osteocalcin that osteoblasts produce is undercarbox-
ylated osteocalcin, and this process is upregulated by vitamin D, while carboxyl-
ation of osteocalcin is mediated by vitamin K [10].
Vitamin K is shown to decrease bone resorption by osteoclasts and inhibits produc-
tion of bone-resorbing agents such as interleukin-6 [11] and prostaglandin E2 [12].
Osteoporosis is a metabolic bone disease of reduced bone density, fragile bone, 
and elevated susceptibility to fracture. Genetic factors, age, sex, race, general health, 
exercise, cigarette smoking, alcohol abuse, hormone replacement therapy, and nutri-
tion are some of the factors that influence an individual’s risk of osteoporosis [13].
The aim of the present paper is to summarize the present knowledge on vitamin 
K and bone metabolism, emphasize the role of vitamin K in bone health, and evalu-
ate vitamin K as a diagnostic and therapeutic marker in osteoporosis.
2. Types of vitamin K
Vitamin K refers to a family of compounds with a common chemical structure of 
2-methyl-1,4-naphthoquinone (Figure 1) [14].
Figure 1. 
Structure of the main forms of vitamin K.
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These compounds include:
1. Vitamin K1 (phylloquinone)
2. Vitamin K2 (menaquinones)
3. Vitamin K3 (menadione) [7]
3. Sources of vitamin K
Vitamin K1 (phylloquinone) comes from vegetables, especially green leafy 
vegetables such as spinach, vegetable oils, broccoli, and some fruits [1].
Vitamin K2 (menaquinone) forms a subfamily in which it has an unsaturated 
isoprenyl side chain (may range from 1 to 13 isoprene residues). The various 
menaquinones are generally denoted as MK-n, where n symbolizes the num-
ber of isoprene residues in the side chain and is designated as MK-4 through 
MK-13, established upon the length of their side chain. The most well-studied 
menaquinones are MK-4, MK-7, MK-8, MK-9, and MK-10 that all occur in the 
human diet.
Menaquinones (except MK-4) are of microbial origin, and relatively high 
concentrations are only found in a few food items. Natto (a traditional Japanese 
food made from fermented soybeans) has high amounts of menaquinones (almost 
exclusively MK-7). Other fermented foods, such as cheese, also contain menaqui-
nones. However, the forms and amounts of vitamin K in these foods likely vary 
relying on the strains of bacteria utilized to make the foods.
Bacteria in the human gut produce most of the menaquinones, especially the 
long-chain menaquinones; the amount of vitamin K that the body acquires in this 
manner is unclear.
Menadione is a synthetic form of vitamin K. It has increased toxic risk, so it is 
not a commonly supplemented form of vitamin K [1, 15].
4. Absorption and transport of vitamin K
In the intestine vitamin K is incorporated into mixed micelles, and it is absorbed 
by enterocytes. From there, vitamin K is combined into chylomicrons, released 
into the lymphatic capillaries, transported to the liver, and then packed again into 
very-low-density lipoproteins. In the circulation, vitamin K is carried mainly in 
lipoproteins [16].
5. Recommended intake
The AI for vitamin K1 is 120 mcg/day for men and 90 mcg/day for women as it 
was determined by the Institute of Medicine in the United States in 2001 [17].
These current AI values are established upon the hepatic vitamin K demanded 
for activation of coagulation factor and absence of abnormal bleeding. There was 
not any DRI for vitamin K2 or an upper limit intake level for vitamin K1 at that 
time. Clinical trials have used vitamin K supplements at doses much higher than the 
DRI levels (10 mg for vitamin K1 and 45 mg for vitamin K2) and found no evidence 
of toxic effects. However, trials which have used supplements of 45 mg/day of MK-4 
demonstrate incidences of skin appendage lesions [18, 19].
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ylated osteocalcin, and this process is upregulated by vitamin D, while carboxyl-
ation of osteocalcin is mediated by vitamin K [10].
Vitamin K is shown to decrease bone resorption by osteoclasts and inhibits produc-
tion of bone-resorbing agents such as interleukin-6 [11] and prostaglandin E2 [12].
Osteoporosis is a metabolic bone disease of reduced bone density, fragile bone, 
and elevated susceptibility to fracture. Genetic factors, age, sex, race, general health, 
exercise, cigarette smoking, alcohol abuse, hormone replacement therapy, and nutri-
tion are some of the factors that influence an individual’s risk of osteoporosis [13].
The aim of the present paper is to summarize the present knowledge on vitamin 
K and bone metabolism, emphasize the role of vitamin K in bone health, and evalu-
ate vitamin K as a diagnostic and therapeutic marker in osteoporosis.
2. Types of vitamin K
Vitamin K refers to a family of compounds with a common chemical structure of 
2-methyl-1,4-naphthoquinone (Figure 1) [14].
Figure 1. 
Structure of the main forms of vitamin K.
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These compounds include:
1. Vitamin K1 (phylloquinone)
2. Vitamin K2 (menaquinones)
3. Vitamin K3 (menadione) [7]
3. Sources of vitamin K
Vitamin K1 (phylloquinone) comes from vegetables, especially green leafy 
vegetables such as spinach, vegetable oils, broccoli, and some fruits [1].
Vitamin K2 (menaquinone) forms a subfamily in which it has an unsaturated 
isoprenyl side chain (may range from 1 to 13 isoprene residues). The various 
menaquinones are generally denoted as MK-n, where n symbolizes the num-
ber of isoprene residues in the side chain and is designated as MK-4 through 
MK-13, established upon the length of their side chain. The most well-studied 
menaquinones are MK-4, MK-7, MK-8, MK-9, and MK-10 that all occur in the 
human diet.
Menaquinones (except MK-4) are of microbial origin, and relatively high 
concentrations are only found in a few food items. Natto (a traditional Japanese 
food made from fermented soybeans) has high amounts of menaquinones (almost 
exclusively MK-7). Other fermented foods, such as cheese, also contain menaqui-
nones. However, the forms and amounts of vitamin K in these foods likely vary 
relying on the strains of bacteria utilized to make the foods.
Bacteria in the human gut produce most of the menaquinones, especially the 
long-chain menaquinones; the amount of vitamin K that the body acquires in this 
manner is unclear.
Menadione is a synthetic form of vitamin K. It has increased toxic risk, so it is 
not a commonly supplemented form of vitamin K [1, 15].
4. Absorption and transport of vitamin K
In the intestine vitamin K is incorporated into mixed micelles, and it is absorbed 
by enterocytes. From there, vitamin K is combined into chylomicrons, released 
into the lymphatic capillaries, transported to the liver, and then packed again into 
very-low-density lipoproteins. In the circulation, vitamin K is carried mainly in 
lipoproteins [16].
5. Recommended intake
The AI for vitamin K1 is 120 mcg/day for men and 90 mcg/day for women as it 
was determined by the Institute of Medicine in the United States in 2001 [17].
These current AI values are established upon the hepatic vitamin K demanded 
for activation of coagulation factor and absence of abnormal bleeding. There was 
not any DRI for vitamin K2 or an upper limit intake level for vitamin K1 at that 
time. Clinical trials have used vitamin K supplements at doses much higher than the 
DRI levels (10 mg for vitamin K1 and 45 mg for vitamin K2) and found no evidence 
of toxic effects. However, trials which have used supplements of 45 mg/day of MK-4 
demonstrate incidences of skin appendage lesions [18, 19].
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6. Serum vitamin K concentration
Vitamin K is being absorbed via chylomicrons; in addition it is distributed via 
lipoproteins. The menaquinones with longer side chain are partitioned into LDL, 
whereas others including vitamin K1 are in the triglyceride rich fragment [20]. 
Vitamin K does appear to bioaccumulate in various tissues following oral ingestion, 
and it appears to have a relatively short time in the body prior to being excreted in 
comparison with the fat-soluble vitamins [16].
The major form of vitamin K in serum is vitamin K1, and it has a relative rapid 
half-life relative to MK-4, whereas MK-7 and other long-chain menaquinones have a 
very extended half-life and greater bioactivity [21].
The normal range of circulating concentrations of vitamin K1 is 05–2.5 nM/L 
(0.22–1.22 ng/ml) without taking any supplements [22]. However the range of 
vitamin K1 in patients and healthy adults was 0,22–8.88 nM/L (0.09–3.96 ng/ml) as 
reported in several clinical studies [23].
7. Bone uptake
Osteoblasts appear to take vitamin K which is transported via lipoproteins, and 
this uptake is facilitated by the LDL receptor which is expressed on these bone cells 
(LRP1 and, to a fewer degree, VLDLR) with the competence of the triglyceride frac-
tion in giving its phylloquinone being greater than HDL but less than LDL, and the 
uptake is relying on ApoE. Hence it is thought that genetic variations in ApoE can 
affect vitamin K status. This region contains several Gla proteins such as matrix Gla 
protein and osteocalcin which need vitamin K to be effective [24].
Delivery of vitamin K to the bone tends to be less than in the liver, as in instances 
where vitamin K-dependent proteins (Gla) are totally γ-carboxylated in the liver, 
while they are not in the bone [20].
8. Vitamin K functions
Vitamin K plays a biological role as a cofactor of gamma glutamyl car-
boxylase, which mediates γ- carboxylation of glutamic acid residues (Glu) to 
γ-carboxyglutamic acid (Gla) on vitamin K-dependent protein. The Ƴ-carboxylation 
of the vitamin K-dependent proteins Gla proteins is essential for their function.
Gla proteins or vitamin K-dependent proteins are a group of proteins that have 
calcium-binding characteristics and are existing in the extracellular matrix or in 
body fluids.
These proteins are included in blood clotting, bone mineralization, cartilage, 
and other soft tissues; and they have an important role in supporting the health of 
bones, joints, and blood vessels [3]. Some studies have suggested that vitamin K has 
anticancer [6], anti-inflammatory, and antioxidant characteristics [25].
There are seven different vitamin K-dependent proteins which all regulate 
coagulation; prothrombin (Factor II) is the most well-known target protein which 
was the first protein to be discovered to be γ-carboxylated by vitamin K. Afterwards 
factors VII, IX, and X as well as proteins C, S, and Z were discovered [8].
9. Vitamin K deficiency
There are not enough studies to determine a limit or threshold for concentration 
of vitamin K in serum that indicate deficiency or insufficiency [24].
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Vitamin K deficiency is rare among adults, and it is determined clinically by bleed-
ing because of low activation of coagulation proteins and is often estimated by measure-
ment of undercarboxylated prothrombin concentration in serum released from the liver. 
Its concentration increases with the degree of severity of vitamin K deficiency [26].
Vitamin K deficiency is usually limited to people with liver and pancreas disease, 
cystic fibrosis, digestive disorders, disorders of fat malabsorption, chronic malnu-
trition, and alcohol dependency or those taking drugs that interfere with vitamin 
K metabolism such as vitamin K antagonist anticoagulants, bile acid sequestrants, 
certain types of antibiotics, and anticonvulsants [27].
The more common condition is subclinical vitamin K deficiency that results 
in increased levels of undercarboxylated or even uncarboxylated Gla proteins in 
serum. This occurs when serum vitamin K concentration is ≤0.5 nM/L [28] or 
serum undercarboxylated osteocalcin is ≥4.0 ng/mL [26].
Gla proteins that are not fully carboxylated are not activated and do not execute 
their role in the bone, cartilage, and soft tissue mineralization. Low vitamin K 
intake and low serum vitamin K concentrations are associated with increased risk of 
osteoporosis, cancer, and aortic calcification as observed by several studies [27–29].
10. The role of vitamin K in the bone
10.1 Mechanisms dependent on the Ƴ-carboxylation via GGCX enzyme
Several vitamin K-dependent proteins have been verified. Some of them exist in 
the skeleton and cartilage such as osteocalcin, matrix Gla protein, Gla-rich protein, 
protein S, and gas 6 [30].
Osteocalcin is the first Gla protein discovered that originated from extrahepatic 
tissues. It is mainly produced by osteoblasts and has been suggested to affect bone 
metabolism by regulating osteoblast activity and bone mineralization [31].
Osteocalcin has three glutamic acid (Gla) residues which undergo gamma 
carboxylation by a process dependent on vitamin K; the Ƴ-carboxylation of osteo-
calcin is necessary for its function. Ƴ-carboxylated osteocalcin shows a high affinity 
to hydroxyapatite and bone matrix, contributing to bone formation. It has been 
shown that decarboxylated osteocalcin cannot bind calcium, thus emphasizing the 
importance role of vitamin K in the activation protein [32].
The percentage of overall osteocalcin that remained uncarboxylated (% ucOC) 
is a biomarker of vitamin K status (more carboxylation indicates a better status, less 
carboxylation indicates a worse status), and osteocalcin continually gets carboxyl-
ated up until a daily intake of around 1000mcg phylloquinone. Dietary recommen-
dations (120 μg/day for men, 90 μg/day for women) are based on saturation of the 
coagulation system. Requirements to maintain bone Gla protein function and bone 
formation might be higher [33, 34].
Some studies have demonstrated that elevated concentration of undercarboxyl-
ated osteocalcin in serum is a predictor of fractures [35, 36].
MGP is included in the organic matrix and mobilization of calcium in the 
skeleton. It is mainly synthesized in the bone, cartilage, dentine, and soft tissues, 
including blood vessels, and is also found in the brain, heart, kidney, liver, lung, 
and spleen [37, 38].
10.2 Mechanisms independent of the Ƴ-carboxylation via GGCX enzyme
Studies also reported that vitamin K prevents bone resorption through a mecha-
nism totally different from that of Ƴ-carboxylation. Vitamin K is shown to improve 
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bone mineralization and decrease bone resorption by osteoclasts [39]. Other 
vitamin K roles have also been reported such as it can promote fracture reparation 
by stimulating bone formation and decrease calcium excretion by urine [3]. These 
results confirm the significant role of vitamin K in bone metabolism.
Vitamin K also functions as a ligand of steroid and xenobiotic receptor (SXR) 
and its murine homolog, pregnane X receptor (PXR), which after heterodimeriza-
tion with the vitamin A receptor (RXR) induces the target genes including tsukushi 
(Tsk), matrilin-2 (Matn2), and CD14. Tsk encodes a protein that has a collagen-
accumulating effect, and Matn2 is a protein comprising an extracellular matrix like 
collagen, whereas CD14 regulates osteoblastogenesis and osteoclastogenesis.
Msx2 is another vitamin K-induced SXR-dependent gene identified, which 
induces osteoblast differentiation. Induction of these genes is not repressed by 
warfarin treatment, indicating a GGCX-dependent mechanism is not involved [30].
It has been reported that osteoporosis is linked with oxidative stress. Moreover, 
supplementation of vitamin K as an antioxidant vitamin could effectively reduce 
levels of oxidative stress, with possibly advantageous influence on bone, as dis-
played in several experimental models [27].
It is possible that higher levels of vitamin K suppress IL-6 secretion from inflam-
matory stressors, although the mechanisms underlying this are not currently known 
[11]. In addition, vitamin K also represses osteoclast activity, therefore averting the 
breakdown of bone [40].
11. Studies on vitamin K and the bone
Osteoporosis is a metabolic bone disease of reduced bone density, fragile bone, 
and elevated susceptibility to fracture [41]. Risk factors for osteoporosis contain 
genetic, nutrition, and hormone [3].
It is a common disease affecting 1 in 3 women and 1 in 12 men, resulting in 
substantial morbidity, excess mortality, and health and social services spending. It 
is therefore important to improve strategies for prevention and treatment osteopo-
rosis in both men and women [42].
Some studies showed that the administration of vitamin K led to an increase 
of bone mineral density (BMD) in osteoporotic patients (Vermeer et al. [43]). In 
addition, administration of vitamin K was found to prevent bone loss and reduce 
the incidence of fractures (Shiraki et al. [44]).
A survey investigating vitamin K intake data from the fifth Korea National 
Health and Nutrition Examination Survey reported that low dietary vitamin K 
intake was related to low bone mineral density in subjects who were included (2785 
men, 4307 women aged over 19 years). In addition, there was a reduction in risk 
for osteoporosis as vitamin K intake increased in women, but this effect was not 
continued after adjusting factors. This survey recommended increasing the dietary 
VK intakes for preserving BMD [45].
A study by Fujita et al. [46] observed that high intake of natto, fermented 
soybean high in phylloquinone, and MK-7 was associated with higher BMD, which 
was also demonstrated in a study by Ikeda et al. [47].
A cross-sectional study (3199 middle-aged Scottish females included) reported 
that females in the highest quartile of dietary intake of vitamin K1 (162 mcg/day) 
have a significantly higher lumbar spine (L2–L4) BMD and left femoral neck BMD 
against the lowest quartile (59 mcg/day) [48]. In vitro experiments by Hara et al. 
showed that vitamin K inhibits bone resorption induced by IL-la, PGE, PTH, and 
vitamin D3 in a dose-dependent manner [12].
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Several studies have shown the relation between vitamin K and bone min-
eral density; a study by Kanai et al. reported that postmenopausal women with 
decreased bone mineral density (mean BMD, 0.73 g/cm2) had significantly lower 
levels of vitamin K1 and MK-7 than women with normal bone density (mean BMD, 
0.99 g/cm2) [49].
In our study we found that serum vitamin K1 level was significantly lower in the 
postmenopausal osteoporotic women group than in the normal control group, the 
mean serum vitamin k1 level was significantly lower in the postmenopausal osteo-
porotic women group than in the normal control group (mean = 0.794 vs. 3.61 ng/
ml, P < 0.0001), and serum vitamin k1 concentration was positively correlated 
with lumbar spine BMD among postmenopausal osteoporotic women (R = 0.533, 
p = 0.009) and in postmenopausal healthy control (R = 0.563, p = 0.02). Diagnostic 
sensitivity and specificity of vitamin k1 for osteoporosis were 90 and 98%, respec-
tively (cutoff value: 0.853 ng/ml). The area under the ROC curve (AUC) value 
for vitamin k1 was 0.984; the odd ratio result was 18.66 [50]. The same result was 
reported also by Heiss et al. [51].
These findings may suggest a role of vitamin K in bone metabolism. And 
therefore it has been thought that it might be effective for treating osteoporosis. 
Furthermore, Booth et al. [52] found that low plasma vitamin K1 concentrations 
were associated with low spine BMD among postmenopausal women not using 
estrogen replacement. These findings suggest a protective role of vitamin K in the 
skeleton in women. In addition, poor vitamin K nutritional status (low plasma phyl-
loquinone concentrations and high serum %ucOC) was correlated with low BMD at 
the hip among men.
High incidence of vertebral fractures has reported to be contrarily correlated 
with BMD of lumbar spine and vitamin k1 concentration in the study on 379 
Japanese women of 30–88 years to 4 years [53].
Vitamin K was found to increase bone mineral density in an in vivo osteoporosis 
model. A study by Hodges et al. deduced that osteoporotic patients had decreased 
levels of vitamin K and increased levels of non Ƴ-carboxylated osteocalcin [54].
The relations between vitamin K intake and bone mineral density are not coher-
ent in observational studies [27].
Fang et al. showed that vitamin K supplements did not have influence on BMD 
at the femoral neck, but there was an increase in mean lumbar spine BMD by 1.3% 
(95% CI: 0.5–2.1) after supplementation for 6–36 months.
In this meta-analysis, seven studies utilized vitamin K1 with portions rang-
ing from 0.2 to 10 mg/day. Ten studies utilized vitamin K2 (eight used MK-4 
with portions of 15–45 mg/day, and two studies utilized MK-7 with portions of 
0.2–3.6 mg/day), and after studies with high risk of bias have been excluded, the 
writer deduced that supplementation with vitamin K did not have significant effect 
on lumbar spine BMD in their subgroup analysis; they found that supplementation 
with vitamin K2 increased mean lumber spine BMD by 1.8% (95% CI, 0.9–2.8). No 
such influence was realized for studies with vitamin K1 supplementation [19].
It has been reported that osteoporosis is related to oxidative stress. Moreover, 
supplementation of vitamin K, as an antioxidant vitamin, could effectively decrease 
levels of oxidative stress, with possibly beneficial effect on the bone, as displayed in 
several experimental models [55].
Vitamin K is necessary for bone health. In fact, low vitamin K intake, low 
vitamin K circulating levels, and high undercarboxylated osteocalcin levels are all 
related with excessive hip fractures risk in observational studies [15].
More studies are required regarding the influences of vitamin K on diagnosis 
and management of osteoporosis and similarly on BMD.
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supplementation of vitamin K, as an antioxidant vitamin, could effectively decrease 
levels of oxidative stress, with possibly beneficial effect on the bone, as displayed in 
several experimental models [55].
Vitamin K is necessary for bone health. In fact, low vitamin K intake, low 
vitamin K circulating levels, and high undercarboxylated osteocalcin levels are all 
related with excessive hip fractures risk in observational studies [15].
More studies are required regarding the influences of vitamin K on diagnosis 
and management of osteoporosis and similarly on BMD.
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12. Conclusion
Studies suggest that vitamin K has a role in bone metabolism and it may contrib-
ute in maintaining BMD and diagnosing osteoporosis. Studies have demonstrated 
that in the healthy population, all clotting factors are synthesized in their active 
form, whereas the synthesis of other Gla proteins is sub-optimal in non-supple-
mented subjects. Prolonged subclinical vitamin K deficiency is a risk factor for 
osteoporosis. Present recommendations for dietary intake are based on the daily 
dose required to prevent bleeding. Scientific data suggests that new, higher recom-
mendations for vitamin K intake should be formulated.
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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Metabolic Disorders in Patients 





In this study, we discuss the peculiarities of metabolic disorders that follow the 
development of chronic osteomyelitis. For the purposes of this study, we analyzed 
the available data as well as results of our own clinical and scientific research. 
Chronic osteomyelitis leads not only to the destruction of bone tissue by pathogen 
but also to the shift of equilibrium between osteogenesis and bone resorption in the 
locus of bone infections. Such shift leads to additional damage not only to the bone 
cells (primarily osteoblasts) but also to the bone matrix. The final complications 
include difficulties with bone consolidation and prolongation of therapy, even when 
the patient is treated using an external fixation method like Ilizarov or similar tech-
niques. Etiopathogenetic therapy, aimed at correction of metabolic disorders, allows 
to shorten the bone consolidation time (and respectively, the treatment time), 
preventing different pathogenetic processes that exacerbate and enhance each 
other’s effects. This study emphasizes the importance of etiopathogenetic therapy 
of metabolic disorders in patients with chronic osteomyelitis. Etiopathogenetic 
therapy should be combined with other necessary methods of the patient’s treat-
ment, such as surgical debridement of the infection locus and antibiotic therapy.
Keywords: chronic osteomyelitis, metabolic disorders, bone tissue
1. Introduction
The empirical experience of surgeons operating patients with orthopedic 
infection shows that the mechanical properties of the bone (including strength) 
differ from physiological ones. The bone in or near the infected area tends to be 
more fragile and soft. Proper mechanical strength of the bone tissue is one of the 
key factors for completing successful osteosynthesis as the mechanical strength of 
the bone directly influences the stability of fixators, treatment of bone tissues in the 
surgery process, and other technical but pivotal aspects of the treatment.
Despite some empirical data, the change of mechanical properties of the bone in 
orthopedic infection remained practically unresearched for a long time. The change 
of the mechanical properties of the bone in inflamed areas had been connected to 
tissue destruction or lysis caused by bacterial pathogen. In other words, this change 
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viewed similarly as the complications in soft tissues in the purulent surgery, widely 
known for a long period of time.
Consequently, this falsely simplified view of the problem has led to a shortage of 
publications. For example, the search query in the PubMed database based on Mesh 
terms “Osteomyelitis” and “Bone mineral density” (latest access time: December 
08, 2019, 0:01 UTC +3) has provided only 30 search results, the earliest of them 
is signed as published in February 1991. Most publications refer to dentistry and 
maxillofacial surgery but not to traumatology and/or orthopedics. Another search 
based on Mesh terms “Osteomyelitis” and “Metabolic disorders” (latest access time: 
December 08, 2019, 0:03 UTC +3) has provided 596 results, but most papers refer 
to other topics and problems: “combinations” of chronic osteomyelitis and diabetes 
mellitus [1, 2], chronic osteomyelitis and bisphosphonate-induced necrosis of 
the jaw [3, 4]; less papers refer to the problem of treating chronic osteomyelitis in 
patients with genetic, systemic, neuropathic, and oncological diseases [5–8]. In sev-
eral papers, the accent is put on the clinical aspects of bone infection with particular 
pathogens only [9–11]. Some papers can be considered of a relatively good quality 
but the accent is put on clinical results themselves and not on the pathogenesis of 
metabolic bone tissue disorders in the presence of bone infection [12, 13].
Numerous clinical guidelines and publications on osteoporosis and related 
disorders have much to offer about the pathophysiology of these diseases, but have 
a rather serious common disadvantage: they do not describe or poorly describe the 
interaction of pathogen and bone tissue, although the infectious and purely osteo-
porotic metabolic processes have similar mechanisms.
Lack of understanding of the metabolic bone tissue disorders as a result of its 
interaction with bacterial pathogen during orthopedic infection practically elimi-
nated the possibility of providing adequate etiological treatment; in most cases, the 
treatment methods were limited to surgical treatment (necrectomy, debridement, 
external fixation, and related methods) and antibiotic therapy. Despite being 
approved and reliable, these methods themselves are not enough to treat chronic 
osteomyelitis. The correction of the impaired bone tissue metabolism is also needed. 
For this purpose, a clinician should be familiar with the aspects of biochemistry, 
physiology, and pathophysiology of the bone affected by orthopedic infections.
At this moment, several fundamental papers in the domain of bone tissue and 
pathogen interaction are available [14, 15], which can be evaluated as a positive 
trend. These works can be useful to systematize the knowledge cumulated by the 
scientific community.
Within this chapter, we made an attempt to synergize the knowledge in 
pathophysiology of the disorders described, as well as illustrate the importance of 
correction of impaired bone tissue metabolism using the results of our own work 
published in 2019 [16].
2.  Pathogenesis of metabolic bone tissue disorders at the site of 
orthopedic infection
Current views on chronic osteomyelitis allow its understanding not simply as a 
“bone-lytic” or “infectious” process, but also as a condition associated with bone 
metabolism alteration. Understanding the nature of these alterations is one of 
the key points in treating chronic osteomyelitis. Without this understanding, the 
process of treatment may not succeed or may be less successful even if supported by 
superb surgery and antibiotic therapy (Figure 1).
As an attempt to describe the links between changes in bone tissue metabolism dur-
ing orthopedic infection, we created a scheme displayed above. From our point of view, 
deep understanding of the pathogenesis is of paramount importance for a clinician.
139
Metabolic Disorders in Patients with Chronic Osteomyelitis: Etiology and Pathogenesis
DOI: http://dx.doi.org/10.5772/intechopen.92052
The overall scheme can be divided into three major parts, which represent main 
pathogenetic pathways enforcing and exacerbating each other while developing at 
the same time:
1. Osteoblast cell death and proliferation lowering.
2. Bone remodeling shift to the resorption prevalence.
3. Matrix destruction.
These parts will be discussed separately to make them easier for understanding, 
even though the pathogenic processes described would influence each other in a 
“crossing-over” manner. De facto, it is hardly possible to separate them because all 
of the components take part in general bone metabolism and remodeling process.
The color of the blocks is associated with their aim:
• Blue blocks represent the stages of pathophysiological processes.
• Red blocks represent the “final” changes in the levels of the markers (e.g., beta-
cross-laps (C-terminal telopeptide) increase). These changes can be detected 
using laboratory methods and are used by a clinician during the diagnostics.
• Yellow blocks represent the background factors (markers and their levels) that 
also can be measured with methods of laboratory diagnostics.
Figure 1. 
Pathogenesis of metabolic disorders of the bone tissue, influence of the background factors and laboratory 
diagnostic markers (figure credits: Gorbatyuk D.S., Tsiskarashvili A.V., Rodionova S.S.).
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3. Osteoblast cell death and proliferation lowering
One of the most obvious effects of bacterial pathogen on a bone tissue is the 
destruction of osteoblasts.
Destruction of osteoblasts includes necrotic and apoptotic pathways. Papers 
contributing to the study of S. aureus’ influence on the osteoblast culture show that 
these two pathways work independently. Apoptosis is triggered by ligand TRAIL 
Figure 2. 
Pathogenetic stages and processes associated particularly with osteoblast cell death and proliferation lowering. 
The link between bone matrix destruction processes and associated decrease in osteoblast proliferation rate (will 
be shown and illustrated in the corresponding part of the chapter).
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linking with “death receptors” DR4 and DR5, and necrosis is triggered by S. aureus 
toxins PSMα и PSMβ that destroy the osteoblast cell membrane [15, 17, 18].
Lowering of the osteoblast number leads to slowing of ossification and mineral-
ization of the bone. The level of bone resorption can remain stable or be increased 
at the same time (see “Bone remodeling shift”).
As a result, the production of bone alkaline phosphatase lowers [15]. We must 
say that alkaline phosphatase itself is not very convenient as a marker: it is produced 
by different cell types in four different forms. In this case, we have an interest in 
bone alkaline phosphatase that is coded with ALPL gene [19]. For precise diag-
nostics, a laboratory should have a specially trained personnel and corresponding 
equipment. A clinician should note that children and adolescents have normally 
elevated levels of bone alkaline phosphatase in comparison to adults, and the 
association between age and serum level of BAP is inverse [20] (Figure 2).
Deficit of D hormone is a background factor that lowers ossification and is 
therefore marked as yellow block [21–23]. It is well known that low level of hormone 
D leads to increase in PTH level and lowering of bone mineral density [24]. Presence 
of generalized osteoporosis can additionally intensify this negative trend [25].
4. Bone remodeling (bone turnover) shift
Orthopedic infection and excessive production of pro-inflammatory cytokines 
[15] influence the bone remodeling balance. Such hyperproduction can be triggered 
by infection itself and can increase when the pathogen persists inside the osteo-
blasts. Furthermore, some pathogens can additionally increase the inflammatory 
response because of paracrine action of their factors, interfering with the cytokine 
balance [26]. As it will be shown later, the inflammatory response tends to turn into 
a hyperergic response because of excessive activation of the cell immunity, which is 
an important factor for chronization of the process.
One of the most well-studied bacterial pathogens that is convenient for illustration 
is S. aureus. Many authors [14, 15, 27] show that S. aureus influences both parts of the 
bone turnover-bone resorption and ossification. During infection, S. aureus not only 
destroys (damages) osteoblasts through necrosis and apoptosis, but also lowers their 
proliferation rate. Influence on bone resorption is based on rapid maturation and 
additional activation of the osteoclasts by this pathogen. This mechanism is based 
on excessive synthesis of prostaglandin Е2 (PGE2) by osteoblasts and persisting of 
S. aureus inside the osteoblasts, as well as auto and paracrine regulatory mechanisms 
in which PGE2 plays its biochemical role. The synthesis of osteoprotegerin (OPG) 
is also impaired because of lowering of the level of corresponding mRNA; [28] as a 
result, more RANK-ligand (RANKL) molecules remain unbound and act as osteoclast 
activators. Excessive activation of the osteoclasts and lowering of the number and 
proliferation rate of the osteoblasts lead to obvious shift of the bone turnover to bone 
resorption. As a result, the loss of bone tissue and impairment of its mineralization 
at the site of orthopedic infection (bone infection) can lead to difficulties in bone 
consolidation in patients with bone defects and/or fractures (Figure 3).
“Red blocks” of this part include the OPG and RANK-ligand (RANKL) level 
changes.
“Yellow blocks” include the pre-existing low level of the osteoprotegerin. An 
example is a case of chronic osteomyelitis development in a patient with pre-
existing low-speed bone turnover and associated osteoporosis with OPG synthesis 
impairment.
These markers are rarely used in routine clinical practice but can be of a certain 
value when an appropriate laboratory is available.
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OPG is a soluble glycoprotein synthesized by different cell types, including 
osteoblasts [29]. This compound can be found in monomeric (50 kDa) or dimeric 
(120 kDa) form (the dimeric form contains disulfide bonds between monomers). 
Dimeric form has a higher affinity to RANKL than a monomeric one, and the 
chemical analogues of OPG should have the features of dimeric form.
RANKL (RANK-ligand) is a compound synthesized by several cell types. It can 
be expressed in three different molecular forms: transmembrane trimer, primary 
(secreted) form, and cell ectodomain [30]. RANKL serves as a ligand for RANK 
receptor that activates osteoclasts. RANKL is a target for osteoprotegerin; if OPG 
is secreted in low amounts, more RANKL remains unbound and the intensity of 
resorption increases.
Therefore, a “pathogenetic chain” is as follows: infection-osteoblast cell death 
and proliferation rate decrease-OPG synthesis decrease-RANKL inhibition 
decrease-osteoclastogenesis activation-bone resorption increase-shift of bone 
remodeling toward a resorption prevalence-decrease in bone tissue quality and 
quantity in the infection site. The resulting clinical effect is slowing of the consoli-
dation of the bone tissue defects, pseudarthroses, and related conditions.
5. Matrix destruction
The matrix destruction in infection can be explained by several factors. The 
“starting point” in pathogenesis is the infection itself. S. aureus is, as shown by 
Figure 3. 
Pathogenetic stages and processes associated particularly with bone turnover shift.
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several authors [14, 31, 32], capable of persisting in osteoblasts and that leads 
to additional stimulation of inflammatory process that stepwise turns into local 
hyperergic reaction. It is important to take into account that pathogens also play a 
role in matrix destruction—particularly S. aureus can adhere to matrix elements and 
destroy them [33].
The hyperergic reaction leads to excessive synthesis of matrix metalloproteases 
(MMPs). Among them, MMP-2 (gelatinase A) and MMP-9 (gelatinase B) [34] play 
the main role. Excessive synthesis of MMP is a key point in the process because it 
has two major effects:
• Osteoblast cell death and lowering of the proliferation rate; this effect weakens 
the regenerative potential of bone tissue.
• MMPs damage the matrix by themselves, being synthesized in excessive 
amounts [34, 35].
Figure 4. 
Pathogenetic stages and processes associated particularly with bone matrix destruction.
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The matrix destruction leads to increase in following resorption markers: 
B-cross-laps (С-terminal telopeptide) and desoxypyridinoline/creatinine ratio.
• B-cross-laps: This marker is a product of collagen destruction that is a basis of 
bone tissue matrix. B-cross-laps have two octapeptide fragments in structure, 
which are linked with a transverse molecular bond. Its level can be evaluated 
using the immunoassay method [36].
• Increase in the desoxypyridinoline/creatinine ratio: Desoxypyridinoline is a 
molecular basis for transverse bonds between collagen I type molecules in bone 
tissue matrix. Its level increases while the matrix is destroyed. It is important to 
note that this factor can be increased as a result of not only osteoclast activa-
tion, but also of a MMP action.
A clinician should note that the destruction of the matrix is combined with low-
ering of its synthesis by osteoblasts. Therefore, both processes act in a synergic way 
and occur at the same time, which negatively influences the treatment (Figure 4).
6. Background factors
The main background factors that can exacerbate bone tissue metabolism 
impairment at the site of bone infection are: generalized osteoporosis, D-deficit, 
D-insufficiency, and secondary hyperparathyreosis. These factors exacerbate also 
the condition of patients with bone infection, lowering the regenerative potential of 
bone tissue. On the scheme, these factors are marked as yellow blocks.
• The lack of D hormone leads to lowered absorption of calcium in the intestine, 
lowered mineralization of the bone, and consequent decrease of the osteoblast 
function [21–23].
• Secondary hyperparathyreosis: This condition is a result of D-deficit or 
D-insufficiency and is actually a compensative reaction. It has rather complex 
pathogenetic action mechanism [37]. It is shown that during short-term 
increase in PTH level, its influence on bone tissue is anabolic, while during a 
long-term constant increase, its effect becomes catabolic with bone loss as a 
result, for example, at the condition of chronic hormone D-deficit or hormone 
D-insufficiency [37].
Thus, because of the excessive PTH action on bone tissue, two major effects, 
that can be “found out” using markers, occur [38–40]:
• “Mobilization” of calcium and phosphates from the bones.
• Increase in calcium and phosphate levels in the urine because of relatively high 
secreted amounts.
As a result, calcium and phosphates are being literally “washed out” of the 
bone in amounts more than physiological. After that, they are secreted out of 
the organism through urine. A bright example is an increase in vertebral bodies 
fractures risk in patients with primary hyperparathyreosis. Even simple densi-
tometry can help to diagnose the lowered bone density and trabecular thinning. 
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Removal of calcium and phosphates exceeds not only the physiological values or 
amounts, but also the compensative intake with the food leading to progressive 
lowering of bone tissue quality in general and its mineralization in particular. 
To cope successfully with these changes, the secondary parathyreosis should be 
treated and compensative therapy, including calcium, phosphates, and hormone 
D medication, introduced.
7. Summary of scheme review
In this part of the chapter, the etiopathogenetic mechanisms of bone tissue 
metabolism impairment are discussed, as well as reasons for change of laboratory-
measured bone metabolism markers and their levels.
The mentioned markers have a direct link with metabolic impairments of a 
certain type. Such impairments can be found in different diseases, especially in 
patients with chronic osteomyelitis and other forms of bone infection.
The therapy of metabolic bone tissue impairments due to bone (orthopedic) 
infection should combine etiopathogenetic and compensating approaches. For 
example, bisphosphonates can be recommended for use in addition to antibiotic 
therapy and surgery, as well as calcium, D hormone, and other drugs because of the 
bisphosphonates’ ability to decrease the osteoclasts’ activity.
8. Our experience
Nowadays, the published data on epidemiology of metabolic diseases in 
healthy volunteers and orthopedic patients without bone infection (except 
patients with osteoporosis and related diseases) are scarce. Therefore, these data 
cannot serve as statistical material for comparison with data in patients with 
bone infection.
Accordingly, our work is limited to patients with bone infection (chronic osteo-
myelitis and related diseases) already diagnosed. The dynamics of the parameters 
was studied with addition of metabolic disorders therapy and without it.
In 2019, we published a retrospective study; the aim was to evaluate dynamics 
and values of markers and parameters of bone metabolism [16], which included 
112 patients with infected pseudarthroses of long bones (humerus, femur, tibia) 
developing as an exacerbation of chronic osteomyelitis. The study had three main 
purposes:
• Gaining the whole “picture” of metabolic bone tissue disorders in these 
patients.
• Studying the dynamics of corresponding marker level and parameters.
• Comparing the duration of consolidation of pseudarthroses after surgical 
treatment, antibiotic treatment, and using external fixation apparatus (with 
and without bone metabolism correction therapy).
We formed two groups of 56 patients each using anatomical segment-stratified 
randomization. The main group received not only surgery and antibiotic therapy 
but also medication for correction of impaired bone metabolism. The control group 
received the same therapy except correction of bone metabolism.
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The dynamics of parameters was evaluated only in the main study group. Data 
from the control group patients were used to evaluate the duration of bone consoli-
dation and comparing them between groups.
To form a “picture” of a bone tissue metabolism, we evaluated the following 
parameters:
• Homeostasis of Ca and P-values: blood Ca, ionized Ca, blood P, PTH, trans-
portation form of D hormone (25(OH)D3).
• Ossification markers: bone alkaline phosphatase, osteocalcin.
• Resorption markers: beta-cross-laps (C-terminal telopeptide).
• Ca and P (daily amount secreted with urine); deoxypyridinoline/creatinine 
ratio.
For therapy, we used calcium medicaments (Ca carbonate, ossein-hydroxyap-
atite complex) and active metabolite of D hormone (alfacalcidol). Dosage was set 
individually for each patient according to a patented way [41] on the basis of the 
following key parameters:
• Sex and age.
• Densitometry results.
• Values of the parameters listed above.
As an anti-resorptive drug, the ibandronate acid was administered (with the 
dosage of 3 mg (3 ml) one time in 3 months).
The described therapy was empirically proved to be effective not only against 
osteoporosis in patients that underwent arthroplasty but also in cases of osteoporo-
sis connected with low intensity of ossification; that was the key reason why it was 
selected for treatment.
The numerical data of patients are described using descriptive statistics. To 
compare the changes in metabolic values after 3 months and before treatment, 
we used the Wilcoxon test. To compare the consolidation duration in main and 
control groups, we used Mann-Whitney U-test. The threshold p-value in all cases 
was set as p < 0.05. The software used was IBM SPSS Statistics 22. All values, 
including theoretically possible outliers, were considered in the statistics (Table 1 
and Figure 5).
Routine screening of the whole population described above exceeds the ranks of 
this study.
We found statistically significant changes after 3 months in osteocalcin level 
(decrease), PTH (decrease), and desoxypyridinoline/creatinine ratio (decrease) 
(respectively: p = 0.043, p = 0.043, p = 0.041). Changes in daily amounts of 
calcium and phosphate secreted with urine, as well as beta-cross-laps were not 
statistically significant but, in our opinion, the follow-up tie of 3 months can be 
insufficient. We suppose that the following mechanisms can take part in forming 
this “picture”:
• Lowering of the resorption because of ibandronic acid use leads to decrease in 
desoxypyridinoline/creatinine ratio.
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• Decrease in osteocalcin level can be explained by lowering of the earlier increased 
(in a compensative way) osteoblast activity that at least partially normalized.
• Decrease of PTH level can be explained by administration of D hormone 
and elimination of D deficit, which also led to decrease in blood calcium. In 
other words, the immediate mechanism of secondary hyperparathyreosis was 
eliminated.
Metabolic marker Value1, 
median ± SD





Са—0 months4 2.4 ± 0.1 2.1–2.71 mmol/l 0.172 0.05 A
Са—3 months5 2.5 ± 0.6 2.38–2.63
Р—0 months 1.2 ± 0.2 0.7–1.6 mmol/l 0.180 B
Р—3 months 1.2 ± 0.147 1.0–1.39











B-cross-laps—0 months 0.7 ± 0.3 0.1–1.1 ng/ml 0.18 E
B-cross-laps—3 months 0.7 ± 0.3 0.2–1.0
Osteocalcin—0 months 22.6 ± 11.1 2.0–46.0 ng/ml 0.043 F
Osteocalcin—3 months 24.9 ± 11.5 11.5–39.0
PTH—0 months 12.5 ± 15.5 1.8–60.0 mol/l 0.043 G
PTH—3 months 2.6 ± 1.0 1.0–4.2





Р (urine, day 
amount)—3 months
9.9 ± 5.3 3.5–17.1










Са (urine, day 
amount)—0 months
3.7 ± 1.5 1.00–6.34 mmol/day 0.180 K
Са (urine, day 
amount)—3 months
2.5 ± 0.8 1.4–3.6
Data represent the study group (56 patients). Control group is quantitatively equal (56 patients).
1Rounded to first decimal place.
2Wilcoxon signed-rank test. Values are rounded to the third decimal place.
3Letters represent the particular plots at Figure 5A-K for the information to be easily to followed.
40 months—value before operative treatment.
53 months—value at 3 months after the operative treatment.
Statistically significant values (p < 0.05) are labeled as bold.
Table 1. 
Comparative data of patients before and after 3-month therapy of metabolic bone disorders.
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Figure 5. 
(A-K) “Box and whiskers” plots illustrating the data provided in Table 1. Blue box and whiskers (left at 
all figures) represent data of patients before therapy. Orange boxes and whiskers represent data of the same 
patients after 3 months of therapy. A: blood calcium. B: phosphate of the blood. C: ionized calcium, D: bone 
alkaline phosphatase levels, E: beta-cross-laps (C-terminal telopeptide), F: osteocalcin, G: PTH. H: phosphate 
(urine, day amount), I: 25 (OH) D3, J: deoxypyridinoline/creatinine, K: calcium (urine, daily amount). Units: 
see Table 1.
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• Decrease of Ca and phosphates in blood and their daily amounts secreted 
with urine is not statistically significant at 3-month follow-up (р = 0.172 for 
Ca, р = 0.18 for phosphates, р = 0.18 for both daily secreted amounts of Ca 
and phosphates in urine), but we can potentially explain these changes as 
an effect—even statistically insignificant—of PTH level decrease (partial 
normalization).
The rationale of metabolic bone tissue impairment correction is proved by clini-
cal results (decrease of fracture consolidation type in the main group that received 
corresponding therapy). In each group (56 patients), the “anatomical distribution” 




The software used was SPSS Statistics 22. All values, including theoreti-
cally possible outliers, were considered in the statistics. Statistically significant 
changes between groups were found in all studied segments (Table 2 and 
Figure 6).
As shown, the additional therapy of metabolic disorders of bone tissue has a 
statistically significant effect on shortening the duration of bone consolidation in 
patients treated by external fixation apparatus.
In our opinion, the next step should be a comparative analysis of bone metabo-
lism aspects in orthopedic patients with and without bone infection and a study of 










































Both groups received “standard” surgery and antibiotic therapy.
1Rounded to first decimal place.
2Mann-Whitney U-test. Values are rounded to the third decimal place.
3Letters represent particular plots in Figure 6A–C.
Table 2. 
Comparison of consolidation time in patients with (main group) or without (control group) bone tissue 
metabolism correction therapy.
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9. Conclusion
In this chapter, we attempted to describe the basic pathophysiology of meta-
bolic processes at the site of orthopedic infection. Knowledge of peculiarities of 
such processes is important for an orthopedic surgeon because the general success 
of treatment relies not only on surgery and antibiotic therapy but also etiologic 
therapy of bone metabolism impairment. This thesis is supported not only by 
pathophysiological rationale but also by the results of our study.
Metabolic disorders of bone tissue associated with orthopedic infection are 
complex and yet poorly understood. Research of this topic will improve not only the 
existing treatment strategy but also the philosophy of it and will greatly contribute 
to development of traumatology and orthopedics.
Figure 6. 
(a-c) “Box-and-whiskers” plots illustrating the duration (in days) of bone consolidation in patients that 
underwent treatment of the fractures of different segments exacerbated by orthopedic infection using the 
external fixation apparatus. Left (a): humerus; in the middle (b): femur; right (c): tibia. Blue box and 
whiskers (at the left at all figures) represent data for the main study group that received surgery, antibiotic 
and etiologic metabolism impairment therapy; red box and whiskers (at the right at all figures) represent the 
control group that received surgery and antibiotic therapy, but no treatment of bone metabolism impairment.
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Abstract
The study of immune responses of peripheral blood in bone regeneration for
bone formation predicting complications is relevant. Studies were carried out on
patients with the facial skeleton injury before and after stable osteosynthesis of the
mandible in a fixing device for external fixation. Of the 136 patients, 17 people’s
bone tissue regeneration has been slow. Laboratory tests were carried out before
and after the operation. The studies included the study of cellular immunity,
humoral immunity, phagocytosis, acute phase proteins and cytokine status. The
obtained data were processed using variation statistics methods and the modified
theorem of T. Bayes. The study revealed that alternating stages of regeneration of
bone tissue (inflammation, proliferation of osteoblasts, collagenogenesis and ossifi-
cation) are accompanied by changes in the immunological status. A comparative
study of the dynamics of immunological parameters at normal and slow osteogene-
sis had made it possible to establish criteria for delayed consolidation of bone tissue.
Prognostic criteria before the operations include increasing the concentration of
IgM and decreasing the concentration of C-reactive protein, in the early postopera-
tive period-increasing the number of leukocytes, the concentration of tumor necro-
sis factor, IgM, as well as reducing the number of CD45+CD3+-cells, the
complement activity and the amount of lactoferrin.
Keywords: monitoring of osteogenesis, prognostic criteria, nitro blue tetrazolium
test, tumor necrosis factor, IgM, C-reactive protein
1. Introduction
Regulation of bone formation when damaged is regulated by a complex set of
factors, including mechanical conditions for the formation of high-grade regenera-
tion, vascular reactions, the influence of the neuroendocrine system, effects of
metabolites and growth factors [1]. A reflection of the processes becomes dynamic
of blood parameters, among which the most important are the changes in the
immune status.
It is known that the immune system and bone tissue have broad functional and
structural connections. The heterogeneity of cell population included in the
immune system and the variety of regulators produced determine its ambiguous
participation in the regulation of bone tissue regeneration.
Both macrophages and osteoclasts develop from the same progenitor cell of the
monocytic line [2]. Both of these cells have the ability to destroy tissues, which leads
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1. Introduction
Regulation of bone formation when damaged is regulated by a complex set of
factors, including mechanical conditions for the formation of high-grade regenera-
tion, vascular reactions, the influence of the neuroendocrine system, effects of
metabolites and growth factors [1]. A reflection of the processes becomes dynamic
of blood parameters, among which the most important are the changes in the
immune status.
It is known that the immune system and bone tissue have broad functional and
structural connections. The heterogeneity of cell population included in the
immune system and the variety of regulators produced determine its ambiguous
participation in the regulation of bone tissue regeneration.
Both macrophages and osteoclasts develop from the same progenitor cell of the
monocytic line [2]. Both of these cells have the ability to destroy tissues, which leads
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to the activation of repair processes carried out by cells of mesenchymal origin,
fibroblasts or osteoblasts. From stromal cells expressing the most important regula-
tors of osteoclastogenesis and being a natural microenvironment for normal hema-
topoiesis, osteoblasts develop [3].
Quantitative and qualitative changes in immunocompetent cells are due to
lymphocyte-macrophage regulation of osteogenesis and are reflected regeneration
of the bone-favorable or delayed.
An important role in the regulation of bone tissue regeneration belongs to
immune cells-lymphocytes. In an animal experiment, it was shown that thymec-
tomy leads to a significant delay in osteogenesis after a bone fracture [4]. Different
lymphocyte populations influence the regulation of bone tissue regeneration
ambiguously: when analyzing the cellular composition of the regeneration zone in
difficultly fused fractures, a significant decrease in the number of T cells, the
absence of mast cells and the predominance of fibroblasts and mononuclear cells
was revealed [5]. There are reports that with severe mechanical polytrauma, deep
disturbances of the cellular immunity are observed in the form of inhibition of the
expression of CD2DR+ receptors and a decrease in the absolute number of cells
with CD4+ and CD8+ phenotypes [6]. It was also shown that the activity of NK cells
is significantly reduced among the patients in the fracture zone, as well as in
peripheral blood [7]. A number of authors have found that in animals with a
deficiency of mature T lymphocytes, physiological metabolism in bone tissue is not
disturbed [8]. However, under conditions when there was a need to increase bone
metabolism (in trauma and after surgery), deficiency of T-lymphocyte function led
to the formation of demineralized bone matrix and loss of density of existing bone
tissue [9]. Clinical studies had also confirmed the role of T lymphocytes in the
regulation of bone density. It was revealed that both CD4+ and CD8+ cells can
produce factors that affect osteoclastogenesis [10]. There are a number of studies
that show the inhibitory role of T lymphocytes in relation to the formation of
osteoclasts and resorptive changes in the bone [11]. It is indicated that activated T
lymphocytes can reduce osteoclastogenesis by producing INF-γ. In vitro, the
removal of CD8+ T lymphocytes from a cell culture containing both osteoclast pre-
cursors and bone marrow cells significantly increases the formation of mature
osteoclasts [12]. Some in vivo data indicate the involvement of the prostaglandin
mechanism in this process [13]. In various pathological conditions, the nature of the
influence of T lymphocytes on osteoclastogenesis is determined by both a set of
locally secreted cytokines and the degree of differentiation of T lymphocytes [14].
Bone resorption caused by some cytokines secreted by T lymphocytes is often
accompanied by further increased bone tissue formation, which leads to an increase
in bone metabolism [15]. The direct molecular mechanisms of influence, as well as
the conditions that determine the stimulating or inhibitory role of T lymphocytes in
the regulation of bone tissue regeneration, are under study.
B lymphocytes are also involved in the regulation of bone tissue regeneration. In
the bone marrow, the earliest precursors of B lymphocytes are in close contact with
the endosteal surface of the bone, and the most mature cells of this series are located
in the center of the bone marrow. Such a spatial organization of B lymphopoiesis in
the bone marrow suggests that the cells of the osteoblastic germ located in the
endosteum, as well as stromal cells located in the connective tissue stroma of the
bone marrow, produce factors that influence the early precursors of B lymphocytes.
It has been suggested that molecules like vascular cell adhesion molecules
(VCAMs), expressed on the surface of stromal cells, mediate the binding of lym-
phocyte precursors, predominantly B lymphocytes, since the latter form an essen-
tial part of the entire lymphoid component of the bone marrow. It was also revealed
that this molecule plays an important role in the phenomenon of homing of
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lymphocytes into the bone marrow [16]. These cells and bone tissue molecules,
as it turned out, ultimately realize their effect on B lymphocytes through the
transcription factor Pax5 (B-cell specific activator). In the absence of this factor,
maturation of B lymphocytes does not occur. In this case, immature pre-B cells
can differentiate into other cells of bone marrow origin, for example, into
macrophages, osteoclasts and other cells [17]. The lack of mature lymphocytes
in bone tissue is reliably associated with an increased volume of trabecular bone
tissue [18]. It is interesting to note that under physiological conditions [19], as well
as under the conditions of ontogenesis [20], the lack of mature B lymphocytes
practically does not affect the cellular balance and metabolism in bone tissue.
However, under pathological conditions or external stimuli, the absence of
mature B lymphocytes does not allow bone tissue to adequately respond to changing
conditions [21].
An important role in the regulation of bone tissue regeneration belongs to
neutrophils. The impact of a damaging factor on the tissues leads to the develop-
ment of acute inflammation, the main effectors of which are these cells. The out-
come of the process largely depends on the reactivity of neutrophils [22].
Neutrophils, while not playing a key role in the repair phase, at the same time have
an effect on collagenosis and remodeling of the extracellular matrix of bone tissue.
They produce factors that activate fibroblasts and metalloproteinases (collagenases,
gelatinases and stromalysin), which can catabolize all the main products of extra-
cellular matrix and play an important role in remodeling of bone matrix [23]. When
studying the state of non-specific protection among the victims of severe mechan-
ical polytrauma, it was found that regardless of the nature of the traumatic agent,
the degree and severity of the damage, in almost all cases, certain changes in the
immune system were observed. For example, in the first week after an injury, the
polymorphonuclear neutrophil system was functionally inferior [6]. Currently,
researchers are inclined to believe that the complex interactions between individual
cells of the immune system during the entire post-traumatic period have not been
sufficiently studied. However, it is widely known that bone damage, like any other
traumatic effect, leads to an increase in the migratory ability of polymorphonuclear
neutrophils [24]. At the same time, the mechanism, according to which a sharp
decrease in this migratory ability is noted several times throughout the post-
traumatic period, remains unclear [25]. A study of the role of polymorphonuclear
leukocytes by other scientists showed that a decrease in the number of cells led to a
significant decrease in the mechanical strength of the regeneration. This, according
to the authors, was associated with the outflow of neutrophils into the focus of
inflammation (hematoma revascularization), which was accompanied by the
release of a large number of inflammatory mediators (serotonin, bradykinins and
histamine). This process violated the revascularization of the forming bone callus
and led to a decrease in its mechanical strength [26].
When bone tissue is damaged, reactive changes are noted not only in the cellular
but also in the humoral component of the immune system. It was found that
activated lymphocytes responded with a significant reduction in proliferation when
interacting with the main component of the extracellular matrix-collagen both
in vitro and in vivo [27]. It is also interesting to note that bone tissue injury leads to
the production of autoantibodies to oxidized low-density lipoproteins, and the
concentration of these autoantibodies is quite strongly related to the intensity of
post-traumatic osteogenesis [28]. In the framework of the study of immunoregula-
tion of osteogenesis, a violation of the synthesis of immunoglobulins by lympho-
cytes with damage to bone tissue was established [29]. Some authors also obtained
data on a decrease in the synthesis of immunoglobulins class G in severe mechanical
polytrauma [6].
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lymphocytes into the bone marrow [16]. These cells and bone tissue molecules,
as it turned out, ultimately realize their effect on B lymphocytes through the
transcription factor Pax5 (B-cell specific activator). In the absence of this factor,
maturation of B lymphocytes does not occur. In this case, immature pre-B cells
can differentiate into other cells of bone marrow origin, for example, into
macrophages, osteoclasts and other cells [17]. The lack of mature lymphocytes
in bone tissue is reliably associated with an increased volume of trabecular bone
tissue [18]. It is interesting to note that under physiological conditions [19], as well
as under the conditions of ontogenesis [20], the lack of mature B lymphocytes
practically does not affect the cellular balance and metabolism in bone tissue.
However, under pathological conditions or external stimuli, the absence of
mature B lymphocytes does not allow bone tissue to adequately respond to changing
conditions [21].
An important role in the regulation of bone tissue regeneration belongs to
neutrophils. The impact of a damaging factor on the tissues leads to the develop-
ment of acute inflammation, the main effectors of which are these cells. The out-
come of the process largely depends on the reactivity of neutrophils [22].
Neutrophils, while not playing a key role in the repair phase, at the same time have
an effect on collagenosis and remodeling of the extracellular matrix of bone tissue.
They produce factors that activate fibroblasts and metalloproteinases (collagenases,
gelatinases and stromalysin), which can catabolize all the main products of extra-
cellular matrix and play an important role in remodeling of bone matrix [23]. When
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polymorphonuclear neutrophil system was functionally inferior [6]. Currently,
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traumatic period, remains unclear [25]. A study of the role of polymorphonuclear
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inflammation (hematoma revascularization), which was accompanied by the
release of a large number of inflammatory mediators (serotonin, bradykinins and
histamine). This process violated the revascularization of the forming bone callus
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When bone tissue is damaged, reactive changes are noted not only in the cellular
but also in the humoral component of the immune system. It was found that
activated lymphocytes responded with a significant reduction in proliferation when
interacting with the main component of the extracellular matrix-collagen both
in vitro and in vivo [27]. It is also interesting to note that bone tissue injury leads to
the production of autoantibodies to oxidized low-density lipoproteins, and the
concentration of these autoantibodies is quite strongly related to the intensity of
post-traumatic osteogenesis [28]. In the framework of the study of immunoregula-
tion of osteogenesis, a violation of the synthesis of immunoglobulins by lympho-
cytes with damage to bone tissue was established [29]. Some authors also obtained
data on a decrease in the synthesis of immunoglobulins class G in severe mechanical
polytrauma [6].
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Lactoferrin is an important regulator of osteocyte activity that increases bone
formation in vivo [30]. Usually, lactoferrin is secreted under the influence of stim-
uli caused by inflammation, as it is contained in neutrophil secretory granules [31].
Lactoferrin affects the synthesis of chemokines, plays an important immunomodu-
latory function to reduce the high concentration of osteolytic cytokines such as
TNF-α and IL-1α [32] and stabilizes binding complexes [33]; therefore, its direct
effects on the activity and development of osteocytes are apparently supplemented
by these intermediary effects [30]. Reliable data have now been obtained, and it
shows that lactoferrin stimulates osteoblastic growth and acts as a powerful factor
in the survival of osteoblasts, preventing cell apoptosis. In addition, lactoferrin
enhances the function of differentiated osteoblasts [34]. The effect of lactoferrin on
the development of osteoclasts was evaluated in mouse’s bone marrow cultures; as a
result, it was found to exceed the response to such strong growth factors as insulin,
amylin, IL-18, adrenomedullin, C-terminal telopeptides and calcitonin [35]. After
local injection of lactoferrin, active bone growth was established, as well as the
fact that it is a powerful factor in osteoblast growth, which can reduce bone
resorption [30]. Lactoferrin acts on preosteoclasts and a large number of mature
cells of this origin; however, it has no effect on bone resorption by isolated mature
osteoclasts [30]. There is also a report on the effects of lactoferrin leading to bone
resorption, which demonstrates that lactoferrin reduces bone function: a mixed
rabbit bone cell culture is resorbed in a manner independent of RANK (receptor
activator of NF-kB)/RANKL (receptor activator of NF-kB ligand)/OPG
(osteoprotegerin) system [36]. Obviously, the identification of the mechanisms by
which lactoferrin acts on bone cells is important due to the revealed possibilities of the
demonstrated effects, and therefore this direction is being actively studied. The puta-
tive lactoferrin receptor is known to have been identified [37]. There is evidence that
lactoferrin acts through a receptor-bound protein related to the low-density lipopro-
tein family (LRP) [38]. Identification of the LRP1 receptor as a functional lactoferrin
receptor in osteoblasts explains the interaction mechanism and makes it possible to
regulate the physiological or pharmacological effects on the bone, as well as the
introduction of vitamins and other necessary substances into the bone tissue [39]. The
same applies to the revealed LRP5 and LRP6 receptors, structurally associated with
LRP1, which are necessary regulators of osteoblast functions [40]. Thus, lactoferrin,
on the one hand, provides bone growth and, on the other hand, can perform the
therapeutic function of a local agent to restore bone integrity after damage.
Integrins for extracellular matrix proteins also take part in the regulation of bone
tissue regeneration. These receptors are a substrate for adhesion, migration and
differentiation of fibroblasts and osteogenic cells [41]. Receptors provide a link
between the cytoskeleton and the extracellular matrix, transmitting information
about stretching and compression of bone tissue through, the cell membrane [42]
and activate certain signaling pathways, affecting gene expression [43]. It was
found that during the recirculation process, when the cells of the immune system
migrate through tissues and interact with one of the main components of the
extracellular matrix (collagen), and integrins act as receptors, the activation signal
is combined with an antigen-recognizing receptor and is able to change the direc-
tion of action of immunocompetent cells [44]. It is known that the metabolism of
bone tissue during damage is provided by numerous cytokines-IL-1 (interleukin),
IL-3, IL-4, IL-6, IL-11, TNF-α (tumor necrosis factor), TNF-β, colony stimulating
factors, leukemia inhibitory factor, INF-γ (interferon), TGF-β (transforming
growth factor) [45, 46]. There is no doubt that the study of blood immune
responses in patients with damage to the bone will assess their relationship with the
passage of bone formation and find the results obtained practical application. Thus,
current is the study of blood immunological reactions during the regeneration of
bone tissue to predict complications osteogenesis.
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2. Material and methods
The study included 136 patients with lesions of the facial skeleton before and
after stable osteosynthesis of the mandible in a fixing device for external fixation.
Limitation of the injury was on average 12.0  3.0 days. Indications for the use of
external fixation devices in damaged bone were complicated by primary and
secondary shifts: mandibular fractures, in 92 persons (67.6%); disjoint fractures, in
20 persons (14.7%); fused fractures, in 21 persons (15.4%); and gunshot defects, in
3 people (2.2%). A study was authorized by the Ethics Committee, guided by the
order of operation, standard operating procedures and international instruments,
which are based on “Declaration of Helsinki of the World Medical Association” and
its subsequent editions, UN documents and of the Council of Europe documents
relating to the rights of the patient, Consolidated Guideline for Good Clinical Prac-
tice and the National Russian Federation Standard “Good Clinical Practice” GOST R
52379-2005 from 01.04.2006. Informed consent to participate in a research project
in accordance with the “Statement of Ethical Control” had been obtained from all
surveyed participants in this test.
The diagnosis is based on clinical and instrumental learning techniques using
X-ray data, orthopantomography and CT. The volume of surgical intervention
determines the nature and localization of lesions. External or intraoral access was
used. The second type of access was a priority, since its implementation in the
postoperative period was excluded orostoma development. The inner edge of the
subsystems was fixed at 1 cm from the skin surface to avoid damaging the soft
tissue. An important moment during the use of external fixation device was to
restore a fractured bone axis creating contact bone fragments across the fracture
surface and compression at the junction of the bone fragments. Some patients have
been diagnosed with osteomyelitis. When the osteomyelitis was detected,
osteosynthesis was done by opening and draining the purulent chamber. Surgical
treatment of purulent focus was conducted by conventional rules.
Permanent rigid fixation of bone fragments and permanent functional damage
to the load of the lower jaw were created to organize the normal course of the
recovery process and a successful fight against purulent infection. These conditions
of bone tissue restoration were achieved by the periodic-every 5–7 days-tension of
weakened rods and displacement of rings of external retainer relative to each other.
When dressing wounds and fistulas, great importance had been attached to
providing constant drainage of purulent separable. Medical dressings are replaced
in a timely and high-quality manner, taking into account the nature and stage of
wound healing, microbial composition of purulent discharge.
An apparatus for external fixation after treatment was taken off when the
following clinical signs of coalescence bone appeared: disappearance of soft tissue
swelling, lack of mobility at the junction of the bone fragments during the clinical
trial on the motility and on the basis of radiographic criteria: identifying fuzziness
of contour ends of the fragments and improving optical densities in the gap region
of bone damage. Terms of use of metal structures averaged 15.0  3.0 days. Long-
term results of treatment patients were followed up to 4 years.
Of the total patients (136 people) based on retrospective analysis of data, a group
with slow regeneration of bone tissue was isolated, because of osteomyelitis pres-
ence. It amounted to 17 people or 12.5% of all patients. Consolidation of bone tissue
in this group was observed after an average 43.0  1.0 postoperative day. The
control group consisted of patients whose postoperative period was uneventful.
Their consolidation of bone tissue occurs on average through 29.0  2.0 days after
the imposition of an external fixation device. It occurred somewhat earlier than in
the treatment with the other ways. Usually, the terms of consolidation of mandibu-
lar fractures make 34.5–39.7 days.
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The main clinical indicators are as follows: the ratio in the group of patients by
gender and by age, the amount of intraoperative blood loss, presence of concomi-
tant pathology of the cardiovascular, respiratory, urinary systems and the gastroin-
testinal tract, and the presence of allergies and operations, which were previously
carried out using steel structures in both groups significantly did not differ. Labo-
ratory studies were performed preoperatively and after 3 and 10 days and 1 and 3
months after its execution. Blood was obtained in the morning fasting from subcla-
vian vein using the phlebotomy method and from the cubital vein or veins on the
back of the hand, to receive physiotherapy.
To assess the lymphocyte population composition, whole blood with K3EDTA
anticoagulant (ethylenediaminetetraacetic acid) was used at a concentration of
1.6 mg/ml (tube S-Monovette® 2.7 ml, Sarstedt, Germany), for determining the
phagocytic activity of the cells-the blood with the anticoagulant heparin Li (lithium
heparin) at a concentration of 16 IU/ml (tube S-Monovette® 7.5 ml, Sarstedt,
Germany). Serum was used for obtaining tubes S-Monovette® 7.5 ml (Sarstedt,
Germany) with polystyrene beads as activators of coagulation.
To evaluate the immune status, a standard set of laboratory tests has been used
complete with modern diagnostic methods [47]. The number of leukocytes was
determined using hematology analyzer Cell-Dyn 1700 (Abbot, USA), reagents and
equipment from the firm Abbott. Differentiation of population composition of leu-
kocytes was carried out in the Romanovsky-Giemsa stained smears. Stab neutrophil
and segmented neutrophil cell ratio was calculated [48]. Lymphocyte subpopulations
were determined by flow cytometry on the device Coulter®Epics®XL (Beckman
Coulter, USA), using a monoclonal antibody produced by Beckman Coulter. Lysis of
erythrocytes was performed by using the sample preparation station Coulter®Q-Prep
(Beckman Coulter, USA) and reagents Immunoprep, manufactured by Beckman
Coulter. Quality control was performed using gauge particles Flow Check. In vitro
activation of T lymphocytes with phytohemagglutinin was performed and evaluated
in the reaction of inhibition of leukocyte migration [49]. The metabolic activity of
neutrophils was evaluated in the reduction reaction of nitro blue tetrazolium peroxide
radicals under the action of cells and evaluated by light microscopy [50]. Spontaneous
and latex-stimulated activity was determined, their ratio was calculated (stimulation
index). The ability of the neutrophils to kill was determined using cytochemical cell
study data. Myeloperoxidase activity was determined by Grantham-Knoll [51], and
the result was expressed by the average cytochemical coefficient of Kaplow [52]. The
level of the lysosomal cationic cytoplasmic proteins was determined by reaction with
bromophenol blue, and the results are also expressed as the average cytochemical
factor [53]. The content of serum immunoglobulin classes A, M and G was deter-
mined by enzyme immunoassay. Lysozyme activity was evaluated by gel-diffusion
test for the ability to lyse cultureM. lysodeikticus [54], and the functional state of the
complement system was adjusted to 50% by assessment of hemolysis of sheep eryth-
rocytes [49]. Contents lactoferrin and cytokines (IL-1α, IL-8, TNF-α, IL-10 and IL-
1ra) were determined using the method of two-site “sandwich” ELISA-variant using
test systems from firms “Protein contour” (St. Petersburg, Russia), “Cytokine” (St.
Petersburg, Russia), “Vector-Best” (Novosibirsk, Russia) and BioSourse International
(USA) on immunoassay equipment Stat Fax (Awareness Technology Inc., USA). The
concentration of C-reactive protein was determined by turbidimetric and ceruloplas-
min - at Ravin [55].
The selection of antibiotic therapy in osteomyelitis was performed based on
bacteriological examination of wound and aspirate purulent contents of the cavity.
The evaluation included a microscopic examination of a Gram stain, inoculation of
culture media production by bioMérieux (France). Identification of microorgan-
isms and determination of their sensitivity to antibiotics were carried out by the
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analyzers Vitek 2-compact and ATB-Expression (bioMérieux, France). Bacteriolog-
ical examination most frequently detected Staphylococcus aureus (92–95% of cases),
among others were Pseudomonas aeruginosa, Burkholderia cepacia, Acinetobacter
baumannii, Enterococcus faecalis and Proteus vulgaris (the proportion of each of them
in the total number of cases was not more than 1%).
Statistical data processing was carried out using the “Microsoft Office Excel
2007” program and “Statistica for Windows v.6.1”. It included an assessment of the
data on the normality of the distribution in the test groups and was based on data on
the mathematical expectation of 0 and the corresponding standard deviation equal
to 1. Kolmogorov–Smirnov test, Lilliefors, Shapiro–Wilk and χ2 were used to test
the hypothesis that the sample has a Gaussian (normal) distribution. To compare
the variance of the studied samples, F-Fisher criterion was used. Statistical hypoth-
esis is considered confirmed with a significance level of p < 0.05. Modified theory
of T. Bayes was used to identify the prediction criteria [56]. Calculation of diagnos-
tic sensitivity, diagnostic specificity and diagnostic information content of immu-
nological tests was performed using the following Eqs. (1)–(3) [57].












where TP is the true-positive results: the number of patients with complications
who were correctly classified using this criterion; FP is the false-positive results: the
number of patients without complications, which have been erroneously attributed
to the number of patients with complications as a result of this test; TN is the true-
negative results: the number of patients without the complications that were cor-
rectly classified with the help of this test; and FN is the false-negative results: the
number of patients with complications who were misclassified using this test.
3. Results and discussion
As a model for studying the dynamics of immunological parameters in normal
and complicated osteogenesis, the study used laboratory parameters in patients
with lesions of the facial skeleton. Injury of facial skeleton, especially with slow
consolidation of bone tissue, leads to disturbances of body functions and generating
esthetic defects. Therefore, the creation of forecasting system complications of
osteogenesis in the recovery of fractures of the lower jaw becomes important. To
address the issue of participation of immunological reactions in the restoration of
bone tissue, first consider the dynamics of the main laboratory parameters during
normal consolidation lesions of the mandible. Before operation values, immunolog-
ical parameters were compared to known literature data [58, 59].
3.1 Features of immune responses of peripheral blood in normal bone
consolidation
Before surgery, along with a slight increase in the relative number of
CD45+CD3+-, CD45+CD19+-cells revealed increased production of IgA and IgM
(Table 1). There was also a decrease in the activity of oxygen-dependent (nitro blue
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analyzers Vitek 2-compact and ATB-Expression (bioMérieux, France). Bacteriolog-
ical examination most frequently detected Staphylococcus aureus (92–95% of cases),
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in the total number of cases was not more than 1%).
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of T. Bayes was used to identify the prediction criteria [56]. Calculation of diagnos-
tic sensitivity, diagnostic specificity and diagnostic information content of immu-
nological tests was performed using the following Eqs. (1)–(3) [57].
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to the number of patients with complications as a result of this test; TN is the true-
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rectly classified with the help of this test; and FN is the false-negative results: the
number of patients with complications who were misclassified using this test.
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osteogenesis in the recovery of fractures of the lower jaw becomes important. To
address the issue of participation of immunological reactions in the restoration of
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normal consolidation lesions of the mandible. Before operation values, immunolog-
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tetrazolium test) and oxygen-independent (neutrophil activity cationic proteins)
killing mechanisms, lowering the concentration of serum lysozyme.
Major changes were detected due to the inflammatory reaction induced by
damage to the bone tissue in the mandible fracture, which was evaluated on the
basis of a complex of acute-phase proteins. Prior to surgery, in particular, it was
revealed that there was an increase in the most sensitive C-reactive protein with
increasing concentration of ceruloplasmin and complement activity, indicating the
presence of acute inflammation (Table 1).
On day 10 after surgery, the number of monocytes increased by 27.8% (p < 0.05)
compared to preoperative level, and at 1 month after surgery, the number of
lymphocytes increased by 13.8% (p < 0.05); the composition of population lym-
phocytes did not change (Table 1). It is known that a recognized mitogen for
assessing the activity of T cells is phytohemagglutinin. According to the stress tests
with phytohemagglutinin, a gain in the functional activity of the cells during the
early postoperative period was identified, that is, for 3–10 days after surgery
(Table 1). In the same period, there was a decrease in the concentration of IgM by
37.9% (p <0.05) with the subsequent restoration of its level in the peripheral blood
(Table 1). Postoperatively, increased activity of “early” killing mechanisms was also
observed: an increase in lactoferrin levels by 51.6% (p < 0.05) and the rise of total
production of reactive oxygen species (nitro blue tetrazolium test) on 83.0% (p < 0.05).
From the humoral immunity, a significant decrease in complement activity was
revealed to be 27.7% (p < 0.05), followed by rapid recovery at 10 days. These changes
appear to have been associated with the participation of complement in the elimination
of foreign substance in the development of inflammatory response.
Due to the fact that not only cellular and humoral reactions played an important role
in the regulation of immunological reactions, but also the effect of a number of low
molecular weight peptides (cytokines) was noted, the dynamics of some of themwas
studied. In particular, it was found that in the postoperative period there was an
increase in the concentration of IL-1α (p <0.05), an activator of the initial stages of the
immune response (Table 1). This is likely to determine the development and course of
a large number of immunological reactions in the reduction of bone tissue. Simulta-
neously, the increasing concentrations of receptor antagonist IL-1–IL-1ra were
revealed,which limited the development of systemic inflammatory response (Table 1).
Concentrations of IL-1α and IL-1ra were increased to respectively 28.4 times and
17.3 times to the 10th day of observation compared to preoperative values. A similar
trend was also characteristic of TNF-α (p < 0.05), similar to having IL-1
phlogogenic properties. On day 10, there was a significant increase in the level of
another factor inflammation-IL-8-whose concentration in the blood was increased
9.7 times as compared to preoperative values (Table 1). However, during the
activation process, the decreased concentrations of IL-10 were revealed, which is a
factor that inhibits the synthesis of most of the cytokines. Its concentration in the
serum was reduced more than 100 times (p < 0.05). The inflammatory response in
normal bone regeneration had little activity and duration.
It is known that the regeneration of bone tissue composed of several sequentially
successive stages: inflammation, proliferation of osteoblasts, collagenogenesis and
ossification. In this case, additional studies were conducted 3 months after the
operation, at the last stage when the external fixing device was dismantled, repara-
tive regeneration is completed, the bone tissue has formed and the mandible func-
tioned normally. By the time of full functional bone formation, immunological
parameters were within normal limits.
In a number of patients with osteomyelitis (17 people) based on clinical and
radiographic data, delayed regeneration of bone tissue of the lower jaw was
revealed. It occurs 1.5 times later than normal consolidation (p < 0.05).
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3.2 Features of peripheral blood response in slow consolidation of the mandible
In this group of patients, before surgery, differences in immunological parame-
ters from data obtained on the bone consolidation without complicating osteomye-
litis were revealed. The number of monocytes (Table 2) was lower, than in the
group with the slow regeneration of bone tissue by 59.3% (p < 0.05). There was a
significant attenuation of the bactericidal activity of mechanisms: the level of
lactoferrin was reduced 3.5 times (p < 0.05) was only 33.6% compared with the
normal values. The same can be mentioned for complement activity-30.2% of the
lower limit of normal and below 4.2 times (p < 0.05) than in the group with normal
bone regeneration. Increased concentration of 37.4% IgM (p < 0.05) in peripheral
blood also exceeded 49.0% and the normal values (Table 2). There was increased
functional activity of CD45+CD3+-cells and it was more than 3.5 times (p < 0.05)-
differences in the recorded response of leukocyte migration inhibition (Table 2).
Serum lysozyme was reduced by 5.8 times. Interestingly, the concentration of the
receptor antagonist of IL-1ra concentration was lower for IL-1α (Table 2) that was
not observed in patients with normal bone consolidation. IL-8 levels were reduced
by 1.8-fold (p < 0.05) (Table 2) in comparison with patients with the other group.
The postoperative period was characterized by leukocytogenesis activation: leu-
kocytosis was marked with the change in the ratio of group cells to the segmented
cells. On day 3, a reduction in the number of T cells was shown (according to the
dynamics of CD45+CD3+-cells) 40.8% (p < 0.05), confirming previously published
data [60]. Recovery of these cell populations occurred in 10 days (Table 2). Perhaps
this change in the amount of T cells in the early postoperative period resulting,
ultimately, in disruption of bone regeneration, because it is known that both by
generating INF-γ, and through prostaglandin mechanism of these cells involved in
suppressing bone destruction and the formation of osteoclasts. Decrease in the
relative number of B cells (based on dynamics of CD45+CD19+-cells) by 55.6%
(p < 0.05) was observed later, on day 10 (Table 2).
Important changes were noted by the indicators characterizing the phagocytic
activity of neutrophils. Amplification reactions were detected at 3 days after surgery
when the spontaneous and stimulated superoxide radical production by neutro-
phils’ superior control values was in the subgroup of 1.6- to 1.7-fold (p < 0.05). It
can be assumed that the changes in neutrophil phagocyte system in the blood reflect
the processes occurring in bone tissue. Of interest for the study was the dynamics of
the content of lactoferrin at the stages of bone tissue consolidation (Table 2). As
noted earlier, prior to the operation, its level was significantly reduced. Due to the
fact that lactoferrin causes proliferation of osteoblasts and bone growth, it is not
excluded that lowering the level of lactoferrin in the blood is also one of the reasons
for slow regeneration of bone tissue. Later, after the operation, the lactoferrin
content was always significantly lower in patients with delayed bone formation
compared with patients who have bone fusion that took place at the usual time.
Slow bone formation was accompanied by significant increase (72.0%) in IgM
levels (Table 2). The revealed changes were statistically significant differences
between these patients with normal bone tissue regeneration. Inflammatory
response was characterized by pronounced dynamics of slow-reacting acute-phase
proteins. Specifically, on day 3, after surgery, ceruloplasmin concentration was
higher by 1.9-fold (p < 0.05) than in patients with normal bone regeneration. The
functional activity of T cells throughout the observation period was 2.0- to 3.3-fold
higher (p < 0.05) than in patients with normal consolidation, while it exceeds the
normal value of 1.5 times (Table 1). Active cationic proteins and myeloperoxidase
neutrophilic granulocytes were higher than in patients with complication of
osteogenesis, respectively, by 33.6% (p < 0.05) and 3.1-fold (p < 0.05).
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presence of acute inflammation (Table 1).
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9.7 times as compared to preoperative values (Table 1). However, during the
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successive stages: inflammation, proliferation of osteoblasts, collagenogenesis and
ossification. In this case, additional studies were conducted 3 months after the
operation, at the last stage when the external fixing device was dismantled, repara-
tive regeneration is completed, the bone tissue has formed and the mandible func-
tioned normally. By the time of full functional bone formation, immunological
parameters were within normal limits.
In a number of patients with osteomyelitis (17 people) based on clinical and
radiographic data, delayed regeneration of bone tissue of the lower jaw was
revealed. It occurs 1.5 times later than normal consolidation (p < 0.05).
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ters from data obtained on the bone consolidation without complicating osteomye-
litis were revealed. The number of monocytes (Table 2) was lower, than in the
group with the slow regeneration of bone tissue by 59.3% (p < 0.05). There was a
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relative number of B cells (based on dynamics of CD45+CD19+-cells) by 55.6%
(p < 0.05) was observed later, on day 10 (Table 2).
Important changes were noted by the indicators characterizing the phagocytic
activity of neutrophils. Amplification reactions were detected at 3 days after surgery
when the spontaneous and stimulated superoxide radical production by neutro-
phils’ superior control values was in the subgroup of 1.6- to 1.7-fold (p < 0.05). It
can be assumed that the changes in neutrophil phagocyte system in the blood reflect
the processes occurring in bone tissue. Of interest for the study was the dynamics of
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noted earlier, prior to the operation, its level was significantly reduced. Due to the
fact that lactoferrin causes proliferation of osteoblasts and bone growth, it is not
excluded that lowering the level of lactoferrin in the blood is also one of the reasons
for slow regeneration of bone tissue. Later, after the operation, the lactoferrin
content was always significantly lower in patients with delayed bone formation
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The concentration of lysozyme in the same period was significantly reduced by 5.4
times (Table 2). The dynamics of cytokine concentrations also had differences: on
day 3 after surgery significantly, namely more than 11-fold (p < 0.05), increased
concentration of IL-1α, one of the stimulants of osteoclasts (Table 2). However
similar changes were observed in patients with normal bone tissue regeneration.
Most likely, the ratio between the level of IL-1α and IL-1ra after surgery (on day 10)
played an important role in the violation of regeneration, when in patients with
normal bone consolidation it was equal (Table 1), and at late bone consolidation,
the level of IL -1ra was almost two times lower than the concentration of IL-1α
(Table 2 and Figure 1).
After one month, when the regeneration of bone tissue in the other group was
completed, in patients with delayed consolidation, it was in the stage
collagenogenesis. Features of the dynamics of immunological parameters are as
follows: the number of neutrophils and lymphocytes in peripheral blood was
reduced by 23.0% (p < 0.05) and 21.0% (p < 0.05) compared to those of patients
with normal bone regeneration. Inhibition signs of humoral immunity were shown:
IgA level was lower by 35.3% (p < 0.05), the concentration of IgM (Table 2), and
IgG – 2.0 times (p < 0.05) was compared with the results in patients with the
normal regeneration of the bone tissue. There was also a decrease in
myeloperoxidase activity by 34.8% (p <0.05) and lysozyme concentration by 2 times
(p < 0.05) reduced (Table 2). One month after surgery, the receptor level antagonist
of IL-1 was higher concentration of IL-1α (Table 2) and TNF-α content was
increased by 2.5-fold (p < 0.05), while the functional activity of the CD45+CD3+-
cells (Table 2), as already mentioned, was increased by 8.3-fold (p < 0.05).
It is interesting that in circumstances where bone regeneration has been com-
pleted, 3 months after the operation, the factors of immune responses, causing the
growth of bone, are reduced. Thus, the concentration of lactoferrin was reduced by
40.5% (p < 0.05) and the number of T cells by 23.4% (p < 0.05). During this same
period, the factors of immune reactions associated with the destruction of the bone
tissue continue to maintain high concentrations. In particular, TNF-α level was
increased by 4.2-fold (p < 0.05) (Table 2). The functional state of T cells in the
neutrophil migration inhibition of the reaction was increased by 4.1 times (Table 2)
metabolic functional activity of neutrophils to normal.
Based on the study, criteria were developed by predicting delayed bone consol-
idation in the treatment of injuries of the lower jaw (Table 3).
These criteria allow for different stages of treatment (before surgery, for 3 or
10 hours after surgery) to predict the development of delayed consolidation of bone
Figure 1.
The ratio of the concentration of IL-1α to IL-1ra, a logarithmic scale was used to represent the data.
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tissue. For each of the criteria, diagnostic sensitivity, diagnostic specificity and
informative test are calculated, that is the ability to predict the possible develop-
ment of delayed consolidation of bone tissue.
To test the statistical hypotheses were recruited separate independent test sam-
ples of 49 people. It included patients with the same embodiments of bone damage
and with the same kind of surgical treatment as the two major groups of the study.
The criteria developed in this study showed that the coefficient of determination in
this independent test sample was in the range of 84.2–97.5%. The joint use of two or
more prognostic indicators allowed to increase the value of a diagnostic test for
3–4%. This fact gives more opportunities to clinicians in predicting delayed bone
formation.
4. Conclusion
The study revealed that the stages of regeneration of bone tissue (inflammation,
proliferation of osteoblasts, collagenogenesis and ossification) are accompanied by
changes in the immunological status. When delayed consolidation of bone tissue
revealed differences of response of individual parts of the immune system, a com-
parative study of the immunological parameter dynamics at normal and slow oste-
ogenesis is possible to establish criteria for delayed consolidation of bone tissue.
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IgM, g/l ↑ 2.7 0.9–2.6 87.7% 88.3% 89.5%
Table 3.
The criteria for predicting delayed consolidation of bone tissue in the treatment of lesions of the mandible.
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well as reducing the number of CD45+CD3+-cells, complement activity and the
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Application of Adipose-Derived 
Stem Cells in Treatment of Bone 
Tissue Defects
Stevo Najman, Jelena Najdanović and Vladimir Cvetković
Abstract
Despite excellent self-regeneration capacity of bone tissue, there are some large 
bone defects that cannot be healed spontaneously. Numerous literature data in the 
field of cell-based bone tissue engineering showed that adipose-derived stem cells 
(ADSCs) after isolation could be subsequently applied in a one-step approach for 
treatment of bone defect, without previous in vitro expansion and osteoinduction. 
However, standard approaches usually involve in vitro expansion and osteoin-
duction of ADSCs as an additional preparation step before its final application. 
Bioreactors are also used for the preparation of ADSC-based graft prior application. 
The commonly used approaches are reviewed, and their outcomes, advantages, dis-
advantages, as well as their potential for successful application in the treatment of 
bone defects are discussed. Difficulty in spontaneous healing of bone defects is very 
often due to poor vascularization. To overcome this problem, numerous methods 
in bone tissue engineering (BTE) were developed. We focused on freshly isolated 
stromal vascular fraction (SVF) cells and ADSCs in vitro induced into endothelial 
cells (ECs) as cells with vasculogenic capacity for the further application in bone 
defect treatment. We have reviewed orthotopic and ectopic models in BTE that 
include the application of SVFs or ADSCs in vitro induced into ECs, with special 
reference to co-cultivation.
Keywords: stromal vascular fraction, adipose-derived stem cells, endothelial cells, 
in vitro-induced differentiation, bone tissue engineering, vascularization, osteogenic 
process stromal vascular fraction, adipose-derived stem cells, endothelial cells,  
in vitro-induced differentiation, bone tissue engineering, vascularization, osteogenic 
process
1. Introduction
Structure of the bone tissue is very dynamic due to environmental influence but 
also because of many factors that act inside the body [1]. The bone can regenerate 
and repair itself, but large fractures and bone defects fail to heal and repair success-
fully. In addition to other adverse factors, this results in delayed unions, malunions, 
or nonunions. To aid bone healing and repair in such situations, build bone-defi-
cient areas, or replace missing bone as well as in purposes of joint reconstruction, 
bone grafting is used [2–5].
Bone grafting is one of the most common options for the treatment of major 
bone defects, and the use of bone grafts is among the most common procedures 
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in orthopedic surgery and the second most frequent transplantation of tissue 
after blood. Over 2 million bone grafting procedures are performed annually in 
surgery [5, 6]. Bone graft material, alone or in combination with other materials, 
can perform bone healing function by having at least one of the features among 
osteogenicity, osteoinduction, and osteoconduction and therefore usually have one 
or more components—scaffold, as an osteoconductive matrix that supports bone 
growth, osteoinductive proteins and factors, and osteogenic cells [5, 7]. The main 
types of bone grafting materials are autografts, allografts, xenografts, synthetic 
and biological tissue engineering biomaterials, and combinations of these materials 
[2–6]. Bone grafts and graft substitutes may differ by material type, source, and ori-
gin and may also be categorized as osteogenic, osteoinductive, and osteoconductive 
agents [7]. The choice of bone graft depends on the condition of the bone tissue, 
defect size, surgical feasibility of the procedure, possible health complications, graft 
structure, its biological and mechanical characteristics, size and shape, cost, and 
ethical issues [5].
Each of the bone graft material and its substituents has its advantages and disad-
vantages, of which there is considerable agreement in surgical practice. Autografts 
are the best clinical solution among grafts because they have all the necessary proper-
ties to stimulate bone repair and regeneration—osteogenicity, osteoinductivity, and 
osteoconductivity—as they provide osteogenic cells, osteoinductive factors, and 
osteoconductive scaffold for bone growth. So far, autografts have proven superior in 
quality and time to bone healing. That is why in orthopedic practice, for the purpose 
of reconstruction of small defects and replacement of lost bone, autografts are the 
“gold standard” [3, 5–7]. Autografts can be of different types such as vascularized 
grafts, bone tissue, or bone marrow. They are usually obtained from the iliac crest, 
as well as from mandibular bone in dentistry, and by osteectomy and osteoplasty in 
various procedures. The vascularized fibula is used for the treatment of congenital 
bone damage, replacement of the bone segment after trauma, and in the case of a 
malignant tumor so that the periosteum and nutrient artery allow the graft to live 
and grow in the transplanted site [4, 8, 9]. The use of autografts often involves addi-
tional surgery and additional pain, and there is a frequent occurrence of morbidity at 
the donor site, which with limited availability is a limitation to their use. Morbidity, 
although low, is significant and ranges from minor to major complications, and there 
is a risk of injury to large blood vessels and visceral organs while taking the graft. The 
type of complications and their severity depends on the donor site as well as whether 
the graft material is taken at the same incision on the primary surgical site [2, 3, 5–8].
Allografts are much more available for orthopedic purposes. They have an osteo-
conductivity property, they can be well remodeled, but they are poorly osteoinduc-
tive, which can be present if they have an organic matrix. All of these properties 
depend on the size of the graft and the grafting site [3–6, 8]. Allografts are obtained 
from a bone bank containing cadaveric bones and can be found in various forms. 
Compared to autografts, allografts lack osteogenic properties and thus have an 
overall weaker bone regenerative potential, and their integration into the recipi-
ent bone over the long term may be insufficient. Allografts can induce immune 
response and rejection and requires caution because of the possibility of transmis-
sion of pathogens from the donor organism, and their disadvantages are also high 
costs and lack of availability of donors [3, 5–8]. To reduce some disadvantages and 
limitations by allografts, cells and proteins that can elicit an immune response can 
be removed, thereby also reducing the possibility of transmission of viral infec-
tion by donors. Usually, the sterilization and deactivation process of the proteins is 
performed before the use of the allograft, but then they lack osteoinductive factors, 
which in turn remain if the demineralized bone matrix is prepared [4, 8].
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Xenografts are obtained from species other than humans, e.g., bovine bone, 
which is much used in dentistry. There are also nonbone xenograft materials such as 
sclera, collagen membranes, and coral-derived materials. Compared to autografts, 
xenografts as allografts only have osteoconductive and osteoinductive but lack 
osteogenic features. There is a risk of zoonotic transmission in xenografts treat-
ment, and rejection is more likely and stronger than in the case of an allograft. 
Xenografts are cheaper, but the results of their application are inconsistent [4–6].
In addition to bone grafts (autograft, allograft, xenograft), newer bone sub-
stitutes are the ceramic types (calcium compounds: hydroxyapatite, tricalcium 
phosphate (TCP), calcium sulfate) and biological factors such as growth factors 
and others (bone morphogenetic proteins (BMPs), platelet-rich plasma (PRP), 
demineralized bone matrix (DBM)). Bone substitutes have been used for decades 
and have been defined as synthetic, inorganic, or organic, as well as biological 
origin materials, or a combination of those used to treat bone defect instead of 
bone [3, 4, 6]. Bone substitutes are especially used in traumatology and oncologic, 
spine, and prosthetic surgeries. Suitable bone substitutes should be biocompatible, 
not provoking an adverse inflammatory response, osteoinductive, osteoconduc-
tive, resorbable, easily molded into the bone defect, nonconductive, sterilizable, 
available, traceable in vivo, and at a reasonable cost [6]. The integration of bone 
substitutes over the long term may not be sufficient. Bone substitute materials of a 
synthetic nature such as calcium phosphate (CaP)-based biomaterials often behave 
osteoconductively only and can be remodeled. Osteoinductivity is possessed by 
biological factors such as bone matrix proteins or BMP-type growth factors that 
can be added to other bone substitutes [3, 8]. Ceramic-based bone graft substitutes 
include hydroxyapatite (HA), TCP, calcium sulfate, and bioglass used alone or in 
combination. Ceramics can be used in the form of granules, blocks, or moldable 
paste shape, and the occurrence of injectable cements was particularly significant 
because it enabled a mininvasive application [6, 7, 10]. Calcium phosphate-based 
bone substitutes have wide clinical use, since they are generally therapeutically 
effective, although they have poor mechanical properties, are less strong than bone 
tissue, and can be completely resorbed. The more advanced variants of HAs have 
biomimetic properties, since they include ions (carbonates, Mg, fluoride, Sr), so 
that natural HA is imitated [6]. Polymer-based bone substitutes can be degradable 
and nondegradable polymers and are applied alone, as co-polymers, or in combina-
tion with other materials [7, 10]. Various marine biomaterials are also used as bone 
substitutes, including chitosan, corals, and sponge skeleton [7]. Although biologi-
cal factors generally influence good bone formation, the clinical application is not 
widespread due to high prices and possible adverse side effects [3]. Growth factors 
as bone substitutes, such as BMPs, transforming growth factor-beta (TGF-beta), 
platelet-derived growth factor (PDGF), and fibroblast growth factor (FGF), can 
be natural and recombinant and can be used alone or in combination with other 
materials [7]. BMPs are bone growth factors that are widely used in spine surgery 
and for the treatment of tibial nonunion. The efficiency of some biological factors, 
as is the case with the PRP and DBM, is still an open question [6, 10].
The shortcomings in the outcomes of bone healing were the impetus to 
seek new types of grafts and bone substitutes. On these motives, a bone tissue 
engineering (BTE) as a new field began to develop in the last decades of the last 
century, integrating multiple disciplines such as cell biology, developmental and 
molecular biology, biomechanics, biomaterials science, immunology, and others. 
With the progressive introduction of innovations and new technologies, BTE has 
been offering more and more solutions to reduce the disadvantages of traditional 
bone grafts and improve the process of healing fractures and defects by achieving 
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better graft incorporation, osteoconductivity, osteoinductivity, and osteogenicity 
[5, 9–11]. Combining tissue scaffolds, growth factors, cells (especially stem cells), 
and gene therapies, along with three-dimensional printing and other new techno-
logical products, makes BTE a promising option. BTE has progressed over time, 
producing grafts with increasing ability to regenerate and repair bone [5–7, 9–12]. 
Cell-based treatment is emerging as a more promising approach in regenerative 
medicine. Cells (e.g., osteogenic or mesenchymal stem cells and others) are used 
to create new bone alone or are seeded onto a support matrix or scaffold to form 
bone tissue in vitro [6, 7, 9, 10, 13]. On these principles, engineered vascularized 
bone grafts can be created with some similarities to autografts [9, 10, 14]. Of 
particular interest in BTE is the application of mesenchymal stem cells because of 
their multipotency and the presence of osteogenic potential [6, 9, 10, 13, 15]. Cells 
can also be used as a vehicle for osteoinductive genes [6, 10]. Recent developments 
include ex vivo bioreactors capable at the very automated and controlled way 
to imitate in vivo environment producing bone with appropriate biomechani-
cal properties before implantation [7, 9, 10, 12, 13]. To test the new features and 
products of BTE, as well as preclinical testing, many in vitro and in vivo methods 
and models have been developed with various advantages and disadvantages 
respectively [11, 16].
2. Sources of cells for tissue-engineered grafts
Nowadays, adult stem cells can be purified from different adult tissues and used 
in BTE as potential progenitors of osteogenic cells. It is reported that stem cells 
intended for BTE can be derived from many different tissues such as bone marrow, 
umbilical cord, dental pulp, as well as adipose tissue [17]. For instance, mesenchy-
mal stem cells (MSCs) derived from bone marrow can be successfully differenti-
ated into cells of various connective tissues [18] as well as in bone cells which give 
opportunity for its implementation in cell-based BTE [10, 19]. Despite its frequent 
use in BTE, bone marrow MSCs are reported to have some disadvantages, espe-
cially low cell quantity at isolation [20]. This is also an unfavorable characteristic 
for many other adult stem cells which imply in vitro cell expansion after their 
isolation in order to obtain sufficient quantity of cells which is mandatory for its 
further implementation in cell-based BTE. Morbidity and pain are also reported as 
accompanying side effects that are consequences of bone marrow MSC harvesting 
[20]. Nevertheless, MSCs are easier to isolate from accessible adipose tissue, which 
can be harvested with minimally harmful [21] and less painful methods. These 
multipotent cells derived from adipose tissue were reported by Zuk et al. [22] and 
suggested as a possible alternative to bone marrow MSCs [22]. Others also reported 
that stromal cells derived from adipose tissue rapidly proliferate and can be 
obtained in sufficient quantity, eliminating the need for in vitro expansion [23, 24] 
which is a tremendous advantage of adipose-derived stem cells (ADSCs) over other 
tissues that are potential sources of adult stem cells. The more recent study showed 
that bone morphogenic protein 2-transduced human adipose-derived MSCs had 
higher capacity for osteogenic differentiation than bone morphogenic protein 
2-transduced MSCs from bone marrow [25]. With all this advantages, MSCs from 
adipose tissue are also reported to have similar potential to differentiate toward 
osteoblast and form bone as bone marrow MSCs [26]. Adipose tissue therefore 
represents a reliable source of adult stem cells intended for therapeutic purposes 
in BTE. In addition to this, in the past decade, we are witnessing an increase of 
 interest for application of ADSCs in cell-based BTE.
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2.1 Adipose-derived stem cells
The capacity to differentiate toward a broad spectrum of specialized cells 
such as bone cells, cartilage cells, muscle cells, endothelial cells, liver cells, neural 
cells, and others [17, 21, 27] makes ADSCs suitable generally for cell-based tissue 
engineering as well as for BTE. ADSCs represent a form of MSCs [28] that could be 
simply isolated from both subcutaneous and visceral adipose tissue that are usually 
sufficiently abundant in almost every individual. Nevertheless, it is reported that 
ADSCs derived from visceral fat have higher osteogenic potential than ADSCs from 
subcutaneous fat in rabbits [29] which should be taken into consideration when 
selecting the type of adipose tissue as starting source for ADSC isolation. Adipose 
tissue in humans could be obtained by liposuction or resection method that are both 
reported to yield similar quantity and good quality of MSCs [30]. More precisely, 
a direct source of ADSCs is stromal vascular fraction (SVF) which is obtained by 
enzymatic digestion of previously isolated fat tissue and its subsequent centrifuga-
tion [15]. There are well-described markers intended for ADSC characterization. 
Particularly, ADSCs are reported to have recognizable fibroblast-like, spindle-
shaped morphology [22, 26], good longevity and plastic adhesion properties in 
in vitro condition [31], and capacity for rapid proliferation in cell culture [23, 32]. 
ADSCs also have characteristic expression pattern of CD cell surface markers. In 
general, there is an accordance in literature about the expression pattern of CD 
markers which should be used for ADSC characterization. For instance, Cai et al. 
[27] summarized that some characteristic CDs, particularly CD166, CD105, CD90, 
CD73, CD44, CD29, and CD13, have high expression in adipose-derived stem 
cells [27] which is in accordance with other reviews [33]. Also, according to Bajek 
et al. (2016) high expressions of CD73, CD44, CD105 and CD90 are indications 
mainly used for adipose-derived stem cell identification [34]. Therefore, before 
further steps in their application and analyses, it is very important to examine and 
determine expression of CDs and other markers like cell morphology in order to 
characterize ADSCs.
3. Bone substitutes and regulatory factors
As it is mentioned in the previous text, apart from cells, there are two more 
components in cell-based BTE, and those are bone substitute materials and regula-
tory factors. These three components together, combined in appropriate manner, 
makes specific construct which is an adequate alternative to bone grafts for the 
treatment of bone tissue defects. Bone substitutes are used as appropriate scaffolds 
for osteogenic cells. Chao et al. [12] described scaffold as logistic templates for 
guided formation of tissue [12]. Three-dimensional scaffolds that support osteo-
genic differentiation of the stem cells are seen as crucial components for in vitro 
engineering of bone construct which can be clinically usable [9]. Even more, to 
respond to special requirements at the defect site, engineering of the customized 
bone grafts was also proposed [35]. Bone substitute materials provide appropri-
ate microenvironment for differentiation and proliferation of bone cells [36], and 
porosity, particle size, and material composition also play important roles [37]. At 
the first place, bone substitutes should be biocompatible which, among the other 
things, implies that they are non-toxic and non-genotoxic [38]. Biomaterials are also 
used to fill defects and compensate lost part of bone tissue at the defect site. Bone 
substitutes that belong to a group of bioactive biomaterials are capable for interaction 
with the biological environment and can provide conditions for cellular actions [39] 
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better graft incorporation, osteoconductivity, osteoinductivity, and osteogenicity 
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medicine. Cells (e.g., osteogenic or mesenchymal stem cells and others) are used 
to create new bone alone or are seeded onto a support matrix or scaffold to form 
bone tissue in vitro [6, 7, 9, 10, 13]. On these principles, engineered vascularized 
bone grafts can be created with some similarities to autografts [9, 10, 14]. Of 
particular interest in BTE is the application of mesenchymal stem cells because of 
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and models have been developed with various advantages and disadvantages 
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intended for BTE can be derived from many different tissues such as bone marrow, 
umbilical cord, dental pulp, as well as adipose tissue [17]. For instance, mesenchy-
mal stem cells (MSCs) derived from bone marrow can be successfully differenti-
ated into cells of various connective tissues [18] as well as in bone cells which give 
opportunity for its implementation in cell-based BTE [10, 19]. Despite its frequent 
use in BTE, bone marrow MSCs are reported to have some disadvantages, espe-
cially low cell quantity at isolation [20]. This is also an unfavorable characteristic 
for many other adult stem cells which imply in vitro cell expansion after their 
isolation in order to obtain sufficient quantity of cells which is mandatory for its 
further implementation in cell-based BTE. Morbidity and pain are also reported as 
accompanying side effects that are consequences of bone marrow MSC harvesting 
[20]. Nevertheless, MSCs are easier to isolate from accessible adipose tissue, which 
can be harvested with minimally harmful [21] and less painful methods. These 
multipotent cells derived from adipose tissue were reported by Zuk et al. [22] and 
suggested as a possible alternative to bone marrow MSCs [22]. Others also reported 
that stromal cells derived from adipose tissue rapidly proliferate and can be 
obtained in sufficient quantity, eliminating the need for in vitro expansion [23, 24] 
which is a tremendous advantage of adipose-derived stem cells (ADSCs) over other 
tissues that are potential sources of adult stem cells. The more recent study showed 
that bone morphogenic protein 2-transduced human adipose-derived MSCs had 
higher capacity for osteogenic differentiation than bone morphogenic protein 
2-transduced MSCs from bone marrow [25]. With all this advantages, MSCs from 
adipose tissue are also reported to have similar potential to differentiate toward 
osteoblast and form bone as bone marrow MSCs [26]. Adipose tissue therefore 
represents a reliable source of adult stem cells intended for therapeutic purposes 
in BTE. In addition to this, in the past decade, we are witnessing an increase of 
 interest for application of ADSCs in cell-based BTE.
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ADSCs derived from visceral fat have higher osteogenic potential than ADSCs from 
subcutaneous fat in rabbits [29] which should be taken into consideration when 
selecting the type of adipose tissue as starting source for ADSC isolation. Adipose 
tissue in humans could be obtained by liposuction or resection method that are both 
reported to yield similar quantity and good quality of MSCs [30]. More precisely, 
a direct source of ADSCs is stromal vascular fraction (SVF) which is obtained by 
enzymatic digestion of previously isolated fat tissue and its subsequent centrifuga-
tion [15]. There are well-described markers intended for ADSC characterization. 
Particularly, ADSCs are reported to have recognizable fibroblast-like, spindle-
shaped morphology [22, 26], good longevity and plastic adhesion properties in 
in vitro condition [31], and capacity for rapid proliferation in cell culture [23, 32]. 
ADSCs also have characteristic expression pattern of CD cell surface markers. In 
general, there is an accordance in literature about the expression pattern of CD 
markers which should be used for ADSC characterization. For instance, Cai et al. 
[27] summarized that some characteristic CDs, particularly CD166, CD105, CD90, 
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cells [27] which is in accordance with other reviews [33]. Also, according to Bajek 
et al. (2016) high expressions of CD73, CD44, CD105 and CD90 are indications 
mainly used for adipose-derived stem cell identification [34]. Therefore, before 
further steps in their application and analyses, it is very important to examine and 
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As it is mentioned in the previous text, apart from cells, there are two more 
components in cell-based BTE, and those are bone substitute materials and regula-
tory factors. These three components together, combined in appropriate manner, 
makes specific construct which is an adequate alternative to bone grafts for the 
treatment of bone tissue defects. Bone substitutes are used as appropriate scaffolds 
for osteogenic cells. Chao et al. [12] described scaffold as logistic templates for 
guided formation of tissue [12]. Three-dimensional scaffolds that support osteo-
genic differentiation of the stem cells are seen as crucial components for in vitro 
engineering of bone construct which can be clinically usable [9]. Even more, to 
respond to special requirements at the defect site, engineering of the customized 
bone grafts was also proposed [35]. Bone substitute materials provide appropri-
ate microenvironment for differentiation and proliferation of bone cells [36], and 
porosity, particle size, and material composition also play important roles [37]. At 
the first place, bone substitutes should be biocompatible which, among the other 
things, implies that they are non-toxic and non-genotoxic [38]. Biomaterials are also 
used to fill defects and compensate lost part of bone tissue at the defect site. Bone 
substitutes that belong to a group of bioactive biomaterials are capable for interaction 
with the biological environment and can provide conditions for cellular actions [39] 
Clinical Implementation of Bone Regeneration and Maintenance
184
which is of benefit for bone regeneration. Nowadays, many different synthetic  
and natural bone substitutes are reported to be in use [10, 39, 40]. Particularly, 
materials based on hydroxyapatite and β-tricalcium phosphate are suitable for 
BTE [41]. In addition, materials based on bone mineral matrix are frequently used 
[42–45]. Also, regulatory factors are not less important components in BTE, and at 
the first place, they should induce and support osteogenic differentiation, adhesion, 
and proliferation of implanted cells. Because of its significant properties, here the 
focus will be on platelet-rich plasma as a source of regulatory factors for cell-based 
BTE. PRP is one of the well-known natural sources of different stimulative regula-
tory factors [46–48]. Last decade, PRPs are constantly drawing attention of many 
researchers in fields of regenerative biology as well as in BTE. That is reasonable 
because regulatory factors from PRP is reported to enhance adhesion, differentia-
tion, and proliferation of the cells and also enhance angiogenesis [46, 49] which may 
support regeneration and reparation of bone tissue. In addition, it was reported that 
regulatory factors from PRP can enhance osteogenic process by inducing prolifera-
tion and differentiation of MSCs [50, 51]. Nevertheless, the question about adequate 
and stimulating concentration of platelets in prepared PRP is of great importance, 
and it is still topical. The opinions about adequate concentration of platelets in PRP 
intended for BTE are different. There are reports that higher platelet concentrations 
might have an inhibitory effect [52], and on the other hand, concentrations that 
are lower than the physiological level is reported to be useful for bone regeneration 
[53]. Finally, there is a recommendation that optimal concentration of platelets in 
PRP intended for bone treatment should be from four to eight folds higher than 
the normal physiological level of platelets in the blood [46]. Another advantage of 
activated PRP is that it can form fibrin fibers which can couple ADSCs with bone 
substitute material and improve retention of all construct components [54, 55] 
similar to reports where fibrin was used for this purpose [56, 57]. Finally, there is a 
growing interest about synergistic effects of ADSCs and PRP for bone regeneration. 
Many studies reported promising osteogenic potential of ADSCs and PRP combina-
tion [45, 54, 55, 58] and stimulative potential of PRP that improves osteogenesis 
in combination with cells [50, 59]. In addition, Fernandes and Yang [48] reviewed 
and summarized some recently published data which implies that adipose-derived 
stem cells obtained from human, mouse, rat and rabbit in combination with PRP 
in in vitro and/or in vivo conditions are related with outcomes which are of benefit 
for BTE [48].
4. Approaches in application of ADSCs in cell-based BTE
4.1 One-step versus multistep approaches
Numerous literature data in the past decade are related with extensive stud-
ies about regenerative potential of adipose-derived stem cells. It is well-known 
that ADSCs in combination with bone substitute materials and regulatory factors 
possess certain osteogenic potential that can initiate and boost osteogenic process 
both in orthotopic and ectopic conditions. Recent studies showed that good yield of 
ADSCs after isolation from adipose tissue provides opportunity for its subsequent 
application in one-step approach in cell-based bone tissue engineering without 
previous in vitro expansion and differentiation. Nevertheless, standard approach 
in cell-based BTE usually involves in vitro pretreatment of ADSCs as an additional 
step before its final application in order to induce differentiation of ADSCs into 
osteogenic cells. Literature data showed that both approaches are promising 
for implementation in treatment of bone tissue defects. Our experience about 
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osteogenic capacity of differently prepared ADSCs is mostly in accordance with 
other related studies. Based on our previously performed experimental studies and 
published results, these two approaches have quite different outcomes, and each 
approach has its advantages and potential to be successfully applied in treatment 
of bone tissue defects. Also, there is a growing number of researches that employed 
bioreactors for bone graft engineering.
There are well-described methods for ADSC preparation prior their applica-
tion in BTE. Without purification, in vitro expansion, and osteoinduction, ADSCs 
contained in freshly isolated adipose-derived SVF could be prepared and applied 
in just one step which is described as intraoperative approach [56, 57, 60] or one-
step procedure [61]. Intraoperative approach implies construct assembling during 
surgical procedure [13] by combining cells, bone substitutes, and regulatory factors 
together in one construct. One of the earlier reports by Aslan et al. [62] presented 
usage of noncultured human MSCs isolated from bone marrow [62]. More recently 
published articles demonstrated intraoperative application of freshly isolated 
SVF cells from human adipose tissue [56, 57] and freshly isolated adipose-derived 
SVF cells from mice epididymal adipose tissue in ectopic bone-forming model 
[55]. One-step surgical procedure is also used in oral and maxillofacial surgery 
for maxillary sinus floor elevation [37, 63]. All these studies suggest that previous 
in vitro pretreatment of ADSCs and their separation from SVF population prior 
their implementation in BTE is not necessary. Good yield of ADSCs enables bypass-
ing of in vitro expansion step which goes in favor of the one-step concept in BTE. In 
addition, the autotransplantation of freshly isolated ADSCs for the treatment of 
bone tissue defects also enables avoiding problems with immune response [60] that 
might occur in allotransplantations and xenotransplantations. Adipose-derived SVF 
is reported to have great capacity for regeneration processes thanks to its hetero-
geneity [28] because it is composed of different cell types and growth factors [15], 
especially with cells that have osteogenic and angiogenic potential [37] which is of 
great importance for treatment of bone defects (Figure 1).
Also, it is reported that the entire procedure can be finished in a few hours 
[13, 56, 64] which reduces wait time for surgery [60] and is one of the major 
advantages of this approach. In addition, Jurgens et al. [61] showed that ADSCs 
can adhere promptly onto materials collagen type I/III and poly(L-lactide-co-
caprolactone); particularly it is reported that nearly 10 minutes is sufficient time 
for ADSC adhesion [61] that significantly reduces time needed for construct 
preparation.
On the other hand, there are many well-described approaches which involve 
several steps for in vitro expansion and osteogenic differentiation of ADSCs before 
its final application [26, 45, 65]. In these approaches, by in vitro cultivation, ADSCs 
are additionally expanded and purified from heterogenous SVF [32] that are directly 
derived from adipose tissue (Figure 1). After that step, purified ADSCs are sub-
jected to in vitro induction in osteogenic media to differentiate toward osteogenic 
cells before further application which follows in the next step. The characteris-
tic components of osteogenic medium are dexamethasone, ascorbic acid, and 
β-glycerophosphate [31, 33, 66] which are frequently used for ADSC osteoinduction 
[67]. There are different data about the duration of in vitro osteogenic induction 
needed for ADSC differentiation toward osteogenic cells, but literature data mostly 
referred to 2 weeks [22, 33, 66, 68, 69] or between 2 and 3 weeks [21] (Figure 2). 
It was summarized that during osteogenic differentiation, ADSCs start expres-
sion of lineage-specific genes for osteogenesis such as osteocalcin, transcription 
 factor osterix, transcription factor Runx2, bone sialoprotein, alkaline phosphatase, 
and others [32, 40] which might be detected by gene expression analysis [61] as 
 confirmation of successful osteogenic differentiation of ADSCs. For instance,  
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published results, these two approaches have quite different outcomes, and each 
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of bone tissue defects. Also, there is a growing number of researches that employed 
bioreactors for bone graft engineering.
There are well-described methods for ADSC preparation prior their applica-
tion in BTE. Without purification, in vitro expansion, and osteoinduction, ADSCs 
contained in freshly isolated adipose-derived SVF could be prepared and applied 
in just one step which is described as intraoperative approach [56, 57, 60] or one-
step procedure [61]. Intraoperative approach implies construct assembling during 
surgical procedure [13] by combining cells, bone substitutes, and regulatory factors 
together in one construct. One of the earlier reports by Aslan et al. [62] presented 
usage of noncultured human MSCs isolated from bone marrow [62]. More recently 
published articles demonstrated intraoperative application of freshly isolated 
SVF cells from human adipose tissue [56, 57] and freshly isolated adipose-derived 
SVF cells from mice epididymal adipose tissue in ectopic bone-forming model 
[55]. One-step surgical procedure is also used in oral and maxillofacial surgery 
for maxillary sinus floor elevation [37, 63]. All these studies suggest that previous 
in vitro pretreatment of ADSCs and their separation from SVF population prior 
their implementation in BTE is not necessary. Good yield of ADSCs enables bypass-
ing of in vitro expansion step which goes in favor of the one-step concept in BTE. In 
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bone tissue defects also enables avoiding problems with immune response [60] that 
might occur in allotransplantations and xenotransplantations. Adipose-derived SVF 
is reported to have great capacity for regeneration processes thanks to its hetero-
geneity [28] because it is composed of different cell types and growth factors [15], 
especially with cells that have osteogenic and angiogenic potential [37] which is of 
great importance for treatment of bone defects (Figure 1).
Also, it is reported that the entire procedure can be finished in a few hours 
[13, 56, 64] which reduces wait time for surgery [60] and is one of the major 
advantages of this approach. In addition, Jurgens et al. [61] showed that ADSCs 
can adhere promptly onto materials collagen type I/III and poly(L-lactide-co-
caprolactone); particularly it is reported that nearly 10 minutes is sufficient time 
for ADSC adhesion [61] that significantly reduces time needed for construct 
preparation.
On the other hand, there are many well-described approaches which involve 
several steps for in vitro expansion and osteogenic differentiation of ADSCs before 
its final application [26, 45, 65]. In these approaches, by in vitro cultivation, ADSCs 
are additionally expanded and purified from heterogenous SVF [32] that are directly 
derived from adipose tissue (Figure 1). After that step, purified ADSCs are sub-
jected to in vitro induction in osteogenic media to differentiate toward osteogenic 
cells before further application which follows in the next step. The characteris-
tic components of osteogenic medium are dexamethasone, ascorbic acid, and 
β-glycerophosphate [31, 33, 66] which are frequently used for ADSC osteoinduction 
[67]. There are different data about the duration of in vitro osteogenic induction 
needed for ADSC differentiation toward osteogenic cells, but literature data mostly 
referred to 2 weeks [22, 33, 66, 68, 69] or between 2 and 3 weeks [21] (Figure 2). 
It was summarized that during osteogenic differentiation, ADSCs start expres-
sion of lineage-specific genes for osteogenesis such as osteocalcin, transcription 
 factor osterix, transcription factor Runx2, bone sialoprotein, alkaline phosphatase, 
and others [32, 40] which might be detected by gene expression analysis [61] as 
 confirmation of successful osteogenic differentiation of ADSCs. For instance,  
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Cvetković et al. [45] recently published that bone-related genes osteocalcin, transcrip-
tion factor osterix, alkaline phosphatase, and collagen I alpha1 chain had the highest 
expression in in vitro osteoinduced ADSCs at 15th day of osteoinduction [45]. Also, 
it is reported that changes in cell morphology during osteogenic induction to a more 
cuboidal shape could be observed in ADSC culture [69]. The presence of mineraliza-
tion signs and proliferation of the ADSCs are also reported as markers of osteogenic 
differentiation during in vitro osteoinduction [65, 69, 70]. Particularly, after in vitro 
osteogenic differentiation, mineralization of the cell matrix could be evaluated using 
Von Kossa and alizarin red staining [31, 66]. In the next step, when osteoinduction 
Figure 1. 
Expansion and purification of ADSCs from adipose-derived SVF through in vitro cultivation. (a) Adipose-
derived SVF 24 h after isolation; (b) adipose-derived SVF 72 h after isolation; (c) adipose-derived SVF 7 days 
after isolation; and (d) ADSCs the first day after the first passage. Black arrows show ADSCs. Magnification 
100×.
Figure 2. 
In vitro osteoinduction of ADSCs. (a) ADSCs 3 days after cultivation in osteogenic media; (b) ADSCs 2 weeks 
after cultivation in osteogenic media. Black arrows show ADSCs. Magnification 100×.
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is confirmed, osteoinduced ADSCs are seeded on bone substitute material and 
supplemented with regulatory factors prior using in BTE. There are examples where 
prepared constructs, after ADSCs seeding on biomaterial (i.e. bone substitute 
 material), are subjected to in vitro osteoinduction before implantation [26] which  
requires additional time for construct preparation and delays final application. Overall, 
in vitro osteoinduction is proven to be an effective method for preparation of the 
ADSCs, and that is confirmed in many different studies [26, 45, 65] which makes this 
method suitable for BTE. But methods that consider at least two steps usually few 
weeks for performing and additional material for preparation of ADSCs are time- 
and money-consuming and more complicated to perform than the one-step method.
According to literature data, both in vitro osteoinduced ADSCs and untreated 
freshly isolated ADSCs are capable to induce osteogenesis to some level in ortho-
topic as well as in ectopic conditions. However, there are differences in their capac-
ity to initiate and maintain osteogenic process. By comparing our two recently 
published studies, it could be concluded that ADSCs prepared and utilized in 
different manners induced different expression patterns of analyzed osteogenic 
markers in ectopic implants [45, 55]. In one of the studies, it was shown that 
untreated ADSCs contained in freshly isolated SVF are capable to quickly initiate 
osteogenic process, but between the 4th and 8th week of implantation, decreasing 
bone-related gene expression was detected [55]. On the other hand, Cvetković et al. 
[45] reported that in vitro osteoinduced ADSCs cause steady osteogenesis with peak 
at the 8th week [45]. In addition, there is a study which confirmed that osteogeni-
cally differentiated human ADSCs induced forming of bone tissue after 8 weeks in 
ectopic condition [26]; thus the application of osteoinduced ADSCs seems to have 
a favorable effect on osteogenesis. In other words, all these findings indicate that 
freshly isolated untreated ADSCs cannot maintain osteogenesis in ectopic condi-
tion to that extent as in vitro osteoinduced ADSCs can do. Previous osteoinduction 
triggered differentiation of ADSCs toward osteogenic cells which had sufficient 
potential to start and maintain osteogenesis for a longer period [45]. It was con-
cluded that one of the reasons why untreated ADSCs within SVF failed to maintain 
osteogenic process for a longer period may be because of the lack of osteogenic 
factors in the ectopic environment which was used as model in this study [55]. Bone 
tissue normally had factors such as cytokines, mechanotransduction, and closeness 
of osteoprogenitor cells that are reported to act stimulative in bone formation, but 
they are reduced in ectopic bone-forming models [71]. Therefore, these factors 
are characteristic only for orthotopic models which allow evaluation of osteogenic 
potential of examined engineered construct in real natural milieu of the bone 
tissue. For that purpose the frequently used orthotopic models in BTE are critical-
sized defects in calvaria bone [23] and long bones [44, 72, 73] where large rodents 
and other mammals are suitable. In addition, it was reported that the presence of 
sufficient doses of osteogenic factors are needed to support osteogenic differentia-
tion of implanted cells and bone formation in ectopic conditions [56, 64].
Deficiency of osteogenic factors in ectopic models may be bypassed to some 
extent by addition of stimulating factors to ADSCs such as activated PRP. The 
addition of activated PRP can make microenvironmental conditions similar to the 
natural ones that occur during bone trauma. But it is known that platelets release a 
major portion of regulatory factors immediately after injury [74], which might be 
sufficient to stimulate ADSCs immediately after its implantation but definitely not 
for a longer period. The manner and applied doses of PRP obviously was enough 
to support development and maintenance of osteogenesis guided by previously 
in vitro osteoinduced ADSCs [45] and was not sufficient to support maintenance 
of osteogenic process guided by untreated ADSCs within SVF [55]. Regarding the 
short period of efficient action of PRP, Fernandes and Yang [48] reported that 
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Cvetković et al. [45] recently published that bone-related genes osteocalcin, transcrip-
tion factor osterix, alkaline phosphatase, and collagen I alpha1 chain had the highest 
expression in in vitro osteoinduced ADSCs at 15th day of osteoinduction [45]. Also, 
it is reported that changes in cell morphology during osteogenic induction to a more 
cuboidal shape could be observed in ADSC culture [69]. The presence of mineraliza-
tion signs and proliferation of the ADSCs are also reported as markers of osteogenic 
differentiation during in vitro osteoinduction [65, 69, 70]. Particularly, after in vitro 
osteogenic differentiation, mineralization of the cell matrix could be evaluated using 
Von Kossa and alizarin red staining [31, 66]. In the next step, when osteoinduction 
Figure 1. 
Expansion and purification of ADSCs from adipose-derived SVF through in vitro cultivation. (a) Adipose-
derived SVF 24 h after isolation; (b) adipose-derived SVF 72 h after isolation; (c) adipose-derived SVF 7 days 
after isolation; and (d) ADSCs the first day after the first passage. Black arrows show ADSCs. Magnification 
100×.
Figure 2. 
In vitro osteoinduction of ADSCs. (a) ADSCs 3 days after cultivation in osteogenic media; (b) ADSCs 2 weeks 
after cultivation in osteogenic media. Black arrows show ADSCs. Magnification 100×.
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is confirmed, osteoinduced ADSCs are seeded on bone substitute material and 
supplemented with regulatory factors prior using in BTE. There are examples where 
prepared constructs, after ADSCs seeding on biomaterial (i.e. bone substitute 
 material), are subjected to in vitro osteoinduction before implantation [26] which  
requires additional time for construct preparation and delays final application. Overall, 
in vitro osteoinduction is proven to be an effective method for preparation of the 
ADSCs, and that is confirmed in many different studies [26, 45, 65] which makes this 
method suitable for BTE. But methods that consider at least two steps usually few 
weeks for performing and additional material for preparation of ADSCs are time- 
and money-consuming and more complicated to perform than the one-step method.
According to literature data, both in vitro osteoinduced ADSCs and untreated 
freshly isolated ADSCs are capable to induce osteogenesis to some level in ortho-
topic as well as in ectopic conditions. However, there are differences in their capac-
ity to initiate and maintain osteogenic process. By comparing our two recently 
published studies, it could be concluded that ADSCs prepared and utilized in 
different manners induced different expression patterns of analyzed osteogenic 
markers in ectopic implants [45, 55]. In one of the studies, it was shown that 
untreated ADSCs contained in freshly isolated SVF are capable to quickly initiate 
osteogenic process, but between the 4th and 8th week of implantation, decreasing 
bone-related gene expression was detected [55]. On the other hand, Cvetković et al. 
[45] reported that in vitro osteoinduced ADSCs cause steady osteogenesis with peak 
at the 8th week [45]. In addition, there is a study which confirmed that osteogeni-
cally differentiated human ADSCs induced forming of bone tissue after 8 weeks in 
ectopic condition [26]; thus the application of osteoinduced ADSCs seems to have 
a favorable effect on osteogenesis. In other words, all these findings indicate that 
freshly isolated untreated ADSCs cannot maintain osteogenesis in ectopic condi-
tion to that extent as in vitro osteoinduced ADSCs can do. Previous osteoinduction 
triggered differentiation of ADSCs toward osteogenic cells which had sufficient 
potential to start and maintain osteogenesis for a longer period [45]. It was con-
cluded that one of the reasons why untreated ADSCs within SVF failed to maintain 
osteogenic process for a longer period may be because of the lack of osteogenic 
factors in the ectopic environment which was used as model in this study [55]. Bone 
tissue normally had factors such as cytokines, mechanotransduction, and closeness 
of osteoprogenitor cells that are reported to act stimulative in bone formation, but 
they are reduced in ectopic bone-forming models [71]. Therefore, these factors 
are characteristic only for orthotopic models which allow evaluation of osteogenic 
potential of examined engineered construct in real natural milieu of the bone 
tissue. For that purpose the frequently used orthotopic models in BTE are critical-
sized defects in calvaria bone [23] and long bones [44, 72, 73] where large rodents 
and other mammals are suitable. In addition, it was reported that the presence of 
sufficient doses of osteogenic factors are needed to support osteogenic differentia-
tion of implanted cells and bone formation in ectopic conditions [56, 64].
Deficiency of osteogenic factors in ectopic models may be bypassed to some 
extent by addition of stimulating factors to ADSCs such as activated PRP. The 
addition of activated PRP can make microenvironmental conditions similar to the 
natural ones that occur during bone trauma. But it is known that platelets release a 
major portion of regulatory factors immediately after injury [74], which might be 
sufficient to stimulate ADSCs immediately after its implantation but definitely not 
for a longer period. The manner and applied doses of PRP obviously was enough 
to support development and maintenance of osteogenesis guided by previously 
in vitro osteoinduced ADSCs [45] and was not sufficient to support maintenance 
of osteogenic process guided by untreated ADSCs within SVF [55]. Regarding the 
short period of efficient action of PRP, Fernandes and Yang [48] reported that 
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there is a need for carrier that would deliver PRP in the manner that it can act more 
efficiently and release growth factors sustainably [48]. This might be the key for 
enhancing osteogenesis guided by freshly isolated and untreated ADSCs within 
SVF. Despite disadvantages of ectopic models, there are many literature data where 
ectopic subcutaneous implantations were conducted [42, 43, 71, 75, 76] because 
they allow examining the real potential of the implanted cells [64] alone and with-
out the impact of the factors that are normally present in bone tissue. Therefore, 
selection of adequate animal model should depend on experimental goal, and 
finally it is important for interpretation and extrapolation of obtained results [1]. 
Nevertheless, osteogenic capacity of previously discussed combinations of differ-
ently prepared ADSCs should be evaluated in orthotopic bone-forming models 
because they are closer to real situations where treatment of bone defect is needed. 
That is especially of great importance for intraoperative (one-step) method because 
it is still unclear if this method ready for clinical implementation. In addition, 
recently a safe and feasible one-step surgical procedure for maxillary sinus floor 
elevation with implants consisting of calcium phosphate and freshly isolated SVF 
was demonstrated [63].
Preparation and utilization of freshly isolated and untreated ADSCs at the first 
place provides tremendous acceleration of procedure performance which is very 
important especially in everyday clinical practice where intraoperative method 
is desirable. Despite much longer period which is needed for ADSC preparation 
and utilization, there is no doubt that osteoinduction is a reliable method for 
the purposes of BTE. Overall, according to studies published so far [45, 49] that 
are mostly in accordance with other related studies, it could be concluded that 
untreated ADSCs contained in freshly isolated SVF have different potential from 
in vitro osteoinduced ADSCs to start and maintain osteogenic process which leads 
to quite different outcomes, at least in ectopic condition. Surely, each of presented 
approaches has its own advantages and potential to be successfully applied in treat-
ment of bone tissue defects. We believe that both approaches could be successfully 
utilized in the treatment of bone tissue defects, but additional research should be 
conducted especially in orthotopic models in order to determine required doses of 
osteogenic factors needed to support osteogenic process.
4.2 ADSCs-based grafts prepared in bioreactors
We previously discuss some methods for ex vivo engineering of the grafts in 
in vitro static condition using cells and bone substitutes as scaffold. The advanced 
method for graft engineering involves the use of bioreactors. Bioreactors are 
defined as devices for precise monitoring and controlling of conditions which are 
necessary for biological and biochemical processes [77]. The controlling and moni-
toring of the conditions are in favor of minimalizing variability of graft production 
as well as standardization of the process [13] for graft engineering. Amini et al. [10] 
reviewed several types of bioreactors which include perfusion bioreactors, rotating 
bioreactors, and spinner flask bioreactors. Perfusion-based bioreactors, which are 
marked as mostly used, significantly stimulate osteogenic cells due to fluid flow 
[10]. Thus, the dynamic conditions, which bioreactors provide, are more similar to 
in vivo conditions which allow proliferation and differentiation of seeded cells of 
three-dimensional scaffolds in a much appropriate way than static in vitro condi-
tions. There is literature evidence where human ADSCs were successfully used for 
engineering bone grafts in stirrer flask bioreactors [78] as well as viable bone tissue 
construct in perfusion bioreactor [79]. However, the engineering of the ready-to-
use bone grafts using bioreactors could last for weeks, and it must be performed 
in several steps. Also, bioreactor devices for BTE purposes have high prizes, and 
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the whole procedure is not economical because it requires a higher consumption of 
medium and other materials which reduces accessibility of this method.
5.  Solving vascularization problems in bone tissue engineering by SVF 
and ADSCs in vitro induced into endothelial cells
5.1 The problem of insufficient vascularization in bone tissue engineering
Bone tissue is a self-renewable tissue with an excellent regeneration capacity [80]. 
Some bone fractures, tumors, or bone loss can cause such large bone deficiencies 
that cannot be healed spontaneously [80], since their size goes beyond bone self-
renewing capacity [81]. In those cases, classical surgical procedures or bone tissue 
engineering strategies must be applied [82]. The main problem that has not yet been 
completely overcome is insufficient vascularization in critical-sized bone defects. 
Therefore, a perfect bone substitute must have excellent angiogenic features [83].
Until now, various BTE methods for resolving insufficient vascularization were 
performed: changing the architecture and interconnectivity of pores of the applied 
biomaterial [84], co-cultivation of different types of cells [85], using mechanical 
stimulation [86], and adding one [87] or a couple of growth factors in the implants 
at the same time [88]. The implants were placed into highly vascularized areas or, 
before the implantation procedure, seeded with cells that secrete chemoattractants 
for attraction of the host’s cells and blood vessels with small diameter [89]. Also, 
microvascular fragments of adipose tissue were incorporated [90], and tissue flap 
procedures [91] and scaffolds made of nano- or microfibers were applied [92].
One of the possible methods to facilitate anastomosing between the bioengi-
neered vascular structures with the ones from the surrounding tissue is the con-
struction of prevascularized scaffolds that contain endothelial cells (ECs) [93]. ECs 
constitute a continuous monolayer among interstitial fluid and blood and have cru-
cial importance in vascularization and in controlling the function of blood vessels 
[94]. By producing, metabolizing, and releasing numerous humoral and hormonal 
agents, these cells create an active antithrombotic surface in order to ease transit of 
plasma and cell components through the blood vessels [94]. Nevertheless, not only 
that ECs are important for successful developing of the functional vascular system, 
other cells that constitute blood vessel wall, smooth muscle cells, and perycites are 
also of great importance [9]. Mural precursor cells participate in vascular remodel-
ing and contribute to better vascularization in cell cultures which is the reason why 
these cells are desirable as one of the cell lines in co-culture [95, 96].
An important question regarding the use of ECs, not only in BTE but in tissue 
engineering generally, is “which type of ECs should be used?” [97]. Sources of 
autologous ECs are limited [98], and mature ECs have limited proliferative capacity 
[99, 100]. In addition, the procedure of isolation is invasive, it is hard to collect a 
plentiful number of cells, and there is a possibility of contamination, infection, and 
change of phenotype and function of ECs during in vitro cultivation [94, 99, 101]. 
Also, ECs isolated from different organs manifest different phenotypes in vivo, 
which mean that EC types for the application in tissue engineering should not be 
selected randomly [102].
Bearing all this in mind, alternative methods have been developed in order to 
obtain more stable sources of ECs. These methods include in vitro induction of 
MSCs into ECs. An easily accessible tissue [103] that attracts a great attention in the 
last few decades is adipose tissue. Primarily cell components of adipose tissue are 
cells filled with lipids—adipocytes. Besides adipocytes, stromal vascular fraction of 
adipose tissue consists of microvascular ECs, pericytes, fibroblasts, macrophages, 
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there is a need for carrier that would deliver PRP in the manner that it can act more 
efficiently and release growth factors sustainably [48]. This might be the key for 
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finally it is important for interpretation and extrapolation of obtained results [1]. 
Nevertheless, osteogenic capacity of previously discussed combinations of differ-
ently prepared ADSCs should be evaluated in orthotopic bone-forming models 
because they are closer to real situations where treatment of bone defect is needed. 
That is especially of great importance for intraoperative (one-step) method because 
it is still unclear if this method ready for clinical implementation. In addition, 
recently a safe and feasible one-step surgical procedure for maxillary sinus floor 
elevation with implants consisting of calcium phosphate and freshly isolated SVF 
was demonstrated [63].
Preparation and utilization of freshly isolated and untreated ADSCs at the first 
place provides tremendous acceleration of procedure performance which is very 
important especially in everyday clinical practice where intraoperative method 
is desirable. Despite much longer period which is needed for ADSC preparation 
and utilization, there is no doubt that osteoinduction is a reliable method for 
the purposes of BTE. Overall, according to studies published so far [45, 49] that 
are mostly in accordance with other related studies, it could be concluded that 
untreated ADSCs contained in freshly isolated SVF have different potential from 
in vitro osteoinduced ADSCs to start and maintain osteogenic process which leads 
to quite different outcomes, at least in ectopic condition. Surely, each of presented 
approaches has its own advantages and potential to be successfully applied in treat-
ment of bone tissue defects. We believe that both approaches could be successfully 
utilized in the treatment of bone tissue defects, but additional research should be 
conducted especially in orthotopic models in order to determine required doses of 
osteogenic factors needed to support osteogenic process.
4.2 ADSCs-based grafts prepared in bioreactors
We previously discuss some methods for ex vivo engineering of the grafts in 
in vitro static condition using cells and bone substitutes as scaffold. The advanced 
method for graft engineering involves the use of bioreactors. Bioreactors are 
defined as devices for precise monitoring and controlling of conditions which are 
necessary for biological and biochemical processes [77]. The controlling and moni-
toring of the conditions are in favor of minimalizing variability of graft production 
as well as standardization of the process [13] for graft engineering. Amini et al. [10] 
reviewed several types of bioreactors which include perfusion bioreactors, rotating 
bioreactors, and spinner flask bioreactors. Perfusion-based bioreactors, which are 
marked as mostly used, significantly stimulate osteogenic cells due to fluid flow 
[10]. Thus, the dynamic conditions, which bioreactors provide, are more similar to 
in vivo conditions which allow proliferation and differentiation of seeded cells of 
three-dimensional scaffolds in a much appropriate way than static in vitro condi-
tions. There is literature evidence where human ADSCs were successfully used for 
engineering bone grafts in stirrer flask bioreactors [78] as well as viable bone tissue 
construct in perfusion bioreactor [79]. However, the engineering of the ready-to-
use bone grafts using bioreactors could last for weeks, and it must be performed 
in several steps. Also, bioreactor devices for BTE purposes have high prizes, and 
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the whole procedure is not economical because it requires a higher consumption of 
medium and other materials which reduces accessibility of this method.
5.  Solving vascularization problems in bone tissue engineering by SVF 
and ADSCs in vitro induced into endothelial cells
5.1 The problem of insufficient vascularization in bone tissue engineering
Bone tissue is a self-renewable tissue with an excellent regeneration capacity [80]. 
Some bone fractures, tumors, or bone loss can cause such large bone deficiencies 
that cannot be healed spontaneously [80], since their size goes beyond bone self-
renewing capacity [81]. In those cases, classical surgical procedures or bone tissue 
engineering strategies must be applied [82]. The main problem that has not yet been 
completely overcome is insufficient vascularization in critical-sized bone defects. 
Therefore, a perfect bone substitute must have excellent angiogenic features [83].
Until now, various BTE methods for resolving insufficient vascularization were 
performed: changing the architecture and interconnectivity of pores of the applied 
biomaterial [84], co-cultivation of different types of cells [85], using mechanical 
stimulation [86], and adding one [87] or a couple of growth factors in the implants 
at the same time [88]. The implants were placed into highly vascularized areas or, 
before the implantation procedure, seeded with cells that secrete chemoattractants 
for attraction of the host’s cells and blood vessels with small diameter [89]. Also, 
microvascular fragments of adipose tissue were incorporated [90], and tissue flap 
procedures [91] and scaffolds made of nano- or microfibers were applied [92].
One of the possible methods to facilitate anastomosing between the bioengi-
neered vascular structures with the ones from the surrounding tissue is the con-
struction of prevascularized scaffolds that contain endothelial cells (ECs) [93]. ECs 
constitute a continuous monolayer among interstitial fluid and blood and have cru-
cial importance in vascularization and in controlling the function of blood vessels 
[94]. By producing, metabolizing, and releasing numerous humoral and hormonal 
agents, these cells create an active antithrombotic surface in order to ease transit of 
plasma and cell components through the blood vessels [94]. Nevertheless, not only 
that ECs are important for successful developing of the functional vascular system, 
other cells that constitute blood vessel wall, smooth muscle cells, and perycites are 
also of great importance [9]. Mural precursor cells participate in vascular remodel-
ing and contribute to better vascularization in cell cultures which is the reason why 
these cells are desirable as one of the cell lines in co-culture [95, 96].
An important question regarding the use of ECs, not only in BTE but in tissue 
engineering generally, is “which type of ECs should be used?” [97]. Sources of 
autologous ECs are limited [98], and mature ECs have limited proliferative capacity 
[99, 100]. In addition, the procedure of isolation is invasive, it is hard to collect a 
plentiful number of cells, and there is a possibility of contamination, infection, and 
change of phenotype and function of ECs during in vitro cultivation [94, 99, 101]. 
Also, ECs isolated from different organs manifest different phenotypes in vivo, 
which mean that EC types for the application in tissue engineering should not be 
selected randomly [102].
Bearing all this in mind, alternative methods have been developed in order to 
obtain more stable sources of ECs. These methods include in vitro induction of 
MSCs into ECs. An easily accessible tissue [103] that attracts a great attention in the 
last few decades is adipose tissue. Primarily cell components of adipose tissue are 
cells filled with lipids—adipocytes. Besides adipocytes, stromal vascular fraction of 
adipose tissue consists of microvascular ECs, pericytes, fibroblasts, macrophages, 
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leukocytes, pre-adipocytes, mastocytes, and adipose-derived mesenchymal stem 
[104, 105]. SVF with heterogeneous cell populations can be obtained upon simple 
enzyme-based adipose tissue isolation procedure that includes enzymatic diges-
tion, filtration, and centrifugation [76, 106–109]. After this procedure, SVF can be 
used as a source of ADSCs directly [108] or after expansion in cell culture through 
few passages [104] and subjecting to differentiation toward certain cell line [66, 76, 
105, 109–111].
ADSCs secrete numerous angiogenesis-related mediators including vascular 
endothelial growth factor (VEGF), bone morphogenic proteins, placental growth 
factor (PGF), angiopoietin-1, hepatocyte growth factor (HGF), transforming 
growth factor-β, and fibroblast growth factor 2 (FGF-2) [112]. Secretion of these 
angiogenic factors makes ADSCs convenient for regenerative cell therapy [106]. 
Among the abovementioned growth factors, VEGF and BMP2 are considered to 
be the main factors during bone regeneration, VEGF on the vascular and BMP2 on 
the osteogenic side [113]. Besides soluble growth factors, ADSCs release plasma 
membrane-derived vesicles (MVs) that can contain some pro-angiogenic and 
osteogenic molecules [114] with an influence on adjacent cells. In addition, growth 
factors and other molecules contained within MVs (cytokines, RNAs, microRNAs) 
can be transported to some more distant target cells all over the body. By taking up 
the content of MVs, target cells use these molecules and perform certain biological 
activity including angiogenesis of target cells which is of crucial importance in bone 
tissue regeneration [115].
In order to apply SVF as a source of cells with vasculogenic capacity in bone 
tissue engineering, several methods have been described. These methods include 
application of SVFs immediately after isolation from adipose tissue as well as after 
in vitro induction of endothelial differentiation.
5.2  Potential of stromal vascular fraction as a source of cells with vasculogenic 
capacity for application in bone tissue engineering
Freshly isolated SVF contains both endothelial and skeletal progenitor cells [116]. 
This property was widely used to construct osteogenic and vasculogenic grafts. It has 
been found that three-dimensional (3D) cultures of ECs and osteoblasts (OBs) as well 
as osteogenic-vasculogenic constructs could be achieved by using perfusion-based 
bioreactor system of single cell source human SVFs in ceramic scaffolds [116]. Namely, 
SVFs were seeded on 3D porous ceramic scaffolds and cultivated during 5 days using 
bioreactor system. Eight weeks after implantation of resulting scaffolds in nude 
mice, formation of functional vascular network that was connected with the host’s 
vasculature as well as ectopic bone formation was observed. Nude mice model was 
also used by Todorov and his colleagues [117]. This team isolated SVFs from human 
abdominal lipoaspirates and obtained hypertrophic cartilage (HC) pellets from 
bone marrow-derived stromal cells. Devitalized HC was embedded in fibrin gel and 
implanted with and without SVFs ectopically and in calvarial defects. Twelve weeks 
after implantations, vascularization and bone formation of grafts enriched with SVFs 
were enhanced in ectopic, subcutaneous, and in orthotopic experimental model.
The use of human SVF-derived vascular progenitor cells can speed up the 
engraftment of critical-sized osteogenic constructs which improves in vivo forma-
tion of the bone tissue [118]. Human SVFs have been isolated, seeded, and cultured 
into hydroxyapatite scaffolds. Perfusion bioreactor system was used in order to 
preserve the cells of CD34+/CD31+ endothelial lineage from the SVF. As a result of 
in vitro cultivation, 5 days after seeding, endothelial and mesenchymal progenitors 
from SVF constituted capillary networks that were able to anastomose with the host 
vasculature 7 days after implantation on an ectopic nude rat model [118].
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With an aim to simulate an intraoperative procedure on an ectopic bone forming 
model, autologous SVFs isolated from epididymal adipose tissue of Balb/c mice and 
platelet-rich plasma were added to the bone mineral matrix (BMM) [108]. BMM 
served as a carrier for cells and growth factors. The constructs were implanted 
subcutaneously, and osteogenic capacity of this combination was examined. Eight 
weeks after implantations, these implants had significantly higher percentage of 
infiltrated tissue and percentage of vascularization than the control (BMM-only 
implants). According to osteogenesis-related gene expression analysis, implants 
with SVFs induced rapid onset of osteogenesis process. One of the reasons for 
such results probably lies in the fact that freshly isolated SVFs had upregulated 
expression of endothelial- and osteogenic-related genes which was proved by using 
real-time PCR analysis.
Non-induced ADSCs cultivated in vitro up to the third passage were mixed with 
allogeneic PRP taken from three healthy Wistar rats [119]. ADSCs-PRP constructs 
were implanted into the jaws of rats that had bisphosphonate-related osteonecrosis 
of the jaw. Eight weeks after the treatment, the incidence of osteonecrosis was 
lower, while the degree of bone turnover and number of osteoclasts were higher 
than the experimental groups that were not treated with ADSCs [119]. These data 
could be explained by the fact that PRP release numerous growth factors that can 
fasten both in vitro and in vivo ADSC differentiation without previous addition 
of any other factors inductive toward certain cell line [109]. One of the possible 
mechanisms of synergistic effect of ADSCs and PRP could be ascribed to the release 
of platelet-derived growth factor from PRP. PDGF has an impact on selectable 
expansion and recruitment of non-induced MSCs, as well as on proliferation and 
migration of progenitors of blood vessel wall cells [120]. It also triggers differentia-
tion of MSCs into blood vessel cells [107] and enhances release of extracellular 
vesicles (EVs)—MVs and exosomes from ADSCs which further influence both 
in vitro and in vivo angiogenic process [121].
On an ectopic model, Man and associates [109] pointed out to the effect of 
ADSCs that is similar to the one shown in the abovementioned orthotopic model. 
ADSCs isolated from inguinal rabbit fat pads and mixed with PRP were loaded 
onto alginate microspheres. Well-developed blood vessel network and good bone 
mineralization were observed 3 months after subcutaneous implantations. Opposite 
results were obtained in another research where non-induced ADSCs were seeded 
on poly (D, L-lactide) scaffolds and implanted in the large rat palatal bone defect 
[122]. Bone formation did not occur even 12 weeks after implantations, and the 
defects were filled with dense fibrous tissue. The differences between the outcomes 
of the different studies could be attributed to the fact that adipose tissue was taken 
from the different localizations of the donors’ body. Also, the implant preparation 
was done in a different manner, and different models were chosen for the implanta-
tion procedure.
Adipose tissue can also be used as a source of microvascular fragments (MVF) 
that can be further applied as vascularization units [123]. MVF isolated from CD-1 
mice were incorporated into thermoresponsive hydrogel (TRH), cultivated, and 
used for filling the osteotomy gaps in the femurs of CD-1 mice. Bone healing was 
assessed 14 and 35 days after induction of osteotomy, while non-incorporated MVF 
as well as no material group served as control groups. It was found that TRH is a 
suitable carrier for MVF since vascularization in MVF-loaded TRH was improved in 
comparison to the control groups. In contrast to this finding, bone formation in this 
group was impaired, probably due to low levels of VEGF expression during the early 
stages of bone healing.
Bone substitute biomaterials based on calcium phosphate, including hydroxy-
apatite (HA), β-tricalcium phosphate (β-TCP), and HA/β-TCP combination, are 
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leukocytes, pre-adipocytes, mastocytes, and adipose-derived mesenchymal stem 
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Among the abovementioned growth factors, VEGF and BMP2 are considered to 
be the main factors during bone regeneration, VEGF on the vascular and BMP2 on 
the osteogenic side [113]. Besides soluble growth factors, ADSCs release plasma 
membrane-derived vesicles (MVs) that can contain some pro-angiogenic and 
osteogenic molecules [114] with an influence on adjacent cells. In addition, growth 
factors and other molecules contained within MVs (cytokines, RNAs, microRNAs) 
can be transported to some more distant target cells all over the body. By taking up 
the content of MVs, target cells use these molecules and perform certain biological 
activity including angiogenesis of target cells which is of crucial importance in bone 
tissue regeneration [115].
In order to apply SVF as a source of cells with vasculogenic capacity in bone 
tissue engineering, several methods have been described. These methods include 
application of SVFs immediately after isolation from adipose tissue as well as after 
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mice, formation of functional vascular network that was connected with the host’s 
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abdominal lipoaspirates and obtained hypertrophic cartilage (HC) pellets from 
bone marrow-derived stromal cells. Devitalized HC was embedded in fibrin gel and 
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The use of human SVF-derived vascular progenitor cells can speed up the 
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into hydroxyapatite scaffolds. Perfusion bioreactor system was used in order to 
preserve the cells of CD34+/CD31+ endothelial lineage from the SVF. As a result of 
in vitro cultivation, 5 days after seeding, endothelial and mesenchymal progenitors 
from SVF constituted capillary networks that were able to anastomose with the host 
vasculature 7 days after implantation on an ectopic nude rat model [118].
191
Application of Adipose-Derived Stem Cells in Treatment of Bone Tissue Defects
DOI: http://dx.doi.org/10.5772/intechopen.92897
With an aim to simulate an intraoperative procedure on an ectopic bone forming 
model, autologous SVFs isolated from epididymal adipose tissue of Balb/c mice and 
platelet-rich plasma were added to the bone mineral matrix (BMM) [108]. BMM 
served as a carrier for cells and growth factors. The constructs were implanted 
subcutaneously, and osteogenic capacity of this combination was examined. Eight 
weeks after implantations, these implants had significantly higher percentage of 
infiltrated tissue and percentage of vascularization than the control (BMM-only 
implants). According to osteogenesis-related gene expression analysis, implants 
with SVFs induced rapid onset of osteogenesis process. One of the reasons for 
such results probably lies in the fact that freshly isolated SVFs had upregulated 
expression of endothelial- and osteogenic-related genes which was proved by using 
real-time PCR analysis.
Non-induced ADSCs cultivated in vitro up to the third passage were mixed with 
allogeneic PRP taken from three healthy Wistar rats [119]. ADSCs-PRP constructs 
were implanted into the jaws of rats that had bisphosphonate-related osteonecrosis 
of the jaw. Eight weeks after the treatment, the incidence of osteonecrosis was 
lower, while the degree of bone turnover and number of osteoclasts were higher 
than the experimental groups that were not treated with ADSCs [119]. These data 
could be explained by the fact that PRP release numerous growth factors that can 
fasten both in vitro and in vivo ADSC differentiation without previous addition 
of any other factors inductive toward certain cell line [109]. One of the possible 
mechanisms of synergistic effect of ADSCs and PRP could be ascribed to the release 
of platelet-derived growth factor from PRP. PDGF has an impact on selectable 
expansion and recruitment of non-induced MSCs, as well as on proliferation and 
migration of progenitors of blood vessel wall cells [120]. It also triggers differentia-
tion of MSCs into blood vessel cells [107] and enhances release of extracellular 
vesicles (EVs)—MVs and exosomes from ADSCs which further influence both 
in vitro and in vivo angiogenic process [121].
On an ectopic model, Man and associates [109] pointed out to the effect of 
ADSCs that is similar to the one shown in the abovementioned orthotopic model. 
ADSCs isolated from inguinal rabbit fat pads and mixed with PRP were loaded 
onto alginate microspheres. Well-developed blood vessel network and good bone 
mineralization were observed 3 months after subcutaneous implantations. Opposite 
results were obtained in another research where non-induced ADSCs were seeded 
on poly (D, L-lactide) scaffolds and implanted in the large rat palatal bone defect 
[122]. Bone formation did not occur even 12 weeks after implantations, and the 
defects were filled with dense fibrous tissue. The differences between the outcomes 
of the different studies could be attributed to the fact that adipose tissue was taken 
from the different localizations of the donors’ body. Also, the implant preparation 
was done in a different manner, and different models were chosen for the implanta-
tion procedure.
Adipose tissue can also be used as a source of microvascular fragments (MVF) 
that can be further applied as vascularization units [123]. MVF isolated from CD-1 
mice were incorporated into thermoresponsive hydrogel (TRH), cultivated, and 
used for filling the osteotomy gaps in the femurs of CD-1 mice. Bone healing was 
assessed 14 and 35 days after induction of osteotomy, while non-incorporated MVF 
as well as no material group served as control groups. It was found that TRH is a 
suitable carrier for MVF since vascularization in MVF-loaded TRH was improved in 
comparison to the control groups. In contrast to this finding, bone formation in this 
group was impaired, probably due to low levels of VEGF expression during the early 
stages of bone healing.
Bone substitute biomaterials based on calcium phosphate, including hydroxy-
apatite (HA), β-tricalcium phosphate (β-TCP), and HA/β-TCP combination, are 
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often used in BTE due to their good biocompatibility and the absence of toxicity 
of their chemical compounds [124]. These materials also have such 3D features 
that allow immediate colonization by MSCs and extensive revascularization [125]. 
For those reasons, Farré-Guasch and his associates used ADSCs-containing SVF 
seeded on calcium-based biomaterials to treat the patients subjected to maxillary 
sinus floor elevation (MSFE)—a surgical procedure that in some patients must 
precede dental implant placement [126]. Autologous SVFs taken from patients were 
seeded on two types of carriers for two different groups of patients: group 1 had 
SVFs seeded on β-tricalcium phosphate, and group 2 had SVFs seeded on biphasic 
calcium phosphate, while the control group had only ceramics, without cells. 
Histomorphometrical analysis and immunohistochemical staining for blood vessel 
markers such as CD34 and alpha-smooth muscle actin revealed higher number of 
blood vessels and immunoexpression of blood vessel markers in both experimental 
than a control group. These results point out pro-angiogenic influence of SVF.
One of the recently published papers regarding pre-vascularization of various 
engineered tissues compares the use of ADSCs as a potential source of cells with 
vasculogenic capacity in combination with different types of gel-based scaffolds 
[127]. ADSCs were isolated from human fat tissue, cultivated, and, after second 
passage, molded in fibrin as well as agarose-collagen gels. After 14 days of incuba-
tion have passed, the gels were analyzed by two-photon laser scanning microscopy. 
Vascularization was achieved in both types of gels which were detected as branched 
networks of tubular vascular structures in both hydrogels. Nevertheless, volume, 
area, and length of vascular structures supported by ADSCs in agarose-collagen 
hydrogels were comparable to human dermal fibroblast control.
5.3  Potential of adipose-derived stem cells in vitro induced into ECs for 
application in bone tissue engineering
5.3.1 Orthotopic model
In order to increase vascularization, ADSCs induced into ECs were applied in 
BTE by using several models, among which orthotopic model is one of the most 
commonly used. Rat ADSCs in vitro induced into ECs during 8 days was used for 
the construction of allografts [128]. The cells were combined with sterilized and 
decellularized banked allografts made of calvaria from earlier sacrificed Lewis rats. 
Allografts were implanted into critical-sized calvarial defects in rats, and 8 weeks 
after the implantation, blood vessel density was increased. As a consequence, 
bone volume was also increased. In parallel, two other types of allografts were 
constructed—allografts seeded with ADSCs induced into OBs and allografts seeded 
with the combination of ADSCs induced into ECs and ADSCs induced into OBs. 
These implants had weaker vascularization and lower bone volume 8 weeks after 
the implantation than the ECs-only allografts.
ADSCs in vitro induced into ECs were also seeded onto poly(D, L-lactide) 
scaffolds and implanted into critical-sized calvarial defects of Lewis rats [110]. 
Scaffolds prevascularized in this manner did not caused an increase in bone forma-
tion by itself, but according to the conclusion of this team, they could possibly be 
used as a source of cells for accomplishing better vascularization and function of 
the existing OBs. On the other hand, the constructs that were constructed out of 
undifferentiated ADSCs or ADSCs induced into OBs had statistically greater bone 
volume than the implants containing ADSCs induced into ECs.
In another study, also performed on critical-sized calvarial defect model of 
Lewis rats, hydroxyapatite/poly(lactide-co-glycolide) [HA-PLG] was used as a 
biomaterial carrier, while adipose tissue was extracted from inguinal fat pads [129]. 
193
Application of Adipose-Derived Stem Cells in Treatment of Bone Tissue Defects
DOI: http://dx.doi.org/10.5772/intechopen.92897
ADSCs were induced into ECs as well as into OBs. Vascularization and osteogenic 
process were evaluated in the following groups: (I) HA-PLG scaffolds without cells, 
(II) HA-PLG scaffolds seeded with non-induced ADSCs, (III) HA-PLG scaffolds 
seeded with ADSCs induced into ECs, and (IV) HA-PLG scaffolds seeded with 
ADSCs induced into OBs. The highest bone mineral density, bone regeneration, and 
vascular density in regenerated bone were found in group IV, although none of the 
found differences had statistical significance (P > 0.05).
In order to repair critical-sized bone defects in rat femur, ADSCs induced 
into ECs were used for prevascularization of the modified hierarchical meso-
porous bioactive glass (MBG) scaffold with an enhanced compressive strength 
and then combined with ADSCs subjected to osteogenic differentiation [108]. 
Prevascularized MBG carrying ADSCs induced into OBs had more advanced 
angiogenesis both on the surface and in the interior than the non-vascularized 
MBG carrying ADSCs induced into OBs and MBG scaffolds that were not seeded 
with cells. Moreover, the group with prevascularized MBG scaffolds had the high-
est mineral deposition rate postoperatively. These results indicate that time-phase 
sequential utilization of ADSCs on MBG scaffolds is a good strategy for reparation 
of massive bone defects.
5.3.2 Ectopic model
Ectopic models are important in bone tissue engineering since they provide 
reducing external influences and side effects, thus concentrating on intrinsic 
potential of the applied implant components [53] and their interactions [42]. With 
an aim to overcome the problem of inadequate blood vessels development and 
consequent inability of bone tissue regeneration, the influence of ADSCs in vitro 
induced into ECs on vascularization and osteogenic process in ectopic osteogenic 
implants was examined [109]. The implants composed of ADSCs, BMM, and PRP 
and the ones composed of BMM and PRP were subcutaneously implanted into 
BALB/c mice. Endothelial-related gene expression, high percentage of vasculariza-
tion, and VEGFR-2 immunoexpression show that implants enriched with ECs have 
increased vascularization compared to the cell-free implants. This was followed by 
more pronounced signs of osteogenic process in ADSCs-BMM-PRP implants than 
in BMM-PRP implants. By examining endothelial-related gene expression, vascular 
cell adhesion molecule-1 (VCAM-1) and osteopontin immunoexpression, it was 
also shown that the composition of implants based on biological triad (ADSCs 
induced into ECs, PRP and BMM) is more favorable for improving vascularization 
in the ectopic bone-forming model than in the BMM-only implants [76].
Uninduced ADSCs cultivated up to the 12th day after the third passage, com-
bined with PRP and BMM and subcutaneously implanted into BALB/c mice, also 
have vasculogenic potential [109]. However, their vasculogenic potential is lower 
than that of ADSCs in vitro induced into osteogenic cells and implanted in combi-
nation with BMM and PRP. Specifically, relative gene expression analysis of endo-
thelial gene markers Vwf, Egr1, Flt1, and Vcam1 was significantly higher (p < 0.05) 
in the group that contained osteoinduced ADSCs than in the group with uninduced 
ADSCs for each single gene and with the exception of Vwf at 1 and 4 weeks after 
implantations, at each single observation point.
Endothelial differentiated ADSCs and osteogenic differentiated ADSCs can 
be simultaneously applied for the construction of ectopic osteogenic implants. 
A method of in vitro prevascularization applied by Zhang and his team included 
construction of double cell sheets (DCS) out of rabbit ADSCs previously in vitro 
induced into ECs and into osteogenic cells [113]. DCS were combined with coral 
hydroxyapatite (CHA) in four different manners. Twelve weeks after ectopic 
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that allow immediate colonization by MSCs and extensive revascularization [125]. 
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Vascularization was achieved in both types of gels which were detected as branched 
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In order to increase vascularization, ADSCs induced into ECs were applied in 
BTE by using several models, among which orthotopic model is one of the most 
commonly used. Rat ADSCs in vitro induced into ECs during 8 days was used for 
the construction of allografts [128]. The cells were combined with sterilized and 
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Scaffolds prevascularized in this manner did not caused an increase in bone forma-
tion by itself, but according to the conclusion of this team, they could possibly be 
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the existing OBs. On the other hand, the constructs that were constructed out of 
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volume than the implants containing ADSCs induced into ECs.
In another study, also performed on critical-sized calvarial defect model of 
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ADSCs were induced into ECs as well as into OBs. Vascularization and osteogenic 
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(II) HA-PLG scaffolds seeded with non-induced ADSCs, (III) HA-PLG scaffolds 
seeded with ADSCs induced into ECs, and (IV) HA-PLG scaffolds seeded with 
ADSCs induced into OBs. The highest bone mineral density, bone regeneration, and 
vascular density in regenerated bone were found in group IV, although none of the 
found differences had statistical significance (P > 0.05).
In order to repair critical-sized bone defects in rat femur, ADSCs induced 
into ECs were used for prevascularization of the modified hierarchical meso-
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Prevascularized MBG carrying ADSCs induced into OBs had more advanced 
angiogenesis both on the surface and in the interior than the non-vascularized 
MBG carrying ADSCs induced into OBs and MBG scaffolds that were not seeded 
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an aim to overcome the problem of inadequate blood vessels development and 
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induced into ECs on vascularization and osteogenic process in ectopic osteogenic 
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induced into ECs, PRP and BMM) is more favorable for improving vascularization 
in the ectopic bone-forming model than in the BMM-only implants [76].
Uninduced ADSCs cultivated up to the 12th day after the third passage, com-
bined with PRP and BMM and subcutaneously implanted into BALB/c mice, also 
have vasculogenic potential [109]. However, their vasculogenic potential is lower 
than that of ADSCs in vitro induced into osteogenic cells and implanted in combi-
nation with BMM and PRP. Specifically, relative gene expression analysis of endo-
thelial gene markers Vwf, Egr1, Flt1, and Vcam1 was significantly higher (p < 0.05) 
in the group that contained osteoinduced ADSCs than in the group with uninduced 
ADSCs for each single gene and with the exception of Vwf at 1 and 4 weeks after 
implantations, at each single observation point.
Endothelial differentiated ADSCs and osteogenic differentiated ADSCs can 
be simultaneously applied for the construction of ectopic osteogenic implants. 
A method of in vitro prevascularization applied by Zhang and his team included 
construction of double cell sheets (DCS) out of rabbit ADSCs previously in vitro 
induced into ECs and into osteogenic cells [113]. DCS were combined with coral 
hydroxyapatite (CHA) in four different manners. Twelve weeks after ectopic 
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implantation into nude mice, a group that contained CHA covered with DCS such 
that endothelial cell sheet was inside and osteogenic cell sheet outside exhibited the 
most favorable results regarding vascularization and bone maturation of the graft.
5.3.3 Co-cultivation
Co-cultivation of ECs with other cell types is one of the approaches for resolving 
the problem of inadequate vascularization in BTE [130]. ECs were co-cultivated with 
different types of cells before the implantation procedure, but the most important 
for BTE is co-cultivation of ECs and OBs since numerous interactions between these 
two cell types exist during normal bone regeneration process [131, 132]. One of the 
mechanisms of those interactions was found by Kaigler and associates [133]. They 
have shown that in vitro, ECs improve osteogenic capacity of bone mesenchymal 
stem cells (BMSCs) during co-cultivation, in direct contact or near each other. In 
part, this role of ECs could be attributed to release of BMP-2. In vivo, transplanted 
ECs enhanced capability of transplanted BMSCs to form the bones.
The positive effect of combination of ECs and OBs was estimated in ectopically 
implanted HA/bTCP scaffolds. The 3D porous ceramic scaffolds were seeded with 
in vitro co-cultivated ADSCs induced into OBs, ADSCs induced into ECs, and 
CD14+ osteoclast progenitors derived from human peripheral blood osteoclasts 
[134]. This three-dimensional organotypic culture model based on human cells 
was cultivated during 21 days in the perfusion bioreactor system. After cultivation, 
the system was implanted subcutaneously into dorsal pockets of nude mice. Eight 
weeks after implantation, blood vessels and bone-like tissue were formed.
In another study, co-cultivation of ADSCs induced into ECs and ADSCs induced 
into OBs did not have such positive effect on vascularization and osteogenic process 
[130]. Co-cultivation increased proliferation of this two cell types in vitro in com-
parison with monocultures or undifferentiated ADSCs. Nevertheless, co-cultures 
in a ratio 1:1 = OBs:ECs seeded on polylactic acid gas-plasma-treated scaffolds have 
not induced increased vascularization and signs of osteogenic process compared to 
the implants constituted out of non-induced ADSCs and polymer scaffolds. Unlike 
the co-culture group, ECs seeded on polymer scaffolds have increased vasculariza-
tion, and OBs seeded on polymer scaffolds have improved osteogenesis more than a 
group with undifferentiated ADSCs [130].
Unlike the results of the above discussed study, ADSCs in vitro induced into 
OBs and ADSCs in vitro induced into ECs and seeded into self-assembling peptide 
RADA16-I scaffolds as co-cultures (1:1) had better osteogeneration and vascular-
ization than the scaffolds seeded with monocultures of this type of cells or non-
induced ADSCs [135]. Before seeding the cells into RADA16-I scaffolds, it has been 
shown that the best interaction of ADSCs induced into OBs and ADSCs induced 
into ECs in co-cultures was achieved when the ratio of the cells was 1:1.
The results obtained by some of the abovementioned research teams, which 
were worse than expected regarding a group of implants that contained previously 
co-cultured ECs and OBs, could lie in the ratio of the applied cell types. It has been 
confirmed that application of too many ECs decreases graft neovascularization 
probably due to increase in metabolic load and enhanced competition for nutrients 
[136]. The other reason for those differences can be the differences in the applied 
biomaterials used for the implant construction [130].
5.3.4 Arteriovenous vascular bundle
Formation of arteriovenous vascular bundle (AVB) belongs to in vivo prevas-
cularization approaches. Incorporation of AVB into scaffolds represents a model 
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of scaffold that have artery and vein inserted into its central part. In this way, stem 
cells as well as cytokines, oxygen, and nutrients can be transported, while waste 
products can be removed from the scaffold. Altogether, that kind of construction 
leads to excellent vascularization and osteogenesis within the scaffold [137].
Scaffolds with AVB were combined with rat ADSCs previously subjected to 
in vitro endothelial differentiation. Obtained ECs were incorporated into porous 
nano-hydroxyapatite-polyamide 66 (nHA-PA 66) scaffolds in vitro [111]. After 
that, AV bundle was inserted into ECs-based nHA-PA 66 in vivo. Also, AV bundle 
was inserted into nHA-PA 66 scaffolds seeded with non-induced ADSCs and into 
empty nHA-PA 66 scaffolds, while one experimental group had nHA-PA 66 scaf-
folds without inserted AV bundle and without cells. Two and four weeks after the 
implantation procedure, the implants were extracted from the animals and ana-
lyzed. Density of blood vessels was significantly higher, and the diameter of blood 
vessels was larger in ECs-based nHA-PA 66 scaffolds than that in all other groups of 
implants.
5.3.5 Gene therapy
Combining ex vivo gene therapy with cell transplantation techniques that 
include endothelial cell line is another approach for overcoming the problem of 
insufficient vascularization in bone. The benefit of this method was assessed 
by using 3D poly (lactide-co-glycolide) sintered microsphere scaffolds in a BTE 
approach [138]. ADSCs were isolated from human infrapatellar fat tissue, and the 
cells were transfected with adenovirus that encodes cDNA of VEGF and combined 
with endothelial ones. As a result, genetically modified ADSCs combined with ECs 
caused prominent growth within 3D poly (lactide-co-glycolide) scaffolds, which 
indicates the potential for ADSCs application in improving vascularization in 
BTE. Another study where gene therapy and ADSCs were combined was conducted 
by Peterson and associates [139]. First, ADSCs were transfected with the BMP-2 
gene, then loaded on the collagen-ceramic carrier, and finally implanted in critical-
sized femoral defect of nude mice. Eight weeks after implantations, histologic, 
radiographic, and biomechanical analyses showed that the collagen-ceramic carrier 
combined with ADSCs previously transfected with the BMP-2 gene caused bone 
formation within the defect.
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of scaffold that have artery and vein inserted into its central part. In this way, stem 
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in vitro endothelial differentiation. Obtained ECs were incorporated into porous 
nano-hydroxyapatite-polyamide 66 (nHA-PA 66) scaffolds in vitro [111]. After 
that, AV bundle was inserted into ECs-based nHA-PA 66 in vivo. Also, AV bundle 
was inserted into nHA-PA 66 scaffolds seeded with non-induced ADSCs and into 
empty nHA-PA 66 scaffolds, while one experimental group had nHA-PA 66 scaf-
folds without inserted AV bundle and without cells. Two and four weeks after the 
implantation procedure, the implants were extracted from the animals and ana-
lyzed. Density of blood vessels was significantly higher, and the diameter of blood 
vessels was larger in ECs-based nHA-PA 66 scaffolds than that in all other groups of 
implants.
5.3.5 Gene therapy
Combining ex vivo gene therapy with cell transplantation techniques that 
include endothelial cell line is another approach for overcoming the problem of 
insufficient vascularization in bone. The benefit of this method was assessed 
by using 3D poly (lactide-co-glycolide) sintered microsphere scaffolds in a BTE 
approach [138]. ADSCs were isolated from human infrapatellar fat tissue, and the 
cells were transfected with adenovirus that encodes cDNA of VEGF and combined 
with endothelial ones. As a result, genetically modified ADSCs combined with ECs 
caused prominent growth within 3D poly (lactide-co-glycolide) scaffolds, which 
indicates the potential for ADSCs application in improving vascularization in 
BTE. Another study where gene therapy and ADSCs were combined was conducted 
by Peterson and associates [139]. First, ADSCs were transfected with the BMP-2 
gene, then loaded on the collagen-ceramic carrier, and finally implanted in critical-
sized femoral defect of nude mice. Eight weeks after implantations, histologic, 
radiographic, and biomechanical analyses showed that the collagen-ceramic carrier 
combined with ADSCs previously transfected with the BMP-2 gene caused bone 
formation within the defect.
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Therapeutics in Osteoporosis
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Abstract
Bone is an active tissue that works as a tissue and an organ as well. It is 
 constituted of cells and blood vessels by nearly 10% of its volume, while the rest 
90% is majorly contributed by extracellular portion. Bone is a living structure 
stably undertaking continual remodeling between bone formation and bone 
resorption, where bone-forming cells (osteoblasts) and bone-resorbing cells 
(osteoclasts) exhibit a crucial role. The differentiation process of osteoblasts 
and osteoclasts takes place in a balanced manner under normal conditions. This 
intricate balance is chiefly sustained by biochemical signaling cascades, facilitat-
ing accurate bone homeostasis in the body. Loss of balance/misregulated signal-
ing in the bone development or disruption may lead to pathological conditions 
such as osteoporosis, arthritis, etc. Among several regulators for bone-signaling 
pathways, microRNAs have appeared as an imperative control of gene expres-
sion at the level of post-transcription while addressing the genes that control 
bone remodeling with appropriate responses in the pathogenesis and perhaps the 
management of bone diseases. Further, microRNAs control the proliferation and 
differentiation of osteoblasts and osteoclasts, which finally influence the bone 
formation. Hence, there is a great possibility in exploiting microRNAs as putative 
therapeutic targets for the medical relief of bone associated disorders, including 
osteoporosis.
Keywords: bone formation, signaling pathways, osteoporosis, microRNAs, 
therapeutics
1. Introduction
Bone is a tough and dynamic tissue that provides shape to our body while 
protecting the organs [1]. Bone formation is chiefly regulated by the precise 
biochemical signaling pathways that maintain the action of the bone cells viz. 
osteoblasts and osteoclasts [2]. These bone cells act in a balanced and stable 
fashion in the normal functioning of the bone. Disruptions in this intricate 
balance results in absurd bone functions with the consequent occurrence of bone 
associated disorders. Osteoporosis is one such well-recognized bone disease that 
is patented by the decreased bone mineral density and loss of connectivity in the 
bone trabeculae [3]. Osteoporosis has been documented to elicit approximately 
8.9 million fractures annually, targeting around 200 million osteoporotic women 
across the globe [4, 5]. As per the International Osteoporosis Foundation, osteopo-
rosis results in 1.5 million fractures per year in the USA while in Europe, more than 
3.5 million osteoporotic fractures have been reported each year [6, 7]. Besides, in 
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India approximately 61 million people are stated as diseased osteoporotic patients 
[8, 9]. Therefore, management of osteoporosis is the urgent need of the hour for 
providing relief to the masses and hence refining the quality of life. Apart from 
numerous therapeutic measures available for the treatment, osteoporosis is still 
largely undertreated and seeks improved strategies that are associated with fewer 
side effects.
MicroRNA (miRNA) antagonism might be a new therapeutic approach for 
the check of osteoporosis. miRNAs are small RNAs (21–23 nucleotides) that act 
as post-transcriptional regulators of gene expression [10]. In a broader sense, 
miRNAs execute their functions either by degrading the gene (mRNAs) or by 
repressing the translation of the protein for the respective gene [11]. miRNA 
mediated targeting of expression for the genes that are involved in bone remodel-
ing and regeneration is a novel and specific mode of therapeutic strategy. Various 
miRNAs control the proliferation and differentiation potential of osteoblasts and 
osteoclasts that ultimately regulates the bone formation [12]. There are numer-
ous studies that report the prominence of miRNA functions and miRNA-based 
antagonism in the maintenance of bone homeostasis [13]. While acting on the 
mRNAs, miRNAs can stimulate as well inhibit the activity of osteoblasts and 
osteoclasts in the bone remodeling [14]. miRNAs are able to obstruct the exces-
sive bone loss during osteoporosis and encourages the bone formation [15]. In 
short, miRNAs are anticipated to serve as putative gene therapy targets for the 
treatment of bone-related injuries [16]. Hence the present chapter details the role 
and efficacy of miRNA in the management of osteoporosis. Finally, we describe 
the mechanism by which miRNAs can regulate the gene expression in bone 
formation and resorption.
2. Bone
Bone is an active connective tissue that behaves like an organ as well [1]. 
The most fundamental function of the bone is to offer support and shape to the 
body [17]. Other than that, bone also serves endocrine functions and assists in 
hematopoiesis [18]. Broadly, the structure of bone is categorized into two types, 
namely cancellous or cortical bone. Cortical/compact type comprises of 80% of 
the bone skeleton, whereas cancellous/spongy makes up to 20% [19]. Cortical 
bone forms the dense outer linings of the strong bones, and spongy bone is pres-
ent at the ends of the long bones [20]. Bone is associated with dynamic character 
and undertakes continual remodeling, wherein the aged bone is resorbed, and 
new bone is continually ossified [21]. The bone resorptive episode takes around 
10 days to complete, whereas the formation of bone persists for a period of 3 
months [22].
2.1 Components of bone
Two vital components of the bone composition are matrix and cells [23]. 
Matrix is further consists of organic part (30%) and inorganic part/ minerals 
(70%) [23]. Around 90% of the bone organic matrix is made of collagen type 1 
and rest 10% includes proteins such as osteocalcin, osteopontin, osteonectin, etc. 
[19]. In addition, bone is a storehouse for minerals, especially calcium and phos-
phorous, that makes the hydroxyapatite element of the bone. Hydroxyapatite 
provides framework and strength to the bone. Furthermore, bone is comprised 
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of four basic cell types, viz. osteoblasts, osteoclasts, osteocytes and bone lin-
ing cells [24]. Osteoblasts are bone-forming cells that arise from mesenchymal 
stem cells. Several growth (FGF) and transcription factors (Runx2, Osterix) 
are responsible for the differentiation of mesenchymal cells to the osteoblastic 
lineage [25]. Osteoclasts are bone-resorbing cells that originate from hematopoi-
etic monocyte-macrophage lineage, which differentiates via the assistance of the 
receptor activator of nuclear factor-κB ligand (RANK ligand) and Macrophage 
colony-stimulating factor (M-CSF) [26]. Osteoclasts are the biggest (in size) 
of all other cell types of the bone. Osteocytes constitute 95% of the cells in the 
mature skeleton [1]. These are the mineralized differentiated osteoblast cells that 
regulate the process of bone remodeling. Bone lining cells are a type of flat osteo-
blastic cells that sheet the quiescent bone surfaces [27]. They favor to safeguard 
the bone, maintain the bone fluids and form a barrier between the bone and bone 
marrow.
3. Physiological bone regeneration
Bone modeling is a specialized process wherein old bones are removed 
from one location and replaced by new bone at a distinct location. This process 
defines the ultimate shape and size of the skeleton [28]. While bone remodel-
ing is a characteristic process in the mature skeleton that is marked by constant 
bone restoration via a frequent exchange of aged bone with the fresh one at 
the same site. The process results in the comprehensive regeneration of mature 
skeleton in an adult every 10 years [29]. The body tries to sustain the balance 
between bone formation and elimination during the process of bone remodel-
ing. It takes place in discrete sites called basic multicellular units (BMU). The 
process initiates by activation phase where an initiating signal (e.g., mechanical 
strain on the bone, fracture healing, etc.) flags the requirement of the remodel-
ing process [30]. After the activation, the commencement of the resorptive 
phase occurs, wherein osteoclasts depletes bone by proteolytic degradation and 
acidification. Osteoblasts travel to the eroded space and begin the ossification 
after the stimulation of transcription factors that encourages the bone forma-
tion [31]. Ossified bone is subsequently mineralized and eventually remodeling 
cycle ends.
4. Biochemical signaling pathways that regulate the bone formation
Bone formation is controlled by numerous elements including transcription 
factors, hormones, growth factors, oxidative processes, mechanical loading, stress, 
bone fractures and aging [32]. Osteoblasts and osteoclasts are able to read these 
external stimulants and propagate the biochemical signals via various signaling 
cascades. The biological response of the selected signaling pathways results either 
in bone formation or disruption. Some of the crucial pathways operating in the 
osteoblasts and osteoclasts are described as follows:
4.1 Wnt/β-catenin pathway
The Wnt signaling pathway has an enormous vital role in the bone development 
and maintenance of bone homeostasis [33]. Wnt is a secreted protein ligand that 
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strain on the bone, fracture healing, etc.) flags the requirement of the remodel-
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4. Biochemical signaling pathways that regulate the bone formation
Bone formation is controlled by numerous elements including transcription 
factors, hormones, growth factors, oxidative processes, mechanical loading, stress, 
bone fractures and aging [32]. Osteoblasts and osteoclasts are able to read these 
external stimulants and propagate the biochemical signals via various signaling 
cascades. The biological response of the selected signaling pathways results either 
in bone formation or disruption. Some of the crucial pathways operating in the 
osteoblasts and osteoclasts are described as follows:
4.1 Wnt/β-catenin pathway
The Wnt signaling pathway has an enormous vital role in the bone development 
and maintenance of bone homeostasis [33]. Wnt is a secreted protein ligand that 
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binds to a receptor complex of Frizzled (Fz) and low-density lipoprotein receptor-
related proteins (LRP). There are two modes of functioning for the Wnt proteins, i.e., 
canonical and non-canonical pathways, wherein the canonical pathway has a more 
specific role to play in the bone development. In the canonical pathway (Figure 1), 
the interaction of Wnt to the receptor complex hinders the functioning of axin, gly-
cogen synthase kinase 3β (GSK-3β) and adenomatous polyposis coli (APC) protein. 
This primes the accumulation of β-catenin in the cytoplasm, further β-catenin travels 
down to the nucleus and ultimately stimulates lymphoid-enhancer-binding factor/T-
cell-specific transcription factors (LEF/TCF). This results in the transcriptional 
activation for the genes that participate in bone formation and regeneration. While 
the absence of Wnt signal leads to phosphoryla tion of the cytosolic β-catenin and its 
subsequent ubiquitin-mediated degradation [34]. The degradation of the β-catenin 
finally turns off the downstream activation of the osteogenic genes. Accurate Wnt 
signaling is a pre-requisite for adequate bone mass in the body while mutation of the 
Wnt signaling components results in fractures and bone injuries [35].
4.2 BMP-Smad pathway
Bone morphogenetic protein (BMP) holds a well-known and fundamental role 
in the bone development [36]. BMP signaling is initiated through the interaction 
of BMPs with the BMP-receptors (type I and type II). This binding stimulates the 
Figure 1. 
Wnt/β-catenin (canonical) signaling pathway in the osteoblasts. [A] In the absence of Wnt protein, the 
degradation complex Axin, GSK-3β and APC protein phosphorylates the β-catenin and results in the 
ubiquitin-mediated degradation of β-catenin. This turns off the transcription machinery for the osteogenic 
genes and hence transcription for the genes involved in osteogenic differentiation is hampered resulting in 
defective bone formation. [B] Wnt ligand interacts with the receptor complex of Fz and LRP that restricted 
the action of Axin, GSK-3β, and APC protein and hence permitted the transport of β-catenin to the nucleus. 
β-catenin combines with LEF/TCF transcription factors in the nucleus, thereby potentiating the transcription 
for the osteogenic genes.
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process of phosphorylation in the receptors that leads to recruitment and activation 
of Smad proteins, i.e., Smad 1, 5, 8 and Smad4. Smad proteins act as transcriptional 
regulators in the nucleus and ultimately induce the expression of the genes respon-
sible for osteoblastogenesis (Figure 2) [37, 38]. There are a total of 14 members in 
the BMP family, out of which BMP-2,4,5,6,7 and 9 are reported to have high bone 
formation ability [37].
4.3 RANKL mediated signaling
RANKL-based pathway is an essential signaling cascade for the osteoclast 
differentiation. RANKL binds to its receptor RANK (present on the osteoclast 
precursors) and recruits TNF receptor-associated factor (TRAF) adaptor pro-
teins to the conserved TRAF domain present at the cytoplasmic domain of the 
RANK [39, 40]. TRAF transduces the signal to downstream proteins viz. nuclear 
factor kappa B (NF-κB), extracellular signal-regulated kinase (ERK), c-Jun 
N-terminal kinase (JNK), and Nuclear Factor Of Activated T Cells 1 (NFATc1)
(Figure 3) [41, 42]. NF-κB is an important regulator for the osteoclast differen-
tiation. It is mainly responsible for the inflammation-based osteolysis and bone 
resorption [43].
Figure 2. 
Bmp-Smad signaling pathway in the osteoblasts. BMP ligand binds to receptor complex viz. type I (BMPRI) 
and type II receptor (BMPRII). Type II receptor which is a serine/threonine kinase in nature phosphorylates 
and stimulates type I receptor. Upon activation, type I receptor causes phosphorylation of the downstream 
proteins—receptor activated Smads (R-Smads), Smad 1/5/8. Further, R-Smads complexes with co-Smad, 
Smad4 and hence the complex transports to the nucleus. In the nucleus, Smad complex interacts with 
coactivators and finally results in the transcription of osteogenic gene viz. Runx2. Runx2 is a master 
transcription factor for the bone development. It aids in the differentiation of mesenchymal stem cells (MSC) to 
the osteogenic lineage.
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5. Osteoporosis
Osteoporosis is regarded as a silent bone disorder. Though it is silent and 
associated with least symptoms, it seeks the most attention. It is reported that 
osteoporosis targets every third woman and every fifth man beyond 50 years of 
their ages [44]. Osteoporosis is a pathological condition in which bone mineral 
density is severely diminished with weakened bone microarchitecture [45]. Bones at 
the areas specific to hip, wrist and spine are highly vulnerable for the osteoporotic 
fractures. The occurrence ratio in female to male for the osteoporosis is 1:6 with 61% 
of fractures befalling in the women [46]. Besides, postmenopausal women have 
a greater tendency towards osteoporosis [47]. It is predicted that there would be 
around 6 million victims having osteoporosis by the year 2050 [48]. Osteoporosis is 
categorized into two major types mentioned as follows:
5.1 Primary osteoporosis
Primary osteoporosis is the most usual type of osteoporosis. It has two sub-
categories: Type-I osteoporosis/postmenopausal osteoporosis, is a well-recognized 
bone issue in the postmenopausal women that is chiefly instigated by estrogen 
deficit due to menopause, while type-II osteoporosis/age-related osteoporosis is 
mainly caused as a result of aging in women and men both [49]. In Type-I primary 
Figure 3. 
RANKL-RANK signaling pathway in the osteoclasts. RANKL (present on the surface of osteoblasts) 
interacts with RANK receptor (on the surface of osteoclasts). RANK does not possess any kinase activity and 
hence recruits TRAF proteins to the cytoplasmic region of the receptor. This further transduces the signal to 
downstream components and activates. (1) TAK1 (member of mitogen activated kinase family, MAPK), 
promotes the ERK dependent activation of NFATc1. (2) NFK-β, after the phosphorylation based degradation 
of inhibitor of NFK-β (IKβ). (3) Other downstream proteins viz. JNK that leads to transcriptional activation 
of NFATc1 and additional factors resulting in the osteoclastogenesis.
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osteoporosis, bone loss hastens in the first 5 years of menopause and then slowly 
becomes constant. Estrogen executes the fundamental role in the bone develop-
ment. It stimulates pro-collagen synthesis in the osteoblasts while acting against the 
bone resorbing cytokines [50, 51]. Estrogen is also capable of supporting osteoblast 
differentiation [52]. Moreover, estrogen deficiency induces the production of reac-
tive oxygen species that results in increased osteoclast differentiation [53]. Thus, a 
shortage of estrogen after menopause is one prime cause of osteoporosis majorly in 
women. In the case of type II primary osteoporosis, age is the main cause that leads 
to fractures. With growing age, availability of minerals decreases, oxidants produc-
tion increases while the body becomes less active and does not absorb calcium and 
vitamin D efficiently that overall thins out the density of bone and reduces the 
strength [54].
5.2 Secondary osteoporosis
Bone disorders which are secondary impediments of other health-related 
issues, e.g., adverse effects of drugs interventions, fluctuations in the cycle 
of physical activities, etc. are acknowledged under the category of secondary 
Osteoporosis [49]. Glucocorticosteroids and anticonvulsant-based interventions 
are majorly reported in the cases of secondary osteoporosis [55]. Several other 
disorders, e.g., endocrinopathies, which have the tendency to reduce the bone mass 
and interfere with normal bone formation, are also capable of inducing secondary 
osteoporosis. This form of osteoporosis is found in both pre/post- menopausal 
women and men [55].
6. Current therapeutic measures for osteoporosis
With recent advances in technology and knowledge, many therapeutic strategies 
are available for the management of osteoporosis (Table 1). Broadly, treatment 
measures against osteoporosis are classified under two classes: anti-resorptive and 
anabolic. Anti-resorptive agents work to reduce the rate of bone dissolution while 
anabolic agents attempt to boost bone formation and development.
Drug Administration 




Alendronate 5 mg, 10 mg Inhibits osteoclastogenesis 
by binding to minerals of 
the bone matrix
Severe joint and bone pain, 
serious allergic reactions, 
and osteonecrosis
Zoledronic acid 5 mg/ml Diminishes osteoclast 
mediated bone disruption, 
also treats hypercalcemic 
conditions
Kidney-related issues, 
seizure, intense dizziness, 
and trouble while breathing
2. Estrogen modulators
Raloxifene 60 mg Mimics estrogen like 
effects in the bone 
that decreases bone 
resorption and enhances 
bone density
Risk of breast cancer, 
venous thromboembolism, 
and leg cramps
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7. New therapeutic drug targets for osteoporosis
Apart from tremendous progress in the therapeutic measures currently avail-
able for the check of osteoporosis, the disease still lacks complete eradication 
and immediate effective relief. The side effects, e.g., in bisphosphonate-based 
treatment, adverse effects like femoral fractures and jaw osteonecrosis, etc. are 
often observed. Moreover, instances of osteosarcoma are also reported in the 
anabolic therapies like parathyroid infusions [56, 58]. Hence, the hunt for the novel 
drugs that are specific in action is still continued. In the past few years, promis-
ing research on the topics related to functional genomics and system biology has 
emerged as a powerful remedial tool. Within this regard, RNAi (RNA interference) 
can serve as a new approach of therapeutics in combating bone associated injuries. 
miRNA-based gene antagonism is one such influential arena in the RNAi technol-
ogy. miRNAs can interact well with genes or proteins involved in the process of 
osteogenic differentiation and mineralization.
7.1 MicroRNAs (miRNAs)
miRNAs, a category of small non-coding RNAs, are basically 21–23 nucleotides 
in length. They regulate the gene expression by interacting and degrading the 
complementary mRNA counterparts. Additionally, they also control the expression 
at the protein level via the mode of translational repression of the selected proteins. 
For the suppression of gene, miRNAs mediate mRNA degradation, mRNA decay, 
insulation in P bodies and mRNA deadenylation [59]. At the protein level, miRNAs 
act via inhibiting the initiation or elongation steps of the translation. miRNA 
might also cause ribosome drops and degradation of the nascent protein chain [59].
miRNAs were discovered in the year of 1990 as regulators of gene expression for the 
Drug Administration 
dose of the drug
Mechanism/effect Harmful effects
3. RANKL antagonist
Denosumab 60 mg/ml It is a human monoclonal 
antibody against RANKL 
that prevents the 
formation and maturation 
of osteoclasts
Shortness of breathing 
cycle, warm skin with pus, 
pain while urinating, and 
night sweats
Anabolic strategies
1. Parathyroid hormone (PTH)
Teriparatide 250 mcg/ml It is a recombinant part of 
PTH, that stimulates the 
osteoblastogenesis with 
augmented bone mineral 
density
Heartbeat rate is increased, 
severe dizziness, allergies, 
itching and swelling of 
face, tongue, faintness, and 
osteosarcoma
Abaloparatide 2000 mcg/ml Same as Teriparatide Hypercalciuria, palpitations, 
and spinning sensation
2. Calcitonin 200 IU/ml Encourages bone 
formation, reduces calcium 
levels in the plasma, 
increases net bone mass
Light-headed sensation, 
flushing, nausea, and 
vomiting
Table 1. 
Different anti-osteoporotic therapeutic measures currently available in the market [56, 57].
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developmental processes in the Caenorhabditis elegans [60]. Interestingly, it has 
been stated that miRNA targets one-third of the genes in the human genome [61].
miRNAs are also found in extracellular fluids apart from the cells. Further, they 
are regarded as highly conserved elements among plant and animal kingdoms. In 
the context of nomenclature for the miRNAs, the preface “miR” is succeeded by a 
number that represents the order of naming, i.e. among miR-150 and miR-180, 150 
represents the fact that it is discovered before 180 was found and named [62].
7.2 Biogenesis of miRNA
The miRNA synthesis can be briefly summarized in the following points 
(Figure 4) [63]:
a. The miRNAs genes are generally transcribed by RNA Polymerase II as 
 pri-miRNA (primary-miRNA) in the animals.
b. A pri-miRNA may encompass one to seven miRNA precursors.
c. Enzymes Drosha and Pasha present in a microprocessor complex cleave the 
long pri-miRNA to shorter pre-miRNA with 2 nucleotide overhangs at 3′ end 
and 5′ phosphates.
d. Finally, a nucleocytoplasmic shuttle protein viz. exportin translocates the 
 pre-miRNA to the cytoplasm.
Figure 4. 
Synthesis pathway for the miRNA. miRNA gene is synthesized by RNA polymerase II in the form of a primary 
transcript (Pri-miRNA). Pri-miRNA is acted upon by microprocessor complex (Drosha and Pasha) resulting 
in the formation of pre-miRNA. From the nucleus, pre-miRNA is transported to the cytoplasm by the shuttle 
protein exportin. In the cytoplasm, dicer targets the pre-miRNA and splices it to miRNA-miRNA duplex. The 
dicer cleavage is linked with the unwinding of the duplex and only one strand is selected to be incorporated into 
the RISC complex. In the RISC complex, miRNA executes its action either on mRNA via mRNA degradation or 
at the protein level by translational repression.
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e. RNase III enzyme called Dicer slices the pre-miRNA into miRNA-miRNA 
duplex in the cytoplasm.
f. The Dicer mediated cleavage is usually associated with the unwinding of 
miRNA duplex wherein one miRNA strand (guide strand) is selected to be 
incorporated in the RISC (RNA induced silencing complex), and the other 
miRNA strand (passenger strand) is frequently degraded. The RISC contains 
Dicer, miRNA, argonaute and other accessory proteins.
g. Argonaute proteins generally interact with the mature miRNA and prepare it in 
the correct orientation for the subsequent binding with mRNA.
h. Perfect base pairing between the miRNA and cognate mRNA leads to degrada-
tion of the target mRNA while imperfect or partial complementarity usually 
results in the suppression at the protein level.
8. miRNA regulation in osteoblast proliferation
Most often, miRNA binds to 3′UTR regions of the genes and executes its action. 
miRNAs are generally regarded as post-transcriptional regulators that check the 
process of proliferation, apoptosis, differentiation and development [64]. Several 
miRNAs are documented to regulate the process of osteogenic proliferation, such as 
excessive expression of miR-221 and miR-215 in the mouse osteoblast cells encour-
ages the proliferative capacity of the cells [65, 66]. Likewise, downregulation of 
miR-185 results in the declined osteoblast proliferation [67]. Besides, increased 
expression of miR-495 in osteoblasts results in diminished proliferation and stimu-
lated apoptosis in the cells [68].
9. miRNA regulation in osteoblast differentiation
Differentiation of the osteoblast cells is an essential facet for the development 
of the adult skeleton. Most importantly, miRNAs have great potential to act against 
miRNA Target gene Targeted signaling pathway Reference
miR-433-3p DKK1 Wnt/β-catenin [69]
miR-208a-3p ACVR1 BMP [70]
miR-1187 BMPR2 BMP2 [71]
miR-29a Histone deacetylase 4 β-catenin [72]
miR-590-5p Smad7 BMP-Smad-Runx2 [73]
miR-450b BMP-3 BMP [74]
miR-135 Smad5 BMP-Smad [75]
miR-34c Notch1 Delta-Notch [76]
miR-224 Smad4 BMP-Smad [77]
miR-21 HIF-1α PTEN/PI3K/Akt [78]
Table 2. 
Role of miRNAs in the osteogenic differentiation by acting on various components in the bone signaling 
pathways.
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or in favor of the genes that are involved in the process of bone differentiation 
(Table 2). miRNA usually targets genes that are participating in the osteo-signaling 
resulting in the bone differentiation.
10. miRNA regulation in bone resorption
miRNAs not only regulates the osteoblastogenesis but also sustains the bone 
disruptive processes by acting on the genes or proteins partaking in the signal-
ing pathways that are functional inside the osteoclast (Table 3). Understanding 
the miRNA mediated regulation of osteoclastic differentiation will highlight the 
mechanism behind the differentiation process for the osteoclasts in the bone [84]. 
Initiating signal (binding of RANKL to the receptors) stimulates various down-
stream pathways (PI3K, NFK-β, MAPK) that on activation of distinct transcription 
factors (c-Fos, NFATc1, PU.1) control the osteoclast differentiation [84].
11. miRNAs as therapeutics
Both the overexpression and inhibition of miRNA can be exploited for the devel-
opment of potential therapeutics. miRNA sponges, Anti-miRNAs and miRNA masks 
are few strategies for the suppression of intracellular miRNAs. Anti-miRNAs are the 
miRNA inhibitors which are constructed as complementary to miRNA sequences. 
They prohibit the binding of miRNAs to the mRNA targets and relieve the gene sup-
pression phenotype. Anti-miRNAs are specific in action as they are custom synthe-
sized as entirely complementary to naturally existing miRNAs [85]. While, delivery 
of miRNA is achieved with the help of miRNA mimics, that imitates the sequence and 
action of miRNAs in the in vitro or in vivo systems. Furthermore, miRNA work as 
both oncogenes and tumor suppressors, thus contributes to the pathogenesis of sev-
eral cancerous diseases. MiR-21 founds to be highly upregulated during breast tumors 
while the levels of miR-196a are significantly increased in the pancreatic cancers 
[86, 87]. Role of miRNAs is also evidently noticed in many other diseases viz. liver 
diseases, cardiac dysfunctions, renal failures, neurodegenerative diseases, etc. [88].
miRNA Target Effect Reference
miR-503 RANK Represses osteoclast formation in PBMC [79]
miR-141 Calcr Suppresses osteoclast differentiation, increases 
bone mineral density
[80]
miR-29a RANKL and 
CXCL12
Decreases osteoclast formation and controls 
osteoporosis
[81]
miR-124 Nfatc1 Represses osteoclast differentiation [82]
miR-155 MITF Suppression of the osteoclastogenesis [83]
miR-21 FasL PDCD4 Hinders the apoptosis of osteoclasts [84]
miR-148a MAFB Encourages osteoclasts development [84]
miR-125a TRAF6 Restricts the formation of osteoclasts [84]
PBMC, peripheral blood mononuclear cells; Calcr, calcitonin receptor; CXCL12, C-X-C motif chemokine 12; MITF, 
microphthalmia-associated transcription factor; PDCD4, programmed cell death protein 4; MAFB, MAF BZIP 
transcription factor B.
Table 3. 
Representation of a few examples where miRNAs have played a vital role in the bone resorption.
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e. RNase III enzyme called Dicer slices the pre-miRNA into miRNA-miRNA 
duplex in the cytoplasm.
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incorporated in the RISC (RNA induced silencing complex), and the other 
miRNA strand (passenger strand) is frequently degraded. The RISC contains 
Dicer, miRNA, argonaute and other accessory proteins.
g. Argonaute proteins generally interact with the mature miRNA and prepare it in 
the correct orientation for the subsequent binding with mRNA.
h. Perfect base pairing between the miRNA and cognate mRNA leads to degrada-
tion of the target mRNA while imperfect or partial complementarity usually 
results in the suppression at the protein level.
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miRNAs are generally regarded as post-transcriptional regulators that check the 
process of proliferation, apoptosis, differentiation and development [64]. Several 
miRNAs are documented to regulate the process of osteogenic proliferation, such as 
excessive expression of miR-221 and miR-215 in the mouse osteoblast cells encour-
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Differentiation of the osteoblast cells is an essential facet for the development 
of the adult skeleton. Most importantly, miRNAs have great potential to act against 
miRNA Target gene Targeted signaling pathway Reference
miR-433-3p DKK1 Wnt/β-catenin [69]
miR-208a-3p ACVR1 BMP [70]
miR-1187 BMPR2 BMP2 [71]
miR-29a Histone deacetylase 4 β-catenin [72]
miR-590-5p Smad7 BMP-Smad-Runx2 [73]
miR-450b BMP-3 BMP [74]
miR-135 Smad5 BMP-Smad [75]
miR-34c Notch1 Delta-Notch [76]
miR-224 Smad4 BMP-Smad [77]
miR-21 HIF-1α PTEN/PI3K/Akt [78]
Table 2. 
Role of miRNAs in the osteogenic differentiation by acting on various components in the bone signaling 
pathways.
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11.1 miRNA-based therapeutics in osteoporosis
During osteoporosis, the balance between bone formation and bone elimi-
nation is disrupted [89]. Bone dissolution dominates the bone formation and 
thereby results in the weakened matrix and compromised bone strength. miRNA 
attempts to correct the imbalance and preserves the bone homeostasis towards 
bone development during the process of remodeling. miRNAs suppress the genes 
or proteins involved in the biological signaling pathway and hence aid the pathway 
to proceed in accurate and normal fashion [90]. This normalization of the pathway 
further facilitates the optimum differentiation of the mesenchymal stem cells to 
the osteoblastic lineage. In the past few years, several investigations have emerged 
which conveys the role of miRNAs in the prognosis and treatment of osteoporosis 
(Table 4).
12. miRNAs as biomarkers
Circulatory miRNAs that are available in the extracellular fluids, e.g., serum, 
plasma, tears, etc., are potent to be utilized as essential biomarkers in the bone 
associated issues. Circulatory miRNAs are generally secreted in the form of exo-
somes or microvesicles, and thus they are guarded against the action of nucleases. 
Blood plasma miRNAs have been reported as biomarkers in the diagnosis of 
Non-small-cell lung carcinoma stage I and II [98]. Further, miRNAs present in the 
human saliva have also been described as biomarkers during the menstrual cycle in 
women [99]. Serum biomarkers from the osteoporotic patients representing precise 
miRNA Treatment: gain/
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OVX mice Diminished bone resorption 
and enhanced bone mass
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Neutralized the loss of 
bone, better bone mass
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pathological condition may serve as crucial diagnostic tools in the clinical practice. 
Studies in the past years have depicted the relevance of extracellular miRNAs in the 
plasma or serum samples from the osteoporotic patients relative to healthy controls. 
miRNAs viz. hsa-miR-122-5p and hsa-miR-4516 have been documented as putative 
markers in the diagnosis of osteoporosis [100]. Similarly, in another study, miR-21, 
miR-23a, miR-24, miR-93 and miR-100 are highly upregulated in the serum of 
osteoporotic patients [101]. Even in the investigation of postmenopausal osteopo-
rosis, miR-422 has been regarded as an essential biomarker gene [102]. Based on 
several validated studies, it can precisely be concluded that miRNAs may act as 
useful potential biomarkers in the examination of distinct medical implications, 
including osteoporosis.
13. miRNA as potential new generation drugs
miRNAs are emerging as promising drugs in the pharmaceutical market. They are 
endogenous and hence associated with less harmful events for the body. Employing 
miRNAs as therapeutic targets have one key benefit that nucleotide content of the 
miRNAs can be easily modified by chemicals for the improved pharmacokinetics 
and pharmacodynamics of the potential miRNA-based drugs. Besides, miRNA has 
the capability of targeting multiple genes at a time. Moreover, nowadays chemical 
locked nucleic acid modifications are present for addressing the issues related to the 
susceptibility of miRNAs to the intracellular nucleases. Likewise, phosphorothioate 
alteration is another way of improving the efficacy of miRNAs in the in vivo systems 
[103]. Recently FDA approved drug, Onpattro against polyneuropathy marks the 
foundation of RNAi technology-based medicines in the commercial space. Table 5 
describes a few miRNA-based therapeutic compounds that are on the success path of 
drug development at the preclinical and clinical stages [104, 105].
14. Conclusion
In healthy body conditions, miRNAs are expected to assist in the maintenance of 
a regulated balance between the osteoblast-based bone-forming activity and osteo-
clast dependent bone-resorbing activity. This balance is dependent on the action of 
miRNAs on the biochemical signaling pathways operating inside the bone. While, 
during pathologies, the aberrant expression of the miRNAs due to misregulated 
miRNA Drug format Disease Stage of clinical trial
miR-122 miR-122 Antisense 
inhibitor
HCV Phase II
RG-012 Anti-miR-21 Alport syndrome At the initiating stage of the 
phase II trial
miR-3 Mimic replacement Cancers including 
hepatocellular
Phase I
Let-7 Mimic Replacement Cancer Preclinical
miR-103/105 miR-inhibitor Insulin resistance Preclinical
miR-10b miR-10b inhibitor Glioblastoma Preclinical
Table 5. 
List of few miRNAs which are presently in the development.
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bone signaling comes into existence. The upregulated or downregulated miRNAs 
during osteoporosis may serve as biomarkers or gene therapy targets respectively 
in the management of bone associated injuries including osteoporosis. As miRNAs 
are expressed in tissue specific manner, therefore miRNA-based biomarkers can 
differentiate between variable bone-related medical conditions, i.e. defects in bone 
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